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Abstract 
 
Autophagy, a cellular self-degradation process, plays important roles in cancer 
development and progression. Autophagy can be inhibited by the anti-apoptotic protein 
BCL-2 which binds and sequesters the autophagy essential protein Beclin-1, therefore 
preventing autophagy induction. It is currently unclear whether BCL-2 inhibits 
autophagy as well as apoptosis in follicular lymphoma (FL) and diffuse large B-cell 
lymphoma (DLBCL) which frequently express BCL-2 at high levels. This study aimed 
to determine (1) the role of BCL-2 in the basal level autophagy status and autophagy 
flux in primary FL and DLBCL samples, and lymphoma cell lines at both the gene and 
protein levels; (2) whether aberrant autophagy activity in these lymphoma patients is 
associated with clinical outcome.   
We initially found that the BCL-2 inhibitor ABT-737 concurrently induced autophagy 
and apoptosis in BCL-2
HIGH
 DLBCL cell lines. Blocking autophagy degradation with 
chloroquine sensitised BCL-2
HIGH
 cells to ABT-737-induced cell death, indicating that 
acquired autophagy acts as a cytoprotective mechanism in these cells. Expression levels 
of autophagy-related genes were analyzed by qRT-PCR. The BCL-2
HIGH
 cell line Su-
DHL4 showed up-regulation of more autophagy machinery genes at both the basal level 
and following starvation-induced autophagy compared with the BCL-2
LOW
 cell line. 
These results suggest that inhibition of BCL-2 can induce cytoprotective autophagy, but 
overexpression of BCL-2 alone may increase basal level autophagy by inhibiting 
apoptosis.  
The expression levels of autophagy-related genes were examined in purified primary FL 
and DLBCL B cells or un-purified whole FL and DLBCL tumour tissue biopsies and 
compared with non-malignant reactive lymph nodes. A number of autophagy machinery 
genes were significantly up-regulated in malignant samples. In particular, more 
autophagy machinery genes showed significantly increased expression in both purified 
and un-purified FL samples, indicating that despite frequently overexpressing BCL-2, 
FL appears to have increased basal level autophagy activity.  
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Expression of the key autophagy proteins p62, Beclin-1, LC3 and BCL-2 were 
determined in FL and DLBCL using tissue microarrays and immunohistochemistry. 
Both p62 and LC3, substrates of autophagic degradation, served as markers for 
autophagy activity. Significantly decreased expression of p62 and LC3, indicating 
active autophagy, was observed in FL samples (n=117). DLBCL samples (n=109) 
showed a heterogeneous expression pattern of these four proteins. We identified p62 as 
an independent prognostic biomarker in DLBCL with decreased expression predicting 
shorter overall, disease specific and progression-free survival. DLBCL patients with 
lower p62 or LC3 expression and higher levels of BCL-2, i.e. active autophagy and 
inhibited apoptosis, had the worst prognosis. Beclin-1 expression was significantly 
reduced in both FL and DLBCL, where lower levels were significantly associated with 
shorter overall and disease-specific survival. 
In summary, this study demonstrates that FL, characterised by overexpression of BCL-
2, shows increased autophagy activity, indicating that BCL-2 may not inhibit basal level 
autophagy in this indolent lymphoma. High levels of BCL-2 and active autophagy did 
not affect the clinical outcome of FL, but significantly shortened the survival rates of 
DLBCL patients. Our data propose that active autophagy could be used as a biomarker 
for DLBCL prognosis, but not FL.  
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CLL  Chronic lymphocytic leukaemia 
CMA  Chaperone mediated autophagy 
CML  Chronic myeloid leukaemia 
CQ  Chloroquine 
CR  Complete remission 
CT  Cycle threshold 
DAB  3,3’-diaminobenzidine  
DAPI  4',6-Diamidino-2-Phenylindole, Dihydrochloride 
dATP  Deoxyadenosine triphosphate 
DEVD  Aspartic acid, glutamic acid, valine, aspartic acid 
DISC  Death induced signalling complex 
DLBCL Diffuse large B-cell lymphoma 
DNA  Deoxyribonucleic acid 
DPX  Distrene 80, Dibutyl phthalate and Xylene 
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DS  Double stranded  
DSS  Disease specific survival 
DTT  Dithiothreitol 
ECD  Evolutionarily conserved domain 
ECOG  Eastern cooperative oncology group 
EDTA  Ethylenediaminetetraacetic acid 
ENDOG Endonuclease G 
ER  Endoplasmic reticulum 
FACS  Flow assisted cell sorting 
FAM   Carboxyfluorescein 
FCS  Fetal calf serum 
FDM  Factor-dependent myeloid  
FL  Follicular lymphoma 
FLIPI  Follicular lymphoma international prognostic index 
FMO  Fluorescence minus one 
GC  Germinal centre 
GCB  Germinal centre B-cell-like 
GDC  Genomic DNA control 
GDE  Genomic DNA elimination 
GEP  Gene expression profile / Gene expression profiling 
GFP  Green-fluorescent protein 
GPR  Good partial remission 
H&E  Haematoxylin and eosin 
HCQ  Hydroxychloroquine 
HDAC  Histone-deacetylase 
HKG  Housekeeping gene 
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HL  Hodgkin’s lymphoma 
HSC  Heat-shock cognate 
iBMK  Immortalised baby mouse kidney 
IC  Initiator complex 
IFM   Immunofluorescent microscopy 
IgH   Immunoglobulin heavy chain 
IgM  Immunoglobulin heavy chain M 
IHC  Immunohistochemistry  
IPI  International prognostic index 
KIR  KEAP1-interacting region 
LC3  Light chain 3 
LDH  Lactate dehydrogenase 
LIR  LC3-interacting region 
MCL  Mantle cell lymphoma 
MEF  Mouse embryonic fibroblast 
miRNA  Micro RNA 
MOMP  Mitochondrial outer membrane permeabilisation 
mRNA  Messenger RNA 
mTOR   Mammalian target of rapamycin 
mTORC1 Mammalian target of rapamycin complex 1  
mTORC2 Mammalian target of rapamycin complex 2 
NES  Nuclear export signal 
NHL  Non-Hodgkin’s lymphoma 
NK  Natural killer  
Nrf2  Nuclear factor, (erythroid-derived 2)-like 2 
NTC  No-template control 
      List of abbreviations  
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OS  Overall survival 
PARP  Poly(ADP-ribose) polymerase 
PAS  Phagophore assembly site 
PB1  Phox/Bem 1p 
PBS  Phosphate buffered saline 
PBST  Phosphate buffered saline with Tween-20 
PCD  Programmed cell death 
PCR  Polymerase chain reaction 
PDAC  Pancreatic ductal adenocarcinoma 
PE  Phosphatidylethanolamine 
PFS  Progression free survival 
PI3K  Phosphoinositide-3 kinase 
PIC  Protease inhibitor cocktail 
PMBL  Primary mediastinal B-cell lymphoma 
PMSF  Phenylmethylsulfonyl fluoride 
PPC  Positive PCR control 
PVDF  Polyvinylidene difluoride 
qRT-PCR Quantitative real-time PCR 
RA  Reactive lymph-nodes 
RAPTOR  Regulatory-associated protein of mTOR 
R-CHOP Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone 
ReTr  Reverse-transcription  
RIN  RNA integrity number 
R-IPI  Rituximab international prognostic index 
RNA  Ribonucleic acid 
ROS  Reactive oxygen species 
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RQ  Relative quantity 
RT  Room temperature 
RTC  Reverse transcription control 
SD  Standard deviation 
siRNA  Short-interfering RNA 
SMI  Small molecule inhibitor 
SQSTM1 Squestosome1 
SS  Single stranded  
Taq  Thermus aquaticus polymerase 
TB  TRAF6-binding 
TEM  Transmission electron microscopy 
TGN  Trans-Golgi network 
TMA  Tissue microarray 
TMRM  Tetramethylrhodamine, methyl ester, perchlorate 
UBA  Ubiquitin-associated 
Ubl  Ubiquitin-like 
Z-VAD.fmk N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluromethyl ketone  
ZZ  Zinc-finger 
ΔCT  Delta CT 
∆∆CT  Delta ∆ CT 
ΔΨm  Mitochondrial membrane potential 
κ  Kappa 
λ  Lambda
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Autophagy is a cellular self-degradation process whose activity is increased in cells 
upon encountering stress such as starvation and hypoxia. Understanding the role of this 
adaptive process in cancer is important as it is now known that tumour cells utilise 
autophagy to prolong their survival. It is also becoming increasingly apparent that 
activity of this pathway can influence the efficacy of chemotherapy agents. While our 
knowledge and understanding of the role autophagy plays in cancer is expanding, it is 
still unclear if this pathway is modulated in the same way in all cancer types. It has been 
reported that autophagy can be inhibited by the anti-apoptotic protein BCL-2 (B-cell 
lymphoma/leukaemia-2) which binds and sequesters the pro-autophagy protein Beclin-1 
and prevents autophagy induction. It is currently unclear if BCL-2 inhibits autophagy as 
well as apoptosis in human follicular lymphoma (FL) and diffuse large B-cell 
lymphoma (DLBCL) which frequently overexpress BCL-2, and if autophagy activity is 
associated with clinical outcome in these lymphomas.  
1.1 Autophagy 
Autophagy is a bulk degradation process involved in maintenance of cellular 
homeostasis. Typically considered a pro-survival mechanism, autophagy occurs at a 
basal level within the majority of cell types where it functions to remove and recycle old 
and damaged cellular organelles and protein aggregates (Choi et al., 2013a; Deter et al., 
1967; Galluzzi et al., 2012; He and Klionsky, 2009). Autophagy activity increases under 
stressed conditions such as nutrient deprivation and hypoxia to allow cells to avoid such 
stresses and prolong their survival. Substrates of the autophagy pathway include long-
lived proteins, large organelle/protein aggregates and intracellular pathogens 
(Korolchuk et al., 2010; Levine and Klionsky, 2004; Levine and Kroemer, 2008; 
Schmid and Munz, 2007).  
This pathway is also involved in physiological processes such as development, 
immunity and aging (Dikic et al., 2010; Mizushima et al., 2008). As part of the innate 
and adaptive immunity, autophagy aids in maintenance of lymphocyte homeostasis and 
the removal of microorganisms while increased autophagy activity has been found to 
delay aging and improve longevity (Deretic et al., 2013; Rubinsztein et al., 2011). This 
degradation process also plays a role in the pathogenesis of various diseases including 
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neurodegenerative disorders, muscular diseases and cancer (Choi et al., 2013a; Lucin 
and Wyss-Coray, 2013). 
1.1.1 The distinct types of autophagy  
There are three types of autophagy – chaperone mediated autophagy (CMA), 
microautophagy and macroautophagy – which degrade cellular proteins by different 
mechanisms (Boya et al., 2013; Choi et al., 2013a; Schmid and Munz, 2007). 
During CMA, proteins destined for degradation are recognised by the heat-shock 
cognate (HSC) chaperone protein HSC-70 which binds LAMP-2 and facilitates 
translocation of bound proteins to the lysosome where they are degraded. Conversely, in 
microautophagy, proteins targeted for degradation are engulfed by direct invagination of 
the lysosomal membrane. A small vesicle containing these proteins then buds off into 
the lysosomal lumen where the contents are degraded. Macroautophagy (referred to as 
autophagy), which is the best understood of these subtypes, involves formation of 
double layered-membrane vesicles called autophagosomes which sequester cytosolic 
components including protein aggregates and old cellular organelles destined for 
degradation. Autophagosomes fuse with lysosomes forming autophagolysosomes within 
which lysosomal hydrolases function to degrade the contents of the autophagosome 
(Section 1.1.3) (Boya et al., 2013; Choi et al., 2013a; Schmid and Munz, 2007).  
Autophagy can be non-selective or selective with regards the substrates it degrades (He 
and Klionsky, 2009; Johansen and Lamark, 2011). Non-selective autophagy removes 
general, long-lived, damaged proteins/organelles from cells by sequestering a large bulk 
of the cytosol. Conversely, selective autophagy targets specific proteins and organelles 
to the autophagosome for degradation, with different terms used for selective 
degradation of specific cargo; for example mitophagy and ribophagy refer to autophagic 
degradation of mitochondria and ribosomes respectively (He and Klionsky, 2009; 
Johansen and Lamark, 2011). 
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1.1.2 The autophagy genes and proteins  
Although we have known about autophagy since the 1950s through the visualisation of 
autophagosomes by electron microscopy, we have only begun to understand the 
molecular basis of this pathway in the last 20 years. A key turning point in our 
understanding of this pathway came when Ohsumis’ group identified the autophagy-
related gene (Atg) Atg1 by screening for autophagy mutants in the yeast Saccharomyces 
cerevisiae, the sequence of which was published in 1997 (Matsuura et al., 1997; 
Tsukada and Ohsumi, 1993). More than a decade on a further 30 Atg genes have been 
identified, the majority of which are evolutionarily conserved from yeast to mammals 
(Kabeya et al., 2007; Klionsky, 2007). While some genes such as Atg8 were first 
identified in yeast and their homologs (e.g. LC3) subsequently discovered in mammals, 
others, such as the Atg12 and Atg5, were found first in mammals and later in yeast, 
again highlighting the conservation of these genes (Klionsky, 2007; Mizushima et al., 
1998).  
The Atg genes are essential to the autophagy process and are involved in all stages of 
the pathway. They are particularly prevalent in the early phases of autophagy where 
they aid in autophagosome membrane formation, elongation and expansion (Section 
1.1.3) (He and Klionsky, 2009; Rubinsztein et al., 2012). 
Other genes and proteins which are important in the autophagy pathway include LC3, 
p62, Beclin-1 and BCL-2 which can act as biomarkers, inducers and inhibitors of 
autophagy respectively, which will be discussed in later sections (Lee et al., 2012; 
Rubinsztein et al., 2012; Russell et al., 2013).   
1.1.3 The autophagy flux  
Autophagy is a dynamic process comprised of different stages including initiation, 
elongation, sequestration and fusion (Figure 1.1) (Rubinsztein et al., 2012). 
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1.1.3.1 Initiation / Formation 
Autophagy begins with the generation of a single layered membrane termed the 
phagophore which forms at the phagophore assembly site (PAS) and requires an 
initiator complex (IC) for nucleation and assembly. The IC comprises multiple proteins 
including the class III PI3K Vps34, Vps15/p150, Beclin-1 (the mammalian homolog of 
Atg6), Atg14 or UVRAG and AMBRA1, which facilitate phagophore formation (Boya 
et al., 2013; Pyo et al., 2012; Rubinsztein et al., 2012). This complex is regulated by 
Atg13 as well as ULK1 and ULK2, the mammalian homologs of Atg1. For example 
ULK1 promotes IC activity by phosphorylating Beclin-1 leading to activation of Vps34 
and induction of autophagy (Rubinsztein et al., 2012; Russell et al., 2013). Despite our 
increasing understanding of the autophagy pathway, there is still debate as to the origin 
of the phagophore which is thought to arise from cellular organelles such as the 
mitochondria, endoplasmic reticulum (ER), Golgi-apparatus or plasma membrane. (Pyo 
et al., 2012; Rubinsztein et al., 2012).  
 
 
 
 
 
 
Figure 1.1 The autophagy flux 
Autophagy begins with nucleation of a single layered membrane, the phagophore from an existing 
organelle such as the ER. Proteins including Beclin-1 and Vps34 form an initiator complex (IC) at the 
phagophore where they function to recruit autophagy genes (Atg) to the membrane. These genes promote 
elongation of the phagophore allowing it to surround and engulf portions of the cytoplasm destined for 
degradation. Upon closure the phagophore forms the autophagosome to which LC3-II is bound. The 
autophagosome then binds a lysosome forming the autophagolysosome in which the contents of the 
autophagosome are degraded by lysosomal hydrolases such as cathepsin B and cathepsin D. Adapted 
from Kang, Zeh et al. 2011. 
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1.1.3.2 Maturation and Elongation  
Elongation and maturation of the phagophore from a single a layered membrane vesicle 
to a double layered autophagosome is facilitated by two ubiquitin-like (Ubl) conjugation 
systems - Atg12-Atg5-Atg16 and Atg8-phosphatidylethanolamine (PE) (He and 
Klionsky, 2009; Rubinsztein et al., 2012).  
In the Atg12-Atg5-Atg16 system, Atg12 is activated by Atg7 which acts as an E1 
ubiquitin-activating enzyme and transferred to Atg10, an E2 ubiquitin-conjugating 
enzyme. Atg12 is then covalently bound to Atg5 forming the Atg12-Atg5 conjugate 
which binds Atg16 non-covalently inducing self-oligomerisation and the formation of a 
tetramer which binds the phagophore (Figure 1.2) (He and Klionsky, 2009; Rubinsztein 
et al., 2012). 
In the second Ubl system, Atg8 is cleaved by Atg4 resulting in exposure of a C-terminal 
glycine residue. Atg8 is then activated by Atg7, transferred to Atg3 which acts as an E2 
enzyme and conjugated to PE by an amide bond via the Atg12-Atg5 conjugate which 
acts as an E3 enzyme (Figure 1.2) (He and Klionsky, 2009; Rubinsztein et al., 2012). 
There are three mammalian homologs of Atg8 – LC3, GATE-16 and GABARAP 
(Wang et al., 2011). Of these, LC3 is the best characterised and is commonly used as an 
autophagy marker. Upon receipt of an autophagy inducing stimulus LC3 is cleaved and 
bound to PE, altering its cellular distribution from a diffuse cytoplasmic form (LC3-I) to 
a membrane-bound punctate form, LC3-II. Conversion of LC3-I to LC3-II and an 
increase in LC3-II levels is typically considered a sign of active autophagy; however, 
this is not always the case and LC3-II levels should be interpreted carefully (section 
1.1.4)  (He and Klionsky, 2009). 
Once bound to the phagophore, the Ubl conjugation systems aid in its expansion and 
elongation to a double layered membrane vesicle which surrounds and engulfs 
autophagy substrates and upon closure forms the autophagosome (Figure 1.1).  
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Figure 1.2 The Atg12-Atg5-Atg16 and Atg8-PE Ubl conjugation systems involved in 
autophagosome expansion and elongation 
Two Ubl-conjugation systems aid in the elongation and maturation of the single-layered phagophore to a 
double-layered autophagosome. Atg12 is activated by Atg7, transferred to Atg10 and subsequently 
covalently conjugated to Atg5. This Atg12-Atg5 conjugate then interacts with Atg16 resulting in self-
oligomerisation of the Atg12-Atg5-Atg16 complex and its incorporation into the phagophore whose 
elongation it promotes. Atg8 is cleaved by Atg4 exposing a C-terminal glycine residue. Atg7 transfers 
cleaved-Atg8 to Atg3 which promotes conjugation of Atg8 to PE via the Atg12-Atg5 conjugate. Atg8-PE 
is incorporated into the autophagosome membrane and also promotes its maturation. Lipidation and 
membrane incorporation of Atg8 and its mammalian homolog LC3 is widely used as a marker of active 
autophagy. Adapted from Levine, Klionsky, 2004.   
 
1.1.3.3 Autophagosome / Lysosome fusion 
The final step in the autophagy process involves fusion of the autophagosome with a 
cellular lysosome which is facilitated by LAMP-2 and the small GTPase Rab7 and 
results in formation of the autophagolysosome (He and Klionsky, 2009; Wang et al., 
2011). Following fusion, resident lysosomal acid hydrolases including cathepsin B and 
cathepsin D break down and degrade the autophagy substrates, which include protein 
aggregates and old organelles, along with the inner autophagosome membrane (Figure 
1.1). Degradation generates new macromolecules and amino acids which are released 
back into the cytosol and utilised in protein synthesis (Figure 1.1) (He and Klionsky, 
2009; Wang et al., 2011).  
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1.1.4 Measuring the autophagy flux  
Examination of the autophagy flux is not straight-forward. While a number of criteria 
and assays are routinely used to determine autophagy activity within a cell, our 
increased understanding and improved ability to study this pathway means these criteria 
are changing and expanding. The difficulty in studying the autophagy flux was 
summarised by Klionsky and colleagues who state that “there are no absolute criteria 
for determining autophagy status that are applicable in every biological or experimental 
context” (Klionsky et al., 2012a).  
Not all assays report the dynamic flux through the entire autophagy pathway but rather 
reflect activity at a specific stage. The timing at which autophagy is evaluated following 
autophagy induction or inhibition is important as it is a dynamic process. Some reports 
suggest examination after 30min while others suggest up to 8hr or more (Amaravadi et 
al., 2007; Shi et al., 2013). Selection of an appropriate time is further complicated by 
the fact that degradation of substrates (e.g. p62) generally occurs after the appearance of 
induction markers (e.g. LC3-II) (Klionsky et al., 2012a).  
1.1.4.1 Western blotting    
Upon activation of autophagy, pro-LC3 is cleaved by Atg4 to LC3-I which is present in 
cells in a diffuse cytoplasmic manner. LC3-I becomes conjugated to PE forming LC3-
II, which integrates into the autophagosome membrane and is visible as puncta within 
cells (Pyo et al., 2012). Conversion of cytoplasmic LC3-I to membrane-bound LC3-II, 
resulting in a decrease in LC3-I levels and an increase in LC3-II, is commonly used as a 
marker of autophagosome formation and active autophagy when detected by Western 
blotting (Kabeya et al., 2000; Klionsky et al., 2012a; Mizushima and Yoshimori, 2007). 
However, care must be taken with this interpretation as LC3-II is itself an autophagy 
substrate which is degraded by active autophagy. Therefore, absence of an LC3-II band 
may indicate either impaired autophagy or increased autophagic degradation of LC3-II. 
It is also reported that LC3-II can be more amenable to detection by immunoblotting 
than LC3-I and that conversion of LC3-I to LC3-II can be cell-type specific (Klionsky 
et al., 2012a; Mizushima and Yoshimori, 2007). Treatment of cells with an autophagy 
inhibitor such as chloroquine (CQ) can be used to determine if increased LC3-II levels 
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represent increased autophagy flux or impaired substrate degradation. CQ is an 
autophagosome/lysosome inhibitor which prevents degradation of autophagy substrates 
including LC3-II, resulting in their accumulation (Amaravadi et al., 2007; Jia et al., 
2012). An increase in LC3-II levels upon treatment with an autophagy inducer and CQ 
compared to induction-only treated cells indicates an increase in the autophagy flux and 
autophagy activity, while an increase in LC3-II levels by the same degree in induction-
only and induction/inhibition treated cells suggests a block in autophagy degradation 
(Mizushima and Yoshimori, 2007).  
p62 binds ubiquitinated proteins and delivers them to the autophagosome via 
interactions with LC3-II meaning this adaptor protein is itself an autophagy substrate 
whose cellular levels are commonly used as a marker of autophagy activity. Active and 
inhibited autophagy result in degradation and accumulation of p62 respectively 
(Bjorkoy et al., 2005; Klionsky et al., 2012a; Mathew et al., 2009). However care 
should be taken when correlating p62 levels with autophagy flux activity as this protein 
is involved in a variety of pathways which modulate and affect its cellular levels 
(section 1.5). In a similar manner to LC3-I/LC3-II, p62 levels should be examined in 
cells treated with an autophagy inhibitor (e.g. CQ). A decrease in p62 levels following 
autophagy stimulation which is inhibited by CQ resulting in p62 accumulation indicates 
an increase in the autophagy flux (Klionsky et al., 2012a; Mizushima and Yoshimori, 
2007). A recent publication has demonstrated that prolonged starvation (~4-8hr) can 
promote sustained autophagy which is marked by reappearance of p62. Between 0.5 and 
2hr post-starvation p62 levels decreased; however, starvation for >4hr resulted in re-
emergence of p62 at the protein level (Sahani et al., 2014).  
1.1.4.2 Immunofluorescent microscopy   
Immunofluorescent microscopy (IFM) allows visualisation of the distribution pattern 
and cellular location of autophagy-related proteins, as well as examination of their 
binding partners. LC3-II puncta, which can be identified using IFM, are a widely used 
marker of autophagosomes and an active autophagy flux. Increased numbers of LC3-II 
puncta typically indicate increased numbers of autophagosomes and active autophagy, 
while larger puncta suggest inhibition of autophagic degradation and an accumulation of 
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this autophagy substrate (Figure 1.3 A) (Kabeya et al., 2000). The cellular distribution 
of p62 can also be visualised by IFM to assess autophagy activity. When autophagy is 
active, p62 binds ubiquitinated proteins and LC3-II to form clear cellular aggregates 
which accumulate and increase in size upon autophagy inhibition (Bjorkoy et al., 2005). 
Quantification of LC3-II and p62 by IFM should be done by counting the number of 
punctate/aggregates per cell rather than the number of positive cells (Klionsky et al., 
2012a). The autophagy essential protein Beclin-1 can also be visualised by IFM and is 
typically present in either a diffuse cytoplasmic form or as puncta present in the 
perinuclear region of cells, the latter of which can be indicative of macro-aggregates and 
represent active autophagy (Nicotra et al., 2010b). Dual-fluorescent microscopy can be 
used to examine protein-protein interactions within cells at the basal level and under 
different experimental conditions and to evaluate the effects of treatments on protein 
bindings (Bjorkoy et al., 2005; Pattingre et al., 2005). 
In cases where endogenous protein expression is low, green-fluorescent protein (GFP) 
tagged constructs, (e.g. GFP-LC3) can be transfected into cells and used as surrogate 
markers to monitor the autophagy flux. These assays are extremely useful for 
monitoring autophagy activity. However, transfection may not always be possible as not 
all cell types are amenable to this process and transfection efficiency may not always be 
sufficient or comparable within and between cells. Importantly, the transfection process 
itself may induce or increase autophagy activity (Klionsky et al., 2012a; Klionsky et al., 
2012b). Thus adequate controls, including un-transfected, mock-transfected and 
autophagy-inhibited cells, should be included in these assays and if possible 
endogenous levels examined in parallel. Prior to evaluation of the autophagy flux by 
IFM, stringent criteria of what constitutes puncta/aggregates, the number of cells to be 
examined and selection of a consistent, standardised exposure time should be 
established (Klionsky et al., 2012a). Basal or low level autophagy should also be pre-
determined to correctly identify/differentiate increased autophagy activity.  
 
1.1.4.4 Transmission electron microscopy   
Transmission electron microscopy (TEM) has been used to examine autophagy since 
the 1950s and still remains a widely used technique which can be used to study non-
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selective and selective autophagy (Eskelinen et al., 2011; Jia et al., 1997; Novikoff and 
Essner, 1962). TEM allows visualisation and identification of autophagy vacuoles, from 
phagophores to autophagolysosomes, based on morphological features (Klionsky et al., 
2012a; Yla-Anttila et al., 2009). For example, early autophagosomes are identifiable as 
double-layered membrane vesicles containing morphologically intact substrates not yet 
degraded (Jia et al., 1997), while late-stage autophagolysosomes are characterised by a 
single-layered membrane comprised of autophagy substrates in various states of 
degradation (Figure 1.3 B) (Eskelinen, 2008a, b; Yla-Anttila et al., 2009). Care must be 
taken when using TEM to identify these structures as every double-layered membrane 
vesicle within a cell is not necessarily an autophagy vacuole (Eskelinen, 2008b; 
Giammarioli et al., 2012). Goldlabeling immuno-TEM which uses antibodies bound to 
GFP which are directed against autophagy-related proteins allows more accurate 
identification of autophagy vacuoles compared to standard TEM.  
1.1.4.5 Immunohistochemistry  
Expression levels of various autophagy-related proteins have been examined in animal 
and human tissues using immunohistochemistry (IHC). Endogenous Atg4B, Atg9A and 
LC3 have been studied in rat and mouse tissues while Beclin-1, LC3, and to a lesser 
extent p62 have been evaluated in a number of human cancer tissues, where their 
expression was shown to be prognostically significant (Klionsky et al., 2012b; Klionsky 
et al., 2007; Lu et al., 2001). As IHC is not a technique which lends itself well to 
dynamic assays, it is more likely to provide a snapshot of autophagy activity within a 
cell than give information on the entire autophagy flux (Klionsky et al., 2012a). 
However, IHC is becoming increasingly employed as an autophagy assay. Staining by 
IHC can detect diffuse cytoplasmic proteins (e.g. LC3-I) and protein puncta (e.g. LC3-
II), the latter of which can be difficult to interpret and so should be evaluated with 
caution (Figure 1.3 C).  
Difficulties encountered when performing IHC include selection of an appropriate, 
high-quality antibody and identification of the most appropriate antigen-retrieval 
method which if optimised prior to staining can reduce background levels and false-
negatives (Conway et al., 2008; Shi et al., 2001; Shi et al., 1991). Prior to analysis by 
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IHC a representative tissue area should be selected for examination and clear guidelines 
for quantification established which are maintained across all samples.  
 
 
 
 
 
 
 
Figure 1.3 Representative output images from various autophagy assays 
Late stage inhibition of autophagy by the lysosomal inhibitor chloroquine (CQ) results in accumulation of 
LC3-positive punctate indicative of LC3-II in Su-DHL8 cell lines stained with rabbit polyclonal anti-
LC3B (A). Autophagy vacuoles visualised in isolated mouse hepatocytes by TEM. An early 
autophagosome (AVi) and late autophagolysosome (AVd) are shown. The AVi is identified by a double 
membrane separated by an electron-cleft (arrow) and intact cytoplasmic contents; the AVd is identified 
by its partially degraded contents and rough endoplasmic reticulum (B). Representative image of a 
Beclin-1
+
 hepatocellular carcinoma patient tissue sample stained by IHC using rabbit monoclonal anti-
Beclin-1 antibody and visualised at 400x magnification (C). Adapted from Jia et al 2012, Klionsky et al 
2012, and Ding et al 2008 respectively.  
1.1.4.3 Gene expression analysis / quantitative real-time polymerase chain reaction 
Examination of autophagy at the messenger RNA (mRNA) level using gene expression 
profiling (GEP) and quantitative real-time polymerase chain reaction (qRT-PCR) is 
becoming increasingly common. These assays allow simultaneous examination of 
expression levels of a plethora of genes involved in all stages of the autophagy flux and 
will undoubtedly provide more information and improve our understanding of this 
complex process.  
While we are aware of what happens to key autophagy players such as LC3 and p62 at 
the protein level, it is still unclear what happens these and other proteins at the mRNA 
level when autophagy is active or inhibited. Some reports indicate LC3 mRNA levels 
remain unchanged while others have reported an increase in its synthesis following 
starvation-induced autophagy. It has been suggested that modulations in LC3 mRNA 
are cell-type specific and so should be examined on a case-by-case basis (Klionsky et 
al., 2012b; Mizushima and Yoshimori, 2007; Nara et al., 2002). It is also unclear what 
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happens to Squestosome1 (SQSTM1) levels during autophagy. Unaltered SQSTM1 
levels have been reported where as an increase in p62 mRNA levels following 
autophagy induction has also been observed (Komatsu et al., 2010; Nakaso et al., 2004; 
Sahani et al., 2014).  
1.1.5 Autophagy inducers and inhibitors 
As well as extracellular signals, intracellular genes and proteins (Table 1.1) and a 
variety of chemical compounds (Table 1.2) are involved in induction and inhibition of 
the autophagy pathway.  
1.1.5.1 Inducers of the autophagy pathway 
A well established inducer of the autophagy pathway is oxygen deprivation or hypoxia. 
Increased autophagy activity under hypoxic conditions, particularly in cancer cells, can 
promote cell survival, tumour progression and resistance to treatment (Brahimi-Horn et 
al., 2007). HIF-1 is a transcription factor which induces autophagy and a plethora of 
genes which allow cells to adapt to and survive hypoxia (Semenza, 2010). Hypoxia-
induced autophagy can occur in a HIF-dependent or -independent manner. HIF-1-
dependent autophagy involves HIF-1-mediated transcriptional activation of the BCL2-
homolgy3 (BH3) only proteins BNIP3 and BNIP3α which disrupt binding between 
BCL-2 and Beclin-1, allowing autophagy to proceed (Bellot et al., 2009; Mazure and 
Pouyssegur, 2010). Conversely, HIF-independent autophagy involves increased 
activation of AMPK which functions to inhibit the mammalian target of rapamycin 
(mTOR) pathway and thus increase levels of autophagy activity (Papandreou et al., 
2008).  
Autophagy is also induced by nutrient deprivation or starvation through numerous 
mechanisms. Reactive oxygen species (ROS), particularly hydrogen peroxide (H2O2) 
and super oxide (O2
-
) which originate at the mitochondria, are highly involved in 
starvation-induced autophagy (Scherz-Shouval and Elazar, 2011). Accumulation of 
ROS induces activation of AMPK and the JAK/STAT3 pathway both of which induce 
autophagy activity (Li et al., 2013; Yoon et al., 2010). Starvation also induces 
autophagy by inhibiting mTOR and by inducing phosphorylation of BCL-2 which 
promotes its dissociation from Beclin-1 (Jung et al., 2010; Yang and Klionsky, 2010).  
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The tumour suppressor protein PTEN induces autophagy by acting as an upstream 
negative regulator of the AKT/mTOR pathway through its lipid phosphatase activity 
(Azad et al., 2009; Sarkar et al., 2009). AMPK also promotes autophagy via inhibition 
of mTOR. Direct mTOR inhibition by AMPK occurs following AMPK mediated 
phosphorylation and inhibition of RAPTOR (regulatory-associated protein of mTOR), a 
component of the mTORC1 complex (Alers et al., 2012; Kim et al., 2011). AMPK can 
also indirectly inhibit mTOR by phosphorylating and activating tuberous sclerosis 
complex-2 (TSC2) a member of the TSC1/2 complex which negatively regulates mTOR 
(Feng et al., 2005; Maiuri et al., 2010).  
Rapamycin is a lipophilic secondary metabolite compound used as an 
immunosuppressive agent which induces autophagy by inhibiting the mTORC1 
complex and facilitating activation of the ULK1-Atg13-FIP200 complex required for 
autophagosome formation (Benjamin et al., 2011; Renna et al., 2010; Sarkar et al., 
2009; Wu et al., 2011). ABT-737 is a BH3-mimetic originally developed to bind the 
anti-apoptotic proteins BCL-2, BCL-xL and BCL-w via BH3 domain interactions 
resulting in their sequestration and the subsequent induction of apoptosis (Kang and 
Reynolds, 2009; van Delft et al., 2006; Vogler et al., 2009). Binding of ABT-737 to 
BCL-2 has also been shown to induce autophagy (Levine et al., 2008; Marquez and Xu, 
2012). BCL-2 can bind and sequester the pro-autophagy protein Beclin-1 and inhibit 
autophagy. By binding BCL-2, ABT-737 prevents its interaction with Beclin-1 and thus 
inhibits the anti-autophagic action of BCL-2 (Section 1.4) (Levine et al., 2008; Malik et 
al., 2011; Marquez and Xu, 2012). ABT-737 has also been found to induce autophagy 
by phosphorylating and activating the previously discussed autophagy inducer AMPK 
as well as through inhibition of AKT and mTOR (Malik et al., 2011). The effect of 
ABT-737 on BCL-2 and the autophagy pathway and how this may affect tumour cell 
killing by this BH3-mimetic have yet to be determined in FL and DLBCL cells.   
1.1.5.2 Inhibitors of the autophagy pathway  
One of the key inhibitors of the autophagy pathway is the PI3K/AKT/mTOR pathway, 
with active mTOR signalling promoting cell growth and inhibition of autophagy. 
mTOR is comprised of two complexes – mTORC1 and mTORC2 - and is located 
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downstream in the class I PI3K pathway (Sarkar et al., 2009). It is positively regulated 
by the kinase AKT and the RHEB G-protein but is negatively regulated by TSC2 and 
the TSC1/TSC2 complex (Feng et al., 2007; Renna et al., 2010; Sarkar et al., 2009). 
Inhibition of autophagy by mTOR involves ULK1, Atg13 and FIP200, all of which are 
necessary for phagophore formation. Under nutrient rich conditions mTOR 
phosphorylates and inhibits ULK1 and Atg13 preventing development of the 
phagophore (Nazio et al., 2013; Renna et al., 2010; Sarkar et al., 2009).  
Pharmacological inhibitors of autophagy include 3-methyladenine (3-MA) (Jia et al., 
1997), Bafilomycin-A1 and CQ which exert their function at different stages in the 
pathway. 3-MA is a PI3K inhibitor which negatively regulates autophagy early in the 
pathway by inhibiting the class III PI3K Vps34 and preventing autophagosome 
formation (Liu et al., 2011; Seglen and Gordon, 1982). Conversely, Bafilomycin-A1 
and CQ inhibit autophagy later in the pathway by interfering with autophagosome 
fusion and lysosomal degradation. The widely used anti-malaria drug CQ is a 
lysosomotropic agent which raises the lysosomal pH and prevents 
autophagosome/lysosome fusion and substrate degradation. Impairment of this final 
step in the autophagy pathway results in accumulation of substrate containing 
autophagosomes and prevents recycling of old proteins and organelles back into the 
cytoplasm (Amaravadi et al., 2007; Sasaki et al., 2010). Treatment with CQ therefore 
results in accumulation of LC3-II and p62 which are autophagy substrates sequestered 
by the autophagosome (Amaravadi et al., 2007; Bjorkoy et al., 2005; Jia et al., 2012). 
Table 1.1 Genes and proteins involved in autophagy regulation 
Gene/Protein Inducer/Inhibitor Reference 
AMPK1 Inducer (Alers et al., 2012) 
PTEN Inducer (Azad et al., 2009) 
DAPK1 Inducer (Maiuri et al., 2010) 
ROS (H2O2) Inducer (Scherz-Shouval et al., 2007) 
Nuclear p53 Inducer (Maiuri et al., 2010) 
mTOR (PI3K/AKT//mTOR) Inhibitor (Nazio et al., 2013) 
Cytoplasmic p53 Inhibitor (Maiuri et al., 2010) 
NF-κB Inhibitor (Djavaheri-Mergny et al., 2006) 
BCL-2; BCL-xL Inhibitor (Kang et al., 2011) 
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Table 1.2 Chemical Compounds involved in autophagy regulation 
Compound Inducer/Inhibitor Reference 
TNF-α Inducer (Jia et al., 1997) 
Rapamycin Inducer (Sarkar et al., 2009) 
ABT-737 Inducer (Marquez and Xu, 2012) 
Metformin Inducer (Ben Sahra et al., 2010) 
Lithium Inducer (Renna et al., 2010) 
CQ/HCQ Inhibitor (Jia et al., 2012) 
3-Methylamine (3-MA) Inhibitor (Jia et al., 1997; Liu et al., 2011) 
Bafilomycin-A1 Inhibitor (Klionsky et al., 2008b) 
 
1.1.6 Apoptotic and autophagic cell death 
It is becoming increasingly apparent that autophagy and apoptosis are not mutually 
exclusive pathways, but rather share common regulators and can act in synergy with or 
antagonistically toward one another  (Denton et al., 2012; Eisenberg-Lerner et al., 2009; 
Maiuri et al., 2007c). 
1.1.6.1 Apoptosis - type-I programmed cell death 
Apoptosis, classified as a type-I form of programmed cell death (PCD), is the controlled 
killing of cells which are deemed superfluous or potentially dangerous and is involved 
in maintenance of homeostasis and developmental processes. It can be divided into two 
pathways – intrinsic and extrinsic – which differ with respect to initiation signals, mode 
of action and molecules involved. Morphological characteristics of apoptotic cells 
include nuclear fragmentation, membrane blebbing and chromatin condensation (Kerr et 
al., 1972; Maiuri et al., 2007c; Ola et al., 2011). 
The intrinsic apoptotic pathway is stimulated upon receipt of intracellular signals such 
as oxidative stress and DNA damage and centres on the mitochondria. Triggering of the 
intrinsic pathway promotes translocation of BCL-2 family members Bim, Bid, Bax and 
Bak to the mitochondria. Once there, Bim and Bid, classified as BH3-only activator 
proteins stimulate a conformational change in Bax and Bak promoting their 
oligomerisation and inducing mitochondrial outer membrane permeabilisation (MOMP) 
(Deng et al., 2007; Maiuri et al., 2007c). MOMP decreases mitochondrial membrane 
potential (ΔΨm) and facilitates the release of pro-death molecules such as cytochrome 
c, apoptosis-inducing factor (AIF) and endonuclease G (ENDOG). AIF and ENDOG 
migrate to the nucleus where they trigger large scale DNA fragmentation and the 
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caspase-independent apoptosis pathway, while cytochrome c binds deoxyadenosine 
triphosphate (dATP) and apoptotic protease-activating factor (APAF1) to form the 
apoptosome which induces caspase-dependent apoptosis. The caspase-cascade involves 
‘activator’ caspases (e.g. caspase-8) inducing activation of ‘executioner’ caspases (e.g. 
caspase-3) which once activated facilitate apoptosis by promoting and inducing cellular 
proteolysis and marking cells destined for phagocytic engulfment and cell death (Deng 
et al., 2007; Galluzzi et al., 2012; Ola et al., 2011). 
The extrinsic apoptosis pathway is induced upon receipt of an extracellular signal and 
involves binding of ligands such as FASL, TNF-α and TRAIL to their respective 
transmembrane receptors FAS, TNFR or TRAILR and inducing trimerisation. These 
trimers then recruit cellular inhibitors of apoptosis proteins (cIAPs) and death-domain 
containing adaptor molecules such as FADD to the cytoplasmic side of the 
mitochondrial membrane to form the death induced signalling complex (DISC). The 
DISC then stimulates caspase-8 or caspase-10 to induce the caspase-cascade and cell 
death (Galluzzi et al., 2012; Maiuri et al., 2007c; Ola et al., 2011).  
1.1.6.2 Autophagy - type-II programmed cell death 
Although predominantly considered a pro-survival mechanism, autophagy has also been 
classified as a form of cell death depending on the cell type and the nature of the 
stimulus (Galluzzi et al., 2012). Autophagy was classified as a type-II PCD based on 
morphological features when dying cells were shown to exhibit a different morphology 
to that typically seen in cells undergoing apoptosis. Cells dying by autophagy are 
characterised by the presence of large numbers of autophagosomes and large-scale 
cytoplasmic vacuolisation (Fulda, 2012; Jia et al., 1997; Sasi et al., 2009; Shen and 
Codogno, 2011). However, confirmation of autophagy as a bona fide form of cell death 
is ongoing.  
Some reports suggest autophagy occurs and cell death ensues; however others state that 
cells die directly as a result of the autophagy pathway, with evidence emerging that the 
latter is true (Eisenberg-Lerner et al., 2009; Fulda, 2012; Gonzalez-Polo et al., 2005; 
Rosenfeldt and Ryan, 2011). It has been shown that in Bax
-
/Bak
-
 cells defective for 
apoptosis, an increase in autophagy corresponds to an increase in cell death. Similarly, 
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inhibition of the autophagy pathway using pharmacological inhibitors such as CQ, or 
short-interfering RNA (siRNA) targeted against autophagy genes such as Atg7, results 
in decreased cell death in apoptosis-deficient cells (Fulda, 2012; Shen and Codogno, 
2011; Shimizu et al., 2004). An increase in the entire autophagy flux, not only cellular 
levels of autophagy markers must be observed in order to classify cell death as 
autophagic. Shen and colleagues have proposed three criteria which must be met in 
order for autophagy to be classified as a genuine cell death mechanism: (i) cells must be 
defective for apoptosis, i.e. death occurs without activation of apoptosis; (ii) inhibition 
of autophagy genetically or pharmacologically attenuates cell death and increases cell 
survival; (iii) there is an increase in the autophagy flux (Shen and Codogno, 2011).   
1.1.6.3 Cross-talk between autophagy and apoptosis 
Autophagy and apoptosis are conflicting pathways – one typically promotes cell 
survival, the other cell death. Maintaining the appropriate balance between these 
pathways is therefore important when determining cell fate (Maiuri et al., 2007c; 
Mukhopadhyay et al., 2014). It is also important to consider the cross-talk between 
these pathways when considering the effects of anti-cancer treatments on either 
pathway. 
 
Depending on the stimulus received and cellular conditions, autophagy and apoptosis 
may be induced in a combined or mutually exclusive manner. Upon receipt of a stress 
signal cells generally up-regulate autophagy in a bid to survive, where as death-receptor 
activation typically results in promotion of apoptosis and cell death (Eisenberg-Lerner 
et al., 2009). The sensitivity threshold of cells to different stimuli is also involved in 
deciding which pathway to induce. Low level mitochondrial damage may result in 
increased autophagy, while a high degree of injury to these essential organelles will 
induce apoptotic or necrotic cell death (Maiuri et al., 2007c). Cross-talk between these 
pathways can be divided into three broad categories – co-operative, antagonistic and 
enabling. Under the co-operative setting autophagy and apoptosis promote cell death 
and compensate for one another if needed. For example, in Bax
-
/Bak
-
 apoptosis-
deficient cells autophagy activity can increase and ultimately result in autophagic cell 
death (Maiuri et al., 2007c; Mukhopadhyay et al., 2014). In the antagonist setting, 
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induction of one pathway can prevent promotion of the other. Following administration 
of chemotherapeutic drugs for example, autophagy can be induced by cells as a 
cytoprotective mechanism to escape this stress, mitigate cellular damage and avoid 
apoptosis (Eisenberg-Lerner et al., 2009; Kimmelman, 2011). Finally, induction of 
autophagy can enable apoptosis without itself promoting cell death by responding to a 
stress but subsequently assisting in triggering the apoptotic cascade and cell death 
(Eisenberg-Lerner et al., 2009; Maiuri et al., 2007c).  
Autophagy and apoptosis share many common triggers and regulators. Increased 
cellular levels of ROS which promote MOMP, a key step in induction of the intrinsic 
apoptosis pathway, can also promote autophagy by activating Atg4, an important step in 
autophagy induction (Maiuri et al., 2007c; Scherz-Shouval et al., 2007). Similarly, ER-
stress, a well established trigger of apoptosis, also induces reticulophagy, the 
autophagy-mediated degradation and removal of damaged ER (Abida and Gu, 2008; 
Eisenberg-Lerner et al., 2009; Yorimitsu et al., 2006). BH3-only proteins also regulate 
induction of autophagy and apoptosis. These pro-survival proteins can induce 
autophagy by binding BCL-2 and promoting the release of Beclin-1. They also promote 
apoptosis via inhibitory-interactions with anti-apoptotic proteins such as BCL-2 or 
inducing-interactions with pro-apoptotic proteins, e.g. Bak (Maiuri et al., 2007c; 
Marquez and Xu, 2012; Mukhopadhyay et al., 2014). The cellular location of these 
BH3-only interactions is thought to play a role in determining autophagy/apoptosis 
induction. Binding of BH3-only proteins to Beclin-1 at the ER induces autophagy, 
while their binding to BCL-2 family members occurs at the mitochondria and promotes 
apoptosis (Maiuri et al., 2007b).  
A number of key autophagy genes and proteins have been shown to regulate and be 
regulated by the intrinsic and extrinsic apoptosis pathway. For example the N-terminal 
cleavage product of the autophagy essential protein Atg5 has been shown to translocate 
to the mitochondria where it interacts with BCL-xL to promote cytochrome c release 
and the intrinsic apoptosis pathway, while cleavage of Atg3 by caspase-8 results in 
autophagy inhibition during the extrinsic apoptosis pathway (Mukhopadhyay et al., 
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2014). Table 1.3 lists other autophagy genes and proteins involved in regulation of both 
pathways.  
 
Table 1.3 Dual roles of autophagy and apoptosis genes  
  
1.1.7 Autophagy in cancer  
The role of autophagy in cancer development is a paradoxical one. While on the one 
hand described as a tumour suppressing mechanism, autophagy has also been reported 
to promote and maintain tumour cell survival (Choi et al., 2013a; Eisenberg-Lerner and 
Kimchi, 2009; Mizushima et al., 2008). Autophagy activity, which is regulated by both 
tumour suppressors and oncogenic promoters, has been reported to be increased and 
decreased within tumour cells with both instances shown to be pro- and anti-
tumourogenic (Guo et al., 2011; Liang et al., 1999; Mathew et al., 2009; Rosenfeldt et 
al., 2013; Yang et al., 2011). Levels of autophagy activity can modulate the response of 
tumour cells to chemotherapeutic agents by promoting or hindering their pro-apoptotic 
function, and correlate with clinical outcome in cancer patients (Bellodi et al., 2009; 
Verschooten et al., 2012).  
 
Protein Function Role in Autophagy Role in Apoptosis 
Beclin-1 Autophagy Autophagosome nucleation Cleaved C-fragment induces 
intrinsic apoptosis 
AMBRA Autophagy Up-regulates interaction 
between Vps34 and Beclin-1 
Cleaved by caspase and calpins; 
regulates intrinsic apoptosis 
UVRAG Autophagy Up-regulates interaction 
between Vps34 and Beclin-1 
Inhibits Bax translocation to the 
mitochondria; anti-apoptotic 
ATG5 Autophagy Conjugates to Atg12 and 
promotes membrane elongation 
Promotes intrinsic apoptosis; 
inhibits extrinsic apoptosis via 
FADD interactions 
ATG3 Autophagy Conjugates with Atg12 Regulates intrinsic apoptosis 
p62 Autophagy Delivery of substrates to the 
autophagosome 
Processing and activation of 
caspase-8 
BCL-2/ 
BCL-xL 
Apoptosis Sequesters Beclin-1; inhibits 
autophagy 
Anti-apoptotic 
Bad/Bak Apoptosis Disrupts BCL-2/Beclin-1 
binding; induces autophagy 
Pro-apoptotic 
Bim Apoptosis Sequesters Beclin-1; inhibits 
autophagy 
Pro-apoptotic 
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1.1.7.1. The tumour suppressing role of autophagy 
The principle role of autophagy is to degrade and remove old and damaged cellular 
organelles and proteins which if allowed accumulate in cells can promote instability and 
tumourigenesis. By removing accumulated intracellular aggregates, autophagy 
maintains genomic stability, prevents DNA damage, mitigates oxidative stress and 
suppresses tumourigenesis. Autophagy can also suppress tumour formation by 
degrading damaged cellular organelles and inducing autophagic cell death, therefore 
preventing necrotic cell death and the subsequent inflammatory response it induces 
(Eisenberg-Lerner et al., 2009; Helgason et al., 2013; Mathew et al., 2009; Pattingre and 
Levine, 2006; Rosenfeldt and Ryan, 2011).  
Autophagy was considered a tumour suppressor mechanism when it was shown that 
ablation of key autophagy genes and proteins induces tumour formation. The 
observation that increased expression of the autophagy essential protein Beclin-1 
suppresses tumourigenesis in nude mice identified it as a haploinsufficient tumour 
suppressor molecule (Liang et al., 1999) and demonstrated that active autophagy can act 
as a tumour suppressing pathway. Autophagy inhibition due to ablation of Atg genes 
can also promote tumour growth. For example, it has been reported that mice with liver-
restricted deletion of Atg7 develop hepatocarcinomas while frameshift mutations in 
Atg2B, Atg5, and Atg12 are frequently observed in colorectal and gastric carcinomas. 
Active autophagy can therefore function to suppress the development of multiple 
different neoplasms (Helgason et al., 2013; Kang et al., 2009; Takamura et al., 2011).  
1.1.7.2 The tumour promoting role of autophagy 
Exploitation of the pro-survival role of autophagy is not restricted to healthy cells but is 
also employed by tumour cells which use this pathway to evade stress and maintain 
survival (Kimmelman, 2011; Kroemer et al., 2010). The main manner in which 
autophagy promotes tumour cell survival is by mitigating metabolic stresses 
encountered by malignant cells. It is well known that tumour cells deprived of nutrients 
and/or oxygen (hypoxic cells) induce autophagy to adapt to these stresses and stay alive 
(Degenhardt et al., 2006; Eisenberg-Lerner and Kimchi, 2009; Guo et al., 2011; 
Kimmelman, 2011). A cell autonomous role for autophagy in tumour cell maintenance 
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has also been suggested where neoplastic cells have developed a requirement for active 
autophagy in order to survive (Guo et al., 2011). Yang and co-workers reported that 
active autophagy is necessary for pancreatic tumour cell survival and that inhibition of 
autophagy resulted in attenuation of in vitro cell growth and improved response to 
cancer therapy (Kimmelman, 2011; Yang et al., 2011). It has also been reported that in 
vivo inhibition of autophagy through Atg3 deletion results in decreased BCR-Abl-
induced leukaemogenesis and increased cell death indicating a dependency on the 
autophagy pathway in these cells (Altman et al., 2011). Autophagy is also known to 
play a role in tumour maintenance by allowing malignant cells to escape cellular stress 
induced by anti-cancer therapies (Choi et al., 2013a).  
The role of autophagy in tumour development appears to be cell type-dependent, 
implying that autophagy activity should be examined on a cancer by cancer  basis 
(Eisenberg-Lerner and Kimchi, 2009). A possible model for the role of autophagy in 
malignancies is as follows: inhibition of autophagy results in an increase in genomic 
instability and DNA damage which can induce and promote malignant transformation. 
Once transformation of a normal cell to a cancerous cell has occurred, persistence of 
autophagy inhibition and its cellular effects (e.g. increase ROS production) are 
incompatible with survival. Thus, established tumours reactive or up-regulate the 
autophagy flux to avoid stress, maintain survival and promote growth (Kimmelman, 
2011; Scherz-Shouval and Elazar, 2011).    
1.1.7.3 The role of autophagy in cancer therapy  
It is widely accepted that treatment of neoplastic cells with anti-cancer agents can 
induce autophagy activity. The influence of therapy-induced autophagy on the efficacy 
of chemotherapy drugs varies from a bystander effect to promoting cell death to 
functioning as a cytoprotective, pro-survival mechanism (Choi et al., 2013a; Wu et al., 
2011).  
Although not as commonly reported, therapy-induced autophagy can potentiate the pro-
death function of chemotherapeutic agents. For example, induction of apoptosis and 
autophagy following treatment with ABT-737 and rapamycin respectively has been 
shown to increase sensitivity of non-small cell lung carcinoma in vitro and in vivo (Kim 
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et al., 2009; White, 2012). However, a more common observation is the induction of 
autophagy as a cytoprotective mechanism which allows cancer cells mitigate therapy 
induced stress and avoid apoptosis (Choi et al., 2013a; Helgason et al., 2013).  
Amaravadi and colleagues have shown that in a Myc-induced lymphoma model, 
inhibition of autophagy can increase cell death. They reported that treatment of p53
-
/
-
 
mice with tamoxifen can restore apoptosis but also induces cytoprotective autophagy 
within these cells. Inhibition of therapy-induced autophagy via genetic knockdown of 
Atg5 or pharmacological inhibition by CQ resulted in increased killing of tumour cells, 
indicating a rationale for the use of autophagy inhibitors in conjunction with standard 
alkylating and p53 activating cancer therapies (Amaravadi et al., 2007). It has also been 
shown that prostate cancer and chronic myeloid leukaemia (CML) cells induce 
cytoprotective autophagy following treatment with Tunicamycin and Imatinib, 
respectively, suggesting that combined treatment with autophagy-inhibiting agents may 
improve the efficacy of these therapeutic agents (Helgason et al., 2013). Treatment with 
BH3-mimetic compounds such as (-)-Gossypol induces apoptosis by inhibiting BCL-
2/BCL-xL and also induces cytoprotective autophagy in breast cancer cell lines (Gao et 
al., 2010).  
In contrast with these findings, a recent study by Rosenfeldt and colleagues has shown 
that inhibition of autophagy with CQ in Kras-positive, p53-null mice with pancreatic 
ductal adenocarcinoma (PDAC) results in increased, accelerated tumour formation in 
vivo (Rosenfeldt et al., 2013). They found that autophagy competent mice which 
expressed mutated, activated Kras developed PDAC while mice which were autophagy 
defective due to ablation of Atg5 and Atg7 developed pre-malignant pancreatic lesions 
which did not progress to PDAC. Inhibition of p53 in either setting resulted in 
development of PDAC, however tumour formation and progression was accelerated in 
autophagy-defective cells. They confirmed this finding by treating autophagy competent 
p53
-
/
-
, Kras mutated mice with the late autophagy inhibitor CQ and found that PDAC 
formation occurred at an accelerated rate compared to non-treated cells (Rosenfeldt et 
al., 2013). These findings demonstrate that the effects of autophagy inhibition on 
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tumour progression should be tested on a case by case basis and again highlight the 
conflicting role of this pathway in different malignancies.  
A number of clinical trials are currently underway which are investigating the use of 
autophagy inhibitors in various cancer settings (Helgason et al., 2013). For example the 
CHOICES (CHlOrquine and Imatinib(IM) Combination to Eliminate Stem Cells) phase 
I clinical trial is studying combination of Imatinib with hydroxychloroquine (HCQ) in 
CML patients, while a phase I/II trial investigating the effect of HCQ in combination 
with gemcitabine in pancreatic cancer is also underway (Bellodi et al., 2009; Helgason 
et al., 2013; Sinclair et al., 2013). While CQ and HCQ inhibit autophagy, they are not 
specific inhibitors of this pathway. Therefore, while administration of these drugs does 
potentiate the pro-apoptotic effects of multiple chemotherapy drugs, it cannot be 
definitively stated that this is due to targeted autophagy inhibition (Helgason et al., 
2013; Sinclair et al., 2013).  
New compounds are currently being developed which are more specific inhibitors of 
autophagy. Potential targets for such compounds include Vps34, ULK1/2 and Atg 
genes. Spautin-1, a small molecule inhibitor (SMI) directed against Vps34 has already 
been developed and is showing promise in the pre-clinical setting, while studies have 
also shown that ablation of Atg7 or Atg5 in combination with Imatinib results in 
decreased tumour cell colony formation and cell proliferation (Helgason et al., 2013; 
Sinclair et al., 2013). It therefore seems likely that autophagy inhibiting agents may 
soon be administered alongside standard chemotherapy agents in a bid to improve 
tumour cell killing by these drugs.  
It is unknown if the chemotherapy regimens currently used to treat FL and DLBCL 
induce or inhibit autophagy activity within these tumours and if so, whether controlling 
autophagy modulation can improve the efficacy of these anti-cancer agents.  
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1.2 Beclin-1 
1.2.1 Beclin-1 is essential to the autophagy pathway 
Beclin-1 was discovered by Liang and co-workers in 1998 while searching for binding 
partners of BCL-2. They identified Beclin-1/Vps30, the mammalian homolog of the 
autophagy gene Atg6, a novel 60kDa coiled-coiled protein to be capable of binding this 
anti-apoptotic protein (Liang et al., 1998). Subsequent studies revealed Beclin-1 to be 
essential for autophagy initiation as it binds Vps34 and Vps15 at the PAS as part of the 
IC, recruits other proteins such as AMBRA and UVRAG and promotes phagophore 
formation (He and Levine, 2010; Kihara et al., 2001; Marquez and Xu, 2012; Pattingre 
et al., 2005).  
1.2.2 Beclin-1 is a multi-domain protein  
Beclin-1 is comprised of an N-terminal BH3 domain, a central coiled-coiled domain 
(CCD) and a C-terminal evolutionarily conserved domain (ECD) which allow Beclin-1 
to interact with a wide variety of proteins and are important to its pro-autophagic and 
anti-tumour roles (Figure 1.4 A) (Kang et al., 2011). The autophagy promoters 
UVRAG, AMBRA and Atg14L bind to the CCD, Vps34 binds to the CCD and ECD 
domains, and the autophagy inhibitor BCL-2 binds Beclin-1 via BH3 domain 
interactions (Figure 1.4). Beclin-1s' ECD is essential for promotion of autophagy and 
inhibition of tumourigenesis, as is the nuclear export signal (NES) located in the CCD 
(Kang et al., 2011). Ubiquitination and phosphorylation of residues within the BH3 
domain of Beclin-1 also induces autophagy (Figure 1.4 B; Section 1.4.2.2) (Kang et al., 
2011; Marquez and Xu, 2012).  
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Figure 1.4 Structural organisation of the autophagy essential protein Beclin1 
Beclin1 contains multiple binding domains which facilitate its self-oligomerisation and interaction with 
various proteins (A). The BH3 domain of Beclin-1 can be phosphorylated and ubiquitinated (B). BH3 -  
BCL-2 homology 3; CCD - coiled-coiled domain; ECD - evolutionarily conserved domain; NES - nuclear 
export signal; Ub - ubiquitination site; P - phosphorylation site; N - N-terminal; C -C-terminal. Adapted 
from Kang, Zeh et al 2011. 
 
1.2.3 Beclin-1 localises to the mitochondria and the ER 
This pro-autophagy protein is expressed by various mammalian cells and tissues where 
it interacts with multiple different proteins (Kang et al., 2011; Pattingre et al., 2005). 
Within cells, Beclin-1 was initially reported to locate primarily to the trans-Golgi 
network (TGN); however, further studies by Pattingre and colleagues using confocal 
microscopy revealed co-localisation of  Beclin-1 with dyes targeted to the ER and the 
mitochondria (Pattingre et al., 2005). Beclin-1 interacts with Vps34 at the TGN and 
BCL-2 at the ER and mitochondria.  
1.2.4 Beclin-1 is a tumour suppressor protein 
Beclin-1 maps to chromosome 17q21, a tumour susceptibility locus which is mono-
allelically deleted in 40-75% of human malignancies including spontaneous breast and 
ovarian cancers. This leads to classification of Beclin-1 as a haploinsufficient tumour 
suppressor protein which when overexpressed can inhibit tumourigenesis (Liang et al., 
1999; Marquez and Xu, 2012; Qu et al., 2003; Yue et al., 2003).  
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The direct effect of heterozygous deletion of Beclin-1 on autophagy and tumour growth 
was demonstrated by Liang and co-workers in 1999. Using MCF-7 breast carcinoma 
cells which do not express Beclin-1 (MCF-7.control) and cells transfected with full-
length Beclin-1 (MCF-7.beclin-1) they identified a higher number of autophagosomes 
and increased autophagy activity within MCF-7.beclin-1 cells under normal and starved 
conditions. Proliferation rates were found to be lower in cells expressing Beclin-1 as 
were incidences of tumour formation in nude mice injected with MCF-7.beclin-1 cells 
compared to MCF-7.control treated mice (Liang et al., 1999). Together, these results 
show autophagy activity is inhibited when Beclin-1 is absent and also demonstrate the 
tumour suppressing role of Beclin-1, in turn highlighting the anti-neoplastic role of 
autophagy.  
Expression levels of Beclin-1 have also been shown to be associated with clinical 
outcome (Huang et al., 2010; Marquez and Xu, 2012). A recent study by Nicotra and 
colleagues found that in a cohort of 102 non-Hodgkin’s lymphoma (NHL) patients, 
increased expression of Beclin-1 (≥20%) was associated with better overall survival 
(Nicotra et al., 2010b). Of the 59 NHL cases classified as having high Beclin-1 
expression, 16 were diagnosed as FL and 15 as DLBCL. They reported an overall 
positive correlation between Beclin-1 expression and the presence of LC3-II puncta, and 
thus suggest that higher Beclin-1 expression reflects increased autophagy activity. 
Expression levels of BCL-2 and Beclin-1 were found to be negatively correlated, which 
they propose indicates that in the absence of BCL-2, levels of Beclin-1 and autophagy 
activity are increased (Nicotra et al., 2010b). However, while increased numbers of 
LC3-II puncta are often taken to reflect an active autophagy flux, it is also well 
established that inhibition of autophagy degradation results in accumulation of this 
autophagy substrate (Kabeya et al., 2000; Klionsky et al., 2012b; Maycotte et al., 2012; 
Pankiv et al., 2007). Similarly, while Beclin-1 is known to be an autophagy-essential 
protein, it is not firmly established that its expression levels directly reflect autophagy 
activity (Castino et al., 2011; Klionsky et al., 2012b). In their study, Nicotra and 
colleagues provide no evidence to confirm that increased Beclin-1 expression directly 
reflects increased autophagy activity, or that accumulation of LC3-II puncta is not as a 
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result of a block in degradation. Therefore, while the prognostic significance of Beclin-1 
is clear from this study, it is not fully elucidated that the favourable prognosis associated 
with increased Beclin-1 expression is due to increased autophagy activity. Interestingly, 
p62 expression levels were not evaluated in this study.  
 
1.2.4.1 Expression levels of Beclin-1 can predict clinical outcome  
Cellular levels of Beclin-1 have previously been reported to predict clinical outcome in 
a variety of malignancies (Marquez and Xu, 2012). As it is described as a tumour 
suppressor protein, it is unsurprising that decreased Beclin-1 expression in particular is 
often associated with a poor prognosis. For example, Chen et al have described lower 
levels of Beclin-1 as being a marker of decreased survival rates among oesophageal 
squamous cell carcinoma patients (Chen et al., 2009), while Huang and colleagues 
reported a similar finding in patients with extranodal natural killer T-cell lymphoma 
(Huang et al., 2010). Decreased expression of Beclin-1 has also been shown to predict a 
poor outcome in NHL, as previously discussed (Nicotra et al., 2010b).  
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1.3 The BCL-2 family of proteins   
The BCL-2 family of proteins contains over a dozen members which possess at least 
one of the four BCL-2 homology (BH) domains (BH1 - BH4). These proteins are 
categorised into three groups - anti-apoptotic, pro-apoptotic or ‘BH3’ only pro-apoptotic 
- based on the number of BH domains they contain and their cellular function (Figure 
1.5) (Adams and Cory, 1998; Kelly and Strasser, 2011; Ola et al., 2011).  
Anti-apoptotic BCL-2 family members which include BCL-2, BCL-xL and BCL-w for 
the most part contain all four BH domains and function to inhibit apoptosis. Pro-
apoptotic proteins, of which Bax and Bak are the prototypes, are similar in structure to 
anti-apoptotic proteins but typically contain three BH domains and function to induce 
cell death. ‘BH3-only’ pro-apoptotic proteins, including Bim and Bad, only contain a 
BH3 domain and promote apoptosis (Figure 1.5) (Kelly and Strasser, 2011; Levine et 
al., 2008; Ola et al., 2011). ‘BH3’-only proteins are further classified as activators 
which induce apoptosis by binding Bax/Bak directly or sensitizers which bind anti-
apoptotic proteins, preventing them from binding and inhibiting activator ‘BH3’-only 
proteins (Deng et al., 2007; Kuwana et al., 2005; Letai et al., 2002). Not all 'BH3'-only 
proteins bind all other BCL-2 proteins with the same affinity. For example, Noxa binds 
MCL-1 not BCL-2, while Bad binds BCL-2 but not MCL-1 (Chen et al., 2005; Kelly 
and Strasser, 2011). 
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Figure 1.5 The BCL-2 family of proteins  
Structural organisation of key members of the BCL-2 family of proteins. Members of the BCL-2 family 
are classified based on the number of BCL-2 homology (BH) domains they contain and their function 
within the cell. The anti-apoptotic members of the family contain all four BH domains (BH1-BH4). The 
pro-apoptotic members vary in the number of BH domains they contain. Some members contain three 
while others, termed 'BH3'-only proteins containing only one BH domain. TM – transmembrane domain. 
Adapted from Kelly and Strasser 2011.  
 
1.3.1 The BCL-2 protein  
BCL-2, the founding member of the BCL-2 family of proteins, is a 26kDa protein 
which contains all BH1-BH4 domains (BH1-BH4) (Figure 1.5). This pro-survival 
protein was first identified in a cell line derived from a leukaemic patient harbouring the 
t(14;18)(q32;q21) translocation and was predicted to be of importance in pathogenesis 
of B-cell malignancies carrying this translocation (Tsujimoto et al., 1984). The t(14;18) 
translocation places BCL-2 under the control of Eμ, the promoter of the 
immunoglobulin heavy chain (IgH) gene resulting in increased expression of BCL-2 
which inhibits cell death (Kelly and Strasser, 2011; Tsujimoto et al., 1984; Vaux et al., 
1988).  BCL-2 localises to the ER, nuclear envelope and outer mitochondrial membrane 
via its hydrophobic carboxy-terminal domain where it interacts with various binding 
partners to inhibit apoptosis and/or autophagy (Ola et al., 2011; Rodriguez et al., 2011; 
Strappazzon et al., 2011). 
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1.3.2 BCL-2 - an inhibitor of apoptosis and autophagy  
BCL-2 inhibits the intrinsic apoptosis pathway by binding and sequestering the multi-
domain pro-apoptotic proteins Bax and Bak or the activator ‘BH3’-only proteins Bim 
and Bid (Deng et al., 2007; Kelly and Strasser, 2011). By binding Bax/Bak at the 
mitochondria, BCL-2 prevents MOMP and inhibits the release of pro-apoptotic 
molecules such as cytochrome c and SMAC/DIABLO, thus preventing induction of the 
caspase cascade and inhibiting cell death (Llambi and Green, 2011; Ola et al., 2011). 
Binding of BCL-2 to Bim and Bid at the mitochondria prevents Bim and Bid from 
binding Bax/Bak and exerting their pro-apoptotic function (Letai et al., 2002; Llambi 
and Green, 2011).  
BCL-2 can also act as an anti-autophagic protein by binding and sequestering Beclin-1. 
The mechanism of action by which BCL-2 does this will be discussed in detail in 
section 1.4. BCL-2 has also been shown to inhibit autophagy by binding and 
sequestering the Beclin-1 activator AMBRA1 at the mitochondria (Marquez and Xu, 
2012; Strappazzon et al., 2011). However, it has recently been suggested that BCL-2 
negatively regulates autophagy, not through direct interaction with key players in the 
autophagy pathway such as Beclin-1 and AMBRA1, but rather indirectly, through 
inhibition of the pro-apoptotic molecules Bax and Bak (Lindqvist et al., 2014).  
1.3.3 Overexpression of BCL-2 promotes tumourigenesis 
In 1989 Mc Donnell and colleagues demonstrated BCL-2 to be an oncogene by showing 
that transgenic mice carrying a minigene fusion which mimicked the t(14;18) 
translocation developed lymphoma and follicular hyperplasia (McDonnell et al., 1989). 
Classification of BCL-2 as an oncogene lead to establishment of a new category of 
oncogene which rather than promoting cell proliferation act to inhibit cell death; evasion 
of apoptosis is now considered a hallmark of cancer cells (Hanahan and Weinberg, 
2011; Kelly and Strasser, 2011; Kerr et al., 1972; Pietras and Ostman, 2010).  
While aberrant expression of BCL-2 due to this chromosomal rearrangement is 
frequently observed in FL and some DLBCL patients, increased expression of BCL-2 is 
not restricted to these lymphomas. High levels of BCL-2 are also observed in chronic 
lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and certain solid tumours 
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due to homo- or hemizygous deletion of the BCL-2 inhibiting microRNAs miR-15a and 
miR-16, or as a result of hypo-methylation of the BCL-2 promoter (Castle et al., 1993; 
Cimmino et al., 2005; Hanada et al., 1993; Kelly and Strasser, 2011).  
Neoplastic cells inhibit apoptosis by increasing expression of pro-survival proteins such 
as BCL-2 and MCL-1 or decreasing expression of pro-apoptotic proteins such as Bim, 
rendering tumour cells immortal (Kelly and Strasser, 2011; Llambi and Green, 2011; 
Vaux et al., 1988). In this way, increased expression of BCL-2 and mutations associated 
with this protein promote tumourigenesis by facilitating the survival of damaged, 
deregulated cells. 
Increased expression of pro-survival BCL-2 family members in cancer cells makes them 
attractive targets for therapeutic intervention. Indeed a number of anti-cancer agents 
have been shown to modulate their anti-apoptotic effects at both the gene and protein 
level. For example, treatment with the cytotoxic retinoid fenretinide and depsipeptide a 
histone-deacetylase (HDAC) inhibitor results in decreased expression of BCL-2, BCL-
xL and MCL-1 in leukaemia and multiple myeloma cells respectively and promotion of 
tumour cell death. Although these therapies do not specifically inhibit BCL-2 family 
proteins, their anti-neoplastic function has been proven, suggesting a role for them in 
combination therapy (Kang et al., 2008; Khan et al., 2004).  
‘BH3’-mimetic compounds have been developed which bind anti-apoptotic BCL-2 
proteins via BH3 domain interactions, inhibit their pro-survival function and induce 
tumour cell death (Kang and Reynolds, 2009). ABT-737, ABT-263 and ABT-199 are 
synthetic ‘BH3’-mimetics which bind BCL-2, BCL-w and BCL-xL or BCL-2 only, but 
not MCL-1 (Souers et al., 2013; Tse et al., 2008; Vogler et al., 2009). ABT-737 has 
shown anti-neoplastic activity in combination therapy and as a single agent in 
lymphoma and CLL, while ABT-263 has been effective in myeloma and lymphoma as 
well as relapsed/refractory lymphoid malignancies, again as a single agent or in 
combination therapy (Del Gaizo Moore et al., 2007; Tse et al., 2008; van Delft et al., 
2006). Similarly, treatment with ABT-199 has proved effective in patients with 
refractory CLL (Souers et al., 2013). ‘BH3’-mimetics therefore represent a new and 
promising form of cancer therapeutics.  
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The sensitivity of cancer cells to ‘BH3’-mimetic compounds can potentially be 
determined by identifying a cells BH3 profile (Deng et al., 2007). Deng and colleagues 
have shown that tumour cells which inhibit apoptosis by expressing high levels of anti-
apoptotic proteins such as BCL-2 and BCL-xL are ‘primed for death’ and are sensitive 
to therapeutic intervention by ‘BH3’-mimetics. BH3-profiling has also been shown to 
predict sensitivity to standard chemotherapy agents such as vincristine and etoposide 
(Deng et al., 2007; Llambi and Green, 2011). 
While established as an oncogene with regards its anti-apoptotic function, the role of 
BCL-2 in autophagy inhibition in cancer is unclear. In particular, it is unclear whether 
or not the aberrant expression of BCL-2 observed in FL cells affects autophagy in these 
malignant cells and/or plays a role in FL progression and transformation.  
  
  Chapter I Introduction 
 
56 
 
1.4 Binding between BCL-2 and Beclin-1 can inhibit autophagy  
Binding between BCL-2 and Beclin-1 was initially discovered in a yeast-two-hybrid 
screen in 1998 by Liang and colleagues (Liang et al., 1998). Further work by Pattingre 
and co-workers revealed that this binding sequesters Beclin-1 away from the IC and 
results in autophagy inhibition. Generation of mutant forms of BCL-2 which were 
unable to bind Beclin-1 resulted in increased levels of autophagy activity, confirming 
that binding of BCL2 to Beclin-1 inhibits autophagy (Pattingre et al., 2005). 
Interestingly, this inhibition is unidirectional with BCL-2/Beclin-1 binding having no 
impact on the ability of BCL-2 to inhibit apoptosis (Marquez and Xu, 2012; 
Mukhopadhyay et al., 2014; Rodriguez et al., 2011).  
1.4.1 BCL-2 and Beclin-1 can bind at the ER and mitochondria 
Intracellular Beclin-1 and BCL-2 localise to the mitochondria and ER. Localisation of 
these two proteins within the cell is a determining factor in their interaction and in 
autophagy inhibition (Maiuri et al., 2007a; Marquez and Xu, 2012). Pattingre and 
colleagues have demonstrated that ER-restricted BCL-2 mutants, which maintained 
functional BH3 domains and the ability to bind Beclin-1, were able to inhibit autophagy 
to the same level as wild-type BCL-2. Conversely, mutants targeted to the mitochondria 
had no inhibitory effect on the autophagy pathway, suggesting that BCL-2/Beclin-1 
binding at the ER inhibits autophagy (Kang et al., 2011; Maiuri et al., 2007a; Pattingre 
et al., 2005). This apparent dichotomy may explain why Beclin-1 binding does not 
affect the anti-apoptotic role of BCL-2 - BCL-2 inhibits apoptosis at the mitochondria 
by binding pro-death proteins, where as it inhibits autophagy by binding Beclin-1 at the 
ER (Maiuri et al., 2007a). 
While it is well known that BCL-2 is over expressed in FL due to the t(14;18) 
translocation, it is currently unknown: (a) if this protein binds Beclin-1 in these cells at 
either the mitochondria or the ER and (b) if binding does occur at either site, does BCL-
2 inhibit autophagy in FL?   
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1.4.2 Binding between BCL-2 and Beclin-1 can be disrupted in various ways 
1.4.2.1 Competitive binding inhibits BCL-2/Beclin-1 interactions  
High mobility group box 1 (HMGB1) is a pro-autophagy damage associated molecular 
pattern (DAMP) molecule involved in inflammation, apoptosis and autophagy. HMGB1 
shuttles between the nucleus and the cytoplasm and can disrupt binding between BCL-2 
and Beclin-1 (Tang et al., 2010). The positively charged ‘A Box’ and ‘B Box’ domains 
of HMGB1 contain three cysteines which are essential for its pro-autophagy role. 
Cysteines C23 and C45 facilitate interaction between HMGB1 and Beclin-1 by forming 
a disulfide bridge between the two. This interaction displaces Beclin-1 from BCL-2 and 
facilitates autophagy induction (Figure 1.6 A). Translocation of HMGB1 from the 
nucleus to the cytoplasm which is essential for its pro-autophagy role is promoted by 
C106 and can be induced by Rapamycin and starvation (Kang et al., 2010; Marquez and 
Xu, 2012; Tang et al., 2010).  
BCL-2/Beclin-1 binding can also be disrupted by ‘BH3’-only proteins. Pro-apoptotic 
proteins BNIP3, Bim and tBid and BH3-mimetic compounds such as ABT-737 and (-)-
Gossypol bind BCL-2 via BH3 domain interactions, releasing Beclin-1 and allowing 
autophagy to proceed (Figure 1.6 A) (Bellot et al., 2009; Marquez and Xu, 2012). The 
amphipathic α-helix of the BH3 domain binds the hydrophobic cleft of BCL-2, 
dispelling Beclin-1 and allowing autophagy to proceed. Mutations in the BH3 domain 
of either BCL-2 or Beclin-1 can also inhibit their binding resulting in autophagy 
induction (Kang et al., 2011; Maiuri et al., 2007a). 
1.4.2.2 Post-translational modifications of BCL-2 or Beclin-1 prevents their binding 
Starvation-induced activation of c-Jun N-terminal protein kinase 1 (JNK1) induces 
phosphorylation of threonine (T69) and serine (S70, S87) residues within the 
unstructured loop of BCL-2 which disrupts its binding with Beclin-1 (Marquez and Xu, 
2012; Wei et al., 2008). Similarly DAPK-1, a tumour suppressor regulatory protein can 
induce autophagy by phosphorylating the T119 residue of Beclin-1 and promoting its 
dissociation from BCL-2 (Kang et al., 2011; Zalckvar et al., 2009). HMGB1 also 
promotes phosphorylation of BCL-2 by extracellular signal-related kinase 1/2 
(ERK1/2), promoting BCL-2/Beclin-1 dissociation (Kang et al., 2011; Tang et al., 
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2010). Tumour necrosis factor receptor-associated factor 6 (TRAF6) promotes 
ubiquitination of Lysine
63 
residue of Beclin-1, which induces its self-oligomerisation 
and subsequent activation of the Beclin-1/Vps34/Vps15 complex (Figure 1.6 B). 
Conversely the de-ubiquitinating enzyme A20 removes ubiquitin from Lysine
63
, 
promoting the autophagy-inhibiting interaction of Beclin-1 with BCL-2 (Kang et al., 
2011; Shi and Kehrl, 2010).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Disruption of BCL-2/Beclin-1 binding promotes autophagy  
Binding between the anti-apoptotic protein BCL-2 and the pro-autophagy protein Beclin-1 can be 
inhibited by competitive binding (A) and post-translational modifications (B). The DAMP protein 
HMGB1 and BH3-only proteins can bind Beclin-1 and BCL-2 respectively, freeing Beclin-1 and 
allowing autophagy to proceed. JNK/ERK and DAPK promote BCL-2 and Beclin-1 phosphorylation 
respectively, while TRAF6 induced Beclin-1 ubiquitination, all of which endorse Beclin-1/BCL-2 
dissociation and autophagy activation. P - phosphorylation; Ub- ubiquitination. Adapted from: Kang et al, 
2011. 
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1.5 The adaptor / scaffold protein p62 
p62 is a 62kDa adaptor/scaffold protein encoded for by SQSTM1 which is ubiquitously 
expressed by all types of cells. It was initially identified as a binding partner of atypical 
protein kinase C (aPKC) (Moscat and Diaz-Meco, 2012; Puls et al., 1997; Sanchez et 
al., 1998). As a multi-domain protein, it binds a host of cellular proteins resulting in the 
formation of p62-positive cellular speckles or aggregates within the cytosol and nucleus 
of a cell (Bjorkoy et al., 2005; Moscat and Diaz-Meco, 2012; Nakamura et al., 2010; 
White, 2012). Modulation and accumulation of p62 is associated with the pathogenesis 
of different diseases including protein aggregate disorders and cancer (Bjorkoy et al., 
2005; Komatsu et al., 2012; Mathew et al., 2009).  
1.5.1 p62 is a multi-domain protein involved in different cellular pathways 
p62 is comprised of various binding domains which facilitate its interaction with 
different proteins and promote its involvement in numerous cellular pathways (Figure 
1.7) (Bjorkoy et al., 2005; Shi et al., 2013; White, 2012).  
The centrally located ZZ-type Zinc-finger (ZZ) and TRAF6-binding (TB) domains 
facilitate interaction of p62 with RIP1 (receptor-interacting protein 1) and TRAF6  
respectively, resulting in activation of the NF- B pathway and osteoclastogenesis 
(Moscat and Diaz-Meco, 2012; White, 2012; Wooten et al., 2008). p62 also promotes 
NF- B activation by binding aPKC via its N-terminally located Phox/Bem 1p (PB1) 
domain, where as its binding to ERK1/2 via the same domain inhibits ERK-mediated 
adipogenesis and prevents against the onset of obesity (Mathew et al., 2009; Nakamura 
et al., 2010; Rodriguez et al., 2006). PB1 domain mediated interactions also facilitates 
the role of p62 in autophagy via binding of neighbour of BRCA1 (NBR1) which 
promotes packaging and delivery of p62-positive aggregates to the autophagosome for 
degradation (Lamark et al., 2003; White, 2012). p62s PB1 domain also facilitates 
homodimerisation, resulting in incorporation of this adaptor protein into intracellular 
inclusion bodies (Komatsu et al., 2012; Nakamura et al., 2010; White, 2012). The KIR 
(KEAP1-interacting region) domain of p62 binds KEAP1 (Kelch-like ECH-associated 
protein 1) which results in activation of the transcription factor Nrf2 (nuclear factor, 
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(erythroid-derived 2)-like 2) and expression of numerous antioxidant and cytoprotective 
genes (Figure 1.7) (Komatsu et al., 2010; White, 2012).  
p62 is well established as a key player in the autophagy pathway, a role which is 
facilitated by its ubiquitin-associated (UBA) domain and LC3-interacting region (LIR) 
(Johansen and Lamark, 2011). Ubiquitination was previously thought to only mark out 
proteins destined for degradation by the proteasome. However, we now understand that 
autophagy can selectively degrade larger ubiquitinated substrates by employing UBA 
domain-containing adaptor proteins such as p62 (Kirkin et al., 2009). Via its C-
terminally located UBA domain, p62 acts as a cargo receptor which binds mono- and 
poly-ubiquitinated proteins/ organelles and packages them into p62-positive aggregates. 
It then facilitates delivery of these aggregates to the autophagosome (Kirkin et al., 2009; 
Komatsu et al., 2012; Pankiv et al., 2007). Via its LIR, p62 directly binds 
autophagosome-membrane bound LC3-II and delivers these protein aggregates to the 
autophagosome for degradation. As it is itself a component of the aggregates it forms, 
p62 is also delivered to the autophagosome for degradation and thus has been proven to 
be a substrate of the autophagy pathway (Bjorkoy et al., 2005; Johansen and Lamark, 
2011; Pankiv et al., 2007).  
 
 
 
 
Figure 1.7 The adaptor protein p62 contains multiple binding domains 
The binding domains of p62 facilitate its homodimerisation and heterodimerisation with various cellular 
proteins, thus promoting its participation in different signalling pathways. PB1- Phox/Bem 1p; ZZ-ZZ-
type zinc finger; TB-TRAF6-binding; LIR-LC3-interacting region; KIR - KEAP1-interacting region; 
UBA-Ubiquitin-associated. Adapted from Moscat and Diaz-Meco, 2009.   
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1.5.2 p62 delivers substrates to the autophagosome 
The role of p62 in autophagy was first described by Bjorkoy and colleagues in 2005 
(Bjorkoy et al., 2005). Using confocal microscopy, they showed that p62 
homodimerises and polymerises with ubiquitinated proteins via its PB1 and UBA 
domains respectively, to form inclusion bodies. These inclusions become embedded in 
double-layered membrane vesicles, indicative of autophagosomes. This lead Bjorkoy 
and colleagues to hypothesise that p62 may be involved in the autophagy pathway. To 
test their hypothesis, they studied p62 levels following treatment with Rapamycin or 
Bafilomycin-A1 which induce and inhibit autophagy respectively (Bjorkoy et al., 2005). 
Upon induction of autophagy, a decrease in p62 levels and the number of p62-
containing aggregates was observed. On the other hand, inhibition of late stage 
autophagy by Bafilomycin-A1 resulted in an increase in both the number and size of 
p62-positive inclusion bodies. This data suggested that p62 may be involved in delivery 
of large, ubiquitinated protein aggregates to the autophagosome and that this adaptor 
protein is itself an autophagy substrate. p62 was also shown to co-localise with the 
autophagy essential protein LC3-II with depletion of p62 found to prevent incorporation 
of LC3-II into the autophagosome. This lead to the conclusion that p62 mediates 
delivery of autophagy substrates, including itself, to the autophagosome via interactions 
with the autophagosome-membrane bound protein LC3-II (Bjorkoy et al., 2005).  
Bjorkoy and colleagues suggested that interaction between p62 and LC3 may not be 
direct but mediated by a third party. However, Pankiv and co-workers later 
demonstrated using co-immunoprecipitation and other assays that LC3-II/p62 bind 
directly via a 22-amino acid residue within p62 (the LIR) and that this binding is 
essential for degradation of p62-containing aggregates (Pankiv et al., 2007). Further 
work by Komatsu and colleagues confirmed that autophagy inhibition via Atg7 knock-
down results in p62 accumulation with no increase at the mRNA level, indicating that 
p62 is degraded by the autophagic process (Komatsu et al., 2007).  
As p62 protein levels have been shown to decrease upon activation of autophagy due to 
its increased degradation, cellular levels of p62 have been frequently used as a marker 
of autophagy activity (White, 2012). However, a recent study by Sahani and colleagues 
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reports that care should be taken when interpreting p62 levels as an autophagy marker 
(Sahani et al., 2014). They observed that starvation induced autophagy in mouse 
embryonic fibroblast (MEF) and HepG2 cell lines resulted in an initial decrease in p62 
levels but prolonged nutrient-withdrawal (≥4hrs) resulted in restoration of p62 protein 
levels to almost basal level. Restoration of p62 at the protein level was associated with 
and dependent on an increase in mRNA levels of SQSTM1. They therefore suggest that 
p62 protein levels may not always accurately reflect autophagy activity within a cell and 
so mRNA levels, which heretofore were thought to remain unchanged upon autophagy 
activation or inhibition, should also be examined (Sahani et al., 2014).  
1.5.3 p62 is involved in disease pathogenesis 
As p62 is involved in regulating multiple signalling pathways, it is unsurprising that 
perturbation of this gene can result in a number of disorders. For example, mutations in 
SQSTM1 have been identified as the cause of Paget’s disease of bone, a genetic disorder 
which results in aberrant osteoclastogenesis and disorganised bone formation, while loss 
of p62 is associated with increased activation of ERK and increased adipogenesis 
resulting in obesity (Duran et al., 2004; Moscat and Diaz-Meco, 2009; Rodriguez et al., 
2006). Accumulation of p62 due to defective autophagy is associated with neurological 
disorders such as Parkinson’s and Alzheimer’s as well as liver failure, where toxic p62-
containing aggregates build up in neuronal cells or hepatocytes, causing cell injury and 
death (Komatsu et al., 2012; Komatsu et al., 2007; Moscat and Diaz-Meco, 2009). p62 
has also been shown to play a role in the development and promotion of cancer.  
1.5.3.1 The role of p62 in cancer 
In 2008, Duran and colleagues reported an essential role for p62 in the formation of 
RAS-induced lung adenocarcinomas (Duran et al., 2008). They demonstrated that the 
oncogene RAS promotes p62 activation and polyubiquitination of TRAF6, a positive 
regulator of IKK (I B kinase). In vivo ablation of p62 (p62
-/-
) resulted in decreased 
RAS-induced carcinogenesis, confirming that RAS-induced transformation is p62-
dependent. A similar role has been described for p62 in the promotion of PDAC. (Ling 
et al., 2012). Thus, p62 can act as a tumour promoter by activating the pro-survival NF-
B pathway via the oncogene RAS (Duran et al., 2008; Moscat and Diaz-Meco, 2012).  
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This potential tumour promoting role of p62 was substantiated by Mathew and 
colleagues when they reported that accumulation of p62 in autophagy defective cells 
promoted tumourigenesis in immortalised baby mouse kidney (iBMK) cells (Mathew et 
al., 2009). They demonstrated that in response to a metabolic stress, autophagy 
incompetent iBMK cells showed accumulation of p62, damaged mitochondria, 
increased ROS production and DNA damage. Accumulation of p62 was attributed to 
impaired autophagic degradation as no change was observed in SQSTM1 mRNA levels. 
In vivo experiments revealed that autophagy-defective cells, in which p62 was 
accumulated, had increased tumour growth compared to autophagy-competent cells. 
Atg5
-
/
-
 tumour cells displayed large p62-positive aggregates, giant, heterochromatic 
nuclei indicative of aneuploidy and polyploidy and increased growth. They also found, 
contrary to Duran and colleagues, that accumulation of p62 resulted in decreased NF-
B activity and an increase in ROS levels, oxidative stress and genomic instability 
which promoted tumourigenesis (Mathew et al., 2009). A potential explanation for the 
discrepancy observed in NK- B signalling is that iBMK cells may not facilitate 
polyubiquitination of p62 or TRAF6 which is necessary for NF- B activation (Moscat 
and Diaz-Meco, 2009). Elimination of p62 aggregates from autophagy-defective iBMK 
cells was sufficient to suppress the cytotoxic, tumour promoting effects induced by 
autophagy inhibition. Similar results have been reported in hepatocarcinomas where it 
has been observed that elimination of accumulated p62 from Atg7
-
/
-
 cells inhibits 
tumour formation (Komatsu et al., 2007; Mathew et al., 2009; Moscat and Diaz-Meco, 
2012).      
Thus, p62 appears to be able to promote tumour growth by altering expression of the 
NK- B signalling pathway, promoting the oncogenic function of RAS, and inducing 
oxidative stress and genomic instability. This pro-tumour role of p62 appears to be 
reversible as elimination of p62 can prevent RAS-induced transformation and the 
induction of oxidative stress (Duran et al., 2008; Mathew et al., 2009; Moscat and Diaz-
Meco, 2012).  
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1.5.3.2 p62 expression levels have been used as a prognostic biomarker  
p62 has been shown to act as a biomarker for clinical outcome in a variety of 
malignancies. For example, accumulation of this autophagy-substrate was reported to 
predict a worse outcome and resistance to chemotherapy in oral carcinoma patients (Inui 
et al., 2013), where as in melanoma patients increased p62 expression was associated 
with a better prognosis (Ellis et al., 2014).  
To date, the roles of p62 in autophagy, tumourigenesis or tumour promotion, and its 
association with clinical outcome in FL and/or DLBCL have not been reported.  
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1.6 Lymphomas 
Lymphomas (cancers of the lymphatic system) can be broadly divided into two 
categories – Hodgkin’s lymphoma (HL) and NHL. NHLs, which are more common 
than HLs, can arise from abnormal T or B cells, although the vast majority are B cell 
derived (Skibola et al., 2009).  
1.6.1 FL is an indolent, incurable malignancy of the germinal centre  
FL is the most common form of indolent NHL accounting for 20-40% of newly 
diagnosed cases each year in Western Europe and the United States (Freedman, 2012; 
Glass et al., 1997; Kridel et al., 2012). FL typically presents in middle-aged and elderly 
individuals (median age 60 years) with a slight predominance of occurrence in women 
(Armitage and Weisenburger, 1998; Freedman, 2012). Although an indolent disease 
with a median survival rate of >10 years, FL is still considered to be a fatal incurable 
malignancy associated with a high rate of relapse and/or transformation to the more 
aggressive DLBCL (Kridel et al., 2012; Lossos and Levy, 2003).  
Morphologically, FL B cells resemble normal germinal centre B (GCB) cells and are 
organised into clearly discernible follicle centres (Lossos and Levy, 2003). Centrocytes 
and centroblasts are present in high numbers in FL samples with centroblasts tending to 
be present in greater numbers (Nathwani et al., 1999). FL cells express the pan-B cell 
markers CD19 and CD20, the well defined germinal centre B cell marker CD10 as well 
as BCL-6 and BCL-2 (Dogan et al., 2000; Kridel et al., 2012; Lenz and Staudt, 2010; 
Shaffer et al., 2012). 
The FL cell of origin is not a normal GCB-cell but a more immature B cell. The 
oncogenic hit that gives rise to FL occurs during the early stages of haematopoiesis but 
does not hinder cellular differentiation. Therefore, FL B cells resemble mature GCB-
cells rather than their actual cell of origin (Shaffer et al., 2012). In the case of FL the 
initial oncogenic event, typically the t(14;18) translocation, is acquired by pre-B cells in 
the bone marrow which migrate to lymphoid tissues where they undergo germinal 
centre reaction and remain. Acquisition of this translocation therefore increases BCL-2 
expression but does not affect the differentiation potential of these cells (Kridel et al., 
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2012; Lossos and Levy, 2003). Increased expression of BCL-2, which is not normally 
expressed in the GC, confers a survival advantage to FL cells and promotes treatment 
resistance (Kridel et al., 2012; Shaffer et al., 2012).   
1.6.2 FL is associated with multiple genetic abnormalities  
FL is characterised by the t(14;18)(q32;q21) translocation which is present in 80-90% 
of cases at diagnosis and results in aberrant expression of BCL-2 (Boonstra et al., 2003; 
Fukuhara et al., 1979; Lipford et al., 1987; Yunis et al., 1982). The t(14;18) 
translocation occurs following a double-strand break at the BCL-2 locus (chr18) and the 
IGH locus (chr14) which places the BCL-2 promoter region under the control of the 
heavy-chain locus, resulting in increased expression of the BCL-2 protein (Galteland et 
al., 2005; Kridel et al., 2012; Masir et al., 2009). Despite its near ubiquitous 
overexpression among FL patients, cellular levels of BCL-2 do not impact or predict 
clinical outcome in this indolent NHL (Llanos et al., 2001). While acquisition of this 
translocation is common in FL development, it is not necessary or sufficient to drive 
malignant progression as is evident by ~15% of t(14;18)-negative FL cases, meaning 
secondary mutations are required for full disease manifestation (Table 1.4) (Kridel et 
al., 2012; McDonnell and Korsmeyer, 1991; Shaffer et al., 2012). One of the most 
common secondary chromosomal aberrations in FL is heterozygous deletion of the 
TNFSRF14 gene, a member of the tumour necrosis factor receptor (TNFR) superfamily 
(Cheung et al., 2010; Launay et al., 2012). Other genes mutated in FL include the 
histone3 lysine4 (H3K4), methyl transferase MLL2 and EZH2, a member of the 
polycomb repression complex-2 (PRC2) (Table 1.4) (Bodor et al., 2013; Morin et al., 
2011; Nogai et al., 2011; Pasqualucci et al., 2011; Shaffer et al., 2012).  
Table 1.4 Genetic abnormalities associated with FL 
 
 
 
 
 
 
 
 
 
 
 
      *LOF = loss-of-function; GOF = gain-of-function 
Gene Frequency (~%) Function LOF/GOF
*
 
BCL-2 t(14;18) 85-95 Apoptosis regulator GOF 
TNFRSF14 18-46 Immune Regulator LOF 
MLL2 89 Epigenetic Modifier LOF 
EZH2 7-20 Epigenetic Modifier GOF 
CREBBP 33 Epigenetic Modifier LOF 
BCL-6 6-14 Transcription Factor GOF 
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1.6.3 FL can be divided into distinct clinical grades 
FL is divided into clinical grades based on the proportion of centrocytes to centroblasts. 
According to the World Health Organisation (WHO) classification and the Revised 
European-American Classification of Lymphoid Neoplasms (REAL), there are three 
grades of FL – grades 1-3 – with grade 3 being further subdivided into grade 3A and 3B 
(Table 1.5) (Campo et al., 2011). Grades 1-2 are similar and contain low numbers of 
centroblasts while grade 3A contains a higher number of centroblasts with some 
centrocytes still visible. FL grade 3B contains only centroblasts and is considered to 
appear biologically more similar to de novo DLBCL and lacks CD10 expression 
(Campo et al., 2011; Kridel et al., 2012; Salaverria and Siebert, 2011).  
Table 1.5 Grading of FL 
 
 
 
 
 
1.6.4 FL treatment varies depending on disease stage  
Although treatment of FL has been improved in recent years, it is still considered a fatal 
malignancy plagued by frequent relapses and transformation (Glas et al., 2005; Goy et 
al., 2005). While initially relatively chemosensitive, FL patients become increasingly 
refractory to treatment with each relapse (Glas et al., 2005; Montoto et al., 2007). 
Despite the multiple regimens available for treatment of FL, to date there is no 
consensus on how to treat this clinically variable incurable malignancy (Dave et al., 
2004; Marcus et al., 2008; Solal-Celigny et al., 2004). The most appropriate treatment 
choice for FL is often guided by an individual’s FLIPI (Follicular Lymphoma 
International Prognostic Index) score, a prognostic index which stratifies patients into 
risk groups based on the number of adverse clinical factors they present with at 
diagnosis (Table 1.6) (Marcus et al., 2008; Solal-Celigny et al., 2004). Patients receive a 
mark per adverse variable – age >60 years; Ann Arbor stage III/IV; LDH (lactate 
dehydrogenase) level >480U/L; serum haemoglobin levels <120g/L and >4 affected 
nodal areas – giving them their FLIPI score, which ranges from 0 to 5. Based on this 
Grade Number of Centroblasts per High Power Field 
1 (Low Grade) 0 – 5 
2 (Low Grade) 6 – 15 
3A (High Grade) >15 
3B (High Grade) Solid sheets of Centroblasts 
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score, patients are stratified into one of three risk groups - low (0-1), intermediate (2) or 
high (3-5) (Buske et al., 2006; Solal-Celigny et al., 2004).  
Table 1.6 Prognostic factors considered when determining an FLIPI scores 
 
Asymptomatic, low-grade FL patients are often not treated with chemotherapeutic 
agents but rather observed under a “watch and wait” regimen where they are monitored 
regularly for disease progression, at which point treatment is administered (Ardeshna et 
al., 2003). This regimen is advantageous as it avoids unpleasant side-effects of therapy 
including myeloablative suppression and sicca syndrome (Dreyling et al., 2011). Low-
grade FL patients with limited non-bulky disease are typically treated with radiotherapy 
or radio-immunotherapy, a combination of radiotherapy and radio-labelled monoclonal 
antibodies, which is highly affective (Dreyling et al., 2011; Kaminski et al., 2005; 
Morschhauser et al., 2008). Although considered an incurable malignancy, first-line 
treatment for low-grade FL patients is often administered with curative intent (Dreyling 
et al., 2011; Montoto et al., 2007). 
More advanced stages of FL are typically treated with the standard chemotherapy drugs 
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or CVP 
(cyclophosphamide, vincristine, prednisone) in combination with the monoclonal anti-
CD20 antibody Rituximab (Fisher et al., 1993; Hiddemann et al., 2005; Marcus et al., 
2008). Addition of Rituximab to CHOP/CVP has greatly improved progression free 
survival and partial remission rates in FL. However, patients still frequently relapse, 
becoming less chemosensitive with each relapse (Friedberg, 2011; Glennie et al., 2007; 
Vidal et al., 2011). Administration of Rituximab as maintenance therapy has also 
improved PFS and PR rates, with no clear indications as to its effect on overall survival 
(Dreyling et al., 2011; Friedberg, 2011; Salles et al., 2011; Vidal et al., 2011). The 
proteasome inhibitor bortezomib combined with R-CHOP/R-CVP has also been 
Prognostic Factor Good Prognosis Poor Prognosis 
Age (years) ≤ 60 > 60 
Ann Arbor Stage I/II III/IV 
Serum LDH Level ≤ Normal > Normal 
Haemoglobin (g/L) >120 ≤ 120 
Number of Affected Nodal Areas ≤ 4 > 4 
  Chapter I Introduction 
 
69 
 
reported to prolong PFS in FL (Goy et al., 2005; Salles, 2011). Relapsed patients are 
treated in a similar way to de novo FL cases with modifications made based on previous 
treatment (Dreyling et al., 2011). Stem-cell transplantation may be offered as a form of 
treatment for more advanced stage or relapsed FL patients who have a good outlook 
(Dreyling et al., 2011; Kridel et al., 2012). Patient responses are listed in table 1.7.  
Table 1.7 Treatment response classifications 
 
 
1.6.5 The tumour microenvironment in FL 
It is well established that interactions between FL cells and cells of the 
microenvironment play an important role in the development and progression of this 
indolent NHL (Dave et al., 2004; Yang and Ansell, 2012). Tumour infiltrating immune 
cells can help eradicate malignant cells but conversely may promote and maintain 
tumour cell survival by secreting growth factors and stimulatory cytokines (Lejeune and 
Alvaro, 2009; Yang and Ansell, 2012). The FL tumour microenvironment has been 
reported to include higher numbers of CD4
+
 and CD8
+
 T-cells and CD163
+
 and CD68
+
 
macrophages (Clear et al., 2010; Lejeune and Alvaro, 2009; Yang and Ansell, 2012).  
GEP analysis of 191 FL patient biopsies by Dave and colleagues demonstrated that 
differences in patient outcome are associated with differential expression of genes in 
cells of the microenvironment but not malignant cells. They identified two distinct gene 
signatures - immune-response 1 and immune-response 2 - which were associated with 
monocytes and T-cells, and macrophages and follicular dendritic cells, respectively 
(Dave et al., 2004). They established that patients with an immune-response 1 signature 
had a more favourable outcome and longer OS compared to patients with an immune-
response type-2 signature (Dave et al., 2004).  
Classification Outcome Abbreviation 
1 Complete Remission CR 
2 Good Partial Remission/Complete Remission (Undetermined) GPR/CR(U) 
3 Poor Partial Remission PPR 
4 Stable Stab. 
5 Progression Prog. 
6 Treatment Related Death TRD 
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1.6.6 Transformation of FL to DLBCL is associated with morphological 
changes and acquisition of genetic mutations  
The clinical course of FL is highly variable and typically involves a number of relapses, 
with a large proportion of patients undergoing histological transformation to a higher 
grade lymphoma, typically DLBCL but sometimes acute lymphoblastic leukaemia 
(ALL) or Burkitts lymphoma (BL) (Lossos and Levy, 2003). The reported rate of FL-
DLBCL transformation ranges from 10-60%, with differential reporting possibly due to 
variability in length of patient follow up, differing policies for re-biopsies and 
differences in the definition of transformation (Hubbard et al., 1982; Lossos and Levy, 
2003; Montoto et al., 2007). The risk of transformation increases with time, with an 
average risk of 19.6% at 5 years and 37% at 15 years (Lossos and Levy, 2003; Montoto 
et al., 2007). 
Morphologically, transformation is associated with loss of follicular architecture which 
is replaced by a more diffuse growth pattern. Clinically, it is associated with rapid 
disease progression, the onset of B symptoms, extranodal disease development and 
shorter OS (median survival <2 years) (Al-Tourah et al., 2008; Boonstra et al., 2003; 
Lossos and Levy, 2003; Montoto et al., 2007). Genetic abnormalities associated with 
transformation include mutations in the tumour suppressor gene p53 and gain-of-
function mutations in the proto-oncogene c-Myc (Table 1.8). It is thought that 
transformation is driven by multiple abnormalities which work together to promote 
progression from an indolent to an aggressive NHL (Boonstra et al., 2003). 
Transformation from FL to DLBCL can occur through direct evolution from the 
primary malignant de novo FL clone or thorough divergent, indirect evolution which is 
not associated with the initial FL clone (Kridel et al., 2012; Lossos and Levy, 2003; 
Shaffer et al., 2012). 
Table 1.8 Genes frequently altered in transformation from FL to DLBCL 
 
 
 
Gene Function Abnormality 
TP53 Tumour Suppressor Mutation 
CDKN2A Tumour Suppressor Mutation; deletion 
CDKN2B Tumour Suppressor Loss of Expression; deletion 
c-Myc Proto-Oncogene Rearrangement; mutation; amplification 
BCL-2 Anti-apoptotic Mutation 
BCL-6 Proto-Oncogene Rearrangement; mutation 
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1.7 Diffuse Large B-Cell Lymphoma 
1.7.1 DLBCL is an aggressive B-Cell lymphoma 
DLBCL is the most common aggressive B-cell NHL, accounting for up to 40% of cases 
presented each year. Considered a disease of the elderly, the median age of diagnosis is 
70 years and occurrence is equally common among men and women (Gurbuxani et al., 
2009). Patients can present with de novo DLBCL or DLBCL which has arisen following 
transformation from a lower grade lymphoma, typically FL (Hunt and Reichard, 2008). 
DLBCL cells are large B cells with nuclei twice the size of normal lymphocytes and a 
diffuse cellular growth pattern where normal lymph node architecture is no longer 
discernible (Gurbuxani et al., 2009; Hunt and Reichard, 2008). These cells typically 
express pan-B cell markers such as CD20 and CD19 and variably express CD38 and 
CD138. Germinal centre B-cell like (GCB) type DLBCL cells express markers 
associated with the GC including CD10 and BCL-6 and are typically FOXP1
-
, while 
activated B-cell like (ABC) cells lack IRF4 expression and are FOXP1
+
 (Gurbuxani et 
al., 2009; Prakash and Swerdlow, 2007; Shaffer et al., 2012).  
1.7.2 DLBCL can be divided into two distinct subgroups 
The level of heterogeneity observed among DLBCL patients with respect to cell 
morphology, clinical features and response to treatment prompted examination of the 
genetic profile of this aggressive lymphoma. GEP studies by Alizadeh and colleagues 
divided DLBCL into two distinct subgroups termed GCB and ABC which differ with 
regards to cell of origin, expression of B-cell genes, genetic abnormalities and clinical 
outcome (Alizadeh et al., 2000; Hunt and Reichard, 2008; Lossos et al., 2000).  
The GEP of GCB-type DLBCL patients closely resembles that of normal GCB-cells. 
Cells express GC markers such as CD10 and undergo continuous immunoglobulin 
somatic hypermutation (Lenz and Staudt, 2010; Lossos et al., 2000; Nogai et al., 2011). 
ABC-type patients express genes characteristic of mitogenically activated peripheral 
blood B cells and so more closely resemble these cells; however their terminal 
differentiation to plasma cells is prohibited due to lesions in Blimp-1 (Alizadeh et al., 
2000; Lenz and Staudt, 2010; Wright et al., 2003). ABC-type DLBCL cells may arise 
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from pre-germinal centre (pre-GC) B cells or post-GC B cells which are IgM positive 
and somatic hypermutation is off in the majority of cases (Lenz and Staudt, 2010; 
Lossos et al., 2000; Shaffer et al., 2012). A third DLBCL subtype referred to as type 3 
DLBCL or PMBL (primary mediastinal B-cell lymphoma) exists which expresses a host 
of different genes not particularly associated with either subtype (Lenz and Staudt, 
2010; Lenz et al., 2008b).  
 GCB-type patients typically have a better prognosis, with a high cure rate and a 
survival rate of >60% at 5 years, whereas ABC-type patients have a poor prognosis and 
a survival rate of 16–40% at 5 years (Alizadeh et al., 2000; Shaffer et al., 2012; Wright 
et al., 2003). It is currently unclear which genes differentially expressed by the GCB 
subtype bestows them this survival advantage.  
1.7.3 DLBCL is associated with a variety of genetic aberrations  
Genetic aberrations observed in both the GCB and ABC DLBCL subtypes include 
mutations and deletions in the tumour suppressor gene TP53, amplification and 
translocation of the oncogene Myc and mutation of β2-microglobulin (B2M) (Table 1.9) 
(Hunt and Reichard, 2008; Lenz and Staudt, 2010; Shaffer et al., 2012).  
A number of genetic lesions specific to the GCB subtype are similar to those found in 
FL including mutation of EZH2 and the t(14;18) translocation (Morin et al., 2010; 
Nogai et al., 2011; Rosenwald et al., 2002). Amplification of the c-rel locus and the 
microRNA cluster miR-17-92 are also frequently observed in GCB DLBCL (Table 
1.10) (Lenz and Staudt, 2010; Lenz et al., 2008b; Nogai et al., 2011). Genetic alterations 
specifically associated with the ABC DLBCL subtype include deletions/mutation of 
PRDM1and mutation of MYD88 which results in up-regulation of the JAK-STAT3 and 
NF- B signalling pathways (Table 1.9) (Ngo et al., 2011; Nogai et al., 2011). 
Overexpression of BCL-2 is also observed in the ABC-subtype due to amplification of 
the 18q21 locus (Obermann et al., 2009; Offit et al., 1989).  
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Table 1.9 Genetic abnormalities observed in the GCB- and ABC-subtypes of DLBCL 
 
1.7.4 Up-regulation of various signalling pathways is associated with a poor 
prognosis in DLBCL  
 Increased activity of the NF-κB pathway, frequently observed in the ABC-subtype of 
DLBCL, results in inhibition of apoptosis, increased tumour cell survival and a worse 
prognosis. Up-regulation of this pathway and it's pro-survival target genes may explain 
why ABC-type patients are less sensitive to chemotherapy than GCB-type patients 
(Shaffer et al., 2012). Up-regulation of the JAK/STAT3 pathway has also been reported 
in the ABC-subtype where it supports angiogenesis, tumour cell survival and metastasis 
(Huang et al., 2013; Yu et al., 2009). Persistent STAT3 activation may be due to 
increased NF-κB activity, mutations in MYD88 or increased HDAC3 expression. It has 
recently been shown that increased expression of phosphotyrosine-STAT3 (PY-STAT3) 
and an activated-STAT3 gene signature which mirrors increased mRNA levels of 
STAT3, correlate with a poor clinical outcome in the ABC-subtype of DLBCL (Huang 
et al., 2013).  
Expression levels of the HIF-1 protein which regulates a cells response to hypoxia have 
been shown to correlate with clinical outcome in R-CHOP treated DLBCL patients 
(Evens et al., 2010). Expression of HIF-1 was observed in 62% of GCB- and 59% of 
ABC-subtype DLBCL patients and correlated with a better overall survival compared to 
HIF-1 negative patients (Evens et al., 2010). Autophagy induction is tightly linked with 
Gene Frequency (%) Function LOF/GOF* Subtype 
B2M 12 Immune Regulator LOF GCB/ABC 
CARD11 ~10 Signalling Factor GOF GCB/ABC 
CREBBP 17-41 Epigenetic Modifier LOF GCB/ABC 
MLL2 24-32 Epigenetic Modifier LOF GCB/ABC 
MYC 15-50 Transcription Factor GOF GCB/ABC 
TP53 13-22 Genomic Integrity LOF GCB/ABC 
BCL-2 t(14;18) 25-45 Apoptosis Regulator GOF GCB 
c-rel Locus Amplification 16-28 Transcription Factor GOF GCB 
EZH2 20-25 Epigenetic Modifier GOF GCB 
miR-17-92 12-15 MicroRNA GOF GCB 
TNFRSF14 50 Immune Regulator LOF GCB 
BCL-2 Amplification 34 Apoptosis Regulator GOF ABC 
CD79A; CD79B 18-20 Signalling Factor GOF ABC 
CDKN2A 20 Cell-cycle Regulator LOF ABC 
MYD88 L265P 30 Signalling Factor GOF ABC 
PRDM1 25 Transcription Factor LOF ABC 
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hypoxia via HIF-1 (Mazure and Pouyssegur, 2010); however to date, autophagy status 
and its association with clinical outcome in DLBCL patients has not been reported.  
There is currently no consensus on the prognostic significance of increased expression 
of BCL-2 in DLBCL (Barrans et al., 2003; Iqbal et al., 2006). The t(14;18) translocation 
has been reported to predict shorter overall survival in GCB-type patients carrying it 
while others report it has no effect on outcome. Some studies report increased BCL-2 
due to locus amplification predicts a worse outcome in ABC-subtype of DLBCL 
although this is not always the case (Alizadeh et al., 2000; Barrans et al., 2003; Iqbal et 
al., 2006; Obermann et al., 2009). While increased expression of BCL-2 alone may not 
predict outcome double-hit DLBCL patients which carry Myc and BCL-2 mutations are 
known to have a shorter overall survival compared to single-hit patients (Green et al., 
2012). 
1.7.5 Treatment of DLBCL 
The standard treatment for DLBCL is the multi-drug chemotherapy regimen CHOP 
combined with the anti-CD20 monoclonal antibody Rituximab (R-CHOP) (Coiffier et 
al., 2002; Fisher et al., 1993; Glennie et al., 2007). Addition of Rituximab to CHOP 
treatment has significantly improved survival by several years without an added 
increase in toxicity (Brusamolino et al., 2006; Coiffier et al., 2010). DLBCL patients are 
typically treated immediately with curative intent and with varying but generally high 
initial success rates (Flowers et al., 2010; Mounier et al., 2003; Nastoupil et al., 2012; 
Tomita et al., 2013).  
Not all DLBCL patients respond to R-CHOP treatment in the same way, with less than 
half achieving and maintaining complete remission (CR), meaning alternative 
treatments are required for R-CHOP refractory and relapsed patients (Alizadeh et al., 
2000; Dupire and Coiffier, 2010; Fitoussi et al., 2011). First-line treatments available 
for R-CHOP refractory patients or second-line treatments for relapsed patients include 
R-ACVBP (Rituximab, cyclophosphamide, vindesine, bleomycin, prednisone), R-ICE 
(Rituximab, ifosfamide, carboplatin, etoposide), R-DHAP (Rituximab, dexamethasone, 
ara-C, cisplatin) and R-ESHAP (Rituximab, etoposide, cytarabine, cisplatinum and 
methylprednisolone) which are generally administered in conjunction with an 
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autologous stem-cell transplantation (Alizadeh et al., 2000; Flowers et al., 2010; 
Hagberg et al., 2006; Martin and Caballero, 2009). 
To identify patients likely to respond to R-CHOP and those who may need alternative, 
more aggressive therapy, the International Prognostic Index (IPI) was established (Sehn 
et al., 2007). The IPI is similar to the FLIPI for FL and considers multiple clinical 
parameters such as age and ECOG (Eastern Cooperative Oncology Group) performance 
(Table 1.10). Patients presenting with two or less adverse prognostic factors are 
classified as low-moderate risk and are treated with standard R-CHOP, while patients 
presenting with three or more of these factors are consider high risk and so are treated 
more aggressively (1993; Sehn et al., 2007). A revision of the IPI to include the effect 
Rituximab has had on DLBCL is termed the R-IPI (Rituximab International Prognostic 
Index). DLBCL patient treatment response is reported in the same manner as FL (Table 
1.7). 
Table 1.10 Prognostic factors considered when determining an individual’s IPI/R-IPI 
score 
 
 
Over the last two decades efforts have been made to develop new drugs for the 
treatment of DLBCL, particularly the ABC-subtype which does not respond as well to 
R-CHOP as the GCB-subtype (Dunleavy et al., 2009). While to date no new 
chemotherapeutic agents as effective as R-CHOP have been identified, advances have 
been made in identification of novel agents which can synergise with R-CHOP and 
improve its efficacy, including Bortezomib, Bendamustine and BCL-2 inhibitors 
(Dunleavy et al., 2009; Dupire and Coiffier, 2010; Obermann et al., 2009). 
Overexpression of BCL-2 in DLBCL has been reported to promote resistance to therapy 
indicating that inhibition of this anti-apoptotic protein may improve the efficacy of 
current treatments (Barrans et al., 2003; Obermann et al., 2009). Activation of 
Prognostic Factor Good Prognosis Poor Prognosis 
Age (years) ≤60 >60 
Ann Arbor Stage I/II III/IV 
Serum LDH Level ≤Normal >Normal 
Number of Affected Nodal Areas ≤1 >1 
ECOG Performance 0/1 ≥2 
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cytoprotective autophagy as a result of BCL-2 inhibition should be considered when 
evaluating the utility of BCL-2 inhibitors in the treatment of DLBCL.  
1.7.6 The tumour microenvironment of DLBCL 
The role of the tumour microenvironment in the progression and clinical outcome of 
DLBCL has been firmly established (Alizadeh et al., 2000; Lenz et al., 2008a).   
Gene signatures of the microenvironment have been reported predict outcome in 
DLBCL. Examination of 414 pre-treatment DLBCL patients identified three distinct 
gene-expression signatures – GC B cell, expressed by CD19+ B cells, and stromal-1 and 
stromal-2, expressed by the CD19
-
, microenvironment population (Lenz et al., 2008a). 
The stromal-1 signature is comprised of genes expressed by components of the 
extracellular matrix such as MMP2, fibronectin and osteonectin. Infiltration of cells 
associated with the myeloid lineage including macrophages and monocytes is 
characteristic of this signature which predicts a good clinical outcome (Lenz et al., 
2008a). The stromal-2 signature is thought to represent an “angiogenic-switch” in 
DLBCL samples due to increased expression of angiogenic regulators such as VEGF 
and GRB10. Genes such as EGFL7 and FAB24, expressed in endothelial cells and 
adipocytes respectively, are also associated with the stromal-2 gene signature (Lenz et 
al., 2008a). This signature is prognostically unfavourable in DLBCL patients. The role 
of autophagy in the microenvironment in DLBCL is currently unknown. Alizadeh and 
colleagues (Alizadeh et al., 2000; Rosenwald et al., 2002) also demonstrated that a 
lymph-node signature similar to normal lymph-nodes which included genes encoding 
for natural killer (NK) cells and macrophage markers such as CD14 and CD105 and 
genes involved in extracellular matrix remodelling was present in the majority of 
DLBCL samples.  
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1.8 Aims  
While the pro-survival role of BCL-2 in FL and DLBCL has been established, the effect 
of increased expression of this anti-apoptotic protein on the autophagy pathway in these 
NHLs is unclear. It is also currently unknown whether autophagy is altered in FL and 
DLBCL and whether modulation of this pathway is associated with the clinical outcome 
of these diseases. Therefore, the main aims of this study are: 
1.8.1 To evaluate the role of BCL-2 in autophagy in lymphoma cells  
We aim to evaluate if overexpression of BCL-2 inhibits autophagy in lymphoma cells 
by comparing autophagy activity between BCL-2
HIGH
 and BCL-2
LOW
 DLBCL cell lines 
following treatment with a BCL-2 inhibitor, ABT-737. This will be done by assessing 
cellular levels of the autophagy markers p62 and LC3 and by evaluating if BCL-2 and 
Beclin-1 form an autophagy-inhibiting complex in malignant B cells. We also aim to 
determine whether autophagy induced following inhibition of BCL-2 functions as a 
cytoprotective or pro-apoptotic mechanism. Comparisons will also be made between the 
GEP of DLBCL cell lines following induction of autophagy to assess if BCL-2 
overexpression modulates the autophagy flux at the gene level in response to autophagy 
stress.  
1.8.2 To determine the basal level autophagy status of primary lymphoma 
samples  
BCL-2 overexpression is common among NHLs, particularly FL patients. In order to 
establish if increased expression of BCL-2 inhibits autophagy, we aim to evaluate the 
basal level autophagy status of primary FL and DLBCL samples and lymphoma cell 
lines at both the gene and protein levels. We will do this by analysing the GEP of 
primary purified and unpurified FL and DLBCL samples and evaluating expression 
levels of key autophagy-related proteins including p62 in primary FL and DLBCL 
tissue samples.  
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1.8.3 To establish if expression levels of key autophagy-related proteins can 
be used as prognostic biomarkers in NHL 
The prognostic significance of the key autophagy-related proteins p62, Beclin-1 and 
LC3 has been reported for a variety of malignancies. However, it is currently unclear if 
expression levels of these proteins, and thus the autophagy status of a sample, has 
prognostic value in FL and DLBCL. Using IHC and TMA technology, we aim to 
determine if cellular levels of these proteins can be used as independent biomarkers of 
clinical outcome in FL and DLBCL.  
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2.1 Cell line and cell culture  
The DLBCL cell lines Su-DHL4 and CRL which are t(14;18) positive and have high 
BCL-2 protein expression and Su-DLH8 and Su-DHL10 which are t(14;18) negative 
and have low BCL-2 protein expression (Deng et al., 2007) were used in this study. Su-
DHL4, Su-DHL8 and Su-DHL10 were gifted from Dr. A Letai; CRL cells were 
acquired from the Cancer Research UK tissue bank. Cell lines were cultured using 
RPMI 1640 Media supplemented with 10% heat inactivated fetal calf serum (FCS) 
(56°C for 1 hour), 2mM L-glutamine, 100U/ml penicillin and 100µg/ml streptomycin 
(Appendix I, 1.1). Cells were seeded in 75cm
2
 Nunc tissue culture flasks, grown at 37°C 
in a 5% CO2 humidified incubator and passaged every 2-3 days to maintain viability, 
which was measured using a Beckman Coulter Vi-Cell ™ XR Cell Viability Analyzer 
(Appendix I, 1.2). 
2.2 Patient Samples 
2.2.1 Ethical considerations 
Ethical approval for the human biological material used in this study was obtained in 
accordance with the requirements of the East London and the City Ethics Committee 
(Ref. No. 10/H0704/65). This allowed the use of stored and newly obtained human 
biological samples, including lymph nodes, from patients with haematological 
malignancies and healthy donors. All samples were obtained from patients by informed 
consent. Samples were identified by vial number or hospital number only, with patient 
information held in a secure password protected file.     
2.2.2 Patient sample selection 
Samples were obtained upon request from the tissue bank located in the Centre for 
Haemato-Oncology, Barts Cancer Institute which is maintained according to the Human 
Tissue Act 2004 (Licence No. 12199). FL, DLBCL and reactive DNA samples, single 
cell suspensions and whole tissue samples were selected based on availability and stage. 
Only samples which were classified as pre-treatment at diagnosis, pre-treatment at 
diagnosis on expectant management or pre-treatment at diagnosis - at progression on 
expectant management were selected for further analysis. Due to limited sample 
numbers patients were not age or sex matched. The median patient age was 62 years and 
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55 years for FL and DLBCL patients respectively. Patients selected presented at St. 
Bartholomew’s hospital between the years 1998-2012. Patients included on tissue 
microarrays (TMAs) were also diagnostic, pre-treatment samples which presented at St. 
Bartholomew’s between the years 1968 and 2009. Further information on selection of 
samples for inclusion in TMAs is reported in appendix II table T and U. All clinical 
information was obtained upon request from the clinical database manager Mrs. Janet 
Matthews and was coded to protect patient identity as described above.  
2.3 Preparation of cell lysates for Western blotting  
Cells were spun down at 1200rpm for 5min, washed 1× with 1ml phosphate buffered 
saline (PBS) and centrifuged at 8000rpm for 2min after which all PBS was removed. 
Cell pellets were then mixed by gentle pipetting with 30-100µl cell lysis buffer 
containing protease inhibitor cocktail (PIC), incubated on ice for 20min and spun at 
13,000rpm for 15min at 4°C. Lysates were kept on ice at all times (Appendix I, 2.1.1).  
2.4 Determination of protein concentration – Bradford assay  
The Bradford Assay uses the protein binding dye Coomassie® G-250 to determine 
protein concentration. Binding proteins induces a colour change in the dye from red to 
blue, shifting the absorbance maximum from 465nm to 595nm. This increase in 
absorption observed at 595nm is proportional to protein concentration, with samples 
becoming darker with increasing concentration (Bradford, 1976). Protein concentration 
is calculated by comparing test samples to a standard curve which is a series of defined 
standards that exhibit a linear absorbance profile. Samples are read at 595nm using an 
Opsy MR spectrophotometer and concentrations reported as µg/µl. 
Procedure 
A standard curve (Table 2.1) was prepared per plate using a 0.5mg/ml BSA working 
solution (Appendix I, 2.1.2). Increasing volumes of BSA were mixed with 100µl Bio-
Rad protein assay dye reagent (Appendix I, 2.1.2) in a 96-well plate as per table 2.1. 
Test samples were assayed in triplicate by mixing 1µl of diluted (1:10) protein lysate 
with 100µl Bio-Rad reagent. Lysates were diluted prior to evaluation to ensure 
concentrations fall within the absorbance range of the standards and spectrophotometer. 
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Samples were read at 595nm on a spectrophotometer and protein concentrations 
calculated by linear regression using the equation y = mx + b where y is the average 
sample absorbance at 595nm and x is protein concentration (µg/µl). 
Table 2.1 BSA Standard Curve for Bradford Assay 
 
 
 
 
 
2.5 Western blotting   
Western blotting allows visualisation and examination of the expression levels of 
cellular proteins which have been separated from one another based on their molecular 
weight using SDS-PAGE. The detergent SDS linearises proteins and coats them in 
negative charges meaning molecular weight is the only difference between them. An 
electrical current is applied to the gel and the negatively charged proteins migrate 
towards the anode, with smaller proteins migrating faster than larger proteins. Separated 
proteins are then transferred to a polyvinylidene difluoride (PVDF) membrane which 
allows the protein of interest to be detected using specific antibodies (Kurien and 
Scofield, 2006).  
Procedure 
Sample lysate was mixed with lysis buffer and loading buffer and heated at 100°C for 
10min. 10µl protein molecular weight marker and 15-20µl of sample were loaded onto 
an Nu-PAGE ® 4-12% Bis-Tris gel, proteins separated by SDS-PAGE at 200V and 
transferred to a methanol-wetted PVDF membrane using a semi-dry transfer method for 
1hr at 20V. Following transfer, membranes were blocked for 1hr at room temperature 
(RT) with agitation in 5% milk in phosphate buffered saline with Tween-20 (PBST) to 
avoid non-specific binding (Appendix I, 2.2). Membranes were then incubated with 
primary antibody (Appendix I, Table A) overnight with agitation at 4°C. Unbound 
primary antibody was washed off with PBST (3×10min) after which membranes were 
incubated with anti-rabbit/anti-mouse HRP-conjugated secondary antibody (Appendix I, 
Table B) for 1hr at RT with agitation. Unbound secondary antibody was washed off 
Row 0.5mg/ml BSA (µl) BSA Concetnration (µg) 
0 0 0 
1 0.5 2.5 
2 1 5 
3 2 10 
4 4 20 
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with PBST (4×15min). Membranes were incubated with 1ml ECL PLUS for 5min and 
bands visualised using a FujiFilm LAS 4000 developer. Membranes were washed and 
stripped with PBST and stripping buffer and re-probed as desired. β-actin or GAPDH 
were used as loading controls. In some instances alternative blocking, primary and 
secondary antibody solutions were used which facilitate detection of weakly expressed 
proteins (Appendix I, 2.2). 
2.6 Immunofluorescent microscopy 
IFM allows detection and visualisation of a protein of interest in a tissue or cell and can 
be used to examine protein expression and identify co-localisation between proteins. 
Indirect IFM uses primary and secondary antibodies and produces more specific results 
than direct IFM (Ramos-Vara, 2005). Primary antibodies are raised against a specific 
protein/antigen and secondary antibodies against immunoglobulins of the primary 
antibody species. Following incubation with an unlabelled primary antibody, a 
secondary antibody conjugated to an enzyme maker or flurophore, which fluoresces at a 
certain wavelength and emits a specific colour, is used to visualise the protein of 
interest. The secondary antibodies used in this study were conjugated to the Alexa 
Fluor®488 and Alexa Fluor®546 dyes. The Alexa Fluor®488 dye has an excitation 
wavelength of 495nm and an emission wavelength of 519nm and produces a green 
fluorescence, while the Alexa Fluor®546 dye (excitation/emission wavelengths: 
556nm/573nm) produces an orange-red fluorescence. If carrying out dual staining two 
opposing, non-overlapping wavelengths which allow both antigens to be distinctly 
viewed should be chosen. Alexa Fluor®488 and Alexa Fluor®546 dyes have a minimum 
overlap and so are suitable for dual staining (Figure. 2.1).  
 
 
 
Figure 2.1 Absorption spectra of the Alexa Fluor® dyes  
Note that AF-488 (1) and AF-546 (5) have minimum overlap. 
http://www.invitrogen.com/site/us/en/home/References/Molecular-Probes-The-Handbook/Fluorophores-and-Their-
Amine-Reactive-Derivatives/Alexa-Fluor-Dyes-Spanning-the-Visible-and-Infrared-Spectrum.html).  
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Procedure 
10 l concentrated cell suspension was added to each chamber of a Superfrost™ slide 
and left to air-dry. Cells were fixed and permeabilised with 50 l Cytofix/Cytoperm for 
30min at RT and rinsed with PBST. Non-specific bindings were blocked by incubation 
with 50µl blocking buffer (Appendix I, 3.1) for 30min at RT. Cells were then incubated 
with 50 l primary antibody (1hr at RT) (Appendix I, Table C), washed with PBST 
(3×10min), incubated with 50µl anti-mouse/anti-rabbit secondary antibody conjugated 
with Alexa Fluor-488 or Alexa Fluor-546 (1hr at RT) (Appendix I, Table D) and 
washed again with PBST (4×15min). Nuclei were counterstained by incubation with 
4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) for 5mins (Appendix I, 3.3). 
Slides were allowed to dry completely, mounted using ProLong® Gold to prevent 
quenching and viewed using an Olympus BX40 fluorescent microscope.  
Note: Incubation with blocking buffer, primary/secondary antibodies and DAPI was carried 
out in a covered semi-dry box. All washes were performed with agitation and slides covered 
with aluminium foil to prevent flurophore quenching. 50µl volume is per chamber. 
2.7 Tissue microarray construction  
TMAs are a platform on which 100s of primary tissue samples can be analysed 
simultaneously by established in situ techniques such as FISH, IHC and RNA-ISH 
(Simon et al., 2004). The development of TMAs allows faster, uniform analysis of 
multiple tissue samples at the same time under identical experimental conditions 
(Conway et al., 2008). TMAs are constructed by removing tissue cores 0.6mm–2mm in 
size from formalin-fixed paraffin embedded ‘donor’ tissue blocks and embedding these 
into a 'recipient' paraffin block, with each 'donor'/patient arrayed in triplicate to ensure 
the heterogeneous nature of the tumour is fully represented. 
Procedure 
TMAs used in this study were previously arrayed by our colleagues AC and AO using 
reactive lymph nodes, diagnostic FL and diagnostic DLBCL formalin-fixed, paraffin-
embedded tissue biopsies available from St. Bartholomew's hospital. Sections of these 
tissue biopsies were stained with haematoxylin and eosin (H&E) and examined by our 
histopathologist colleague MC who identified and selected areas rich in malignant cells 
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which were representative of the whole tumour and suitable for sampling and inclusion 
on the TMAs. Using a semi-automated arraying machine (TMABooster-Alphelys, 
Beecher Scientific), 1mm
2
 cores were 'punched' from the selected areas on the donor 
tissue and transferred into previously constructed holes in the recipient paraffin blocks. 
Each patient was arrayed in triplicate.  
2.8 Immunohistochemistry   
IHC allows visualisation of a protein within a tissue sample without disrupting or 
altering the tissue structure. It exploits the principle of antibody-antigen binding and 
allows these interactions to be visualised using fluorescent dyes, enzymes labels or 
radioactive markers (Coons, 1958). Direct IHC involves incubation of the tissue sample 
with a primary antibody which is conjugated to a maker (e.g. a fluorochrome) thus 
allowing direct antigen visualisation. Indirect IHC, which was performed in this study, 
involves a primary antibody acting as an antigen for a conjugated secondary antibody 
and is  preferable to direct staining as it produces clearer results with increased 
sensitivity and specificity (Ramos-Vara, 2005).  
In this study, the dextran polymer IHC staining method (DPM; Biogenix Supersensitive 
Polymer HRP) was used to identify proteins of interest, rather than the traditional 
avidin-biotin complex (ABC) method, which produces a high degree of non-specific 
background staining (Ramos-Vara, 2005). In the DPM method, samples are first 
incubated with an antibody directed against the antigen of interest. This antigen-
antibody complex signal is amplified by binding of a multimeric compound which 
contains a secondary antibody targeted against the primary antibody, and a horseradish-
peroxidase (HRP) conjugated polymer (SuperEnhancer™ and PolymerHRP™) (Figure 
2.2). The antigen-antibody complex, which is bound by the multimeric complex, is then 
detected by adding a substrate that both binds to and is chemically altered by the 
polymer-conjugated HRP, resulting in a detectable colour change. Here, the 
chromogenic substrate used was 3,3’-diaminobenzidine (DAB), which when acted upon 
by HRP produces a dark brown colour and reflects expression of the protein of interest.    
      Chapter II Materials and Methods 
 
86 
 
Prior to examination by IHC samples should be deparaffinised to remove excess wax, 
subjected to antigen-retrieval to unmask epitopes which may have been hidden during 
the fixing process and incubated with a blocking buffer to reduce non-specific bindings 
(Shi et al., 2005). Stained sections can be viewed and analysed manually or using 
automated commercial analysis systems such as ARIOL (Conway et al., 2008; Simon et 
al., 2004). The full list of antibodies used in this study can be found in the appendix 
(Appendix I, Table E).  
 
 
 
 
 
 
 
 
 
Figure 2.2 Dextran polymer indirect IHC staining method  
Samples are incubated with primary antibody directed against the antigen of interest, followed by 
secondary antibody directed against the primary antibody. The secondary antibody is bound to a 
multimeric complex which contains HRP and a polymer and amplifies the signal produced by the primary 
antibody binding the antigen. DAB is then added which is converted to a dark brown colour by polymer-
conjugated HRP if it is bound to the antigen. HRP – horseradish peroxidase; DAB – 3,3’-
diaminobenzidine. Adapted from Ramos-Vara, 2005.  
 
Procedure 
Using a Leica RM2232 microtome, 3µm sections were cut from a TMA paraffin block 
which had been placed on an ice block for 10-15min prior to sectioning. Sections were 
placed on a Superfrost™ slide and placed in a 60ºC oven overnight to dry and fix. 
Following fixation sections were deparaffinised and non-specific bindings blocked by 
immersing them in 100% xylene, peroxidase blocking buffer (Appendix I, 4.1), 100% 
IMS and running tap water (5min per solution). Heat-induced antigen retrieval was 
performed by fully immersing sections in a pre-boiled unmasking solution (Appendix I, 
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4.2) and heating them for 10min in a pressure cooker. Sections were then marked using 
a hydrophobic pen and placed on an automated staining machine which was 
programmed to incubate slides for set periods of time with defined volumes of primary 
antibody (Appendix I, Table E), HRP-labelled polymer and the chromogen DAB 
(Appendix I, 4.4), which is chemically altered by HRP and produces a dark brown 
colour when the HRP-labelled polymer is bound to the antigen-antibody complex. Once 
stained, sections were dipped in acid alcohol (Appendix I, 4.5), counter-stained with 
Mayer haematoxylin which stains the nuclei of cells blue and mounted with coverslips 
using DPX (Distrene 80, Dibutyl phthalate and Xylene) (Appendix I, 4.6). Sections 
were prevented from drying out at all times by incubating with wash buffer (Appendix 
I, 4.7). Slides were then scanned, digitised and analysed using the automated ARIOL 
image analysis software. Image analysis classifiers are trained based on the saturation, 
intensity and hue of a colour such that only areas stained above a pre-determined 
threshold which reflect the highest intensity staining are included as positive staining / 
protein expression; background, lower level non-specific staining is excluded. For this 
study two classifiers were used – one which identified high intensity brown staining and 
was taken to represent the protein of interest, the other which reflected total area of 
viable tissue. Protein expression was calculated as the percent-stained viable tissue area 
for all proteins with the exception of CD68 which was previously analysed by our 
colleague RC as the percent-positive cells per viable tissue area. Poor quality cores were 
excluded from the analysis.  
2.9 Measurement of caspase-3 activity 
Induction of apoptosis results in activation of caspase-3, an essential component in the 
apoptotic pathway (Galluzzi et al., 2012; Porter and Janicke, 1999). Activated caspase-3 
promotes the cleavage of cellular proteins including the DNA repair enzyme PARP, 
which it cleaves at the tetrapeptide DEVD (aspartic acid, glutamic acid, valine, aspartic 
acid), inhibiting its pro-survival function. Caspase-3 is also essential for apoptosis-
induced DNA fragmentation and chromatin condensation (Gurtu et al., 1997; Porter and 
Janicke, 1999). As activated caspase-3 is a key component of apoptosis, caspase-3 
activity can be used as a marker of apoptosis within cells. Conjugation of the flurophore 
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7-amino-4-trifluoromethylcoumarin (AFC) to the DEVD tetrapeptide forms the 
synthetic substrate DEVD-AFC which is cleaved by active caspase-3 during apoptosis, 
resulting in a shift in AFC fluorescence from blue to yellow-green. The amount of AFC 
cleaved from DEVD is proportional to the degree of caspase-3 activity and is defined as 
the amount of enzyme required to release 1µM AFC per hour.  
Procedure 
10µl protein lysate (Appendix I, 5.1) was mixed with 85µl reaction buffer (Appendix I, 
5.2; Table F) and 5µl caspase-3-DEVD-AFC substrate (Appendix I, 5.3) giving a final 
volume of 100µl, protein concentration of 50µg and substrate concentration of 20µM 
per well. Samples were incubated at 37°C for 15min followed by 1min at -20°C and 
subsequently transferred from a clear 96-well culture plate to a black microtiter 96-well 
plate. AFC release was measured at excitation 410nm and emission 510nm using a 
BMG LabTech FLUOstar Omega microplate reader. Samples were analysed in 
triplicate. An AFC standard curve was prepared per plate according to table 2.2 using a 
5µM AFC working solution (Appendix I, 5.4) and caspase-3 activity expressed as AFC 
release (µM/hr/mg protein).  
Table 2.2 AFC Standard Curve for Caspase-3 Assay 
 
 
 
 
 
 
2.10 Flow cytometry 
Flow cytometry is a quantitative and qualitative assay which utilises the principles of 
light scattering and hydrodynamic focusing to measure and identify multiple 
characterises on individual cells (Brown and Wittwer, 2000; Mandy et al., 1995).  
Fluorescent dye -labelled cells are injected into a stream of fluid and hydrodynamically 
compressed, forcing them to pass one by one through a laser which results in 
fluorochrome excitation and emission of a photon. Emitted photons are scattered in 
Row µM 5µM AFC (µl) H2O (µl) 
0 0 0 100 
1 0.1 2 98 
2 0.2 4 96 
3 0.3 6 94 
4 0.4 8 92 
5 0.5 10 90 
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various directions based on cellular properties such as size and granularity, and detected 
by optics and filters which isolate individual wavelengths/fluorochromes (Figure 2.3) 
(Brown and Wittwer, 2000). Multiple fluorochromes can be used simultaneously to 
examine different cellular properties; however fluorochromes with minimally 
overlapping wavelengths should be selected. 
2.10.1 Evaluation of mitochondria membrane potential and cell death  
Tetramethylrhodamine, Methyl Ester, Perchlorate (TMRM) is a fluorescent lipophilic 
cation dye used to examine ΔΨm in cells (Scaduto and Grotyohann, 1999). Uptake of 
TMRM is an energy dependent process, meaning when ΔΨm is high (ΔΨmHIGH), 
TMRM is taken up by mitochondria. Damage to the mitochondria results in a decrease 
in membrane potential (ΔΨmLOW), preventing uptake and incorporation of this 
fluorescent dye into the mitochondria, resulting in its exclusion from cells. Therefore, a 
decrease in TMRM indicates low ΔΨm and mitochondrial damage (Nicholls and Ward, 
2000). DAPI is an AT-specific, DNA binding fluorochrome used to distinguish live and 
dead cells (Schweizer, 1976). Due to increased membrane permeability DAPI 
accumulates in dead or dying cells, deemed DAPI
+
, but is exclude from live cells with 
intact membranes, deemed DAPI
-
. 
 
 
 
 
 
 
Figure 2.3 Example of typical flow cytometer 
Cells in suspension are injected into the sheath fluid where they are forced into single file by 
hydrodynamic focusing. Upon encountering the light source (e.g. laser), light is scattered in various 
directions passing through collection optics, mirrors and filters. This light information is translated into 
digital format and produced as a read out on a computer attached to the cytometer. 
(http://www.clinchem.org/content/46/8/1221/F1.expansion). 
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Procedure 
DAPI (Appendix I, 6.1) and TMRM (Appendix I, 6.2) were prepared in 10mls PBS at a 
concentration of 100ng/ml and 80nM, respectively, as a working solution. 400µl of 
working solution added to each FACs tube. Cells in suspension were added to the tubes 
at a ratio of 1:1 (400µl cell suspension/tube) to make final concentrations of DAPI at 
50ng/ml and TMRM at 40nM. Cells were incubated for 15min at 37°C and read on an 
LSRFortessa cell analyser. DAPI was read under the violet laser channel (405nm) at 
bandpass V450/50 and TMRM under the blue laser channel (488nm) at bandpass 
B695/40. An unstained control containing only PBS and cell suspension in a 1:1 ratio 
was run prior to the fluorescently labelled samples in order to correctly define the 
negatively and positively stained populations. 10,000 cells were acquired per condition 
and data analysed using Summit Version 4.3. 
2.10.2 Isolation of B cell populations by flow assisted cell sorting  
Flow cytometry can identify and isolate distinct cell populations within a heterogeneous 
group of cells based on their immunophenotypes. Samples are incubated with antibodies 
labelled with fluorescent dyes directed against surface antigens expressed by the cell of 
interest, allowing this population to be discerned from others. Cells expressing the 
appropriate immunophenotype are 'gated-out', diverted from the fluid stream and 
collected as a homogeneous cell fraction (Ibrahim and van den Engh, 2007). While 
some populations can be isolated by expression of a single marker, the majority of cell 
types are segregated based on multiple markers. Similarly, more than one homogeneous 
population of cells can be obtained from a single sample at the same time. When 
choosing a fluorochrome panel to identify and isolate various populations care should 
be taken to avoid overlapping wavelengths; when this proves difficult compensation can 
be applied.  
Procedure 
Primary single cell suspensions were incubated with 0.5mg/ml DNase (Appendix I, 6.3) 
for 5min at RT, pelleted by centrifugation at 1,400rpm for 10min, resuspended in plain 
RPMI and separated into groups of 10×10
6
 cells, keeping 2×10
6
 cells for controls. Non-
specific bindings were blocked by incubation with 2% human anti-γ-globulin antibody 
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(Appendix I, 6.4) for 30min on ice. Cells were then incubated with the appropriate 
antibodies (Appendix I, Table G) for 30min on ice in the dark, washed 1× in 2% FACS 
wash (Appendix I, 6.6) and resuspended  in 2% FACS wash containing DNase and 
DAPI (Appendix I, 6.7; 1ml/10×10
6
 cells). B cells were isolated using a BD FACSAria 
flow sorter and collected in 1ml 10% filtered FCS (Appendix I, 6.8). Isolated B cell 
purity was >95% in all cases. An unstained control was included for each sample and a 
single stain and FMO for each antibody tested. DAPI was used to discriminate live and 
dead cells. Following selection of DAPI negative,
 
cells T-cells were excluded by gating 
on CD3 negative (CD3
-
) cells. B cells were isolated from the DAPI
-
/CD3
- 
population 
based on expression of B cell markers. DLBCL and reactive B cells were identified by 
CD20 expression while FL B cells were isolated based on dual expression of CD19 and 
CD10. Purified CD19
+
/CD10
+
 FL B cells and reactive B cells were evaluated for κ/λ 
light chain restriction. 
2.11 RNA extraction 
2.11.1 Phenol-chloroform based RNA extraction (TRIzol® Reagent) 
TRIzol® Reagent is a ready-to-use monophasic guanidine isothiocyanate/phenol 
solution used for extraction of RNA from various biological samples while maintaining 
RNA integrity by effectively inhibiting RNase activity (Chomczynski and Sacchi, 
1987).  
Procedure 
RNA was extracted from solid primary tissue samples using a standard TRIzol® RNA 
extraction protocol. Tissue samples were placed in a 2ml eppendorf containing 1ml 
TRIzol® and a metal ball bearing and homogenised at 4ºC for 3min at 20Hz. The 
homogenised sample (~1ml) was transferred to a fresh 1.5ml eppendorf, incubated at 
RT for 5min, mixed vigorously with 200µl chloroform for 15sec and incubated at RT 
for 3min, followed by centrifugation at 12,000rpm (15min at 4°C). Centrifugation 
results in separation of samples into a bottom white DNA layer, a red middle 
protein/DNA phenol-chloroform layer and a clear top chloroform layer containing 
RNA. This top aqueous layer (~500µl) was transferred to a fresh 1.5ml eppendorf, 
mixed with 500µl isopropanol by pipetting up and down 10-15 times,  incubated at RT 
      Chapter II Materials and Methods 
 
92 
 
for 10min, centrifuged at 12,000rpm (10min at 4°C) and the supernatant completely 
removed. Pellets were washed 1× with 75% ethanol (Appendix I, 7.1) centrifuged at 
7,500rpm for 5min at 4°C, the supernatant completely removed and pellets left to air 
dry for 5-10min on ice. Pellets were then re-suspended in 50-100µl RNase free water 
and RNA quality and quantity assessed.   
2.11.2 RNA extraction using QIAGEN RNeasy® mini kit 
The QIAGEN RNeasy® Mini Kit is a widely used method of RNA extraction which 
does not require toxic, potentially contaminating compounds such as chloroform (Morse 
et al., 2006).  
Procedure 
RNA was extracted from cells according to the QIAGEN RNeasy® Mini Kit protocol. 
Cells in suspension were pelleted by centrifugation at 1,500rpm for 5min, mixed with 
350µl buffer RLT containing β-mercaptoethanol (Appendix I, 8.1), transferred to a 
QIAshredder spin column and centrifuged at full speed (~14,000rpm) for 2min. The 
sample flow-through was retained, mixed with 350µl 70% ethanol (Appendix I, 8.2), 
transferred to an RNeasy spin column and centrifuged at 9,300rpm for 15sec. An on-
column DNase digestion was then performed to eliminate any residual genomic DNA. 
350µl buffer RW1 was added to the RNeasy spin column and centrifuged at 9,300rpm 
for 15sec, after which the membrane was incubated with 80µl DNase I incubation mix 
(Appendix I, 8.3) for 15min at RT. 350µl buffer RW1 was then added to the membrane 
and centrifuged for 15sec at 9,300rpm. The membrane was washed 2× by incubation 
with 500µl buffer RPE (Appendix I, 8.4) for 2min at RT followed by centrifugation at 
9,300rpm for 15sec or 2min and centrifugation at ~14,000rpm for 1min to dry the 
membrane. RNA was eluted by incubation of the membrane with 25µl RNase-free 
water for 2min at RT followed by centrifugation at 9,300rpm for 1min and subsequently 
assessed for quality and quantity.  
NOTE: Care was taken when removing the spin column from the collection tube so as to avoid 
carryover of ethanol. Flow through was discarded unless otherwise stated.  
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2.12 RNA quantity and quality assessment 
2.12.1 NanoDrop spectrophotometer  
RNA concentration and quality was determined using a NanoDrop spectrophotometer 
which measures the amount of ultraviolet (UV) light absorbed by nucleic acids at 
260nm. Nucleic acid absorbance equals optical density (OD), where taking a path length 
of a 1cm, 1 OD unit is equal to 50ng/µl (Cicinnati et al., 2008). Quality was assessed by 
determining the 260/280nm and 260/230nm absorbance ratios. The optimal 260/280nm 
ratio for RNA is ~2, with a lower value suggesting possible contamination with protein 
or other impurities which absorb strongly at 280nm (Wilfinger et al., 1997). 260/230nm 
ratios should be between 2 and 2.2, although no consensus has been reached as to what 
constitutes an acceptable cut-off. (Wilfinger et al., 1997).  
Procedure 
Prior to testing of samples the NanoDrop was blanked using 1µl of RNase-free water. 
RNA samples were tested using 1µl of RNA and the RNA quantity (ng/µl), 260/280nm 
and 260/230nm values recorded for each sample. 
2.12.2 Agilent bioanalyser 
The Agilent 2100 Bioanalyser is a microfluidics-based automated system used to 
establish the quality and integrity of an RNA sample (Schroeder et al., 2006) The 
bioanalyser generates an RNA integrity number (RIN) per sample which is calculated 
based on the RNAs electrophoretic trace while taking into account the presence/absence 
of degraded RNA products and the height of the 18S peak (Imbeaud et al., 2005; 
Schroeder et al., 2006). An electropherogram which shows degraded RNA products as 
well as the 18S and 28S ribosomal RNA peaks is produced per sample (Figure 2.4). A 
RIN of 1 indicates poor quality, degraded RNA while a RIN of 10 suggests good 
quality, intact RNA (Imbeaud et al., 2005). When carrying out RNA-based assays only 
samples with similar RIN should be compared.  
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Figure 2.4 Representative Electropherogram generated by the Agilent 2100 Bioanalyser 
For each sample run on the Agilent 2100 Bioanalyser an electropherogram is generated which shows the 
ladder, 18S subunit, 28S subunit and any degraded RNA. The sample shown has a RIN number of 7.9.  
Procedure 
Reagents (Agilent RNA 6000 Nano Kit) were equilibrated to RT for at least 30min prior 
to use (Appendix I, 9.0). The procedure was carried out according to the manufactures 
guidelines. 550µl RNA gel matrix was transferred to a spin filter and centrifuged at 
4,000rpm for 10min. 1µl RNA dye concentrate was added to 65µl filtered gel, mixed by 
vortexing and spun at 11,800rpm for 10min. 9µl gel-dye mix was added to the well 
marked ‘G’ of an RNA bioanalyser chip and dispersed. A further 9µl of gel-dye mix 
was added to the second and third wells marked ‘G' after which 5µl RNA marker was 
added to each well including the ladder well. Samples and the Agilent RNA 6000 ladder 
were denatured by heating at 70°C for 2min. 1µl RNA 6000 ladder was added to the 
ladder well and 1µl of sample added to each well.  A further 1µl of RNA marker was 
added to any well which did not contain an RNA sample. The chip was then vortexed 
for 1min, inspected for bubbles and run on the Agilent 2100 Bioanalyser using the 
Eukaryote RNA Nano chip assay.  
2.13 Gene expression analysis by qRT- PCR  
2.13.1 Complementary DNA synthesis  
RNA is not a suitable assay template as it is highly unstable and readily broken down by 
ubiquitous RNases (Bustin, 2002; Fleige et al., 2006). Therefore in order to examine 
RNA it must first be converted by the enzyme reverse-transcriptase to complementary 
DNA (cDNA) which acts as a stable template for RNA-based assays (Bustin, 2000). 
Conversion of RNA to cDNA begins with binding of primers to mRNA that act as a 
reference point from which reverse-transcription begins. Commonly used primers 
Ladder 18S 28S 
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include oligo dTs and random hexamer primers which bind RNA at the 3’ poly-A tail 
and multiple different sites along the RNA template respectively (Bustin et al., 2005). A 
combination of both primers can also be used as was the case in this study. Following 
primer binding the reverse-transcriptase enzyme converts ssRNA to ds-cDNA which is 
suitable for use in RNA-based assays.  
Procedure 
RNA was converted to cDNA using the QIAGEN RT
2
 First Strand Kit. A 10µl genomic 
DNA elimination (GDE) mix was prepared per sample (Appendix I, Table H). For 
samples where RNA volume exceeded 8µl, RNA was spun down for 3-5 min at medium 
speed in a 60Hz speed vac to reduce volume but maintain concentration. GDE mix was 
incubated at 42°C for 5min followed by at least 1min at 4°C using a thermo cycler. A 
reverse-transcription (ReTr) mix was prepared (Appendix I, Table I), 10µl mixed with 
each samples GDE mix and incubated on a thermo cycler at 42°C for 15min followed 
by 5min at 95°C to stop the reaction. 91µl RNase-free water was then added to each 
sample and mixed by gently pipetting up and down. cDNA was stored at -20°C. 
2.13.2 Quantitative real-time polymerase chain reaction    
qRT-PCR allows enzymatic amplification and real-time detection of specific mRNA 
transcripts within a given sample. This RNA-based assay utilises fluorescent molecules 
to determine the relative abundance of an mRNA transcript by measuring the release of 
a fluorescent molecule such as carboxyfluorescein (FAM) or the incorporation of a 
fluorescent molecule such as SYBR Green. SYBR Green based qRT-PCR begins with 
denaturation of ds-cDNA to a single-stranded template which is bound by primers 
targeted against a specific complementary mRNA sequence. Primers are extended by 
HotStart DNA Taq (Thermus aquaticus) polymerase, resulting in synthesis of a new ds-
DNA complex to which SYBR Green binds, causing it to fluoresce. This cycle is 
repeated 40 times and amplifies the ds-cDNA exponentially, resulting in accumulation 
of SYBR Green fluorescence. The amount of SYBR green which accumulates is 
therefore proportional to the amount of newly synthesised ds-DNA and thus the amount 
of PCR product/mRNA initially present.   
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The RT
2
 Profiler PCR Array combines qRT-PCR technology with a microarray format 
to allow rapid, simultaneous detection of multiple genes expression levels. For example 
the RT
2
 Profiler Human Autophagy PCR Array contains primers targeted against 84 
genes involved in all aspects of the autophagy pathway, from key machinery genes to 
regulatory genes. This array also contains primers targeted against a number of controls, 
namely five housekeeping genes (HKGs) used for data normalisation, along with 
genomic DNA (GDC), reverse-transcription (RTC) and positive PCR (PPC) controls 
(Figure 2.5).  
 
 
 
 
 
Figure 2.5 RT
2
 Profiler PCR Array, 384-well plate, Format E Layout   
The RT
2 
Profiler PCR Array contains primers against 84 genes with each primer replicated four times 
(e.g. A1, A2, B1, and B2). Rows A - N contain primers directed to the autophagy-related genes, while 
rows O and P contain primers against various endogenous and reaction controls. HKG - housekeeping 
gene; GDC - genomic DNA control; RTC - reverse transcription control; PPC - positive PCR control. 
Procedure 
A PCR reagents mix was prepared per sample (Appendix I, Table J) using previously 
synthesised cDNA. Each samples’ PCR-mix was placed into a loading reservoir and 
from here 10µl transferred to the samples designated well on the 384-well array. Once 
loaded the plate was sealed, centrifuged for 1min at 3,300rpm at RT and subsequently 
placed on ice. The Applied Biosystems 7900HT real-time cycler was then programmed 
according to the protocol and a dissociation curve analysis step included to verify PCR 
specificity (Appendix I, Table K). 
2.13.3 Validation of qRT-PCR  
Validation experiments were carried out in a cohort of patients to confirm a sub-set of 
gene expression changes observed using the RT
2
 Profiler PCR Array. Following 
conversion of RNA to cDNA, samples were prepared for qRT-PCR (Appendix I, Table 
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L) and the qRT-PCR assay run under previously stipulated cycling conditions 
(Appendix I, Table K). All genes validated, including the HKG RPLPO, were analysed 
in triplicate and a no-template control (NTC) also included per gene. Primers used in 
validation experiments were identical to those present on the RT
2
 Profiler Human 
Autophagy PCR Array.  
2.13.4 Endogenous control selection 
When performing gene expression analysis by qRT-PCR there are a number of 
parameters including efficiency of cDNA synthesis and technical variation which 
should be controlled for to ensure expression measures obtained are reliable and robust 
(Andersen et al., 2004). The most common way to minimise the potential effect of such 
variables is to normalise data to an internal HKG which ideally, should be stably 
expressed in all cell types and under all experimental conditions (Andersen et al., 2004; 
Vandesompele et al., 2002). Arbitrary selection of such a gene is advised against; 
instead, software programmes which use algorithms to determine the best 
HKG/combination of genes within and between different sample groups should be used. 
In this study the freely available programmes gNorm and Normfinder were used to 
identify the most stable HKG(s). 
2.13.4.1 gNorm 
gNorm identifies the most stably expressed HKG(s) within and between sample groups 
by using non-normalised CT values to calculate the expression ratio between two HKGs 
and works on the principal that this ratio should be identical under all experimental 
conditions in all sample types. From this ratio the gene-stability measure M, which is 
the arithmetic mean of all pairwise variations of a particular gene with all other HKGs, 
is calculated (Vandesompele et al., 2002).  A low M value is indicative of a gene with 
stable expression while a high M value is representative of a less stably expressed gene. 
gNorm compares M values between all possible combinations of genes and in a 
stepwise exclusion manner removes unstable genes with a high M value and retains 
those with similar, low M values, thus systematically identifying which gene(s) are the 
best to use as a housekeeping/normalisation gene (Figure 2.6) (Vandesompele et al., 
2002).  
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Figure 2.6 Identification of the most stable endogenous control gene(s) using gNorm 
software 
Raw CT values generated from qRT-PCR were imputed into the gNorm programme which analyses data 
and identifies the most stable HKG. gNorm returns a VNF value which indicates whether or not a 
combination of genes is more stable than a single HKG. In this example, no pair of controls is 
significantly more stable than using a single gene on its own (a). gNorm also returns the M value which 
indicates the stability of the HKGs. The lower the M value of a HKG the more stable it is. In this 
example, the most stable gene is RPLPO (b).    
2.13.4.2 Normfinder 
Normfinder is a Microsoft Excel algorithm-based add-on which identifies the optimal 
HKG within any number of samples or groups (Andersen et al., 2004). It calculates a 
stability value for each HKG across all samples/groups by combining the intra- and 
intergroup variation and ranks genes according to this value. Gene(s) with a low 
stability value are deemed the most stable and thus the most appropriate to use as a 
normalisation gene (Andersen et al., 2004).  Raw CT values cannot be used for 
Normfinder; instead, data should be linearised relative to a user-defined calibrator 
sample and these values imputed.  
2.13.5 Calculation of relative quantification values  
The qRT-PCR assay generates cycle threshold (CT) values which represent the 
abundance of mRNA transcript present for each gene in each sample. The CT value is 
defined as the number of cycles required for the fluorescence signal to cross a defined 
threshold during the exponential phase of the PCR reaction.  The threshold limit is user-
defined and should be standardised across all plates within a given experiment. CT 
values are inversely proportional to mRNA abundance – the greater the amount of target 
mRNA present the lower the CT value. CT values obtained from qRT-PCR assays are 
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non-normalised meaning direct comparison of these values within and between groups 
is not an accurate reflection of gene expression profiles. To allow direct comparisons, 
CT values must first be converted to relative quantity (RQ) values. 
Procedure 
Prior to calculation of RQ values, genes with a CT value of >35 were excluded from 
further analysis as this value surpasses the threshold of the qRT-PCR cycler and may 
not be an accurate measure of gene expression (Kreth et al., 2010). All plates within a 
single experiment were standardised to the same threshold. For samples analysed in 
triplicate the average CT value was used provided standard deviation (SD) was <0.5. In 
cases where SD was >0.5, data was visualised and if a clear outlier was identified this 
value was excluded and the average of the remaining duplicates used.  
RQ values were calculated using the formula RQ = 2
-∆∆C
T. Target CT values were 
normalised to a previously selected HKG by subtracting the CT value of the HKG from 
the target gene CT, generating a delta CT (∆CT) value for each gene. 
   CT Target Gene – CT Endogenous Control Gene = ∆CT 
The delta ∆CT (∆∆CT) value, which represents the quantity of mRNA present in each 
sample, was determined by subtracting the ∆CT of a user-defined calibrator sample from 
the ∆CT of test samples. In this study the average ∆CT of reactive control samples or 
untreated cell lines was used as the calibrator sample on a per gene basis.  
             ∆CT Test Sample – ∆CT Calibrator Sample = ∆∆CT 
Calculation of the ∆∆CT value in this manner produces data which is log2-transformed. 
Data was therefore transformed to a linear scale using the formula below, producing the 
final RQ value which is comparable across all genes and sample types in all groups.  
                2
-∆∆C
T = RQ  
To identify differences in gene expression levels between groups the average RQ value 
of each gene was calculated within each patient group. The average of one group was 
then divided by the average of another (e.g. average FL/average DLBCL) which 
generated a fold change (FC) value for each. A FC of ≥2 or ≤-2 which was statistically 
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(p< 0.05) significant using a Mann-Whitney U test was taken to be biologically 
meaningful.  
2.13.6 Hierarchical clustering   
Hierarchical clustering is a technique commonly used in GEP to identify genes or groups of 
genes which are similarly expressed between samples. Using a distance metric which 
measures distances between observation pairs, samples are clustered based on similarities or 
differences in RQ values/gene expression levels. A linkage criterion is also used which 
groups’ samples based on similarity by calculating the distance between sets of 
observations as a function of the pairwise distance between observations within sets and 
produces linkage trees or dendrograms which depict similarities between samples. In this 
study, hierarchical clustering was performed using the Euclidean distance measure and an 
average agglomeration available within the R statistical computing environment, and 
which determine similarity between genes and samples and calculate the distance 
between samples or genes respectively. All hierarchical clustering was performed by JM. 
2.14 Co-Immunoprecipitation  
Co-immunoprecipitation (co-IP) is used to detect protein-protein interactions within 
cells (Phizicky and Fields, 1995). While IP experiments aim to identify a primary target 
within a sample, co-IP experiments aim to identify any ligands or proteins bound to the 
primary antigen (www.piercenet.com). Co-IP works by incubating whole cell lysate with 
antibody directed against the primary target antigen. This antibody/protein complex, 
which will also contain proteins interacting with the primary antigen, is then captured 
on a solid support such as beads. This protein complex is eluted off the support, 
denatured and analysed by SDS-PAGE and immunoblotting (Phizicky and Fields, 
1995). Secondary target antigens are probed for initially followed by detection of the 
primary target antigen to verify its presence (Figure 2.7) (www.piercenet.com). Normal 
whole cell lysate and an immunoglobulin control should be used for each sample. 
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Figure 2.7 Diagrammatic representation of a co-IP experiment 
Whole cell lysate is incubated with antibody target to a specific protein. A solid support (e.g. beads) is 
added to the mixture to capture the primary antigen and any proteins with which it interacts. The samples 
are spun and washed and the protein complex eluted off. Samples are analysed using SDS-PAGE. 
http://www.piercenet.com/browse.cfm?fldID=9C471132-0F72-4F39-8DF0-455FB515718F. 
Procedure 
Samples were prepared by mixing 300-400µg of protein with IP incubation buffer 
(Appendix I, Table M) to a total volume of 200µl. 2µg of mouse anti-IgG or hamster 
anti-BCL-2 was added to the protein/buffer mixture and samples incubated on a rotator 
overnight at 4°C. Samples were then incubated with 20µl of Protein A/G beads on a 
rotator for 1hr at RT, spun down and washed 3× with IP wash buffer (Appendix I, Table 
N). 20µl of eluting solution (Appendix I, 11.3) was added to each pellet and samples 
denatured by heating at 100°C for 5min. Proteins were separated by SDS-PAGE and 
Beclin-1 and BCL-2 probed for by Western blotting. 
2.15 Statistical analysis 
2.15.1 General statistical analysis 
Data were expressed as mean ± SD of three separate experiments. A student’s unpaired 
t-test was used to compare differences between two groups, where data was deemed to 
follow a normal Gaussian distribution (Shapiro-Wilk p value >0.05). To examine the 
effect of treatment on a single cell line, a paired student’s t-test was used. Non-normally 
distributed data were analysed using the non-parametric Mann-Whitney U test. All tests 
performed were two-tailed. Comparisons were made between more than 2 groups using 
a 2-way analysis of variance (ANOVA) with Bonferroni post-test analysis for multiple 
comparisons. A Pearson correlation test was used to assess correlation between two data 
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sets. A p value of <0.05 (*), <0.01 (**) or <0.0001 (***) was deemed significant for all 
comparisons. Statistical tests were performed using Prism software Version 5.03 and 
Excel. Specific statistical tests used in each experiment are stated in the corresponding 
text or figure legend.    
2.15.2 X-tile 
X-tile Version 3.5 (Yale University) is a statistical software package which divides 
patients into two or more groups based on optimal cut-points which are derived from 
the variable being assessed, without the need for validated normal ranges (Camp et al., 
2004). X-tile first divides the patient cohort into two independent data sets – test and 
validation– in a 1:2 ratio. It then determines the optimal cut-point(s) for each marker 
within the test set, and subsequently applies this to the validation set (Altman et al., 
1994; Greaves et al., 2013). 
2.15.3 Kaplan-Meier survival analysis  
Kaplan-Meier survival curves were generated using Prism Version 5.03. Patients were 
stratified according to X-tile derived cut-points. Statistically significant differences in 
clinical outcome between groups, arising from differential expression of each marker or 
protein, were determined using a log-rank test. Outcomes compared in this study were 
overall survival (OS), disease-specific survival (DSS), time to transformation (TTT) and 
progression free survival (PFS) which were calculated according to table 2.10. Where 
the event (e.g. death) occurred patients were coded ‘1’; where the event did not occur, 
patients were censored and coded ‘0’.  A p value of <0.05 was deemed significant.  
Table 2.3 Calculation of Survival Outcomes 
 
 
Outcome Obtained 
Overall Survival (OS) Date of diagnosis to date of death or date of last follow up 
Disease Specific Survival (DSS) Date of diagnosis to date of disease related death or date 
of last follow up 
Time to Transformation (TTT) Date of diagnosis to date of transformation or date of last 
follow up 
Progression Free Survival (PFS) Date of diagnosis to date of progression/relapse 
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2.15.4 Continuous data analysis  
Continuous univariate data analysis assesses the ability of a single variable to predict 
outcome using the Cox proportional hazards model (Greaves et al., 2013). This model 
evaluates the association between a single continuous variable and a defined event by 
estimating its Hazard ratio (HR) and corresponding 95% confidence intervals (CI). HR 
ratios represent the incremental increase in risk of an event occurring. In order for a 
variable to be classified as a significant prognostic marker using this analysis, p must be 
<0.05. All continuous data analysis was performed using IBM SPSS Statistics Version 
22.  
2.15.5 Categorical (cut-point) data analysis  
Categorical data analysis stratifies patients into groups, typically ‘low’ and ‘high’, using 
X-tile generated cut-points (Greaves et al., 2013). Kaplan-Meier survival curves were 
then generated using these cut-points and significant differences between groups with 
respect to clinical outcome analysed using a log-rank (Mantel-Cox) test, which provides 
a p value, HR and 95% CI for each variable assessed. HR ratios represent the 
instantaneous risk of an event occurring in one group but not the other by the next time 
point. In order for a variable to be classified as a significant prognostic marker using 
this analysis, p must be <0.05, the HR must be <1 or 1>, but not equal to 1, and 95% 
CIs must not cross 1. Univariate categorical analysis included only one variable or two 
variables combined. For multivariate categorical analysis, each variable assessed was 
adjusted for FLIPI (FL) or IPI (DLBCL) scores. All categorical data analysis was 
performed using Prism Version 5.03 and IBM SPSS Statistics Version 22.  
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Chapter III  
 
 
 
 
 
 
Evaluation of the dual roles of BCL-2 in apoptosis and 
autophagy in DLBCL cell lines 
 
 
 
 
 
 
 
 
 
      Chapter III Results 
 
105 
 
3.1 Introduction  
The aim of conventional chemotherapy is to kill malignant cells via apoptosis so as to 
avoid necrosis-mediated inflammation while sparing normal, healthy cells (Kaufmann 
et al., 1993; Kaufmann and Earnshaw, 2000). The response of tumour cells to 
chemotherapy is in part governed by cellular levels of BCL-2 family proteins, with a 
higher ratio of anti-apoptotic to pro-apoptotic proteins known to promote resistance to 
chemotherapy-induced apoptosis in malignant cells (Kaufmann and Earnshaw, 2000; 
Malik et al., 2011). 
Increased expression of BCL-2 in FL and DLBCL allows neoplastic cells to evade 
therapy-induced apoptosis making treatment of these haematological malignancies 
difficult (Campos et al., 1993; Miyashita and Reed, 1993). This obstacle may be 
overcome and chemotherapy-driven killing of FL and DLBCL cells improved via 
targeted inhibition of BCL-2 which has shown therapeutic potential in other 
malignancies. For example the synthetic BH3-mimetic ABT-737, which binds BCL-2 
and BCL-xL via BH3-domain interactions and promotes induction of the intrinsic 
apoptosis pathway, has been shown to be effective as both a single and combination 
therapeutic agent in MCL and other malignancies (Song and Kraft, 2012; Touzeau et al., 
2011).  
It has been reported that the naturally occurring BH3-mimetic (-)-Gossypol can induce 
autophagy by binding BCL-2 via BH3-domain interactions and disrupting its binding to 
the pro-autophagy protein Beclin-1. Sequestration of BCL-2 by (-)-Gossypol frees 
Beclin-1, allowing it to promote autophagy activity within cells (Gao et al., 2010; Lian 
et al., 2011). As well as inducing apoptosis, ABT-737 has also been shown to mediate 
the autophagy pathway via different mechanisms including competitive binding of 
BCL-2 (Malik et al., 2011). It is currently unclear whether this BH3-mimetic can trigger 
autophagy while inducing apoptosis in lymphoma cells. We therefore aimed to evaluate 
which pro- or anti-apoptotic protein(s) determine sensitivity of our panel of DLBCL cell 
lines to ABT-737-induced cell death, and whether ABT-737 also induces autophagy in 
these cells.  
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3.2 Results 
3.2.1 BCL-2 family proteins are differentially expressed in DLBCL cell lines 
Basal expression levels of key pro- and anti-apoptotic BCL-2 family proteins were 
evaluated in DLBCL cell lines by Western blotting (Figure 3.1). We observed that Su-
DHL4 and CRL cells expressed considerably higher levels of BCL-2 compared to Su-
DHL8 and Su-DHL10 cells, which expressed little to no BCL-2 (Figure 3.1 A). This is 
unsurprising as both Su-DHL4 and CRL cells carry the t(14;18) translocation which 
results in increased, aberrant expression of BCL-2 (Deng et al., 2007; Kelly and 
Strasser, 2011). For this reason Su-DHL4 and CRL cells will hereafter be referred to as 
BCL-2
HIGH 
and Su-DHL8 and Su-DHL10 as BCL-2
LOW
 cells.  
All four cell lines were found to express the anti-apoptotic proteins BCL-xL and MCL-1 
(Figure 3.1 A). Expression of pro-apoptotic proteins also differed between these cell 
lines. Bak expression was strongest in Su-DHL4 cells while Su-DHL10 was the only 
cell line which did not express Bax. Similarly, both isoforms of the 'BH3'-only protein 
Bim (Bim EL and Bim L/S) were detected in Su-DHL4, CRL and Su-DHL10 cells but 
not in Su-DHL8 cells (Figure 3.1 B). 
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Figure 3.1 Expression of BCL-2 family proteins in DLBCL cell lines 
50µg whole cell lysate was loaded onto a 4-12% Bis-Tris gel and proteins separated by SDS-PAGE. Key 
anti-apoptotic proteins BCL-2, BCL-xL and MCL-1 (A), and pro-apoptotic proteins Bim, Bax and Bak 
(B) were visualised by Western blotting; β-actin was used as a loading control. Bands are representative 
of a single experiment. Densitometry values were obtained using Gelscan software and represent the ratio 
of specific proteins to β-actin.  
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3.2.2 DLBCL cell lines exhibit differential sensitivity to ABT-737-induced 
cell death 
Cellular levels of the apoptosis regulating BCL-2 family of proteins can modulate and 
affect cellular response to therapeutic agents. For example an increase or decrease in 
anti- or pro-apoptotic proteins respectively may confer resistance to malignant cells 
resulting in decreased therapy efficacy. To evaluate how differential expression of BCL-
2 proteins among these cell lines affects their response to ABT-737 (Appendix I, 12.1), 
we next compared the cellular response induced by this BH3-mimetic using flow 
cytometry. 
Levels of ABT-737-induced cell death were measured by assessing its effect on ΔΨm 
using TMRM. A decrease in TMRM levels corresponds to decreased ΔΨm, indicating 
damage to the mitochondrial membrane (Hao et al., 2004; Marchetti et al., 1996). We 
also evaluated the effect of ABT-737 on cell viability using the DNA-intercalating dye 
DAPI which is taken up by dead/dying cells with permeable membranes but excluded 
from live cells. Therefore, an increase in the percentage of ΔΨmLOW cells and in the 
percentage of DAPI
+
 cells indicates increased mitochondria-dependent cell death.  
Treatment of Su-DHL4 and CRL cells with 1µM ABT-737 resulted in a significant 
increase (p< 0.001) in the percentage of cells with low ΔΨm (ΔΨmLOW cells) compared 
to untreated controls in both cell lines (Su-DHL4: 38.75% ± 5.1 vs. 11.5% ± 4; CRL: 
58.5% ± 10.79 vs. 20.5% ± 5.2). Conversely, ABT-737 had no effect on the ΔΨm of Su-
DHL8 or Su-DHL10 cells (Figure 3.2 A; Figure 3.3 B). This suggests that ABT-737 
induces mitochondrial membrane depolarisation in BCL-2
HIGH
 but not BCL-2
LOW
 cells. 
ABT-737 also induced a significant increase in cell death in Su-DHL4 (19.25% ± 2.7 
vs.9.25% ± 1.9) and CRL (41.25% ± 2.2.5 vs.16.5 ± 2.98) cells (p< 0.05). Viability 
remained unaltered between untreated and treated BCL-2
LOW
 cells (Figure 3.2 B; Figure 
3.3 C). These results indicate that BCL-2
HIGH
 Su-DHL4 and CRL cell lines are more 
sensitive to ABT-737-induced cell death compared to BCL-2
LOW
 Su-DHL8 and Su-
DHL10 cells.  
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Figure 3.2 Comparison of the sensitivity of BCL-2
HIGH
 and BCL-2
LOW
 DLBCL cell lines to 
ABT-737 
2 × 10
6 
viable Su-DHL4, CRL, Su-DHL8 and Su-DHL10 cells were cultured with or without 1µM ABT-
737 for 15hrs. Cells were incubated with 40nM TMRM and 50ng/ml DAPI for 15min at 37°C to assess 
the percentage of ∆ΨmLOW cells and percentage of cell death, respectively. The fluorescent density of 
TMRM (∆Ψm) (A) and DAPI (cell death) (B) were evaluated by flow cytometry under the PE and Violet 
channels. Data was analysed using Summit software V4.3 and is displayed as the mean ± SD of three 
separate experiments. Histograms are representative of three separate experiments.  
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3.2.3 Association between expression of BCL-2 family of proteins and 
sensitivity to ABT-737-induced cell death 
A well established hallmark of malignant cells is their ability to evade apoptosis. It has 
previously been shown that by evaluating the BCL-2 family profile of a malignant cell 
line it can be classified as exerting a particular type of apoptotic block which can then 
be specifically targeted and inhibited (Deng et al., 2007). According to this 
classification there are three types of apoptosis blocks - Class A, B and C. A class A 
block involves inhibition of upstream 'BH3'-only proteins such as Bim and Bad while a 
class B block occurs due to inhibition or loss of the pro-apoptotic multi-domain proteins 
Bax and Bak. Finally, a class C block occurs when there is increased expression of anti-
apoptotic proteins like BCL-2 and BCL-xL, resulting in inhibition of pro-apoptotic 
proteins and apoptosis (Deng et al., 2007). 
Combining Western blotting and flow cytometry data from Figure 3.1 and Figure 3.2, 
we demonstrated that the BCL-2
HIGH
 Su-DHL4 and CRL cell lines, which also express 
BCL-xL at a high level, exhibit a class C apoptotic block. Conversely, Su-DHL8 cells 
which do not express Bim are likely to evade death via a class A block, while Su-
DHL10 cells lack Bax and so most likely exert a class B block (Figure 3.3 A).  
While increased expression of pro-survival proteins allows tumour cells to avoid 
apoptosis, it has been suggested that their overexpression causes cells to be 'primed for 
death', meaning tumour cells are more sensitive to BH3-mimetic drugs such as ABT-
737 which target these BH3-proteins. Indeed, we found that Su-DHL4 and CRL cells 
which express BCL-2 at high levels were more susceptible to ABT-737-mediated 
killing compared to BCL-2
LOW
 Su-DHL8 and Su-DHL10 cells (Figure 3.3 B and C). 
These data suggest that despite all cell lines evaluated expressing BCL-xL, another 
target of ABT-737, the sensitivity of these cells to ABT-737 is largely dependent on 
increased expression of BCL-2 (Figure 3.3). It is possible that Su-DHL8 and Su-DHL10 
cells are resistant to ABT-737 partly due to lack of Bim and Bax respectively (Figure 
3.3). 
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Figure 3.3 Association between expression of BCL-2 family proteins and the sensitivity of 
DLBCL cells to ABT-737-mediated ∆Ψm reduction and cell death  
Densitometry values obtained from Western blotting (Figure 3.1) were used to generate a heat-map which 
allows direct comparison of expression levels of BCL-2 family proteins. Protein expression levels were 
placed into one of five categories (0, 0.2, 0.4, 0.6, 0.8) based on their densitometry value and assigned a 
colour from green (0) to red (≥1) (A). Flow cytometry data previously generated (Figure 3.2) was 
analysed using a paired student's t-test to identify significant changes in the percentage of ∆ΨmLOW cells 
(B) and the percentage cell death (C) between controls and cells treated with 1µM ABT-737. Flow 
cytometry data are displayed as the mean ± SD of three separate experiments. Data were analysed using 
the statistical analysis software Prism. * p< 0.05, *** p< 0.001.  
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3.2.4 Evaluation of DLBCL cell lines sensitivity to ABT-737-induced Bax 
activation  
Translocation of Bax to the mitochondria followed by a change in its conformation 
results in activation of this pro-apoptotic protein, and is an essential step in 
mitochondria-dependent apoptosis (Kelly and Strasser, 2011; Ola et al., 2011). We next 
aimed to evaluate whether DLBCL cell lines differ in their sensitivity to ABT-737-
induced Bax activation. Bax activity was assessed by monitoring its translocation to the 
mitochondria and changes in its conformation following treatment with ABT-737 
(Figure 3.4). Using IFM, active Bax was probed for using the anti-Bax, clone 6A7 
antibody which only recognises the conformationally changed, active form of Bax 
(Krajewski et al., 1994).  
Prior to treatment with ABT-737, Bax was present in the cytoplasm of both BCL-2
HIGH
 
and BCL-2
LOW
 cells in a diffuse, smeared pattern (Figure 3.4 A and B; top panels). 
Following treatment with ABT-737, large, bright Bax puncta representative of its 
conformationally changed, active form which is situated at the mitochondria, were 
observed in BCL-2
HIGH
 Su-DHL4 and CRL cells (Figure 3.4 A; lower panel) but were 
absent from BCL-2
LOW
 cells (Figure 3.4 B; lower panel). Increased numbers of cells 
with condensed, fragmented nuclei, indicative of cells dying by apoptosis and consistent 
with Bax activation, were observed in BCL-2
HIGH
 cells following ABT-737 treatment 
where as Su-DHL8 and Su-DHL10 nuclei remained unaltered (Figure 3.4).  
Combined, these results indicate that BCL-2
HIGH
 but not BCL-2
LOW
 cells are sensitive to 
ABT-737-inducued Bax activation, further confirming our previous findings that the 
sensitivity of DLBCL cells to ABT-737-induced cell death is dependent on BCL-2 
expression.  
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Figure 3.4 ABT-737-induced Bax activation in BCL-2
HIGH 
and BCL-2
LOW
 DLBCL cells 
BCL-2
HIGH
 (A) and BCL-2
LOW
 (B) DLBCL cells were cultured with or without 1µM ABT-737 for 3hrs, 
harvested and fixed and permeabilised with Cytofix/Cytoperm solution. Non-specific bindings were 
blocked by incubation with blocking buffer containing 5% donkey serum and 0.1% saponin. Cells were 
stained with mouse anti-Bax antibody clone 6A7 and Alexa Fluor
®
 488 donkey anti-mouse secondary 
antibody (green). Nuclei were counterstained with DAPI (blue). Arrows highlight Bax punctate which are 
indicative of the active form of Bax at the mitochondria; smeared pattern represents background antibody 
staining.  
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3.2.5 Sensitivity of DLBCL cell lines to ABT-737-induced PARP cleavage  
Poly(ADP-ribose) polymerase (PARP) is a 116kDa protein involved in sensing and 
repairing DNA-breaks and consequently maintenance of cell survival (Strosznajder et 
al., 2005). It is well established that during apoptosis PARP is cleaved into smaller 
89kDa and 24kDa fragments by activated caspase-3, rendering the PARP enzyme 
inactive and unable to repair breaks in cellular DNA. Without PARP to repair DNA 
breaks, cells cannot survive and so undergo apoptosis (Ame et al., 2004; Boulares et al., 
1999; Strosznajder et al., 2005). We next aimed to evaluate the sensitivity of BCL-2
HIGH
 
and BCL-2
LOW
 DLBCL cell lines to ABT-737-induced PARP cleavage, a down-stream 
event in mitochondria-dependent cell death.  
Following treatment with ABT-737, PARP cleavage was detected in Su-DHL4 and 
CRL cells but not Su-DHL8 or Su-DHL10 cells indicating BCL-2
LOW
 cells are resistant 
to ABT-737-induced PARP cleavage (Figure 3.5). The presence of an established 
apoptosis marker in BCL-2
HIGH 
cells post-ABT-737 treatment further highlights the 
sensitivity of these cells to ABT-737-induced apoptosis.   
 
 
 
 
 
 
Figure 3.5 ABT-737-induced PARP cleavage in BCL-2
HIGH
 and BCL-2
LOW
 DLBCL cells  
4×10
6 
viable Su-DHL4, CRL, Su-DHL8 and Su-DHL10 cells were cultured with or without 1µM ABT-
737 for 15hrs. 50µg whole cell lysate was loaded onto a 4-12% NuPAGE Bis-Tris gel and proteins 
separated by SDS-PAGE. Full-length (116kDa) and cleaved PARP (89kDa) were visualised by Western 
blotting. β-actin was used as a loading control. Bands are representative of a single experiment.  
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3.2.6 ABT-737 induces autophagy in BCL-2
HIGH
 DLBCL cell lines  
Having shown that ABT-737 induces apoptosis in a BCL-2-dependent manner, we next 
sought to evaluate if this BH3-mimetic can induce autophagy in Su-DHL4 and CRL cell 
lines.  
p62 is an adaptor protein that binds damaged and aggregated cellular proteins which it 
delivers to the autophagosome for degradation via interactions with LC3 (Ichimura et 
al., 2008). As a component of these cellular aggregates p62 is itself an autophagy 
substrate - its cellular levels decrease when autophagy is active while inactive 
autophagy results in accumulation of this multi-domain protein (Bjorkoy et al., 2005; 
Johansen and Lamark, 2011). LC3-I is a diffuse cytoplasmic protein which upon 
activation of autophagy is conjugated to the lipid PE and converted to a punctate form 
known as LC3-II, which becomes embedded in the autophagosome membrane. The 
presence of LC3-II puncta within a cell is the most commonly used marker of 
autophagy of activity; however LC3-II is also a substrate of the autophagy pathway 
meaning its levels can decrease due to degradation when autophagy is active (He and 
Klionsky, 2009; Kabeya et al., 2000). Therefore, changes in cellular levels of the key 
autophagy proteins p62 and LC3 were used as markers of autophagy activity in Su-
DHL4 and CRL cells. 
Cells were treated with increasing concentrations of ABT-737 (0µM - 1µM) in the 
presence or absence of the autophagy inhibitor CQ (Appendix I, 12.2) which prevents 
autophagic degradation, resulting in an accumulation of autophagy substrates 
(Amaravadi et al., 2007). Treatment of Su-DHL4 cells with ABT-737 (0.3µM - 1µM) 
and CRL cells with 1µM ABT-737 resulted in a decrease in p62 compared to untreated 
controls indicating autophagic degradation is increased following treatment with ABT-
737 (Figure 3.6 A). Following the addition of CQ, p62 levels increased in these BCL-
2
HIGH
 cells in an ABT-737 dose-dependent manner, further suggesting this BH3-
mimetic induces autophagy within these cells (Figure 3.6 A). Consistent levels of p62 
were observed in Su-DHL8 and Su-DHL10 cells following treatment with ABT-737, 
suggesting this BH3-mimetic does not induce autophagy in these cells (Figure 3.6 B). 
Treatment of these BCL-2
LOW
 cells with ABT-737 and CQ resulted in an increase in 
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p62 levels, indicating basal level autophagic degradation of p62 was inhibited by CQ 
(Figure 3.6 B).  
Treatment of BCL-2
HIGH
 cells with ABT-737 resulted in a decrease in LC3-I and LC3-II 
levels in these cells (Figure 3.6 A). While a decrease in LC3-I may indicate increased 
conversion of LC3-I to LC3-II and thus increased autophagy activity, lack of a 
corresponding increase in LC3-II is contrary to previous reports that LC3-II levels 
increase during active autophagy. One possible explanation for this apparent 
discrepancy is the time frame in which autophagy was evaluated. Autophagy activity 
was examined after a 15hr incubation period during which time LC3-II may have been 
degraded as an autophagy substrate; LC3-I may have been converted to LC3-II which 
was then degraded as part of the autophagolysosome resulting in a decrease in  cellular 
levels of both LC3-I and LC3-II in Su-DHL4 and CRL (Figure 3.6 A). Treatment with 
ABT-737 and CQ resulted in an increase in LC3-II levels in an ABT-737 dose-
dependent manner similar to the trend observed for p62. LC3-I and LC3-II levels did 
not vary between untreated and ABT-737-treated Su-DHL8 and Su-DHL10 cells 
(Figure 3.6 B), further indicating ABT-737 does not induce autophagy in these BCL-
2
LOW
 cells. LC3-II levels increased following addition of CQ; however in a similar 
manner to p62, no difference in LC3-II levels was observed between ABT-737 doses, 
indicating that this increase was due to inactive basal level autophagic degradation 
(Figure 3.6 B).  
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Figure 3.6 Evaluation of ABT-737-induced autophagy in BCL-2
HIGH
 and BCL-2
LOW
 
DLBCL cell lines 
4×10
6 
cells viable BCL-2
HIGH
 (A) and BCL-2
LOW
 (B) cells were treated with increasing concentrations of 
ABT-737 for 15hrs in the presence or absence of CQ (50µM); untreated cells were cultured under 
standard growth conditions. 50µg of whole cell lysate was loaded onto a 4-12% Bis-Tris gel and proteins 
separated by SDS-PAGE. p62 and LC3 were visualised by Western blotting. β-actin was used as a 
loading control. Bands are representative of a single experiment. Densitometry values were obtained 
using Gelscan V5.1 and represent the ratio of p62 or LC3-II to β-actin. 
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Although p62 and LC3 protein levels are well established markers of autophagy 
activity, neither of them should be used in isolation to determine or represent autophagy 
activity (Klionsky et al., 2012b). Combining a decrease in p62 and LC3 (I/II) levels in 
response to ABT-737 with an ABT-737-dose dependent accumulation of p62 and LC3-
II following autophagy inhibition suggests ABT-737 induces autophagy in BCL-2
HIGH
 
DLBCL cell lines. We therefore propose that BCL-2 is a specific target for ABT-737 
and treatment with this BH3-mimetic induces both apoptosis and autophagy in BCL-
2
HIGH
 cells.  
3.2.7 BCL-2 and Beclin-1 co-localize, but do not bind in BCL-2
HIGH
 cells 
It has previously been reported that binding of BCL-2 to the autophagy essential protein 
Beclin-1 sequesters this pro-autophagy protein and prevents autophagy induction (Liang 
et al., 1998; Pattingre et al., 2005). Therefore, one possible mechanism by which ABT-
737 may induce autophagy is by competitively binding BCL-2 via BH3-domain 
interactions, hindering its sequestration of Beclin-1. It is currently unclear whether 
BCL-2 binds Beclin-1 to form an autophagy inhibiting complex in lymphoma cells and 
if so whether ABT-737 disrupts this binding. We therefore aimed to assess BCL-
2/Beclin-1 binding in the BCL-2
HIGH
 cell line Su-DHL4 and evaluate the effect of ABT-
737 treatment on this interaction.  
In order for BCL-2 to bind Beclin-1, both proteins must be situated at the same cellular 
compartment. It has been shown that BCL-2 localizes to the outer mitochondrial 
membrane and ER and Beclin-1 resides at the ER, TGN and mitochondria (Pattingre et 
al., 2005). Using dual immunofluorescent staining and microscopy, we determined 
whether BCL-2 and Beclin-1 co-localize at the ER and/or mitochondria in Su-DHL4 
cells. The ER was identified using the 72kDa protein marker BiP (Gething, 1999), while 
mitochondria were identified by the well established mitochondrial marker, cytochrome 
c oxidase subunit IV (Cox IV) (Xue et al., 2001).  
Dual immunofluorescent staining of Su-DHL4 cells with BCL-2 and BiP antibodies 
revealed a number of yellow puncta within cells, representative of co-localization 
between these proteins, indicating BCL-2 localizes to the ER (Figure 3.7 A). Co-
staining of cells with BCL-2 and Cox IV antibodies revealed a similar yellow-punctate 
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pattern showing BCL-2 also resides at the mitochondria in Su-DHL4 cells (Figure 3.7 
B).  
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Determination of the cellular location of BCL-2 in Su-DHL4 cells  
Su-DHL4 cells were fixed and permeabilised with Cytofix/Cytoperm and non-specific bindings blocked 
by incubation with 5% donkey serum and 0.1% saponin. Cells were co-stained for BCL-2 and BiP (A) or 
Cox IV (B). BCL-2 and BiP/Cox IV were probed for using Alexa Fluor
®
 488 donkey anti-mouse and 
Alexa Fluor
®
 546 donkey anti-rabbit secondary antibodies respectively. Nuclei were counterstained with 
DAPI and slides mounted and viewed using an Olympus BX40 fluorescent microscope. Arrows highlight 
yellow punctate, indicative of areas of co-localization between BCL-2 and BiP or Cox IV.  
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Co-staining of Su-DHL4 cells with Beclin-1 and either BiP or Cox IV revealed a similar 
localization pattern to that of BCL-2 (Figure 3.8 A and B), indicating the pro-autophagy 
protein localizes to both the ER and the mitochondria in these BCL-2
HIGH
 DLBCL cells.   
 
 
 
 
 
 
 
 
Figure 3.8 Determination of the cellular location of Beclin-1 in Su-DHL4 cells  
Su-DHL4 cells were fixed and permeabilised with Cytofix/Cytoperm and non-specific bindings blocked 
by incubation with 5% donkey serum and 0.1% saponin. Cells were co-stained for Beclin-1 and BiP (A) 
or Cox IV (B) as previously described. Beclin-1 and BiP/Cox IV were probed for using Alexa Fluor
®
 488 
donkey anti-mouse and Alexa Fluor
®
 546 donkey anti-rabbit secondary antibodies respectively. Nuclei 
were counterstained with DAPI and slides mounted and viewed as previously described. Arrows highlight 
yellow punctate, indicative of areas of co-localisation between Beclin-1 and BiP or Cox IV.  
 
These results demonstrate that BCL-2 and Beclin-1 reside in the same cellular 
compartments in Su-DHL4 cells, indicating the potential for interaction between the 
two and the formation of an autophagy inhibiting complex at both organelles. Dual 
immunofluorescent staining of Su-DHL4 cells for BCL-2 and Beclin-1 revealed a 
number of yellow punctate in these cells, indicative of co-localisation between Bcl-2 
and Beclin-1 at the basal level (Figure 3.9).  
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Figure 3.9 Evaluation of BCL-2 and Beclin-1 co-localisation in Su-DHL4 cells 
Su-DHL4 cells were fixed and permeabilised with Cytofix/Cytoperm and non-specific bindings blocked 
by incubation with 5% donkey serum and 0.1% saponin. Cells were co-stained for BCL-2 and Beclin-1 as 
previously described. BCL-2 and Beclin-1 were probed for using Alexa Fluor
®
 546 donkey anti-rabbit 
and Alexa Fluor
®
 488 donkey anti-mouse secondary antibodies respectively. Nuclei were counterstained 
with DAPI and slides mounted and viewed as previously described. Arrows highlight yellow punctate, 
indicative of areas of co-localisation between BCL-2 and Beclin-1.  
 
Co-localization between two proteins as determined by IFM does not definitively prove 
protein-protein interaction. Therefore, we next evaluated whether BCL-2 and Beclin-1 
bind in BCL-2
HIGH
 DLBCL cells, and whether ABT-737 can disrupt this binding, using 
co-IP. No binding was observed between endogenous BCL-2 and endogenous Beclin-1 
in Su-DHL4 DLBCL cells at the basal level, or following treatment with ABT-737 
(Figure 3.10). We therefore propose that despite residing in the same cellular organelles, 
BCL-2 and Beclin-1 do not directly bind one another in BCL-2
HIGH
 DLBCL cells to 
form an autophagy inhibiting complex. Therefore, ABT-737 may not induce autophagy 
in these cells by disrupting binding between these proteins. Instead, induction of 
apoptosis by ABT-737-mediated BCL-2 inhibition may promote autophagy as a pro-
survival mechanism which cells utilise to avoid death.  
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Figure 3.10 Determination of BCL-2 and Beclin-1 interaction by co-immunoprecipitation   
30×10
6
 viable Su-DHL4 cells were incubated with 1µM ABT-737 for 3hr; untreated cells were incubated 
under standard growth conditions. Proteins were extracted using 2% CHAPS buffer containing 10µl 1M 
DTT, PMSF and PIC. Dynabeads® Protein A was prepared at a 1:10 dilution in 2% CHAPS buffer 
containing DTT, PMSF and PIC. 200µl Dynabeads® Protein A were incubated with 2µg anti-rabbit IgG 
or anti-rabbit Bcl-2 antibody for 20 min at RT with rotation and washed 1 × 1% CHAPS buffer. 1mg cell 
lysate was prepared in a final volume of 200µl using 2% CHAPS buffer containing DTT and PMSF and 
incubated with the antibody/bead complex at RT with rotation for 20 min after which beads were washed 
3× in 1% CHAPS buffer. 25µl eluting buffer was added to each sample, samples denatured at 100°C for 
5min and mixed with 25µl lysis buffer. 45µl sample was loaded onto a 1.5mm 4-12% NuPAGE Bis-Tris 
gel and proteins separated by SDS-PAGE. Whole cell lysate samples were prepared to a 100µg 
concentration in 40µl. Beclin-1 and BCL-2 were visualised by Western blotting as previously described. 
Data are representative of a single experiment.   
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3.3 Discussion  
In this chapter, we found that treatment with ABT-737 simultaneously induced 
autophagy while triggering apoptosis in BCL-2
HIGH
 lymphoma cell lines. Assessment of 
BCL-2/Beclin-1 interaction revealed these proteins do not bind to form an autophagy 
inhibiting complex in BCL-2
HIGH
 cells, indicating ABT-737 induces autophagy by 
another mechanism.  
We found that BCL-2
HIGH
 Su-DHL4 and CRL cells are more sensitive to ABT-737-
induced apoptosis compared to Su-DHL8 and Su-DHL10 cells, which express low 
levels of this anti-apoptotic protein. Our findings are in agreement with previous reports 
which state that cells expressing high levels of BCL-2 are sensitive to ABT-737-
induced death (Deng et al., 2007). We also found that ABT-737 induces autophagy in 
BCL-2
HIGH
 Su-DHL4 and CRL cells, i.e. in a BCL-2-dependent manner.  
Induction of autophagy by ABT-737 via disruption of BCL-2/Beclin-1 binding has been 
reported in different cell types (Kang et al., 2011; Marquez and Xu, 2012; Pattingre et 
al., 2005). However in our setting, we found that endogenous BCL-2 and Beclin-1 do 
not bind at the basal level to form an autophagy inhibiting complex, indicating ABT-
737 may not induce autophagy via disruption of BCL-2/Beclin-1 binding. Treatment of 
DLBCL cell lines with various anti-cancer agents has been shown to induce autophagy 
(Jia et al., 2012). We therefore propose that induction of apoptosis by ABT-737 via 
BCL-2 inhibition results in an increased autophagy activity. Chemotherapy-induced 
autophagy can act as a cytoprotective mechanism which allows malignant cells to evade 
therapy-induced cell death (Kimmelman, 2011). Whether BCL-2
HIGH
 DLBCL cell lines 
utilise acquired autophagy as a pro-survival mechanism which confers resistance to 
ABT-737-induced apoptosis remains to be determined. 
3.3.1 Conclusions 
Treatment with ABT-737 induces mitochondria-dependent apoptosis in DLBCL cell 
lines in a BCL-2-dependent manner. This BH3-mimetic also induces autophagy in 
BCL-2
HIGH
 cells, but not via disruption of BCL-2/Beclin-1 binding. 
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Evaluation of the role of autophagy in ABT-737-induced 
cell death 
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4.1 Introduction  
Therapy-induced autophagy can promote, prevent or have no effect on the killing of 
malignant cells by anti-cancer drugs. While therapy-induced autophagy has been shown 
to potentiate the pro-death effects of chemotherapeutic-agents in vitro and in vivo, it is 
more commonly reported to act as a cytoprotective, pro-survival mechanism utilised by 
cancer cells to evade therapy-induced death (Choi et al., 2013a; Helgason et al., 2013; 
Kim et al., 2009). For example, treatment of CML cells with Imatinib and prostate 
cancer cells with tunicamycin has been reported to induce cytoprotective autophagy in 
malignant cells, resulting in decreased efficacy of these anti-cancer agents and 
decreased levels of drug-induced tumour cell death (Ding et al., 2007; Helgason et al., 
2013). 
It has been reported that inhibition of therapy-induced cytoprotective autophagy via 
ablation of key autophagy genes such as Atg5 or using inhibitors such as CQ or HCQ, 
sensitizes tumour cells to  chemotherapy-mediated cell death (Amaravadi et al., 2007; 
Bellodi et al., 2009). A number of clinical trials are currently investigating the potential 
use of such autophagy inhibitors in combination with standard chemotherapy agents. 
For example, the phase I CHOICES (CHlOrquine and IM Combination to Eliminate 
Stem Cells) clinical trial is currently investigating combination of HCQ with Imatinib in 
CML patients and is showing promising results (Helgason et al., 2013; Sinclair et al., 
2013).  
The BH3-mimetic compounds (-)-Gossypol and ABT-737 have been shown to induce 
apoptosis and cytoprotective autophagy in breast cancer and Myc-driven lymphoma 
cells (Amaravadi et al., 2007; Gao et al., 2010). We have also shown that ABT-737 can 
induce autophagy in BCL-2
HIGH
 DLBCL cell lines. It is unclear whether this therapy-
induced, acquired autophagy functions as a pro-survival mechanism or potentiates the 
pro-apoptotic role of ABT-737 in BCL-2
HIGH
 lymphoma cell lines. We therefore aim to 
evaluate if ABT-737-induced autophagy plays a cytoprotective role in BCL-2
HIGH
 
DLBCL cell lines.  
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4.2 Results  
4.2.1 Inhibition of autophagy by chloroquine sensitises BCL-2
HIGH
 cells to 
ABT-737-induced cell death 
To determine the effects of ABT-737-mediated autophagy on ABT-737-induced 
apoptosis, we examined whether inhibition of autophagy by CQ sensitizes BCL-2
HIGH
 
and BCL-2
LOW
 DLBCL cells to ABT-737-induced apoptotic cell death. Cells were 
treated with 50µM CQ which has previously been shown to inhibit autophagic protein 
degradation without inducing cell death (Jia et al., 2012; Maclean et al., 2008).  
Cell death was determined by flow cytometry as previously described. Treatment with 
ABT-737 induced a dose-dependent increase in the percentage of cell death in Su-
DHL4 and CRL cells (Figure 4.1 A and B) compared to untreated controls, confirming 
that this BH3-mimetic induces death in BCL-2
HIGH
 cells. Blocking autophagy 
degradation by CQ significantly (p< 0.05) increased ABT-737-induced cell death in Su-
DHL4 and CRL cells compared to treatment with ABT-737 alone (Figure 4.1 C and D). 
We also confirmed that treatment with ABT-737 or ABT-737+CQ did not have a 
cytotoxic effect on the BCL-2
LOW
 cell lines Su-DHL8 and Su-DHL10 (Figure 4.2). 
These data suggest that ABT-737-induced autophagy acts as a cytoprotective 
mechanism which allows lymphoma cells to avoid drug-induced apoptosis and indicate 
that inhibition of this drug-induced autophagy with CQ increases sensitivity of BCL-
2
HIGH 
cells to ABT-737-mediated apoptosis.  
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Figure 4.1 Evaluation of the effect of the autophagy inhibitor CQ on ABT-737-induced cell 
death in BCL-2
HIGH
 cells  
2 × 10
6 
viable Su-DHL4 and CRL cells were treated with increasing doses of ABT-737 (0µM - 1µM) for 
15hr in the presence or absence of CQ (50µM); untreated cells were cultured under standard growth 
conditions. Cells were incubated with 100ng/ml DAPI for 15min at 37°C. The fluorescent density of 
DAPI was determined by flow cytometry under the Violet channel (A, B) Data were analysed using 
Summit software V4.3 and significant changes between treatment conditions analysed using a two-way 
ANOVA and the statistical software Prism (C, D). Data are displayed as the mean ± SD of three separate 
experiments. Histograms are representative of three separate experiments.  
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Figure 4.2 Evaluation of the effect of the autophagy inhibitor CQ on ABT-737-induced cell 
death in BCL-2
HIGH
 cells  
2 × 10
6 
viable Su-DHL8 (A and C) and Su-DHL10 (B and D) cells were treated with increasing doses of 
ABT-737 (0µM - 1µM) for 15hr in the presence or absence of CQ (50µM); untreated cells were 
incubated under standard growth conditions. Cell death was determined by flow cytometry as described in 
Figure 4.1.  
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We next examined the effect of CQ on ABT-737-induced reduction in ΔΨm by flow 
cytometry in both BCL-2
HIGH
 and BCL-2
LOW
 cell lines. Treatment of Su-DHL4 and 
CRL cells with ABT-737 alone resulted in a dose-dependent increase in the percentage 
of ΔΨmLOW cells in both cell lines (Figure 4.3 A and B). The percentage of ΔΨmLOW 
Su-DHL4 and CRL cells also significantly (p< 0.05) increased following dual treatment 
with ABT-737+CQ (Figure 4.3 C and D). As expected, and again in line with our 
previous findings, treatment with ABT-737 alone or in combination with CQ did not 
affect ΔΨm in BCL-2LOW cell lines (Figure 4.4).    
These results support our previous findings that inhibition of ABT-737-induced 
autophagy with CQ increases sensitivity of BCL-2
HIGH
 DLBCL cell lines to ABT-737-
induced apoptosis.  
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Figure 4.3 Effect of the autophagy inhibitor CQ on ABT-737-induced ∆Ψm depolarization 
in BCL-2
HIGH
 DLBCL cells  
2 × 10
6 
viable Su-DHL4 and CRL cells were treated with increasing doses of ABT-737 (0µM - 1µM) for 
15hr in the presence or absence of CQ (50µM); untreated cells were cultured under standard growth 
conditions. Cells were incubated with 40nM TMRM for 15min at 37°C. The fluorescent density of 
TMRM (∆Ψm) was determined by flow cytometry under the PE channel (A and B). Data were analysed 
using Summit software V4.3 and significant changes between treatment conditions analysed using a two-
way ANOVA and the statistical software Prism (C and D). Data are displayed as the mean ± SD of three 
separate experiments. Histograms are representative of three separate experiments.  
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Figure 4.4 Effect of the autophagy inhibitor CQ on ABT-737-induced ∆Ψm in BCL-2LOW 
DLBCL cells  
2 × 10
6 
viable Su-DHL8 (A and C) and Su-DHL10 (B and D) cells were treated with increasing doses of 
ABT-737 (0µM - 1µM) for 15hr in the presence or absence of CQ (50µM); untreated cells were 
incubated under standard growth conditions. Experimental conditions are as same as described in the 
legend of Figure 4.3. 
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4.2.2 Inhibition of autophagy by CQ sensitises BCL-2
HIGH
 cells to ABT-737-
induced PARP cleavage  
We have shown that ABT-737 induces PARP cleavage in a BCL-2 dependent manner 
and that inhibition of autophagy with CQ further sensitises BCL-2
HIGH
 cells to ABT-
737-induced cell death. We next examined the effect of ABT-737+CQ on PARP 
cleavage in BCL-2
HIGH
 cell lines.  
DLBCL cell lines were treated with increasing doses of ABT-737 (0µM - 1µM) with or 
without CQ (50µM) and PARP cleavage evaluated by Western blotting. We found that 
treatment with ABT-737+CQ resulted in increased PARP cleavage in the BCL-2
HIGH
 
cell lines Su-DHL4 and CRL compared with treatment with ABT-737 alone (Figure 4.5 
A and B). PARP cleavage was not observed in BCL-2
LOW
 cell lines following ABT-737 
or combination treatment (Figure 4.5 C and D).  
These data support our previous findings that inhibition of ABT-737-induced autophagy 
further sensitises BCL-2
HIGH
 cells to ABT-737-induced apoptosis.   
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Figure 4.5 Evaluation of the effect of autophagy inhibition on ABT-737-induced PARP 
cleavage in BCL-2
HIGH
 and BCL-2
LOW
 DLBCL cell lines  
4×10
6 
viable Su-DHL4 (A), CRL (B), Su-DHL8 (C) and Su-DHL10 (D) cells were treated with 
increasing concentrations of ABT-737 (0µM -1µM) for 15hr in the presence or absence of CQ (50µM). 
50µg whole cell lysate was loaded onto a 4-12% NuPAGE Bis-Tris gel and proteins separated by SDS-
PAGE. Full length (116kDa) and cleaved (89kDa) PARP were visualised by western blotting; β-actin was 
used as a loading control. Bands are representative of a single experiment. Densitometry values were 
obtained using Gelscan software and represent the ratio of cleaved PARP to β-actin. 
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4.2.3 Inhibition of caspase activation blocks ABT-737 and ABT-737+CQ-
induced apoptosis in BCL-2
HIGH
 DLBCL cell lines  
We next aimed to evaluate if ABT-737+CQ-induced cell death is caspase-dependent by 
assessing caspase-3 activity in cells treated with ABT-737 ± CQ in the presence or 
absence of the pan-caspase inhibitor N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) 
fluromethyl ketone (Z-VAD.fmk).  
Incubation of Su-DHL4 and CRL cells with CQ alone (25µM or 50µM) did not increase 
caspase-3 activity in these cells, confirming that treatment with CQ does not induce 
caspase activation. We also confirmed that treatment of these BCL-2
HIGH
 cells with 
0.5µM ABT-737 for 3hr results in increased caspase-3 activity indicating that this BH3-
mimetic induces caspase-dependent apoptosis (Figure 4.6). 
 
 
 
 
 
 
 
 
 
Figure 4.6 Comparison of the effect of CQ and ABT-737 on caspase-3 activation in BCL-
2
HIGH
 DLBCL cell lines 
2 × 10
6  
viable Su-DHL4 (A) or CRL (B) cells were treated with 25µM or 50µM CQ for 3hr or 24hr or 
0.5µM ABT-737 for 3hr at 37°C; untreated cells were cultured under standard growth conditions. 50µg 
protein lysate was incubated with reaction buffer and caspase-3-DEVD-AFC substrate for 15min at 37ºC 
followed by 1min at -20ºC. AFC release was measured at excitation 410nm and emission 510nm using a 
BMG LabTech FLUOstar Omega plate reader. Samples were analysed in triplicate and caspase-3 activity 
calculated as the average AFC release per sample (µM/hr/mg protein). Data were analysed using Prism 
software.  
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We first identified which concentration of Z-VAD.fmk (Appendix I, 12.3) completely 
inhibits caspase activation. TRAIL-induced caspase-3 activation and PARP cleavage 
were examined in Su-DHL4 cells treated with TRAIL alone or in combination with Z-
VAD.fmk (20µM or 50µM) (Figure 4.7).  
Treatment of Su-DHL4 cells with TRAIL induced a remarkable increase in caspase-3 
activity compared with untreated controls. TRAIL-induced caspase-3 activation was 
dramatically decreased in the presence of 20µM or 50µM Z-VAD.fmk (Figure 4.7 A). 
Similarly, treatment with TRAIL resulted in an increase in PARP cleavage which was 
ablated following incubation with Z-VAD.fmk (Figure 4.7 B). These results indicate 
that incubation of cells with 20µM or 50µM Z-VAD.fmk completely inhibits TRAIL-
induced caspase-3 activation and PARP cleavage.  
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Inhibitory effect of Z-VAD.fmk on TRAIL-induced caspase-3 activation and 
PARP cleavage  
2 × 10
6 
viable Su-DHL4 cells were treated with 10µM TRAIL in the presence or absence of 20µM or 
50µM Z-VAD.fmk for 3hr at 37°C; untreated cells were cultured under standard growth conditions. 50µg 
protein lysate was incubated with reaction buffer and caspase-3-DEVD-AFC substrate for 15min at 37ºC 
followed by 1min at -20ºC and caspase-3 activity calculated as previously described (A). 50µg whole cell 
lysate was loaded onto a 4-12% Bis-Tris gel and proteins separated by SDS-PAGE. Cleaved PARP was 
probed for and bands visualised as previously described. Densitometry values were obtained using 
Gelscan software and calculated as the ratio of cleaved PARP to full length PARP (B).  
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We next determined whether ABT-737+CQ-induced cell death is caspase-dependent. 
Su-DHL4 and CRL cells were treated with ABT-737 alone or in combination with CQ 
in the presence or absence of Z-VAD.fmk. Caspase-3 activity was determined using a 
fluoregenic assay.  
We found that treatment with ABT-737 alone induced significantly (p< 0.001) 
increased caspase-3 activity in Su-DHL4 and CRL cells, while dual treatment with 
ABT-737+CQ resulted in a further significant (p< 0.001) increase in caspase-3 activity 
in these BCL-2
HIGH 
cells (Figure 4.8). Incubation of cells with Z-VAD.fmk did not alter 
caspase-3 activity in untreated or CQ treated BCL-2
HIGH
 cells; however levels of 
caspase-3 activity were significantly decreased (p< 0.001) in both cell lines following 
treatment with ABT-737 or ABT-737+CQ in the presence of this pan-caspase inhibitor  
(Figure 4.8).  
 
 
 
 
 
 
 
Figure 4.8 Effect of Z-VAD.fmk on ABT-737+CQ-induced caspase-3 activation  
2 × 10
6  
viable Su-DHL4 (A) or CRL (B) cells were treated with 0.5µM ABT-737 with or without 50µM  
CQ in the presence or absence of 20µM Z-VAD.fmk for 3hr at 37°C; untreated cells were cultured under 
standard growth conditions. Data represent mean ± SD of three independent experiments. Significant 
changes between treatment conditions analysed using student t-test.  *** p< 0.001. 
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We also evaluated the effect of caspase inhibition on PARP cleavage in Su-DHL4 cells 
treated with ABT-737 or ABT-737+CQ. The 89kDa cleaved PARP fragment was 
observed in cells treated with ABT-737 alone and to a greater extent in cells treated 
with ABT-737+CQ (Figure 4.9). Following administration of Z-VAD.fmk, levels of 
cleaved PARP were comparable between treated and untreated cells, indicating that 
pan-caspase inhibition can inhibit ABT-737+CQ-induced PARP cleavage and thus, 
apoptosis (Figure 4.9). 
 
 
 
 
 
Figure 4.9 Inhibition of caspase activation blocks ABT-737+CQ-induced PARP cleavage  
2 × 10
6 
viable Su-DHL4 cells were treated with 0.5µM ABT-737 with or without 50µM CQ in the 
presence or absence of 20µM Z-VAD.fmk for 3hr at 37°C; untreated cells were cultured under standard 
growth conditions. PARP was probed for as previously described.  
 
Combined, these results show that inhibition of caspase activity in BCL-2
HIGH
 DLBCL 
cell lines using the pan-caspase inhibitor Z-VAD.fmk ablates ABT-737+CQ-induced 
apoptosis, indicating that this treatment combination induces the intrinsic caspase-
dependent apoptosis pathway in BCL-2
HIGH 
DLBCL cell lines. 
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4.2.4 Inhibition of caspase activation showed less inhibitory effect on ABT-
737+CQ induced ΔΨm depolarization  
It has been reported that BH3-mimetics such as ABT-737 exert their pro-apoptotic 
effects at the mitochondria where they bind BCL-2 allowing Bax/Bak mediated 
apoptosis to proceed (Maiuri et al., 2007b). While Z-VAD.fmk can prevent activation of 
the caspase cascade, this pan-caspase inhibitor does not necessarily inhibit upstream 
events of apoptosis. We therefore sought to evaluate if treatment with Z-VAD.fmk 
affects ΔΨm depolarization and cell viability in ABT-737+CQ treated cells.  
Cells were treated with ABT-737 with or without CQ in the presence or absence of Z-
VAD.fmk and cell viability and ΔΨm depolarization evaluated as previously described. 
We found that ABT-737 and ABT-737+CQ-induced cell death was significantly (p< 
0.001) inhibited by Z-VAD.fmk in Su-DHL4 and CRL cells as demonstrated by the 
dramatic decrease in the percentage of DAPI
+
 cells (Figure 4.10). Z-VAD.fmk also had 
a limited but significant (p< 0.01) inhibitory effect on ABT-737+CQ-mediated m 
depolarization (Figure 4.11) reflected by a decrease in percentage of m
LOW
 cells. 
This suggests that despite inhibition of caspase activation treatment with ABT-737+CQ 
results in damage in the mitochondria. 
These data suggest that ABT-737+CQ-induced caspase activation occurs downstream of 
mitochondrial damage, confirming mitochondria as a primary target of ABT-737.   
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Figure 4.10 Evaluation of the effect of caspase inhibition on ABT-737+CQ-induced cell 
death in Su-DHL4 and CRL cells   
2 × 10
6 
viable Su-DHL4 (A) and CRL (B) cells were treated with 0.5µM ABT-737 with or without 50µM 
CQ in the presence or absence of 20µM Z-VAD.fmk for 3hr at 37°C; untreated cells were cultured under 
standard growth conditions. Data were analysed using Summit software V4.3 and significant changes 
between treatment conditions analysed using student t-test. Data are displayed as the mean ± SD of three 
separate experiments. Histograms are representative of three separate experiments. *** p< 0.001. 
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Figure 4.11 Evaluation of the effect of caspase inhibition on ABT-737+CQ-induced ΔΨm 
in Su-DHL4 and CRL cells   
2 × 10
6 
viable Su-DHL4 (A and C) and CRL (B and D) cells were treated with 0.5µM ABT-737 with or 
without 50µM CQ in the presence or absence of 20µM Z-VAD.fmk for 3hr at 37°C; untreated cells were 
cultured under standard growth conditions. Significant changes between treatment conditions analysed 
using student t-test. Data are displayed as the mean ± SD of three separate experiments. Histograms are 
representative of three separate experiments. ** p< 0.01; *** p< 0.001. 
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4.3 Discussion  
In this chapter we aimed to evaluate if ABT-737-induced autophagy acts as a 
cytoprotective mechanism which allows tumour cells to escape death. We found that 
inhibition of acquired autophagy with CQ resulted in increased levels of ABT-737-
induced ΔΨm depolarization, caspase-3 activation, PARP cleavage and cell death in Su-
DHL4 and CRL cells, demonstrating that blocking autophagy sensitizes BCL-2
HIGH 
DLBCL cell lines to ABT-737-induced cell death.  
Inhibition of caspases was found to result in significantly decreased levels of cell death 
following dual treatment, indicating that activation of the caspase-cascade is essential 
for ABT-737+CQ-induced apoptosis. To a lesser extent, ΔΨm depolarization also 
decreased upon caspase inhibition, indicating treatment with ABT-737+CQ induces 
mitochondrial damage upstream of caspase activation, confirming the mitochondria as a 
primary target for ABT-737.  
These findings indicate that ABT-737-acquired autophagy is used by cells as a pro-
survival mechanism to escape ABT-737-induced apoptosis. Combining autophagy 
inhibitors with standard chemotherapy drugs is showing promising results in a number 
of ongoing clinical trials across a variety of malignancies (Helgason et al., 2013). Our 
data demonstrate that the use of such inhibitors in the treatment of FL and DLBCL 
patients warrants further investigation and may improve treatment outcome.  
4.3.1 Conclusions  
Inhibition of autophagy with CQ sensitises BCL-2
HIGH
 DLBCL cell lines to ABT-737-
induced apoptosis. ABT-737+CQ-induced cell death is caspase-dependent. Damage to 
mitochondria by ABT-737 occurs upstream of caspase activation confirming the 
mitochondria as a primary target of ABT-737. We propose that acquired treatment 
resistance can be partly overcome by inhibition of autophagy.  
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Chapter V  
 
 
 
 
 
 
Evaluation of the effect of increased BCL-2 expression 
on the autophagy status and autophagy flux in 
lymphoma cells 
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5.1 Introduction 
The roles of autophagy in cancer are paradoxical (Choi et al., 2013a). On the one hand, 
autophagy can inhibit tumourigenesis by removing old and damaged organelles, which 
prevents DNA damage and maintains genomic stability. Autophagy can also suppress 
tumourigenesis by preventing the inflammatory response induced by necrotic cell death 
(Rosenfeldt and Ryan, 2011). On the other hand, autophagy can promote 
tumourigenesis and tumour cell survival by allowing malignant cells to adapt to stresses 
such as nutrient deprivation and hypoxia (Kimmelman, 2011). It is also now known that 
autophagy can mitigate tumour cells response to chemotherapeutic agents and either 
promote or hinder their pro-death role (Choi et al., 2013a).  
As well as inhibiting apoptosis, BCL-2 has been shown to inhibit autophagy by binding 
and sequestering the autophagy essential protein Beclin-1, which is involved in 
assembling the pre-autophagosomal structure that gives rise to the autophagosome 
(Kang et al., 2011; Marquez and Xu, 2012). Overexpression of this anti-apoptotic 
protein is observed in the majority of FL and ~20% of DLBCL patients (Kelly and 
Strasser, 2011). While increased expression of BCL-2 in FL and DLBCL is known to 
promote tumour growth by inhibiting apoptosis, the role of BCL-2 in autophagy 
regulation in NHL is currently unclear. Gene expression profile (GEP) studies have 
been carried out in FL and DLBCL in a bid to identify markers of progression and 
clinical heterogeneity (Alizadeh et al., 2000; Dave et al., 2004). However to date, there 
is no report of examination of the autophagy-related GEP of primary FL or DLBCL 
samples which overexpress BCL-2.  
To study the role of BCL-2 in autophagy, we compared the autophagy-related GEP of 
BCL-2
HIGH
 DLBCL cell lines with BCL-2
LOW
 DLBCL cell lines, and primary FL or 
DLBCL samples with reactive lymph-nodes (RA).  
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5.2 Results 
5.2.1 BCL-2
HIGH
 DLBCL cells have higher basal level autophagy activity 
compared to BCL-2
LOW
 DLBCL cells 
We first aimed to assess if increased expression of BCL-2 inhibits basal level autophagy 
by comparing expression levels of key autophagy-related proteins and the autophagy-
related GEP of BCL-2
HIGH
 Su-DHL4 and BCL-2
LOW
 Su-DHL8 cells. 
Using Western blotting we confirmed increased expression of BCL-2 in Su-DHL4 cells 
and found expression of BCL-xL and Beclin-1 to be similar in both cell lines. 
Expression of p62 and total levels of LC3 (LC3-I/LC3-II) were lower in BCL-2
HIGH
 
cells compared to BCL-2
LOW
 cells (Figure 5.1), suggesting increased degradation of 
these autophagy substrates and a higher basal level of autophagy activity in BCL-2
HIGH
 
cells. Lower levels of LC3-I observed in Su-DHL4 may reflect its increased conversion 
to LC3-II, further suggesting basal level autophagy is increased within BCL-2
HIGH
 cells.  
 
 
 
 
 
 
 
 
 
Figure 5.1 Evaluation of expression of key autophagy-related proteins in Su-DHL4 and 
Su-DHL8 DLBCL cell lines 
50µg whole cell lysate was loaded onto a 4-12% Bis-Tris gel and proteins separated by SDS-PAGE. 
Proteins were transferred to PVDF membrane and probed overnight at 4°C for the key autophagy-related 
proteins BCL-2, BCL-xL, p62, LC3 and Beclin-1; GAPDH was used as a loading control. Bands are 
representative of a single experiment. Densitometry values were obtained using Gelscan software and 
represent the ratio of specific proteins to GAPDH; LC3 values represent the ratio of LC3-I to GAPDH.   
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We next evaluated the autophagy status of these BCL-2
HIGH
 and BCL-2
LOW
 cell lines by 
examining their basal level autophagy-related GEP. mRNA levels of 84 autophagy-
related genes were examined and compared between Su-DHL4 and Su-DHL8 cell lines 
using the RT
2
 Profiler PCR Array. This PCR array analyses mRNA levels of 84 genes 
involved in all aspects of the autophagy pathway. Like whole genome microarrays, 
qRT-PCR allows evaluation of mRNA/gene expression levels but it differs in its 
method of data normalisation. While analysis of microarray data uses a global 
normalisation approach, qRT-PCR data are normalised to an individual endogenous 
control which is selected based on its stability across all samples under all experimental 
conditions (Andersen et al., 2004).  
RNA was extracted from each cell line (three replicates per cell line), assessed for 
quality, converted to cDNA and analysed by qRT-PCR. RIN and 260/280 values were 
comparable across all samples and were within the accepted ranges for good quality 
RNA (Appendix II, Table O). CT values generated by the qRT-PCR reaction, which 
represent mRNA transcript levels and reflect the number of cycles taken for the 
fluorescence signal to cross a user-defined threshold, were normalised to RPLPO which 
was identified as the most stably expressed HKG using gNorm and Normfinder 
programmes. Normalised CT values were converted to RQ values using the formula 2
-
ΔΔCt
. RQ values reflect expression of a gene relative to an internal control gene and 
allow direct comparison of mRNA levels across samples, meaning a standard curve is 
not required for each condition. Fold changes (FC) were calculated by dividing the 
mean Su-DHL4 RQ value by the mean Su-DHL8 RQ value on a per gene basis. A gene 
was classified as being significantly differentially expressed between cell lines if it had 
a FC ≥2 or ≤-2 and a p value <0.05. 
Both autophagy-machinery (Table 5.1) and autophagy-regulatory (Table 5.2) genes 
were identified as being significantly differentially expressed in Su-DHL4 cells 
compared to Su-DHL8 cells (Figure 5.2). A supervised hierarchical clustering analysis 
performed using RQ values of significantly differentially expressed genes successfully 
resolved these cell lines into two groups (Figure 5.2 A). The autophagy-machinery 
genes Atg10 (10.5-fold) and Atg4C (3.8-fold) were among the 13 genes significantly up-
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regulated in BCL-2
HIGH
 Su-DHL4 cells compared to BCL-2
LOW
 Su-DHL8 cells, while 
CTSS (-2.4-fold) and MAP1LC3A (-9.3-fold) were two of the six autophagy-machinery 
genes significantly down-regulated in Su-DHL4 cells (Figure 5. 2 B). GAA (-2.2-fold) 
and HTT (3-fold) were among the autophagy-regulatory genes significantly 
differentially expressed by these BCL-2
HIGH
 cells (Figure 5. 2 C). BCL-2 expression 
was shown to be up-regulated 59-fold in Su-DHL4 cells (Figure 5.2 C) which is 
unsurprising as this cell line carries the t(14;18) translocation. Successful identification 
of a gene previously known to be differentially expressed between these cell lines 
demonstrates the validity and applicability of the RT
2
 Profiler PCR array in the 
evaluation of the autophagy-related GEP of these cells. An unsupervised clustering 
analysis incorporating all genes, irrespective of significance or FC, also successfully 
separated Su-DHL4 and Su-DHL8 cell lines into two groups (Appendix II, Figure 1).  
These results show that BCL-2
HIGH
 DLBCL cell lines have a higher basal level of 
autophagy activity compared to BCL-2
LOW
 cells as demonstrated by increased 
expression of multiple autophagy-related genes in Su-DHL4 cells. Increased 
degradation of autophagy substrates in Su-DHL4 cells also indicates a higher rate of 
autophagy-flux in these BCL-2
HIGH
 cells, indicating that despite its increased 
expression, BCL-2 does not inhibit basal level autophagy activity in these cells.  
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Figure 5.2 Su-DHL4 and Su-DHL8 cells differ in their expression of autophagy-related 
genes 
1µg RNA extracted from untreated Su-DHL4 and Su-DHL8 cell lines (three replicates per cell line) was 
converted to cDNA and analysed using the RT
2
 Profiler PCR Array according to the manufactures 
protocol. CT values were normalised to the HKG RPLPO and genes with a FC ≥2 or ≤-2 and a p value 
<0.05 were deemed to be significantly differentially expressed between cell lines. P values were 
calculated using an unpaired student t-test.  A supervised hierarchical clustering analysis was performed 
by JM using a Euclidean distance measure and an average agglomeration where each row represents a 
gene and each column an RQ value. Gene expression levels are represented on a scale of blue to red 
colour indicative of low to high expression (A). Graphs depict fold-changes of autophagy-machinery (B) 
and autophagy-regulatory (C) genes significantly differentially expressed in Su-DHL4 cells compared to 
Su-DHL8 cells.  
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Table 5.1 Autophagy-machinery genes 
 
 
 
 
 
 
 
 
Gene Name Full name Function 
AMBRA1 Autophagy/Beclin-1 regulator 1 Autophagic vacuole formation 
ATG12 Autophagy related protein 12 Autophagic vacuole formation/co-
regulator for autophagy and apoptosis 
ATG16L1 Autophagy related protein 16-1 Autophagic vacuole formation/protein 
transport 
ATG4 A, B, C, D Autophagy related protein 4 A, B, 
C, D 
Autophagic vacuole formation/protein 
targeting to vacuole/protein 
transport/with protease activity 
ATG5 Autophagy related protein 5 Autophagic vacuole formation 
ATG9A Autophagy related protein 9A Autophagic vacuole formation/protein 
transport 
ATG9B Autophagy related protein 9B Autophagic vacuole formation 
BECN1 Beclin-1 Autophagic vacuole formation/co-
regulator of autophagy and apoptosis 
GABARAP GABA(A) receptor-associated 
protein 
Autophagic vacuole formation/protein 
targeting to vacuole/protein 
transport/linking to lysosome 
GABARAPL1 GABA(A) receptor-associated 
protein-like 1 
Autophagic vacuole formation 
GABARAPL2 GABA(A) receptor-associated 
protein-like 2 
Autophagic vacuole formation/protein 
transport 
IRGM Immunity-related GTPase family,M Autophagic vacuole formation 
MAP1LC3A Microtubule-associated protein 1 
light chain 3-α (LC3A) 
Autophagic vacuole formation 
MAP1LC3B Microtubule-associated protein 1 
light chain 3-  
Autophagic vacuole formation 
RGS19 Regulator of G-protein signalling 19 Autophagic vacuole formation 
ULK1 Serine/threonine-protein kinase 
ULK1 (ATG1) 
Autophagic vacuole formation 
WIPI1 WD repeat domain, 
phosphoinositide interacting 1 
Autophagic vacuole formation 
ATG10 Autophagy related protein 10 Protein transport 
ATG16L2 Autophagy related protein 16-2 Protein transport 
ATG3 Autophagy related protein 3 Protein transport/ubiquitination 
ATG7 Autophagy related protein 7 Protein transport/ubiquitination 
RAB24 RAB24 Protein transport 
DRAM1 DNA-damage regulated autophagy 
modulator 1 
Linking to lysosome/co-regulator of 
autophagy and apoptosis 
LAMP1 Lysosomal-associated membrane 
protein 1 
Linking to lysosome; autophagy 
induction 
NPC1 Niemann-Pick disease, type C1 Linking to lysosome 
CTS B, D, S Cathepsin B, D, S Linking to lysosome 
HDAC6 Histone Deacetylase 6 Protein Ubiquitination 
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     Table 5.2 Autophagy-regulatory genes  
Gene Name Full name Function 
AKT1 v-akt murine thymoma viral 
oncogene homolog 1 
Co-regulator of autophagy and apoptosis 
APP Amyloid beta (A4) precursor protein Co-regulator of autophagy and apoptosis 
ATG5 Autophagy related protein 5 Co-regulator of autophagy and apoptosis 
BAD BCL-2-associated agonist of cell 
death (Bad) 
Co-regulator of autophagy and apoptosis 
BAK1 BCL-2 antagonist/killer 1 Co-regulator of autophagy and apoptosis 
BAX BCL-2 associated X protein Co-regulator of autophagy and apoptosis 
BCL2 B-cell CLL/lymphoma 2 Co-regulator of autophagy and apoptosis 
BCL2L1 BCL-2 like 1 Co-regulator of autophagy and apoptosis 
BID BH3 interacting domain death 
agonist 
Co-regulator of autophagy and apoptosis 
BNIP3 BCL-2/adenovirus E1B 19kDa 
interacting protein 3 
Co-regulator of autophagy and apoptosis 
CASP3, 8 Caspase-3, 8 Co-regulator of autophagy and apoptosis 
CDKN1B Cyclin-dependent kinase inhibitor 
1B (p27) 
Co-regulator of autophagy and apoptosis 
and cell cycle 
CDKN2A Cyclin-dependent kinase inhibitor 
2A (p16) 
Co-regulator of autophagy and apoptosis 
and cell cycle 
CLN3 Battenin Co-regulator of autophagy and apoptosis 
CXCR4 Chemokine (C-X-C motif) receptor 
4 
Co-regulator of autophagy and apoptosis 
DAPK1 Death-associated protein kinase 1 Co-regulator of autophagy and apoptosis 
EIF2AK3 Eukaryotic translation initiation 
factor 2 alpha kinase 3 
Co-regulator of autophagy and apoptosis 
and autophagy induction 
FADD Fas (TNFRSF6)-associated via 
death domain 
Co-regulator of autophagy and apoptosis 
FAS Fas cell surface death receptor Co-regulator of autophagy and apoptosis 
HDAC1 Histone deacetylase 1 Co-regulator of autophagy and apoptosis 
HTT Huntingtin Co-regulator of autophagy and apoptosis 
IFNG Interferon  Co-regulator of autophagy and apoptosis 
and cell cycle and autophagy induction 
INS Insulin Co-regulator of autophagy and apoptosis 
MAPK8 Mitogen-activated protein kinase 8 Co-regulator of autophagy and apoptosis 
MTOR Mechanistic target of rapamycin Co-regulator of autophagy and apoptosis 
NFKB1 Nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells 1 
Co-regulator of autophagy and apoptosis 
PIK3CG Phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic 
subunit  
Co-regulator of autophagy and apoptosis 
PRKAA1 Protein Kinase, AMP-Activated, 
Alpha 1 
Co-regulator of autophagy and apoptosis 
PTEN Phosphatase and tensin homolog Co-regulator of autophagy and apoptosis 
and cell cycle 
SNCA synuclein, alpha Co-regulator of autophagy and apoptosis 
SQSTM1 Sequestosome 1 (p62) Co-regulator of autophagy and apoptosis 
TGFB1 Transforming growth factor beta 1 Co-regulator of autophagy and apoptosis 
and cell cycle 
TGM2 Transglutaminase 2 Co-regulator of autophagy and apoptosis 
TNF Tumour necrosis factor Co-regulator of autophagy and apoptosis 
TNFSF10 Tumour necrosis factor (ligand) Co-regulator of autophagy and apoptosis 
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5.2.2 Increased expression of BCL-2 does not inhibit the autophagy flux  
We next aimed to assess if BCL-2 expression levels affect the autophagy-flux. 
Expression levels of autophagy-related proteins and genes were evaluated and compared 
following modulation of the autophagy flux in BCL-2
HIGH
 and BCL-2
LOW
 DLBCL cell 
lines. The autophagy-flux was either inhibited with CQ or induced by culturing cells in 
HANKS Balanced Salt Solution (HBSS), a starvation media established to induce 
autophagy (Alers et al., 2012; Shang et al., 2011). Cellular levels of the key autophagy 
proteins p62, LC3 and Beclin-1 were evaluated in Su-DHL4 and Su-DHL8 cells which 
were cultured for up to 6hrs in normal media with or without CQ or cultured in HBSS.  
Inhibition of the autophagy flux by incubation with 50µM CQ resulted in a time-
dependent increase in levels of p62, LC3-I and LC3-II in both Su-DHL4 and Su-DHL8 
cells, indicative of a block in autophagy degradation and accumulation of these 
autophagy substrates (Figure 5.3 A). Beclin-1 levels remained stable following addition 
superfamily, member 10 
TP53 Tumour p53 Co-regulator of autophagy and apoptosis 
and cell cycle 
RB1 Retinoblastoma 1 Co-regulator of autophagy and cell cycle 
EIF4G1 Eukaryotic translation initiation 
factor 4 gamma, 1 
Autophagy in response to other 
intracellular signals 
ESR1 Estrogen receptor 1 Autophagy in response to other 
intracellular signals 
GAA Glucosidase, α; acid Autophagy in response to other 
intracellular signals 
HGS Hepatocyte growth factor-regulated 
tyrosine kinase substrate 
Autophagy in response to other 
intracellular signals 
MAPK14 Mitogen-activated protein kinase 14 Autophagy in response to other 
intracellular signals 
PIK3C3 Phosphatidylinositol 3-kinase, 
catalytic subunit, type 3  
Autophagy in response to other 
intracellular signals 
PIK3R4 Phosphatidylinositol 3-kinase, 
regulatory subunit 4  
Autophagy in response to other 
intracellular signals 
RPS6KB1 Ribosomal protein S6 kinase, 
70kDa, polypeptide 1 
Autophagy in response to other 
intracellular signals 
TMEM74 Transmembrane protein 74 Autophagy in response to other 
intracellular signals 
ULK2 Unc-51 like autophagy activating 
kinase 2 
Autophagy in response to other 
intracellular signals 
UVRAG UV radiation resistance associated 
gene 
Autophagy in response to other 
intracellular signals 
HSP90AA1  Heat shock protein 90 alpha class 
A1  
Chaperone-mediated autophagy 
HSPA8 Heat shock protein 8 Chaperone-mediated autophagy 
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of CQ (Figure 5.3 A) and incubation in HBSS for up to 6hrs (Figure 5.3 B), indicating 
this protein may not be a substrate of autophagic degradation.   
Nutrient deprivation caused LC3 and p62 levels to fluctuate within cell lines (Figure 5.3 
B). Cellular levels of LC3-I decreased in Su-DHL4 and Su-DHL8 cells during the 6hr 
starvation period. Similarly, aside from an initial increase in Su-DHL4 cells following 
2hr starvation, LC3-II levels also decreased in a time-dependent manner during the 
starvation period (Figure 5.3 B). A decrease in LC3-I may be due to its conversion to 
LC3-II, while a decrease in LC3-II may be caused by increased autophagic degradation.  
p62 levels initially decreased in both cell lines following 2-4hr starvation, indicative of 
its degradation by active autophagy. However levels of this adaptor protein increased 
after 4-6hrs starvation (Figure 5.3 B).  An increase in p62 at the protein level seems to 
conflict with increased autophagy activity. However, in a similar finding to ours, Sahani 
and colleagues observed an initial decrease in p62 levels in MEF and HepG2 cell lines 
following 1-2hr starvation. but levels of p62 were found to increase again under 
conditions of prolonged (4-8hr) starvation, which was due to an increase in p62 at the 
mRNA/gene level (Sahani et al., 2014).  
These data indicate that increased expression of BCL-2 does not inhibit the autophagy-
flux in BCL-2
HIGH 
cells. Despite differences in their basal level autophagy activity, 
BCL-2
HIGH
 and BCL-2
LOW
 cells appear to regulate their autophagy-flux in a similar way 
in response to modulation of autophagy activity.  
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Figure 5.3 Incubation with HBSS induces autophagy in Su-DHL4 and Su-DHL8 cell lines 
Cells were cultured under standard growth conditions in normal media with or without 50µM CQ (A) or 
in HBSS (B) for 0, 2, 4 or 6hr. 50µg whole cell lysate was loaded onto a 4-12% Bis-Tris gel and proteins 
separated by SDS-PAGE. Proteins were transferred to PVDF membrane and probed overnight at 4°C for 
the key autophagy-related proteins p62, LC3 and Beclin-1; GAPDH was used as a loading control. Bands 
are representative of a single experiment. Densitometry values were obtained as previously described; 
LC3 densitometry values represent the ratio of LC3-I and LC3-II to GAPDH.   
 
We next examined the effects of nutrient deprivation on the autophagy-related GEP of 
Su-DHL4 and Su-DHL8 cells. The GEP of starved cells was compared to cells cultured 
under nutrient replete conditions, referred to as untreated cells. RNA was extracted from 
cells (three replicates per cell line) (Appendix II, Table O) and analysed by qRT-PCR. 
FC differences were calculated by dividing the mean HBSS RQ value by the mean 
untreated RQ value within each cell line.  
A supervised clustering analysis successfully resolved starved and untreated cells into 
two groups in Su-DHL4 (Figure 5.4 A) and Su-DHL8 (Figure 5.4 B) cell lines. 
Starvation up-regulated autophagy at the gene level in BCL-2
HIGH
 and BCL-2
LOW
 cells 
as demonstrated by increased expression of a number of key autophagy-related genes in 
both cell lines (Figure 5.4 C and D). Three autophagy-regulatory genes CDKN1B, 
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UVRAG and SQSTM1/p62 were significantly up-regulated in starved Su-DHL4 and Su-
DHL8 cells compared to untreated controls (Figure 5.4). An increase in p62 mRNA 
levels explains our previous observation of increased expression of p62 at the protein 
level following 6hr starvation and is in agreement with the findings of Sahani and 
colleagues (Sahani et al., 2014). GABARAPL1 and GABARAPL2, mammalian homologs 
of Atg8, were also up-regulated in starved Su-DHL4 cells (Figure 5.4 A and C). The 
autophagy-machinery genes Atg7, Atg16L2 and Atg9B were significantly down-
regulated in Su-DHL4 and/or Su-DHL8 cells following nutrient withdrawal despite an 
increase in the autophagy flux (Figure 5.4). An unsupervised clustering analysis also 
resolved starved and untreated cells in both cell lines (Appendix II, Figure 2 and 3) 
Increased expression of autophagy-machinery and autophagy-regulatory genes in both 
starved BCL-2
HIGH
 and BCL-2
LOW
 cell lines indicates BCL-2 expression may not affect 
autophagy induction or the autophagy flux at the gene level. More genes were found to 
be significantly up-regulated in Su-DHL4 cells compared to Su-DHL8 cells, suggesting 
increased autophagy activity in BCL-2
HIGH
 cells following nutrient deprivation.  
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Figure 5.4 HBSS-induced starvation alters the autophagy-related GEP of Su-DHL4 and 
Su-DHL8 cell lines 
1µg RNA was extracted from Su-DHL4 (A and C) and Su-DHL8 (B and D) cell lines cultured in normal 
media (untreated) or cultured in HBSS for 6hr, converted to cDNA and analysed by qRT-PCR according 
to the manufactures protocol. CT values were normalised to RPLPO and genes with a FC ≥2 or ≤-2 and a 
P value <0.05 deemed significantly different. P values were calculated using a paired student t-test. A 
supervised hierarchical clustering analysis was performed by JM using a Euclidean distance measure and 
an average agglomeration where each row represents a gene and each column an RQ value. Gene 
expression levels are represented on a scale of blue to red colour indicative of low to high expression (A 
and B). Graphs depict fold-changes of autophagy related genes significantly differentially expressed in 
Su-DHL4 (C) and Su-DHL8 (D) HBSS cultured cells compared to cells cultured in normal supplemented 
media. Red bars indicate changes in autophagy machinery genes; black and white bars indicate changes in 
autophagy regulatory genes.  
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5.2.3 Purification of B cells from primary FL, DLBCL and reactive control 
samples for gene expression analysis 
Autophagy is a cellular process which occurs in the majority of cell types. Therefore, in 
order to determine the autophagy status of malignant FL and DLBCL cells specifically, 
we isolated B cells from primary FL and DLBCL single-cell suspensions using cell 
sorting by flow cytometry. B cells isolated from RA were used as controls.  
We first selected the viable, non-T cell fraction of cells by gating on DAPI
-
/CD3
-
 cells 
(Figure 5.5). B cells were then isolated from this dual negative population based on 
their expression of well established B cell markers. DLBCL and RA B cells were 
identified by expression of the pan-B cell marker CD20 (Figure 5.5 A; middle and 
bottom panels) (Shaffer et al., 2012) while FL B cells were isolated according to co-
expression of the pan-B cell marker CD19 and the germinal centre B cell marker CD10 
(Figure 5.5 A; top panel) (Dogan et al., 2000; Gurbuxani et al., 2009). B cells were 
isolated from all samples with >95% purity.   
In healthy individuals, normal B cells are polyclonal and express both kappa and 
lambda light chains, typically in a kappa: lambda ratio of 2:1 or 1.5:1 (Katzmann et al., 
2005; Schmid et al., 2011), while FL B cells are monoclonal and express either kappa or 
lambda at a high levels (~>90%), skewing the kappa: lambda ratio (Schmid et al., 2011; 
Warnke and Levy, 1978). Healthy B cells are therefore light-chain unrestricted while 
malignant B cells are light-chain restricted (Katzmann et al., 2005; Schmid et al., 2011). 
Evaluation of light-chain restriction in our population of CD19
+
/CD10
+
 isolated FL B 
cells revealed expression of either the kappa (Figure 5.5 B; top panel) or the lambda 
(Figure 5.5 B; middle panel) light-chain only, indicative of light-chain restriction and a 
monoclonal, neoplastic population of B cells. In comparison, reactive B cells expressed 
kappa and lambda at approximately equal levels (kappa: lambda - 0.92:1) indicating a 
polyclonal B cell population (Figure 5.5; bottom panel). This demonstrates that isolation 
of B cells from primary FL samples based on dual expression of CD19 and CD10 
successfully identifies the malignant cell population. 
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Figure 5.5 Flow sorting strategy for purification of B cells from primary FL, DLBCL and 
RA single cell suspensions 
FL, DLBCL and RA samples were prepared as described in materials and methods. Following exclusion 
of DAPI
+
 dead cells, CD3
+
 T cells and CD3
-
 cells were identified and B cells isolated from the live, non-
T cell (DAPI
-
/CD3
-
) population. FL B cells were isolated according to co-expression of CD19 and CD10 
(CD3
-
/CD19
+
/CD10
+
); DLBCL and RA B cells were identified based on expression of CD20 (CD3
-
/CD20
+
) (A). CD3
-
/CD19
+
/CD10
+ 
FL B cells were further evaluated for kappa/lambda light chain 
restriction. CD19
+
 RA B cells were used as a positive control for the normal kappa: lambda ratio (B). 
Purity of isolated B cells was >95% in all cases. Fluorochromes were visualised under the following 
channels: DAPI - Violet-Blue; CD3 - FITC; CD20 - APC-H7; CD19 - APC-Cy7; CD10 - PE; Kappa - 
APC; Lambda - PerCP-Cy5.5. Further antibody information is listed in appendix I, 7.5; table I. 
      Chapter V Results 
 
157 
 
5.2.4 FL samples displayed higher autophagy activity despite increased 
expression of BCL-2 
Next, we compared the autophagy-related GEP of purified primary FL and DLBCL B 
cells to those of RA non-malignant B cells. RNA was extracted from five FL, two 
DLBCL and three RA primary purified samples.  Full patient information is given in the 
appendix (Appendix II, Table P and Q). RINs were comparable across all samples 
ranging from 7-10, and were considered high enough to deem the RNA as non-degraded 
and of good quality. 260/280 values were also within the accepted range and were 
comparable across samples (Appendix II, Table R). Expression levels of autophagy-
related genes were assessed using the RT
2
 Profiler Human Autophagy PCR array and 
RQ values calculated as previously described. FC values were obtained by dividing the 
mean FL or mean DLBCL RQ value by the mean RA RQ value on a per gene basis. 
Genes with a fold change ≥3 or ≤-3 or a FC ≥2 or ≤-2 and a p value <0.05 were taken to 
be biologically meaningful.  
An unsupervised hierarchical clustering analysis successfully separated purified RA B 
cells from purified FL and DLBCL B cells (Figure 5.6 A). Of the five FL samples 
studied, three had similar autophagy-related gene expression profiles and expressed a 
number of genes at higher levels compared to RA controls; DLBCL sample T2628 was 
similar to these FL patients. FL sample T6697 resembled RA B cells, while T6713, 
which showed up-regulation of a number of genes compared to sample T6697, clustered 
separately to all other FL samples (Figure 5.6 A). DLBCL sample T3531 expressed 
autophagy genes at low levels comparable to RA controls, suggesting decreased 
autophagy activity in this sample. These data indicate that despite increased expression 
of BCL-2, purified primary FL B cells have increased basal level autophagy activity 
compared to non-malignant B cells and DLBCL B cells. The autophagy-related GEP 
and status of DLBCL B cells was heterogeneous and so could not be definitively 
defined; a greater number of purified DLBCL samples are therefore required to 
establish aberrant expression of autophagy genes in this aggressive disease.  
Among those genes significantly up-regulated in FL B cells were the early and late 
autophagy-machinery genes Atg9A, LAMP1 and GABARAPL1 (Table 5.3), the latter of 
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which was also up-regulated in Su-DHL4 cells following starvation (Figure 5.4). 
MAP1LC3A was up-regulated in both FL and DLBCL B cells, as was the autophagy-
regulatory gene CDKN2A (Table 5.3 and 5.4). SQSTM1, which encodes for p62, was 
up-regulated in three of the five FL samples evaluated (T5728, T0167, T6713), although 
this increase did not reach statistical significance. Unsurprisingly, expression of BCL-2 
was increased in FL B cells compared to RA B cells (Table 5.4).  
The median, overall expression of autophagy-related genes was comparable between 
purified RA B cells suggesting similar expression of autophagy-related genes and 
autophagy activity between these samples (Figure 5.6 B). Global expression of 
autophagy genes varied among purified FL and DLBCL B cells indicating heterogeneity 
amongst lymphoma patients with respect to their expression of autophagy-related genes 
and their autophagy pathway activity. However, we observed that with the exception of 
sample T6697, FL B cells expressed autophagy-related genes at a higher level compared 
to RA B cells (Figure 5.6 B), suggesting increased autophagy activity in these malignant 
B cells.  
Up-regulation of autophagy-machinery and autophagy-regulatory genes in purified FL 
B cells indicates higher basal level autophagy activity in these cells despite increased 
expression of BCL-2. This suggests that overexpression of BCL-2 does not inhibit 
autophagy in FL B cells.  
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Figure 5.6 Evaluation of the autophagy-related GEP of primary FL, DLBCL and RA B 
cells  
300ng RNA extracted from diagnostic primary FL, DLBCL and RA B cells previously isolated by flow 
sorting  was converted to cDNA and analysed by qRT-PCR according to the manufactures protocol CT 
values were normalised to RPLPO and genes with a FC ≥2 or ≤-2 and a p value <0.05 deemed 
significantly different. p values were calculated using a Mann Whitney U test. An un-supervised 
hierarchical clustering analysis was performed by JM using a Euclidean distance measure and an average 
agglomeration. Heat-map shows RQ values where each column represents a patient and each row a gene. 
Gene expression levels are represented as a gradient of blue to red colour indicating low and high 
expression respectively; gray indicates missing data (A). Data were visualised based on their total global 
expression level of those genes included in the un-supervised hierarchical clustering; mid-line represents 
the median for each sample; box-limits - 25
th 
-75
th
 percentiles; whiskers - 5
th
 - 95
th
 percentiles (B). Dashed 
line reflects median global expression of autophagy-related genes across RA samples.  
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While examination of autophagy at the mRNA level in purified B cells gives us an 
understanding of this pathways activity in malignant cells, it does not provide 
information on activity of this pro-survival process in cells of the tumour 
microenvironment. We therefore evaluated the autophagy-related GEP of primary FL, 
DLBCL and RA tissue biopsies, classified as un-purified, to establish if FL samples can 
still be distinguished as having increased expression of autophagy genes. The 
autophagy-related GEP of eight FL and ten DLBCL un-purified samples were compared 
to eight un-purified primary RA controls (Appendix II, Table P and Q).  RINs and 
260/280 values were comparable between samples and were within the acceptable limits 
to deem the RNA of good quality (Appendix II, Table S).  
Unsupervised hierarchical clustering grouped seven of the eight FL samples together, 
with sample F9713 behaving differently. The DLBCL sample T1486 also clustered with 
these FL samples (Figure 5.7 A). The remaining nine DLBCL samples clustered with 
RA controls and expressed autophagy-related genes at low levels compared to FL 
samples (Figure 5.7 A). Based on this unsupervised clustering, un-purified FL samples 
appear to up-regulate a number of autophagy-related genes compared to RA and 
DLBCL samples, indicating increased autophagy in these samples. Similarities in 
expression levels of autophagy genes between DLBCL samples and RA controls 
suggest lower basal level autophagy in DLBCL compared to FL. Multiple autophagy-
machinery and autophagy-regulatory genes were significantly up-regulated in un-
purified FL samples compared to RA controls (Table 5.3 and 5.4). For example Atg9A, 
Atg16L1 and MAP1LC3A, previously shown to have increased expression in purified 
FL B cells, were up-regulated in this larger cohort of un-purified FL samples. Similarly 
UVRAG and GABARAPL2, both previously identified as being significantly up-
regulated in Su-DHL4 cells following starvation, were expressed at significantly higher 
levels in un-purified FL samples. SQSTM1 expression was variable among un-purified 
FL samples, with half of the samples evaluated showing increased expression compared 
to RA controls. A greater number of autophagy genes were found to have altered 
expression in un-purified FL samples compared to purified B cells, indicating that 
expression of autophagy genes may also be altered in cells of the tumour 
microenvironment. Only three autophagy-regulatory genes CTSD, DRAM1 and TGM2 
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were significantly differentially expressed in un-purified DLBCL samples compared to 
RA (Table 5.3 and 5.4).  
Comparing samples based on their overall median expression levels of autophagy-
related genes, FL samples showed global up-regulation of autophagy genes compared to 
DLBCL and control samples (Figure 5.7 B). Autophagy activity varied among DLBCL 
samples although generally, the global autophagy-related GEP of un-purified DLBCL 
samples were similar to RA controls (Figure 5.7 B).  
These data demonstrate that autophagy activity is higher in FL tumour cells and cells in 
the surrounding microenvironment, suggesting overexpression of BCL-2 does not 
inhibit autophagy in this indolent NHL.  
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Figure 5.7 Evaluation of the autophagy-related GEP of primary FL, DLBCL and RA 
whole tumour samples  
400ng RNA extracted from diagnostic primary FL, DLBCL and RA whole tissue biopsies was converted 
to cDNA and analysed by qRT-PCR according to the manufactures protocol CT values were normalised 
to RPLPO and genes with a FC ≥2 or ≤-2 and a p value < 0.05 deemed significantly different. p values 
were calculated using a Mann Whitney U test. An un-supervised hierarchical clustering analysis was 
performed by JM using a Euclidean distance measure and an average agglomeration. Heat-map shows RQ 
values where each column represents a patient and each row a gene. Gene expression levels are 
represented as a gradient of blue to red colour indicating low and high expression respectively; gray 
indicates missing data (A). Data were visualised based on their total global expression level of those 
autophagy genes included in the clustering analysis; mid-line represents the median for each sample; box-
limits - 25
th 
-75
th
 percentiles; whiskers - 5
th
 - 95
th
 percentiles (B). Dashed line reflects median global 
expression of autophagy-related genes across RA samples.  
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Table 5.3 Autophagy-machinery genes differentially regulated in primary lymphoma 
samples compared to RA controls 
Gene name and 
function 
FL DLBCL 
F.C 
(UP) 
P 
value 
F.C 
(P) 
P 
value 
F.C 
(UP) 
P 
value 
F.C 
(P) 
P 
value 
BECN1  2.07 <0.005       
RGS19 2.14 <0.05       
AMBRA1  2.23 <0.005       
ATG16L1  2.42 <0.05 3.00 0.24     
MAP1LC3A  2.60 <0.005 5.38 0.2   5.22 0.33 
GABARAPL1    7.98 0.65     
GABARAPL2  2.64 <0.005       
GABARAP  2.06 <0.005       
ATG9A  3.26 <0.005 2.56 <0.05     
ATG4D  3.75 <0.005       
ATG4B  4.66 <0.005       
ULK1    3.29 0.06     
WIPI1  3.97 <0.005       
ATG16L2  2.047 <0.05       
RAB24  2.38 <0.05       
ATG7  2.39 <0.005       
ATG10 7.21 <0.005       
DRAM1 2.38 <0.05   4.24 <0.05 10.77 0.27 
CTSD  2.41 <0.005   4.14 <0.05   
LAMP1 2.65 <0.05 2.02 <0.05     
HDAC6 3.91 <0.005 2.23 <0.05     
F.C. - Fold change; UP - unpurified; P - purified  
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Table 5.4 Autophagy-regulatory genes differentially regulated in primary lymphoma 
samples compared to RA controls 
Gene name and 
function 
FL DLBCL 
F.C 
(UP) 
P 
value 
F.C 
(P) 
P 
value 
F.C 
(UP) 
P 
value 
F.C 
(P) 
P 
value 
BNIP3    -2.8 0.05   -15.37 0.12 
FADD  2.07 <0.005       
BAD  2.12 <0.005       
BID        3.96 0.11 
FAS 2.16 <0.05 3.58 0.10   7.16 0.08 
MTOR 2.18 <0.005       
MAPK8 2.31 <0.05       
BAK1  2.31 <0.05       
CLN3 2.33 <0.005       
CXCR4 2.25 <0.05       
AKT1 2.69 <0.005       
BAX  2.95 <0.05       
IFNG    3.04 0.34 6.54 0.1 -5 0.44 
HTT 3.20 <0.005       
HDAC1  3.23 <0.005     -2.0 <0.05 
PIK3CG 3.33 <0.005     -8.07 <0.005 
BCL2L1 3.81 <0.005       
DAPK1  5.04 <0.05       
BCL2 8.88 <0.005 7.03 0.1     
TGM2      2.99 <0.05 4.56 0.16 
TP53  2.98 <0.005       
CDKN1B  2.11 <0.05       
CDKN2A 6.19 <0.05 4.22 0.11 3.27 0.12 4.12 <0.05 
EIF4G1  2.16 <0.005       
UVRAG 2.33 <0.005       
RPS6KB1  2.36 <0.005       
MAPK14  2.50 <0.05       
ESR1  2.52 <0.05       
GAA  2.95 <0.005       
TMEM74 3.56 0.31 3.71 0.51   5.69 0.33 
HGS  7.38 <0.05       
F.C. - Fold change; UP - unpurified; P - purified  
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The experiments described above were performed using biological rather than technical 
replicates due to limited availability of RNA, particularly amongst purified samples. We 
therefore validated a cohort of genes previously identified as being significantly 
differentially expressed among purified and/or un-purified lymphoma samples and 
included triplicate technical replicates and a NTC for each gene in each sample. 
Validation was carried out in a subset of un-purified primary samples for which 
sufficient amounts of good quality RNA were available. In total, validation was carried 
out in five RA, five FL and five DLBCL samples. Prior to calculation of RQ values 
triplicate CT values returned for each gene following qRT-PCR were compared for 
similarity by assessing their SD. Only replicates with a SD of ≤0.5 were carried forward 
for further analysis meaning in some instances duplicate rather than triplicate CT values 
were used to generate the average CT of a gene. Data were normalised to averaged 
RPLPO and RQ and FC values calculated as previously described.  
Five genes previously identified as being significantly up-regulated in lymphoma 
samples were selected for validation. MAP1LC3A was validated as it was found to be 
up-regulated in purified FL and DLBCL B cells and un-purified FL samples (Table 5.3) 
while DRAM1 was validated due to its increased expression in un-purified DLBCL and 
FL and purified DLBCL samples (Table 5.4). CTSD, BECN1 and Atg4B were also 
included in the validation cohort due to their high FC in one or more population (Table 
5.3). 
Expression levels of MAP1LC3A, Atg4B and DRAM1 were found to be significantly up-
regulated in un-purified FL and DLBCL samples respectively compared to RA controls 
(Table 5.5), confirming our previous findings. CTSD was also found to be significantly 
up-regulated in both patient cohorts, again in line with our previous findings (Table 
5.5). BECN1 and DRAM1 were not up-regulated ≥2-fold in this un-purified FL cohort 
which may be due to a smaller sample size. Unsurprisingly, BECN1, Atg4B and 
MAP1LC3A, which were not previously identified as being significantly differentially 
expressed in DLBCL patients, were not up-regulated in this validation cohort (Table 
5.5). 
 
      Chapter V Results 
 
166 
 
Table 5.5 Validation of differential expression of autophagy-related genes in FL and 
DLBCL samples compared to RA controls 
Gene name and 
function 
FL DLBCL 
F.C 
(Array) 
P 
value 
F.C 
(V) 
P 
value 
F.C 
(Array) 
P 
value 
F.C 
(V) 
P 
value 
BECN1 2.07 <0.005 1.46 0.06   1.23 0.46 
MAP1LC3A 2.60 <0.005 2.08 <0.05   1.59 0.32 
ATG4B 4.66 <0.005 2.72 <0.05   1.78 0.13 
DRAM1 2.38 <0.05 1.05 0.18 4.24 <0.05 5.77 0.05 
CTSD 2.41 <0.05 2.27 <0.05 4.13 <0.05 8.99 <0.05 
F.C. - Fold change; P - purified; Array - microarray; V - validation  
 
These validation experiments confirmed differential expression of autophagy-related 
genes in a smaller cohort of un-purified primary FL and DLBCL samples, indicating 
that our previous experiments accurately identified differentially expressed autophagy-
related genes despite lack of technical replicates.  
Having shown FL has higher basal level autophagy at the gene level, we next evaluated 
if increased mRNA levels of autophagy-related genes translates into increased protein 
expression. Using Western blotting, we examined protein expression levels of Atg4B 
and ULK1, which were previously identified as being up-regulated in purified and/or 
un-purified FL samples. Protein expression levels were evaluated in un-purified 
lymphoma and RA samples previously included in qRT-PCR analysis.  
Based on densitometry values, expression levels of Atg4B and ULK1 were significantly 
higher in FL compared to DLBCL samples and RA controls (Figure 5.8). These data 
indicate increased expression of autophagy-related genes in FL patients translates into 
increased protein expression and that basal level autophagy is higher in FL patients at 
both the gene and protein level, further indicating overexpression of BCL-2 does not 
inhibit autophagy in these patients. 
 
 
      Chapter V Results 
 
167 
 
FL DLBCL RA
0
1
2
3
4
5 *
**
R
a
ti
o
 o
f 
A
T
G
4
B
/G
A
P
D
H
FL DLBCL RA
0
2
4
6
8
*
**
R
a
ti
o
 o
f 
U
L
K
1
/G
A
P
D
H
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Analysis of expression levels of autophagy-related proteins in un-purified 
primary FL, DLBCL and RA tissues 
50µg whole cell lysates extracted from primary tissue samples were loaded onto a 4-12% Bis-Tris gel and 
proteins separated by SDS-PAGE. Autophagy-related proteins Atg4B and ULK1 were visualised by 
Western blotting; GAPDH was used as a loading control. Bands are representative of a single experiment. 
Densitometry values were obtained as previously described and represent the ratio of specific proteins to 
GAPDH (A). Differences in expression levels/densitometry values were compared using a student t-test 
(B, C). Data representative of a single experiment. * p< 0.05, ** p< 0.05, *** p< 0.001.  
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5.2.5 Autophagy-related genes are up-regulated in cells of the tumour 
microenvironment    
CTSD and TGM2, which are predominantly expressed by stromal cells, fibroblasts and 
macrophages (Martinez et al., 2013; O'Donoghue et al., 1995), were significantly up-
regulated at the mRNA level in un-purified FL and DLBCL and purified DLBCL B 
cells (Table 5.3 and 5.4) We therefore aimed to assess which cell type(s) express these 
proteins in lymphoma samples, and if their expression levels differ between patient 
samples and controls.  
Primary RA and diagnostic FL and DLBCL samples on TMAs were stained for CTSD 
or TGM2 using IHC. We first assessed the morphology of cells expressing CTSD 
(Figure 5.9 A; top panel) and TGM2 (Figure 5.9 A; bottom panel) and found both 
proteins to be expressed by large elongated cells with an irregular shape, a morphology 
which does not resemble that of B cells. To confirm these proteins are primarily 
expressed by cells in the microenvironment, we stained DLBCL and RA samples on 
TMAs for the pan-macrophage marker CD68 (Figure 5.9 D) (Greaves et al., 2013) and 
observed that CD68
+
, CTSD
+
 and TGM2
+
 cells were morphologically similar. Cells 
which highly expressed CTSD and TGM2 were confirmed to be macrophages by our 
histopathologist colleagues MC and RC. Expression of CTSD (Figure 5.9 E) and TGM2 
(Figure 5.9 F) was significantly positively correlated with CD68 expression in 144 
DLBCL patients, further confirming these lysosomal enzymes are expressed by 
macrophages, not B cells. 
We also assessed if these proteins are differentially expressed between FL and DLBCL 
patients and RA controls. Using the automated ARIOL analysis system we quantified 
brown positive staining, indicative of CTSD or TGM2 expression, as the percent-
stained area of viable tissue within cores. As each patient was arrayed in triplicate an 
average of these cores was taken as the percent stained area for CTSD or TGM2. 
Expression of CTSD was significantly higher in DLBCL patients (n=144) compared to 
RA controls (n=21; p< 0.05) (Figure 5.9 B), whereas protein levels of TGM2 were 
significantly lower (Figure 5.9 C). Both CTSD and TGM2 expressed at significantly 
      Chapter V Results 
 
169 
 
0 5 10 15 20 25
0
5
10
15
20 DLBCL  r=0.35 P<0.0001
n=144
CD68
C
a
th
e
p
s
in
 D
0 5 10 15 20 25
0
10
20
30
40 DLBCL  r=0.57 P<0.0001
n=144
CD68
T
G
M
2
FL DLBCL RA
0
5
10
15
20
25
***
***
*
n=128 n=144 n=21
 C
T
S
D
 %
 s
ta
in
e
d
 a
re
a
FL DLBCL RA
0
10
20
30
40
***
*** ***
n=128 n=144 n=26
T
G
M
2
 %
 s
ta
in
e
d
 a
re
a
lower levels in FL patients compared to DLBCL patients and RA controls (Figure 5.9 B 
and C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 Analysis of CTSD and TGM2 expression in primary lymphoma samples using 
IHC  
RA, diagnostic FL and diagnostic DLBCL TMAs previously constructed by AC and AO were stained for 
CTSD and TGM2, RA and DLBCL TMAs stained for CD68 and nuclei counterstained with 
haematoxylin. CD68 staining was previously carried out by RC and AC. Expression of these proteins is 
shown by HRP-DAB immunostaining and was analysed using the automated ARIOL analysis system 
which was trained to recognise areas of viable tumour and brown-positive staining. Positive brown 
staining was taken to be that staining which was strongest; non-specific, background staining was 
excluded. Representative images of CTSD and TGM2 staining in FL, DLBCL and RA tissue cores (A). 
CTSD and TGM2 expression was calculated as the average percent stained viable area for each patient 
and differences in expression levels of these proteins compared between samples using a student's t-test 
(B, C). Representative image of CD68 staining in a DLBCL tissue core (D). CD68 expression was 
analysed by RC as the average number of positive cells per patient within a viable tissue area. Expression 
levels of CTSD (E) and TGM2 (F) were correlated with CD68 expression in DLBCL patients using a 
Pearson's product-moment correlation method.  
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Next, we evaluated if cellular levels of CTSD or TGM2 could predict OS in our FL or 
DLBCL patient cohorts by performing a univariate, categorical analysis.  X-tile 
software was used to generate optimal cut-points which divided FL and DLBCL 
patients into two groups based on CTSD or TGM2 levels. Kaplan-Meier curves were 
generated and significant differences in OS between groups evaluated using a log-rank 
(Mantel-Cox) test.  
Increased expression of CTSD has previously been reported to predict a poor outcome 
in NHLs (Nicotra et al., 2010a). In agreement with these findings, we found that higher 
expression of CTSD was associated with shorter OS in FL and DLBCL (Figure 5.10 A 
and C). TGM2 did not predict outcome in either patient cohort (Figure 5.10 B and D), 
despite being identified as a prognostic marker in other malignancies (Miyoshi et al., 
2010; Park et al., 2010).  
These results show that CTSD and TGM2 proteins are primarily expressed by tumour-
associated macrophages (TAMs), not malignant B cells. Evaluation of autophagy 
activity in un-purified tumour samples reflects expression of autophagy-related genes in 
not only tumour cells, but also tumour infiltrating cells. This may affect or skew 
accurate interpretation of autophagy gene expression levels and thus autophagy activity 
within a sample. 
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Figure 5.10 Higher levels of CTSD are associated with a poor prognosis in FL and DLBCL  
Evaluation of OS in 128 FL and 144 DLBCL patients based on low and high (percent-stained viable 
tissue area) CTSD (A and C) and TGM2 (B and D) expression using Kaplan-Meier survival analysis. 
Patients were stratified into low and high protein expressing groups using optimal cut-points generated by 
the statistical software X-tile. Generation of Kaplan-Meier curves and evaluation of differences in 
survival between groups using a log-rank (Mantel-Cox) test were performed using GraphPad Prism 
software. p value of <0.05 was deemed significant. OS= overall survival; n= number. 
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5.3 Discussion  
In this chapter we have demonstrated that overexpression of BCL-2 does not modulate 
the autophagy status or inhibit basal level autophagy flux in B-cell lymphomas. FL, 
which frequently overexpresses BCL-2 showed higher expression of autophagy-related 
genes compared to RA-LN controls. We therefore propose that despite increased 
expression of BCL-2, autophagy activity may be up-regulated in FL samples.  
As BCL-2 has previously been shown to inhibit autophagy in a cardiac BCL-2 
transgenic mouse model (Pattingre et al., 2005), we reasoned that overexpression of 
BCL-2 in B-cell NHLs might lead to autophagy inhibition. We therefore evaluated the 
autophagy status and autophagy flux of BCL-2
HIGH
 and BCL-2
LOW
 DLBCL cell lines at 
the protein and gene level to assess the effect of BCL-2 overexpression on autophagy 
activity in B-cell lymphomas. We found that BCL-2
HIGH
 Su-DHL4 cells had increased 
expression of a number of autophagy-related genes at the basal level compared to BCL-
2
LOW
 Su-DHL8 cells. We also demonstrated that BCL-2
HIGH
 and BCL-2
LOW
 cells 
modulate the autophagy flux in a similar way following autophagy induction by 
starvation or inhibition with CQ, as demonstrated by similar patterns of p62 and LC3 
accumulation and degradation respectively. Starvation-induced autophagy resulted in 
up-regulation of a greater number of genes in BCL-2
HIGH
 cells, suggesting that despite 
its increased expression BCL-2 does not inhibit the autophagy flux in BCL-2
HIGH
 cells 
at the basal level or following autophagy stress. Instead, BCL-2
HIGH
 cells appear to have 
higher basal level autophagy activity compared to BCL-2
LOW
 cells. A possible 
explanation for this is that inhibition of apoptosis by BCL-2 increases autophagy 
activity as a pro-survival mechanism to remove old and damaged cellular organelles and 
proteins which have accumulated within cells. It is also possible that increased 
expression of BCL-2 promotes increased basal level autophagy in cells where it is 
overexpressed, although the mechanistic route through which is may occur is currently 
unclear.   
We also compared the autophagy-related GEP of primary NHL samples to RA to 
evaluate the role of BCL-2 in autophagy in the primary setting. B cells were purified 
from FL and DLBCL samples to assess the autophagy-associated gene signature of the 
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malignant cell population compared to RA B cells; the autophagy-related GEP of un-
purified lymphoma and RA samples were also evaluated. As expected, BCL-2 was 
expressed at a higher level in purified and un-purified FL samples compared to DLBCL 
samples and RA controls. Unsupervised hierarchical clustering identified FL B cells as 
having increased basal level expression of autophagy-related genes compared to 
DLBCL and RA samples. Among those genes significantly up-regulated in FL B cells 
were ATG9A, MAP1LC3A and LAMP1, which are involved in protein transport, vacuole 
formation and lysosomal degradation respectively. This suggests that despite 
overexpression of BCL-2, basal level autophagy is higher in FL B cells compared to 
DLBCL and RA controls. The autophagy status of DLBCL B cells varied; however due 
to limited sample numbers, autophagy activity within these malignant cells could not be 
fully elucidated.  
Comparison of the autophagy-related GEP of un-purified FL, DLBCL and RA samples 
again identified FL samples as having higher autophagy-related GEPs and increased 
expression of autophagy-related genes compared to DLBCL and RA controls. Genes 
aberrantly expressed in FL samples included the autophagy-machinery genes 
MAP1LC3A and LAMP1, previously found to have increased expression in purified FL 
B cells and CDKN2A, UVRAG and GABARAPL2 which were also up-regulated in BCL-
2
HIGH
 Su-DHL4 cells following starvation-induced autophagy. These results again 
suggest that basal level autophagy activity is higher in FL samples, and that both 
DLBCL and RA samples have low basal level autophagy activity. Interestingly, a 
greater number of autophagy-related genes were significantly differentially expressed in 
un-purified FL samples compared to purified FL B cells, which suggests autophagy 
activity might also be altered in cells of the FL microenvironment.  
Fewer genes were differentially expressed in DLBCL, irrespective of sample purity. 
CTSD and TGM2, which are involved in regulation of the autophagy flux through the 
lysosome and the autophagy-dependent clearance of ubiquitinated proteins respectively, 
were two of the three genes significantly up-regulated un-purified DLBCL samples. 
IHC staining showed that CTSD and TMG2 proteins in DLBCL were expressed by 
CD68
+
 TAMs, not B cells. Both proteins were expressed at significantly lower levels in 
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FL, while CTSD was expressed at significantly higher levels in DLBCL compared to 
RA controls. In line with previous findings (Nicotra et al., 2010a), increased expression 
of CTSD was associated a shorter OS in FL and DLBCL patients. TGM2 was not 
identified as a prognostic marker in either NHL patient cohort, despite previously being 
shown to predict outcome in non-small cell lung cancer and colorectal cancer (Miyoshi 
et al., 2010; Park et al., 2010). Aberrant expression of CTSD and TGM2 in DLBCL did 
not reflect their altered expression in malignant B cells but rather cells of the tumour 
microenvironment. We therefore propose that determination of autophagy-related gene 
expression using un-purified samples may be distorted by TAMs and other tumour-
infiltrating cells.  
The role of BCL-2 in autophagy in NHL is currently unclear. Here, we have shown that 
BCL-2
HIGH
 lymphoma cells, FL samples and cells of the FL microenvironment express 
autophagy-related genes at a higher basal level and have increased autophagy activity 
compared to RA controls, despite overexpression of BCL-2. The mechanism by which 
FL cells up-regulate autophagy at the gene level is currently unknown and may be due 
to multiple factors. One possibility is that inhibition of apoptosis by BCL-2 up-regulates 
autophagy to promote elimination of old, damaged organelles and proteins. It is also 
unclear if the autophagy status and autophagy activity of FL and DLBCL patients is 
associated with clinical outcome.  
5.3.1 Conclusions  
BCL-2 does not inhibit the autophagy flux at the basal level or in response to autophagy 
stress in BCL-2
HIGH
 lymphoma cell lines or primary FL samples. Increased expression 
of autophagy-related genes and autophagy activity in BCL-2
HIGH
 lymphoma cells may 
be a consequence of BCL-2-mediated inhibition of apoptotic cell death.  
 
 
  Chapter VI Results 
175 
 
 
 
 
 
Chapter VI  
 
 
 
 
 
 
Evaluation of the prognostic significance of autophagy-
related proteins in non-Hodgkin’s lymphomas  
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6.1 Introduction 
The clinical course of FL and DLBCL is highly variable (Shankland et al., 2012). FL 
and DLBCL patients are risk-stratified based on their FLIPI and IPI scores respectively. 
These are prognostic indexes based on clinical risk factors including age, Ann Arbor 
stages, numbers of extranodal sites, and serum LDH levels. Patients are classified as 
high risk if they present with more than three adverse clinical factors, for example Ann 
Arbor stage >III/IV, age >60 years and LDH levels >480U/L. However, these risk 
factor based indexes provide no information or understanding about the underlying 
biology of these indolent and aggressive malignancies (Johnson et al., 2012; Shankland 
et al., 2012). DLBCL can also be stratified by GEP into GCB- and ABC-subtypes, 
which have markedly different clinical outcomes (Alizadeh et al., 2000). While 
GCB/ABC stratification provides information on the biology of this aggressive 
malignancy, and can help explain the clinical heterogeneity observed among DLBCL 
patients, routine segregation of patients using GEP is currently not feasible in the 
clinical setting. However, advances in technology which allow for rapid turnover and 
declining costs mean that routine GEP analysis of patient tumour samples may soon 
become a reality (Alizadeh et al., 2000). Therefore, it is desirable to identify biomarkers 
which can stratify patients based on clinical outcome, are feasible for clinical use, and 
provide an understanding of disease biology.  
Autophagy, whose activity varies among cancer types, can be tumour promoting or 
tumour suppressing (Choi et al., 2013a). The roles of this degradation pathway in NHL 
are currently unclear. Expression levels of the key autophagy-related proteins Beclin-1, 
LC3 and p62 have previously been shown to predict clinical outcome in a variety of 
malignancies. For example, accumulation of p62 due to defective autophagy has been 
shown to promote tumourigenesis and is associated with a worse prognosis in patients 
with oral cancer and adenocarcinoma (Inoue et al., 2012; Inui et al., 2013). Decreased 
expression of Beclin-1 has been identified as a poor prognostic marker in squamous cell 
carcinoma and extranodal natural killer T-cell lymphoma (Chen et al., 2009; Huang et 
al., 2010), while its increased expression was associated with a good clinical outcome in 
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a small cohort of FL and DLBCL patients (Huang et al., 2011; Nicotra et al., 2010b). It 
is unclear if Beclin-1 levels directly reflect autophagy activity.  
The anti-apoptotic protein BCL-2, a co-regulator of apoptosis and autophagy, is 
overexpressed in ~85% of FL and ~20% of DLBCL patients (Kridel et al., 2012; 
Marquez and Xu, 2012; Obermann et al., 2009). The role of BCL-2 in autophagy 
regulation in FL and DLBCL is currently unknown. Similarly, whether expression 
levels of the key autophagy proteins p62, LC3 and Beclin-1 are altered in NHL, and 
whether their levels can predict clinical outcome in NHL, has not been reported. We 
therefore aimed to assess the basal level autophagy status of primary FL and DLBCL 
tissue biopsies at the protein level by evaluating expression levels of p62, LC3, Beclin-1 
and BCL-2 using IHC and TMA technology. We also evaluated if expression levels of 
these proteins can be used as prognostic biomarkers to risk-stratify FL and/or DLBCL 
patients at diagnosis.  
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6.2 Results 
6.2.1 p62, LC3 and Beclin-1 proteins are expressed at lower levels in 
primary FL tissue biopsies 
Using IHC, we first determined expression levels of the key autophagy-related proteins 
p62, LC3 and Beclin-1 in primary FL, DLBCL and RA tissue biopsies present on 
TMAs to evaluate the autophagy status of FL and DLBCL compared to RA controls. 
TMAs used in this study were constructed using un-treated diagnostic tissue biopsy 
material from FL and DLBCL patients and non-malignant individuals.  
Sequential FL, DLBCL and RA TMA sections were stained for the proteins of interest 
and expression levels, defined as the percent-stained viable tissue area, quantified using 
ARIOL (Lieca Microsystems) automated digital analysis software. An advantage of 
using this automated software is that user error, bias, variability and fatigue are avoided, 
ensuring consistent, uniform analysis of all samples. A user-defined classifier was 
created for each protein which selected only high intensity brown staining as positive 
protein expression; non-specific background staining was excluded (Figure 6.1 A; red 
arrows). A second classifier was created to determine the total viable tissue area per 
core. Protein expression levels, classified as the percent-stained viable tissue area, were 
then calculated by combining these classifiers. FL and RA samples were also stained 
with CD10 antibody, a marker of germinal centre (GC) B cells, to distinguish GC/intra-
follicular areas (CD10
+
) from non-GC/inter-follicular areas (CD10
-
) (Figure 6.1 B). 
Diffuse cytoplasmic LC3-I was not distinguishable from membrane-bound LC3-II 
puncta using IHC; therefore, 'LC3' refers to total cellular levels of LC3.  
Due to technical difficulties and tissue loss, not all patients present on the original 
TMAs were included in the final analysis. To ensure those patients used for further 
analysis were representative of the total patient population, clinical characteristics were 
compared between 'included' and 'excluded' patients. Using a chi-squared (χ2) test, no 
significant difference was observed between staging and FLIPI scores of FL patients. A 
difference was observed between these groups with respect to clinical grade; however as 
this variable is incorporated into the FLIPI score which did not differ between groups, 
this subset of patients can still be considered representative of the total population. 
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DLBCL patient groups differed with respect to staging but not IPI scores, which include 
this variable. No significant difference was observed between DLBCL groups with 
respect to B symptoms or ECOG performance.  
Comparison of protein expression levels between FL follicles, DLBCL whole cores and 
RA whole cores revealed that expression levels of p62, LC3 and Beclin-1 were 
significantly lower in FL follicles (Figure 6.2 A, C and E), while only Beclin-1 
expression was significantly decreased in DLBCL samples (Figure 6.2 E). LC3 and 
Beclin-1 expression levels were heterogeneous among FL and DLBCL samples, 
whereas p62 was expressed at a homogeneously low level in FL (Figure 6.2 A, C and 
E). Significantly decreased expression of p62, LC3 and Beclin-1 was also observed in 
FL inter-follicular regions compared to CD10
-
 areas in RA controls (Figure 6.2 B, D 
and F). 
In this study, positive protein expression was defined as the highest, most intense brown 
cytoplasmic staining, indicative of protein accumulation and lower autophagy activity. 
Therefore, decreased expression of the autophagy substrates p62 and LC3 in FL 
follicles suggests an increased autophagy activity in FL compared to DLBCL and RA 
controls. Decreased expression of these autophagy-related proteins in inter-follicular 
regions of FL samples suggests autophagy activity is also increased in the 
microenvironment. We have previously shown that Beclin-1 expression levels were not 
altered in response to autophagy stress (Figure 5.3), indicating that it may not be an 
autophagy substrate. Therefore, differential expression of Beclin-1 in FL and DLBCL is 
unlikely to reflect altered autophagy activity in these NHLs.  
These data indicate that basal level autophagy is higher in FL compared to DLBCL and 
RA controls, based on decreased expression/increased degradation of the autophagy 
substrates p62 and LC3. Our findings also suggest autophagy activity is increased in 
tumour-infiltrating cells of the microenvironment as well as tumour cells. 
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Figure 6.1 Representative images of immunohistochemical staining of p62, LC3, Beclin-1 
and CD10 in primary RA, FL and DLBCL tissue  
Representative images of p62, LC3 and Beclin-1 IHC staining in primary RA, diagnostic FL and 
diagnostic DLBCL tissue biopsies (A). RA, FL and DLBCL TMAs previously constructed by AC and 
AO were stained with polyclonal p62, polyclonal LC3B and mouse anti-Beclin-1 under optimised 
conditions; nuclei were counterstained with haematoxylin. Proteins were visualised using a peroxidase-
labelled system which uses 3,3'-diaminobenzidine (DAB) as the chromogen (Super-Sensitive Polymer-
HRP IHC Detection System, BioGenex). Positive brown staining was taken to be high-intensity, strong 
staining indicated by red arrows; weak, non-specific background staining was excluded. Representative 
images of CD10 staining in RA and FL tissue samples (B). CD10 was visualised using the DAB 
chromogen. GC/intra-follicular regions were selected based on CD10
+ 
staining and clear GC morphology;  
non-GC/inter-follicular regions were CD10
-
.  
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Figure 6.2 Comparison of p62, LC3 and Beclin-1 protein expression in primary RA, FL 
and DLBCL tissue samples  
Expression levels of p62, LC3 and Beclin-1 previously stained by IHC (Figure 6.1) were analysed and 
quantified using the digital analysis software ARIOL, which was trained with the help of AC to recognise 
areas of brown positive staining as stipulated in figure 6.1 (classifier 1) and viable tumour areas (classifier 
2) based on protein hue, saturation and intensity levels. Protein expression levels were calculated as the 
percent-stained viable tissue area by combining these classifiers and an average expression value obtained 
for each patient. Significant differences in protein expression levels, i.e. percent-stained viable tissue area, 
were compared between whole RA and DLBCL cores and FL CD10
+
 follicles (A, C and E) and between 
inter- and intra-follicular regions in RA and FL samples (B, D and F) using a Mann Whitney U test. Data 
are presented as the median ± SD. Sample numbers are reported below each group; sample numbers for 
RA and FL in B, D and F were the same as in A, C and E. **p <0.01; *** p <0.001.   
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We also evaluated expression levels of the anti-apoptotic protein BCL-2 in FL, DLBCL 
and RA tissue biopsies (Figure 6.3). Using the ARIOL analysis system we calculated 
the percent BCL-2-positive cells in FL follicles, and RA and DLBCL whole cores. 
BCL-2 was strongly expressed in the inter-follicular regions of RA samples, 
ubiquitously expressed among DLBCL samples and strongly expressed in FL follicles 
(Figure 6.3 A). Samples were classified as overexpressing BCL-2 if >30% of cells were 
BCL-2 positive. As expected, the majority of FL samples (~90%) had significantly 
increased expression of BCL-2 in their follicles compared to DLBCL and RA controls, 
while expression was heterogeneous among DLBCL samples (Figure 6.3 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Evaluation of BCL-2 expression in primary RA, FL and DLBCL tissue biopsies 
Representative images of BCL-2 IHC staining in primary RA, FL and DLBCL tissue cores (A). TMAs 
were stained for BCL-2 and nuclei counterstained with haematoxylin. BCL-2 expression visualised using 
the DAB chromogen and analysed using the ARIOL analysis system. Positive cells were taken to be cells 
with high-intensity, strong brown staining; weak, non-specific background staining was excluded. 
Samples in which >30% of cells expressed BCL-2 were taken to be BCL-2 positive. Significant 
differences in the percent BCL-2-positive cells were compared between whole RA and DLBCL cores and 
FL CD10
+
 follicles using a Mann Whitney U test (B). Data are presented as the median ± SD; sample 
numbers are reported below each group. * p < 0.05; ** p <0.01; *** p <0.001.  
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6.2.2 Expression levels of p62, LC3 and Beclin-1 were correlated in FL and 
DLBCL  
In order to understand whether these autophagy-related proteins are associated with 
each other, we next assessed correlation between p62, LC3, Beclin-1 and BCL-2 
expression levels in FL and DLBCL 
Using the Pearson product-moment correlation method, we found that expression levels 
of p62 and LC3 were significantly positively correlated in FL (p< 0.0001; γ= 0.536), 
DLBCL (p< 0.0001; γ= 0.589) and RA (p< 0.0001; γ= 0.659) samples (Table 6.1). 
During active autophagy, p62 binds membrane-bound LC3 to facilitate delivery of 
autophagy substrates, including themselves, to the autophagosome for degradation. 
Observation of a positive correlation between these proteins suggests that cellular levels 
of p62 and LC3, individually or in combination, can be used as a marker of autophagy 
activity. However, in all sample types the correlation coefficient (γ) was low, indicating 
that the correlation was weak (Table 6.1). p62 also correlated with Beclin-1 in all three 
sample groups, while Beclin-1 levels were correlated with LC3 expression in DLBCL 
and FL samples but not RA controls (Table 6.1 B and C). There was a weak negative 
correlation between BCL-2 and p62 protein expression in FL samples (p< 0.05; γ =-
0.342), which suggests that higher BCL-2 is correlated with lower p62, implying this 
anti-apoptotic protein does not inhibit autophagy in FL (Table 6.1 B).  A significant 
positive correlation was observed between BCL-2 and p62, LC3 and Beclin-1 in 
DLBCL samples (p< 0.01; γ< 0.5) (Table 6.1 C).  
These results demonstrate that expression levels of p62 and LC3 proteins can be used as 
markers of autophagy activity in primary FL and DLBCL samples. Increased expression 
of BCL-2 may not inhibit autophagy in FL.  
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Table 6.1 Evaluation of correlation between autophagy-related proteins in primary RA 
(A), FL (B) and DLBCL (C) tissue samples  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein  Beclin-1  LC3  p62  Correlation 
parameters  
BCL-2  0.079  0.140  0.166    
>0.05  >0.05  >0.05  P value  
 Beclin-1  0.005  0.453    
>0.05  <0.05  P value  
 LC3  0.659    
<0.0001  P value  
Protein  Beclin-1  LC3  p62  Correlation 
parameters  
BCL-2  0.207  -0.087  -0.342    
>0.05  >0.05  <0.05  P value  
 Beclin-1  0.417 0.390   
<0.01  <0.01  P value  
 LC3  0.536   
<0.0001  P value  
Protein  Beclin-1  LC3  p62  Correlation 
parameters  
BCL-2  0.359  0.281 0.275   
<0.01  <0.01  <0.01  P value  
 Beclin-1  0.573  0.359    
<0.0001  <0.0001  P value  
 LC3  0.589    
<0.0001  P value  
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6.2.3 Decreased expression of p62 is associated with a worse prognosis in 
DLBCL   
Having shown p62, LC3, Beclin-1 and BCL-2 proteins are differentially expressed in 
FL compared to DLBCL and RA samples, we next assessed if expression levels of these 
autophagy-related proteins, individually or in combination with BCL-2, can be used to 
predict outcome in FL and/or DLBCL patients at diagnosis.  
Continuous and categorical univariate survival analysis was carried out in 117 FL and 
109 DLBCL patients for whom FLIPI and IPI scores were available. Full patient 
information is given in the appendix (Appendix II, Table T and U). 
The Cox proportional hazards model was used to evaluate the association between a 
continuous variable and a defined event, e.g. death, and estimate the Hazard ratio (HR) 
and its corresponding 95% confidence intervals (CI) for each variable. For a continuous 
variable, the HR represents the incremental increase of the event happening per unit 
increase in the variable. In order for a continuous variable to be classified as a 
prognostic marker the p value must be <0.05 and the HR must be greater than or less 
than, but not equal to 1. 
Categorical univariate analysis divides patients into groups based on protein expression 
levels. First, X-tile software is used to identify the optimal cut-point at which patients 
separate into two groups with differential outcome. X-tile does this by dividing patients 
into training and validation sets in a ratio of 1:2, identifying the point at which patients 
in the training set separate into two groups and applying this cut-point to the validation 
set. Patients are then stratified into two groups, typically low and high, based on this 
cut-point and Kaplan-Meier curves generated to visualise differences in survival 
between groups. Significant differences in outcome due to differential protein 
expression are then evaluated using the log-rank (Mantel-Cox) test. HR and 95% CI are 
also generated in categorical survival analysis. Here, the HR represents the 
instantaneous risk of an event occurring in one group but not the other by the next time 
point; for example a HR of 2 would indicate that the event, e.g. death, is twice as likely 
to occur in one group over the other. The clinical outcomes evaluated in this study were 
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OS, DSS, TT and PFS which were measured from the date of diagnosis to the date of 
event occurrence or date of last follow-up.  
Using univariate continuous and categorical analysis, we confirmed FLIPI and IPI to be 
prognostic markers of OS and DSS in FL and DLBCL, respectively. As expected, both 
FL (Appendix II, Table V) and DLBCL (Appendix II, Table W) patients with a FLIPI 
or IPI score >3 (i.e. FLIPI/IPI
HIGH
) had significantly shorter OS and DSS rates 
compared to patients with low FLIPI/IPI scores (Appendix II, Figure 4). TT was also 
significantly lower in FLIPI
LOW
 patients.  
We assessed expression levels of p62, LC3, Beclin-1 and BCL-2 for their ability to 
predict outcome in FL and DLBCL. In a continuous, univariate analysis we found that 
p62 expression levels were prognostically significant in DLBCL for OS (p= 0.015) and 
DSS (p= 0.037) (Table 6.2) and that the HR was lower than 1, with a negative 
regression coefficient, indicating that lower expression of p62 is associated with a worse 
clinical outcome. This result indicates that p62 is an independent prognostic biomarker 
for DLBCL. LC3, Beclin-1 and BCL-2 expression levels were not associated with 
outcome in DLBCL (Table 6.2). None of these autophagy-related proteins were 
identified as prognostic biomarkers for OS, DSS or TT in FL using continuous data 
analysis (Table 6.3). 
Table 6.2 Univariate Cox-regression analysis of autophagy-related proteins as continuous 
variables in DLBCL  
 
Variable Overall survival Disease-specific survival Progression-free survival 
HR (95% CI) P HR (95% CI) P HR (95% CI) P 
p62 0.98 (0.97-1.00) 0.015 0.98 (0.97-1.00) 0.037 0.99 (0.97-1.00) 0.090 
LC3 0.99 (0.98-1.00) 0.256 1.00 (0.98-1.01) 0.610 0.99 (0.98-1.00) 0.125 
Beclin-1 0.99 (1.00-1.01) 0.245 0.99 (0.97-1.01) 0.210 0.99 (0.97-1.01) 0.398 
BCL-2 1.00 (1.00-1.01) 0.282 1.00 (0.99-1.01) 0.385 1.00 (0.99-1.00) 0.082 
HR= Hazard ratio; CI= Confidence interval 
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Table 6.3 Univariate Cox-regression analysis of autophagy-related proteins as continuous 
variables in FL 
 
Variable Overall survival Disease-specific survival Time to Transformation 
HR (95% CI) P HR (95% CI) P HR (95% CI) P 
p62 1.02 (0.98-1.06) 0.432 1.02 (0.97-1.07) 0.360 1.03 (0.97-1.09) 0.358 
LC3 1.00 (0.99-1.01) 0.665 1.00 (0.99-1.01) 0.901 1.00 (0.99-1.02) 0.771 
Beclin-1 0.99 (0.98-1.01) 0.474 0.99 (0.97-1.01) 0.214 1.00 (0.99-1.02) 0.795 
BCL-2 1.00 (0.99-1.01) 0.893 1.00 (0.99-1.02) 0.548 0.99 (0.98-1.00) 0.146 
HR= Hazard ratio; CI= Confidence interval 
 
We next evaluated the prognostic significance of these autophagy-related proteins using 
a univariate categorical analysis. FL and DLBCL patients were divided into two groups 
with low and high expression of autophagy-related proteins (e.g. p62
LOW
 and p62
HIGH
) 
for each outcome evaluated using X-tile generated cut-points (Appendix II, Table X). 
Separation of groups was visualised using Kaplan-Meier curves and significant 
differences in outcome arising from differential protein expression analysed using a log-
rank (Mantel Cox) test. 
Lower expression of p62 (p62
LOW
) in DLBCL patients was significantly associated with 
shorter OS, DSS and PFS rates compared with p62
HIGH 
patients (Figure 6.4 A-C). 5 year 
survival rates were worse for patients expressing lower levels of p62 (Appendix II, 
Table Y). This finding indicates that increased autophagy activity is associated with a 
poor prognosis in DLBCL and confirms that p62 is a prognostic biomarker of clinical 
outcome in this aggressive lymphoma.  
Although decreased expression of p62 was associated with a shorter TT (p= 0.07) 
among FL patients, its levels did not reach prognostic significance. Similarly, OS and 
DSS rates did not differ between p62
HIGH
 and p62
LOW
 patients (Figure 6.5 A-C) 
(Appendix II, Table Z). This suggests that despite FL expressing p62 at significantly 
lower levels compared to DLBCL samples and RA controls, levels of this autophagy 
substrate do not impact or predict clinical outcome in this indolent lymphoma.  
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Figure 6.4 Decreased expression of key autophagy-related proteins in DLBCL predicts a 
worse clinical outcome   
Evaluation of OS, DSS and PFS in DLBCL patients based on low and high expression of the key 
autophagy related proteins p62 (A-C), Beclin-1 (D-F), LC3 (G-I) and BCL-2 (J-L). Patients were 
stratified into low and high protein groups using optimal cut-points generated by the statistical software 
X-tile. X-tile generated cut-points are listed in appendix II, Table X. Generation of Kaplan-Meier curves 
and evaluation of differences in survival between groups using a log-rank (Mantel-Cox) test was 
performed using GraphPad Prism software. OS= overall survival; DSS= disease specific survival; PFS= 
progression free survival; n= number. 
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Figure 6.5 Decreased expression of Beclin-1 predicts shorter overall and disease specific 
survival in FL  
Evaluation of OS, DSS and TTT in FL patients based on low and high expression of the key autophagy 
related proteins p62 (A-C), Beclin-1 (D-F), LC3 (G-I) and BCL-2 (J-L). Patients were stratified into low 
and high protein expressing groups as previously described. X-tile generated cut-points are listed in 
appendix II, Table X. Kaplan-Meier curves were generated and differences in survival compared as 
previously described. OS= overall survival; DSS= disease specific survival; TT= Time to transformation; 
n= number. 
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Multivariate proportional hazards model analysis was performed to further confirm p62 
is an independent prognostic biomarker of clinical outcome in DLBCL. This 
multivariate analysis evaluates the prognostic significance of p62 following adjustment 
for IPI scores and LC3, BCL-2 and Beclin-1 expression levels. The prognostic value of 
p62 in FL was not evaluated by multivariate analysis as it was not identified as a 
significant biomarker using univariate analysis.  
Following adjustment by IPI scores, p62 retained its prognostic significance for OS and 
DSS, further confirming that p62 can be used as an independent biomarker of clinical 
outcome in DLBCL (Table 6.4). For both parameters evaluated, the HR returned for 
p62 was >1 (OS: HR= 2.06; DSS: HR= 1.97). As comparisons were made between 
p62
LOW
 and p62
HIGH
 patients following adjustment for IPI scores, these HR values 
confirm that patients expressing low levels of p62 have a worse prognosis compared to 
patients expressing this protein at high levels.  Adjustment of p62 by LC3, Beclin-1 or 
BCL-2 expression levels confirmed this autophagy-substrate is a prognostic biomarker 
in DLBCL independent of LC3, Beclin-1 or BCL-2 expression.  
These results demonstrate for the first time that p62 is a novel independent biomarker 
for clinical outcome in patients with DLBCL, and that decreased expression of this 
autophagy substrate predicts a worse outcome. It will be important to validate these 
findings in an independent patient cohort, and it would also be desirable to evaluate if 
p62 retains its prognostic significance following adjustment for GCB/ABC-subtype 
classification.  
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Table 6.4 Categorical multivariate proportional hazard model analysis for IPI, p62, LC3, 
Beclin-1 and BCL-2 in DLBCL and for Beclin-1 in FL 
 
 
 
 
 
 
 
 
 
 
‘a’: comparison was low (IPI 0-2) vs. high (IPI 3-4); ‘b’: comparison was low expression vs. high 
expression for each protein; ‘c’: comparison was low (FLIPI 1-2) vs. high (FLIPI 3-4). DLBCL: n=109. 
FL: n=86. Data shown were either as single risk factor or in combination with other factor(s) in the same 
panel. OS= overall survival; DSS= disease specific survival; PFS= progression free survival; n= number 
 
Disease Covariates OS DSS 
HR (95% CI) P HR (95% CI) P 
DLBCL IPI
a
 0.47 (0.25-0.89) 0.02 0.40 (0.19-0.84) 0.02 
p62
 b
 2.41 (1.35-4.28) 0.003 2.40 (1.19-4.85) 0.014 
BCL-2
 b
 0.59 (0.33-1.02) 0.060 0.63 (0.33-1.19) 0.151 
Beclin-1
 b
 2.29 (1.17-4.47) 0.015 1.73 (0.85-3.51) 0.130 
LC3
 b
 1.66 (0.84-3.25) 0.143 1.36 (0.72-2.56) 0.346 
IPI
a
  
p62
b
 
0.53 (0.30-0.92) 
2.06 (1.22-3.47) 
0.02 
0.007 
0.47 (0.25-0.89) 
1.97 (1.05-3.70) 
0.02 
0.04 
IPI
a
 
BCL-2
b
 
0.56 (0.32-0.98) 
0.70 (0.41-1.18) 
0.04 
0.18 
0.50 (0.26-0.94) 
0.76 (0.41-1.42) 
0.03 
0.40 
IPI
a
 
Beclin-1
b
 
0.57 (0.33-1.00) 
1.67 (0.94-2.97)  
0.05 
0.08 
0.51 (0.27-0.97) 
1.64 (0.83-3.24) 
0.04 
0.16 
IPI
a
 
LC3
 b
 
0.52 (0.30-0.91) 
1.61 (0.87-2.96) 
0.02 
0.13 
0.47 (0.25-0.89) 
1.41 (0.64-3.05) 
0.02 
0.40 
p62
 b
 
BCL-2
 b
 
Beclin-1
 b
 
LC3
 b
 
2.15 (1.67-3.95) 
0.49 (0.28-0.87) 
1.74 (0.98-3.10) 
1.22 (0.61-2.42) 
0.01 
0.01 
0.06 
0.58 
2.67 (1.25-5.72) 
0.53 (0.28-1.01) 
1.69 (0.87-3.29) 
0.80 (0.37-1.69) 
0.01 
0.05 
0.12 
0.55 
FL FLIPI
C
 0.44 (0.25-0.76) 0.003 0.46 (0.23-0.92) 0.03 
Beclin-1
 b
 3.39 (1.47-7.83) 0.004 3.94 (1.47-10.6) 0.006 
FLIPI
c
 
Beclin-1
b
 
0.43 (0.25-0.76) 
2.47 (1.31-4.67) 
0.003 
0.005 
0.46 (0.23-0.93) 
2.63 (1.21-5.73) 
0.03 
0.02 
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6.2.4 Beclin-1 is an independent biomarker of clinical outcome in FL 
We next evaluated the prognostic significance of Beclin-1 in FL and DLBCL using 
categorical analysis. Patients were classified as Beclin-1
LOW
 or Beclin-1
HIGH
 as 
previously described (Appendix II, 4.0 Table X) and differences in survival analysed 
using a log-rank (Mantel Cox) test. 
In agreement with its role as a tumour suppressing protein, decreased expression of 
Beclin-1 was significantly associated with shorter OS and PFS in our DLBCL patient 
cohort (Figure 6.4 D-F). Unsurprisingly, 5 year OS and PFS rates were significantly 
lower in Beclin-1
LOW
 DLBCL patients (Appendix II, Table Y). After adjusting for IPI 
scores, Beclin-1 lost its prognostic significance in DLBCL (Table 6.4). This 
demonstrates that while its expression levels are associated with clinical outcome, 
Beclin-1 is not an independent prognostic marker of outcome in DLBCL. Lower levels 
of Beclin-1 were significantly associated with shorter OS and DSS in FL (Figure 6.5 D-
F) (Appendix II, Table Z). Using multivariate analysis, Beclin-1 retained its prognostic 
significance, indicating that it is an independent prognostic biomarker of clinical 
outcome in FL patients, irrespective of patients FLIPI scores (Table 6.4). 
These findings indicate that although Beclin-1 expression may not reflect autophagy 
activity within a sample, levels of this autophagy-essential tumour suppression protein, 
which were decreased in both FL and DLBCL, can be as an independent biomarker for 
predicting clinical outcome in patients with FL but not DLBCL.  
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6.2.5 LC3 or BCL-2 alone do not predict clinical outcome in patients with 
FL or DLBCL 
Although a trend was observed between decreased expression of LC3 and shorter OS, 
DSS and PFS, its levels were not found to be prognostically significant in DLBCL, as 
analysed by univariate and multivariate analysis (Figure 6.4 G-I, Table 6.4). Similarly, 
although it was expressed at significantly lower levels in FL patients compared to RA-
LN controls, LC3 expression did not impact or predict clinical outcome in FL (Figure 
6.5 G-I). This suggests that levels of this autophagy-substrate may not be of prognostic 
value in NHL. 
Previous studies have reported BCL-2 as being a prognostic marker in DLBCL, with 
BCL-2
LOW
 patients having a more favourable outcome compared to BCL-2
HIGH
 patients 
(Gascoyne et al., 1997). We found that in our DLBCL cohort, while there was a trend 
towards a poor prognosis among BCL-2
HIGH
 patients, expression levels of this anti-
apoptotic protein alone did not predict outcome in DLBCL (Figure 6.4 J-L); however in 
the multivariate analysis, BCL-2 gained statistical significance when it was adjusted by 
p62, LC3 and Beclin-1 expression levels (Table 6.4). This indicates that the prognostic 
value of BCL-2 in DLBCL is dependent on other autophagy-related biomarkers. No 
difference in survival rates was observed between BCL-2
HIGH
 and BCL-2
LOW
 FL 
patients, indicating BCL-2 expression levels do not impact on survival in this indolent 
NHL (Figure 6.5 J-L). This finding is in agreement with previous reports (Llanos et al., 
2001).   
These results demonstrate that neither LC3 nor BCL-2 alone predict clinical outcome in 
DLBCL or FL, and that BCL-2 is a dependent marker of survival in this aggressive 
NHL.  
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6.2.6 Lower levels of autophagy-related proteins combined with high BCL-2 
expression predicts a worse outcome in DLBCL  
The results above show that the prognostic value of BCL-2 in DLBCL is dependent on 
other biomarkers. We therefore evaluated the impact of BCL-2 expression levels on 
autophagy status and clinical outcome based on combined expression levels of the 
autophagy related proteins p62, LC3 and Beclin-1 with BCL-2.  
Using cut-points previously generated in X-tile (Appendix II, Table X), patients were 
divided into four groups based on expression levels of BCL-2 and p62: BCL-
2
LOW
/p62
LOW
; BCL-2
LOW
/p62
HIGH
; BCL-2
HIGH
/p62
LOW
; BCL-2
HIGH
/p62
HIGH
. Patients 
were categorised in the same way based on BCL-2/LC3 expression and BCL-2/Beclin-1 
expression. We then compared OS and DSS between these four groups using the 
Kaplan-Meier method and a multivariate Cox-regression analysis. This analysis was 
carried out in DLBCL patents only, as ~90% of FL patients overexpressed BCL-2 
(Figure 6.3), meaning too few BCL-2
LOW
 cases were available with which meaningful 
comparisons could be made. 
We found that patients with high levels of autophagy-related proteins and low levels of 
BCL-2 had a favourable clinical outcome compared to patients with high BCL-2 and 
low levels of p62, LC3 or Beclin-1 (Figure 6.6). BCL-2
HIGH
/p62
LOW
 patients showed the 
shortest OS and DSS compared to all other groups, particularly BCL-2
LOW
/p62
HIGH
 
patients (Figure 6.6 A and B). A multivariate Cox-regression analysis confirmed a 
significant difference in survival rates between BCL-2
HIGH
/p62
LOW
 and BCL-
2
LOW
/p62
HIGH 
patients (Table 6.5 A). Combining BCL-2 and Beclin-1 expression levels, 
BCL-2
HIGH
/Beclin-1
LOW
 and BCL-2
LOW
/Beclin-1
LOW
 patients were shown to have 
significantly shorter OS compared with BCL-2
LOW
/Beclin-1
HIGH
 patients (Figure 6.6 C). 
BCL-2
HIGH
/Beclin-1
LOW
 patients also had significantly shorter DSS (Figure 6.6 D; Table 
6.5 B). Similarly, patients categorised as BCL-2
HIGH
/LC3
LOW
 were found to have 
significantly shorter OS and DSS compared to BCL-2
LOW
/LC3
HIGH
 patients (Figure 6.6 
E and F; Table 6.5 C). 
These data indicate that inhibition of apoptosis due to increased BCL-2 expression, 
combined with decreased expression of the autophagy-substrates p62 and LC3, an 
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indicator of increased autophagy activity, predicts a worse outcome in DLBCL. As the 
number of patients analysed in some groups was limited, it will be important to validate 
these findings in a larger, independent cohort of patients.  
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Figure 6.6 Decreased expression of p62 combined with BCL-2 overexpression predicts a 
worse outcome in DLBCL  
Evaluation of OS and DSS in DLBCL patients based on low and high expression of the key autophagy 
related proteins p62 (A and B), Beclin-1 (C and D) and LC3 (E and F) in combination with BCL-2. 
Patients were stratified into four groups, using optimal cut-points previously generated using X-tile 
software (Appendix II, Table X), based on low or high expression of autophagy-related proteins and low 
or high BCL-2 expression. Kaplan-Meier curves were generated using GraphPad Prism software and 
differences in survival outcomes evaluated using a Cox-regression analysis and SPSS software. OS= 
overall survival; DSS= disease specific survival; n= number. 
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Table 6.5 Categorical multivariate analysis of expression levels of autophagy-related 
proteins in combination with BCL-2 expression levels in primary DLBCL samples 
 
BCL-2
LOW
 /p62
HIGH 
= Reference against which all other groups were compared  
  
 
 
 
Variable  Overall survival Disease-specific survival 
HR (95% CI) P HR (95% CI) P 
BCL-2
LOW
/ Beclin-1
HIGH
   0.045  0.19 
BCL-2
HIGH
/ Beclin-1
HIGH
  1.75 (0.93-3.27) 0.08 0.37 (0.15-0.92) 0.51 
BCL-2
LOW
/ Beclin-1
LOW
  2.17 (1.05-4.52) 0.04 0.49 (0.2-1.18) 0.59 
BCL-2
HIGH
/ Beclin-1
LOW
  2.89 (1.21-6.93) 0.02 0.48 (0.18-1.34) 0.03 
BCL-2
LOW
 /Beclin-1
HIGH
 = Reference against which all other groups were compared  
 
 
 
 
Variable  Overall survival Disease-specific survival 
HR (95% CI) P HR (95% CI) P 
BCL-2
LOW
/LC3
HIGH
   0.22  0.15 
BCL-2
LOW
/LC3
LOW
  1.36 (0.64-2.89) 0.42 1.02 (0.42-2.52) 0.97 
BCL-2
HIGH
/LC3
HIGH
  1.5 (0.82-2.74) 0.19 1.17 (0.48-2.88) 0.65 
BCL-2
HIGH
/LC3
LOW
  4.69 (1.75-12.58) 0.002 2.04 (0.84-4.93) 0.04 
BCL-2
LOW
 /LC3
HIGH
 = Reference against which all other groups were compared  
 
 
These results indicate that decreased levels of the autophagy substrates p62 and LC3, 
which indicates active autophagy, coupled with inhibition of apoptosis due to BCL-2 
overexpression, predicts a worse outcome in DLBCL. These data also suggest that 
increased expression of BCL-2 does not affect autophagy activity or the autophagy 
status of DLBCL samples.  
Variable  Overall survival Disease-specific survival 
HR (95% CI) P HR (95% CI) P 
BCL-2
LOW
/p62
HIGH
   <0.0001  0.001 
BCL-2
HIGH
/p62
HIGH
  1.27 (0.63-2.59) 0.65 1.02 (0.44-2.35) 0.97 
BCL-2
LOW
/p62
LOW
  1.61 (0.79-3.23) 0.30 1.23 (0.49-3.05) 0.66 
BCL-2
HIGH
/p62
LOW 
 4.95 (2.32-10.61) <0.0001 4.69 (1.96-11.29) <0.0001 
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6.3 Discussion 
In this chapter, we have shown that autophagy activity is increased in FL compared to 
RA controls and DLBCL samples as demonstrated by decreased expression/increased 
degradation of the autophagy substrates p62 and LC3. We also found that despite being 
significantly differentially expressed in FL, these autophagy-related proteins were not 
associated with the outcome of this indolent lymphoma. Most importantly, we identified 
p62 is as a novel independent prognostic biomarker in DLBCL. We therefore propose 
that overexpression of BCL-2 does not inhibit autophagy activity in both FL and 
DLBCL.  
Using continuous and categorical univariate analysis and multivariate analysis, we 
identified that p62 is an independent biomarker of clinical outcome in patients with 
DLBCL. We found that patients with decreased expression of this autophagy-substrate 
had significantly shorter survival rates compared to patients expressing this protein at 
high levels. This suggests that increased autophagy activity, as demonstrated by 
increased p62 degradation, predicts a worse outcome in DLBCL. While this finding is at 
odds with some previous reports (Luo et al., 2013), it is in agreement with the 
observation of  Ellis et al who identified decreased expression of p62 as being a poor 
prognostic marker in melanoma (Ellis et al., 2014).  
Decreased expression of p62 in combination with increased BCL-2 predicted the worst 
outcome in DLBCL, with BCL-2
HIGH
/p62
LOW
 patients having the shortest OS and DSS 
rates compared to all other groups. Simultaneous inhibition of apoptosis by BCL-2 and 
an increase in autophagy activity are associated with a poor clinical outcome in 
DLBCL. These results further indicate overexpression of BCL-2 does not negatively 
regulate autophagy activity in NHLs. In both patient cohorts, decreased expression of 
Beclin-1 predicted a worse outcome, a finding which is in line with previous reports 
(Nicotra et al., 2010b). In particular, Beclin-1 expression levels had greater prognostic 
significance in FL.  
A caveat of using p62 and LC3 expression levels as biomarkers of autophagy activity is 
that accumulation or increased expression of these autophagy substrates can indicate 
either enhanced autophagosome formation and thus active autophagy or, impaired 
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autophagic degradation of substrates and autophagosomes due to autophagy inhibition 
(Klionsky et al., 2008b). Decreased expression of these substrates would suggest their 
degradation by active autophagy pathway; however it may also indicate decreased 
delivery of substrates to the autophagosome and reduced autophagosome formation, 
meaning lower levels of autophagy. As p62, LC3 and other autophagy-substrates are 
degraded by lysosomal hydrolayses, dual staining of samples for p62 or LC3 and a 
lysosomal marker may clarify this confusion; that is, establish if the autophagy flux is 
increased or if autophagic degradation is inhibited. However, double staining using IHC 
is difficult and can often produce a large number of false positives or false negatives 
making accurate interpretation of results difficult. As with all IHC-based analysis, it 
will be important to validate these findings in an independent cohort of patients, ideally 
at another institution. It will also be important to confirm p62 as a prognostic marker 
independently of patients GCB/ABC-subtype classification. However, this may be 
difficult as GEP information is not available or easily obtainable for samples present on 
TMAs, especially the historic cases. While it is possible to stratify patients into these 
subtypes using IHC-based algorithms, there is poor concordance among these different 
algorithms as to what truly classifies a patient as GCB or ABC (Coutinho et al., 2013).  
We have shown that basal level autophagy activity is increased in primary FL samples 
despite increased expression of BCL-2 and increased autophagy activity is not directly 
associated with clinical outcome in this indolent lymphoma. We have also shown that 
Beclin-1 can be used as an independent biomarker in FL and that decreased expression 
of p62 independently predicts a poor outcome in DLBCL. DLBCL patients with 
decreased expression of p62 in combination with increased BCL-2 showed the lowest 
survival rates, indicating that inhibition of apoptosis and increased autophagy activity 
predicts a worse prognosis in DLBCL.  
6.3.1 Conclusions 
Here we show that FL has increased autophagy activity as detected at the protein level, 
which is in agreement with an increased autophagy-related GEP in the same disease. 
Overexpression of BCL-2 did not appear to have an inhibitory effect on autophagy in 
NHL. Increased expression of Beclin-1 predicts a favourable outcome in FL and 
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DLBCL. Decreased expression of p62 independently, and in conjunction with increased 
expression of BCL-2 predicts poor survival rates in DLBCL.  
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7.1 The main findings of this study  
In this study, we report for the first time that expression levels of p62 can be used as an 
independent biomarker of overall, disease specific and progression free survival in 
DLBCL but not FL. We have shown that basal level autophagy activity is higher in 
primary FL samples, as demonstrated by global up-regulation of the autophagy-related 
gene expression profile and decreased expression of the autophagy substrate p62 at the 
protein level. This suggests that overexpression of BCL-2 in FL does not inhibit basal 
level autophagy in this indolent lymphoma.  
Expression levels of autophagy-related genes were also up-regulated in BCL-2
HIGH
 
DLBCL cell lines compared to BCL-2
LOW
 cells at the basal level and in response to 
autophagy stress. Inhibition of BCL-2 by ABT-737 induced both apoptosis and 
cytoprotective autophagy in BCL-2
HIGH 
lymphoma cell lines.  
7.2 Autophagy plays paradoxical roles in cancer development  
As autophagy is regulated by a number of oncogenes and tumour suppressors, it is 
unsurprising that this degradation process is involved in cancer development. However, 
the role of autophagy in cancer is complex and paradoxical, and is dependent on tumour 
stage, type and genetic content (Kimmelman, 2011; White, 2012).  
Defective autophagy due to activation of autophagy inhibiting oncogenes provides 
indirect evidence for the tumour suppressing role of this pathway. PI3K activating 
mutations and Akt amplifications which activate mTOR and lead to autophagy 
inhibition are frequently observed in a variety of cancers (Diaz-Troya et al., 2008; 
Kimmelman, 2011). Similarly in some instances, BCL-2 has been shown to bind and 
sequester Beclin-1, leading to autophagy inhibition (Kimmelman, 2011; Pattingre et al., 
2005). The direct evidence for the tumour suppressing role of autophagy came from 
work by Liang et al, who reported that monoallelic deletion of Beclin-1 lead to 
autophagy inhibition and predisposed mice to a variety of tumours (Liang et al., 1999). 
Indeed, a large number of ovarian and breast cancers are heterozygous for the Beclin-1 
gene, which is classified as a haploinsufficient tumour suppressor (Marquez and Xu, 
2012; Yue et al., 2003). Ablation of Atg5 has also been shown to promote the 
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development of hepatocarcinomas (Takamura et al., 2011). Active autophagy is thought 
to suppress tumourigenesis by mitigating genomic instability and DNA damage and 
preventing accumulation of ROS (Kimmelman, 2011).  
While autophagy inhibition appears to be important for the initiation of tumourigenesis, 
active autophagy is thought to be necessary for cancer progression and maintenance of 
established tumour cells. Indeed, a tumour promoting role of autophagy has been 
described in a variety of malignancies (Kimmelman, 2011; Kroemer et al., 2010). 
Increased autophagy has been shown to potentiate survival of tumour cells under 
conditions of nutrient deprivation and hypoxia, stresses frequently encountered by 
evolving tumours (Karantza-Wadsworth et al., 2007; White, 2012). It has also been 
reported that active autophagy allows malignant cells evade death induced by anti-
cancer agents, thus promoting therapy resistance (Carella et al., 2012; Sinclair et al., 
2013; Verschooten et al., 2012). Evidence is emerging which supports the concept of a 
cell autonomous role for autophagy in tumour cell maintenance. Yang et al and White 
and colleagues have reported that the survival of RAS-driven tumours is dependent on 
active autophagy (Guo et al., 2011; Lock et al., 2011; Yang et al., 2011). Elevated 
autophagy activity has been proposed to act as a mechanism which allows rapidly 
dividing tumour cells to meet their increased metabolic requirements and energy needs 
(Eng and Abraham, 2011), but that this stress-induced autophagy differs from basal 
level autophagy which degrades substrates in a more specific manner (Kimmelman, 
2011) . In this study, we report that basal level autophagy is increased in the indolent 
NHL FL compared to faster growing DLBCL. Autophagy may be up-regulated in slow 
growing FL cells to prolong their survival by facilitating the removal of old, damaged 
aggregates and organelles. We found that autophagy activity varies largely among 
DLBCL samples, and that higher levels of autophagy activity are associated with a 
worse clinical outcome in DLBCL. Therefore, it is possible that increased autophagy 
activity in both FL and DLBCL favours tumour cell survival.   
The proposed model for the role of autophagy in tumourigenesis is that in normal tissue, 
autophagy maintains homeostasis and is involved in quality control of proteins and 
organelles. Inhibition of autophagy disrupts this homoeostasis, resulting in DNA 
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damage, genomic instability and aneuploidy, which leads to tumour initiation. Once 
established, tumour cells re-activate the autophagy pathway, allowing them to meet 
their metabolic needs, promote survival and growth, and often, resistance to therapy.  
7.3 Do key autophagy markers reflect autophagy activity in 
lymphoma cells? 
The autophagy status and activity of a sample is typically determined by evaluating 
expression levels and cellular patterns of the key autophagy-related proteins p62, LC3 
and sometimes Beclin-1, whose modulation is known to reflect progress through the 
autophagy flux.  
7.3.1 p62 is a marker of autophagy activity in lymphoma cells  
The adaptor protein p62 was identified as an autophagy substrate and marker by 
Bjorkoy et al in 2005. Using HeLa cells, IFM and Western blotting, they observed a 
decrease in p62 levels following Rapamycin-induced autophagy, and found that 
inhibition of autophagic degradation with Bafilomycin A1 resulted in p62 accumulation 
(Bjorkoy et al., 2005). p62 is now well established as an autophagy substrate whose 
cellular levels decrease when the autophagy flux is active (Pankiv et al., 2007; White, 
2012), and its accumulation/increased expression has proven to be an accurate marker 
of defective/inactive autophagic degradation in a number of cell types including iBMK 
cells (Mathew et al., 2009), neuronal cells (Bartlett et al., 2011) and mouse liver cells 
(Komatsu et al., 2007). A recent study by Sahani et al has however highlighted that care 
should be taken when using p62 as an autophagy marker. They report that following an 
initial decrease in p62 protein levels during starvation-induced autophagy, prolonged 
starvation and autophagy resulted in reappearance of p62 in MEF and HepG2 cells 
(Sahani et al., 2014). In line with these findings, using Western blotting we found that 
starvation-induced autophagy resulted in a decrease in p62 protein levels over a short 
time period, followed by a reappearance of p62 to the basal level after prolonged 
nutrient deprivation. We confirmed re-expression of p62 was due to increased mRNA 
expression. Blocking autophagy degradation with CQ resulted in p62 accumulation in 
BCL-2
HIGH
 and BCL-2
LOW
 DLBCL cell lines. Therefore, p62 can be used as a marker of 
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autophagy activity in lymphoma cells, but with caution and taking timing and the 
method of autophagy induction into account.  
p62 expression levels have also been evaluated by IHC in a variety of tissues. Lee et al 
(Lee et al., 2012) assessed whether evaluation of p62 expression by IHC could be used 
as a diagnostic marker for drug-induced autophagic vaculoar myopathies such as Danon 
disease. Staining of formalin-fixed paraffin embedded (FFPE) tissue from patients 
treated with CQ or HCQ revealed darkly stained p62 puncta which reflected 
accumulation of this autophagy substrate and protein aggregates, indicative of defective 
autophagy degradation. On the other hand, p62 puncta were absent from normal tissues 
not treated with either drug (Lee et al., 2012). Doi and colleagues also used IHC to 
evaluate p62 expression, however not in the context of autophagy, and showed strong, 
dark, nuclear staining to reflect p62 expression in skeletal muscle (Doi et al., 2013). 
These findings suggest p62 expression levels can be assessed by IHC and in turn, can be 
used as a maker of autophagy activity.  
In this study strong, dark brown DAB staining which included only areas stained above 
a pre-determined threshold, was taken to represent the highest intensity staining, and 
was classified as p62 positive. Low level background staining was excluded. Similar to 
Lee et al, this p62 staining pattern was taken to reflect higher expression of p62 due to 
autophagy inhibition. Using this scoring method, we found p62 expression is 
significantly lower in FL intra- and inter-follicular regions compared to RA controls and 
DLBCL samples, indicating degradation and accumulation of p62 in FL and DLBCL 
respectively, and suggesting increased autophagy activity in FL. Our findings also 
indicate that evaluation of p62 expression levels using IHC, and indeed Western 
blotting, is a valid method by which to assess the autophagy status of a lymphoma 
sample.  
7.3.2 Active autophagy results in decreased expression of LC3 in lymphoma 
cells 
Kabeya et al first described LC3-II as a marker of active autophagy in 2000 (Kabeya et 
al., 2000). Using Western blotting, they showed that following starvation-induced 
autophagy levels of LC3-II, a 16kDa processed form of LC3, were increased in HeLa 
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cells compared to non-starved controls. Greater numbers of LC3-II-positive puncta were 
also observed under starvation conditions using IFM (Kabeya et al., 2000). Increased 
expression of LC3-II and increased numbers of LC3-II puncta have since been reported 
to reflect increased autophagy activity in MEFs (Klionsky et al., 2012b), HEK293 
(Tanida et al., 2005) and MPC  cell lines (Asanuma et al., 2003) among many others.  
However, care should be taken when utilising LC3 as an autophagy marker. It has been 
reported that autophagy-induced increases in LC3-II are tissue and cell type dependent 
(Klionsky et al., 2012b; Mizushima et al., 2004), and that increased expression of LC3-
II can reflect inhibition of autophagic degradation rather than increased autophagy 
activity (Kabeya et al., 2000; Pankiv et al., 2007). Pankiv et al (Pankiv et al., 2007) 
reported that LC3-II is a substrate of the autophagy pathway. They reported that 
membrane-bound LC3-II binds p62 via its LIR and facilitates the delivery of autophagy 
substrates to the autophagosome. Using a mCherry/GFP tag construct, they then 
demonstrated that as a component of the aggregates it delivers for degradation, LC3-II 
is itself degraded in the autophagolysosome. They also described an increase in LC3-II 
levels following lysosomal inhibition and subsequent inhibition of autophagy 
degradation with Bafilomycin A1, confirming LC3-II is degraded by active autophagy  
(Pankiv et al., 2007). Increased LC3-II as a result of defective autophagy has also been 
described in breast cancer (Maycotte et al., 2012), squamous cell carcinoma 
(Verschooten et al., 2012) and numerous other cell lines (Klionsky et al., 2012b).  
Therefore while LC3 levels are modulated during an active autophagy flux, using this 
protein as an autophagy marker is not straight forward. On the one hand, increased 
LC3-II expression may be due to conversion of LC3-I to LC3-II by an active autophagy 
flux; on the other, it may be due to a block in autophagy degradation which results in 
accumulation of this membrane-bound autophagy substrate (Klionsky et al., 2012b; 
Mizushima and Yoshimori, 2007). We found that treatment of BCL-2
HIGH
 and BCL-
2
LOW
 DLBCL cell lines with the late autophagy inhibitor CQ resulted in an 
accumulation of LC3-II under nutrient replete conditions, indicative of a block in 
autophagic degradation. Evaluation of LC3 in these cell lines following starvation-
induced autophagy revealed a time dependent decrease in both LC3-I and LC3-II 
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expression levels, which suggests conversion of LC3-I to LC3-II and subsequent 
degradation of LC3-II, i.e. an active autophagy flux. In this study, we therefore 
considered decreased expression of total LC3 (i.e. LC3-I and LC3-II) to reflect active 
autophagy. On the other hand, increased LC3-II combined with slightly increased LC3-I 
expression was used as a marker of inactive autophagy in lymphoma cells.  
Cellular levels of endogenous LC3 have also been assessed in a variety of malignancies 
using IHC, including lymphomas (Huang et al., 2010; Nicotra et al., 2010b), colorectal 
carcinoma (Giatromanolaki et al., 2010) and breast cancer (Sivridis et al., 2010). We 
have evaluated LC3 primarily for its prognostic significance but also its ability to 
predict autophagy activity. While IHC is becoming an increasingly common technique 
with which to evaluate LC3 levels, there are a number of caveats which can make it 
difficult to interpret the results of this assay correctly. For example, staining tissue for 
LC3 can produce a number of different patterns which are hard to differentiate and 
distinguish from one another. These patterns are also reported to vary between cell and 
tissue types (Klionsky et al., 2012b; Sivridis et al., 2010). Also, LC3 can localise to 
structures other than autophagosomes within cells (e.g. lipid droplets), meaning 
increased LC3 puncta does not always reflect increased numbers of autophagosomes 
(Shibata et al., 2009). It is also quite difficult to differentiate between LC3-I and LC3-II 
using this assay.  
Sivridis et al evaluated LC3 staining and expression levels in 102 breast cancer cases, 
and identified three distinct staining patterns for this autophagy-essential protein - 
cytoplasmic, cytoplasmic/juxta-nuclear, and "stone-like" pattern (SLS). The latter of 
these appeared as dense, strongly stained structures and were taken to be reflective of 
autophagosomes and increased autophagy activity in tumour cells (Sivridis et al., 2010). 
Similar patterns of staining were also observed in colorectal carcinomas and xenograft 
models (Giatromanolaki et al., 2010). On the other hand, the study previously described 
by Lee et al which evaluated p62 staining using IHC also evaluated LC3 expression and 
staining (Lee et al., 2012). Similar to their p62 finding, they observed increased LC3-
positive puncta in patients treated with the late autophagy inhibitors CQ or HCQ. They 
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therefore took large, densely stained LC3 aggregates to be reflective of an accumulation 
of autophagosomes due to blocked autophagy degradation (Lee et al., 2012).  
To evaluate LC3 expression in our FL and DLBCL patient cohorts, we employed a 
similar scoring system to that previously described for p62. Dark, strong staining was 
identified as being LC3 positive, and in a similar manner to Lee et al, was taken to 
reflect high expression/accumulation of LC3, indicative of an inactive autophagy flux. It 
is important to note that in this study, evaluation of 'LC3' in tissue biopsies refers to 
total LC3, i.e. LC3-I and LC3-II, as these isoforms could not be distinguished by IHC. 
We believe that the scoring method used in this study is valid and comprehensive as it 
takes the total autophagy flux, not just LC3-II formation, into account. Also, without 
using autophagy inhibitors such as CQ it is difficult to tell, particularly by IHC, if 'LC3-
II aggregates' are due to increased autophagy activity or a block in autophagic 
degradation. We therefore propose that LC3 may not be the most suitable marker by 
which to evaluate autophagy activity in lymphoma cells, particularly using IHC, and 
that if it is to be used it should be in conjunction with a more robust marker such as p62.  
7.3.3 Beclin-1 is not a marker of the autophagy flux in lymphoma cells  
Beclin-1 is an essential component of the autophagy initiating complex which functions 
to promote autophagosome formation and elongation (Marquez and Xu, 2012). While 
Beclin-1 is known to be involved in the early stages of the autophagy flux, it is less well 
established if this protein is a substrate of the autophagy pathway, and if its cellular 
levels can be used as a general marker of autophagy activity in a similar manner as p62 
and LC3.  
Beclin-1 macroaggregates identified in the Golgi apparatus of neuronal cells using TEM 
and IFM have been proposed to reflect autophagy induction in these cells, and suggests  
Beclin-1 may be used as a marker of autophagy activity (Castino et al., 2010; Castino et 
al., 2011; Yue et al., 2002). We found that Beclin-1 expression levels did not fluctuate 
in BCL-2
HIGH
 or BCL-2
LOW
 DLBCL cell lines following autophagy induction by 
starvation or inhibition of autophagic degradation with CQ. This finding indicates that 
Beclin-1 is most likely not a substrate of the autophagy flux in lymphoma cells and 
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suggests its expression levels should not be used as a direct marker of autophagy 
activity within these cells.  
Expression levels of Beclin-1 have been evaluated by IHC in malignancies including 
colon cancer (Koukourakis et al., 2010), nasopharyngeal carcinoma (Wan et al., 2010) 
and lymphomas (Nicotra et al., 2010b). As with p62 and LC3, in this study positive 
Beclin-1 staining was characterised as the most intense, darkest staining and low level 
background staining was excluded. In line with others, we found that Beclin-1 staining 
is primarily cytoplasmic when examined using IHC. While we observed a difference in 
Beclin-1 expression levels between FL, DLBCL and RA samples using this assay, this 
was not taken to reflect differential autophagy activity between sample types as our 
previous findings demonstrated that Beclin-1 levels do not vary during the autophagy 
flux. We did however find that expression levels of Beclin-1 protein are positively 
correlated with p62 levels in FL and DLBCL - lower expression of p62, indicative of 
active autophagy, is associated with decreased Beclin-1 expression, suggesting that 
autophagy activity in NHLs is not dependent on the Beclin-1 protein.  
7.4 The autophagy-related GEP of lymphoma cells reflects their 
autophagy status 
It has been reported that in some instances, an active autophagy flux is accompanied by 
an increase in the mRNA levels of autophagy-related genes (Klionsky et al., 2012b; 
Moussay et al., 2011). Transcription levels of Atg5 and Atg7 for example have been 
reported to increase in neutrophils and during neurogenesis when the autophagy flux is 
active (Rodriguez-Muela et al., 2012; Vazquez et al., 2012). Similarly, up-regulation of 
Atg12 and GABARAPL1 has been reported in C2C5, MEF (Kouroku et al., 2007) and 
neuronal cells (Le Grand et al., 2013) following ER-induced autophagy (Klionsky et al., 
2012b). Increased knowledge of the autophagy pathway at the gene level will improve 
our understanding of the role this degradation process plays in cancer development. 
Evaluation of the autophagy-related GEP should be done on a per cell-type basis as 
changes in autophagy-related genes mRNA levels is reported to be cell type and 
stimulus specific (Klionsky et al., 2012b; Klionsky et al., 2008a). 
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7.4.1 p62 mRNA levels increase when autophagy is induced 
It has been reported that during active autophagy, mRNA levels of SQSTM1 are up-
regulated, which often results in increased expression of p62 at the protein level 
(Bjorkoy et al., 2005; Fujita et al., 2011; Ishii et al., 1997). For example Puissant et al 
reported that resveratrol-induced autophagy resulted in increased expression of p62 at 
the mRNA and protein level in CML cells (Puissant et al., 2010). Sahani and colleagues 
recently demonstrated that this is also the case in MEF and HepG2 cells, but not HeLa 
or HEK293 cell lines, following starvation-induced autophagy (Sahani et al., 2014). 
They found that pro-longed starvation promoted transcriptional up-regulation of 
SQSTM1 in MEF and HepG2 cells, and that up-regulation of p62 at the mRNA level 
was accompanied by an increase at the protein level (Sahani et al., 2014). Up-regulation 
of SQSTM1 during active autophagy is thought to occur to ensure sufficient levels of 
p62 are available within cells for autophagy to continue. p62 is degraded as part of the 
autophagolysosome; however it is also essential for the delivery of substrates to the 
autophagosome. Therefore, by up-regulating SQSTM1 at the mRNA level, cells 
maintain a pool of p62 to replace that which is degraded by autophagy, and so allow 
continued activity of the autophagy process (Klionsky et al., 2012b; Sahani et al., 2014).  
 
On the other hand, accumulation of p62 due to defective autophagy is independent of 
changes at the mRNA level. In their study, Matthew et al described how increased 
expression of p62 in autophagy defective iBMK cells was due to its accumulation at the 
protein level rather than up-regulation of SQSTM1, and demonstrated that p62 mRNA 
levels were comparable between wild-type and autophagy-null cells (Mathew et al., 
2009). In a similar finding, Komatsu and colleagues reported no change in SQSTM1 
mRNA levels in Atg7-defecient/autophagy inactive liver cells, despite increased 
expression of p62 at the protein level (Komatsu et al., 2007). 
 
In line with the findings of Sahani et al, we found that SQSTM1 was up-regulated in 
BCL-2
HIGH 
and BCL-2
LOW
 DLBCL cell lines following 6 hrs’ starvation. We believe 
this shows differential expression of SQSTM1, and indeed other autophagy-related 
genes at the mRNA level can be taken to reflect changes in the autophagy flux and 
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autophagy status of lymphoma cells. Expression of SQSTM1 was also increased in a 
number of purified and un-purified primary FL samples compared to DLBCL and RA-
LN controls, which coupled with decreased expression of p62 at the protein level 
indicative of its degradation, further suggests increased autophagy in this indolent NHL. 
Moussay et al have reported a similar finding in endothelial cell lines (Moussay et al., 
2011).  
 
7.4.2 LC3 and Beclin-1 mRNA levels can be used as a marker of autophagy 
activity  
Previous studies have reported an increase in LC3 at the mRNA level when autophagy 
is active (Klionsky et al., 2012b; Moussay et al., 2011). Nara and colleagues described 
how following starvation-induced autophagy LC3 was up-regulated, which resulted in 
increased synthesis of the LC3 protein (Nara et al., 2002). In their study, Rouschop et al 
(Rouschop et al., 2010) also reported an increase in LC3 mRNA levels in various cell 
lines including MCF7 and HT29 cells under hypoxic conditions, and found that LC3 
increased to differing degrees from one cell type to another. LC3 is essential to the 
autophagy pathway as it recruits substrates to the autophagosome for degradation; 
however as it is an autophagy substrate its levels are depleted when autophagy is active. 
Therefore in a similar manner to p62, it is postulated that LC3 is up-regulated at the 
gene level to ensure sufficient amounts of LC3 are produced to replenish protein that is 
degraded by autophagy, and in doing so, ensures autophagy activity can be maintained. 
Modulation of LC3 is autophagy-stimulus and cell-type dependent (Klionsky et al., 
2012b; Klionsky et al., 2008a), indicating that its mRNA levels should be evaluated on 
a cancer-by-cancer basis.  
It is well established that monoallelic deletion of the BECN1 results in autophagy 
inhibition and leads to the development of spontaneous breast and ovarian tumours in 
mice (Sahni et al., 2014; Yue et al., 2003). Similarly, increased expression of Beclin-1 
has been reported in a panel of pancreatic cancer cell lines where autophagy activity 
was increased (Yang et al., 2011). Moussay et al also reported an increase in Beclin-1 
mRNA levels, along with LC3 and p62, in endothelial cells (Moussay et al., 2011).  
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In this study, starvation-induced autophagy did not result in increased expression of 
LC3 or BECN1 at the mRNA level in BCL-2
HIGH
 or BCL-2
LOW
 DLBCL cell lines when 
compared to cells cultured under nutrient replete conditions. We did however observe 
increased expression of GABARAPL1 and GABARAPL2, the other mammalian 
homologs of Atg8. On the other hand, BECN1 and MAP1LC3A mRNA levels were 
increased in primary FL samples compared to RA controls, which again suggests 
increased autophagy activity in these lymphoma cells.  
7.5 Does overexpression of BCL-2 inhibit autophagy in lymphoma 
cells?  
7.5.1 BCL-2 inhibits apoptosis but not autophagy in lymphoma cells   
The role of BCL-2 as an anti-apoptotic protein is well established (Galluzzi et al., 2012; 
Llambi and Green, 2011). By binding pro-death proteins such as Bax or Bim, BCL-2 
inhibits permeablisation of the mitochondrial membrane which prevents the release of 
apoptotic factors such as cytochrome c, and subsequent induction of the apoptotic 
cascade (Kroemer et al., 2007; Ola et al., 2011). While inhibition of cell death is 
considered to be its primary function, over the last decade it has been demonstrated that 
BCL-2 can also inhibit the autophagy pathway through binding and sequestration of the 
autophagy essential protein Beclin-1 (Marquez and Xu, 2012; Pattingre et al., 2005). 
Interaction between BCL-2 and Beclin-1 prevents the latter from forming the IC, an 
essential step in autophagy initiation, and thus prevents autophagy induction (Kang et 
al., 2011).  
While binding between BCL-2 and Beclin-1 was first described by Liang et al in 1998 
(Liang et al., 1998), it was Pattingre and colleagues who demonstrated that this 
interaction plays a role in regulating the autophagy process (Pattingre et al., 2005) . By 
evaluating accumulation of transfected GFP-LC3 by IFM, Pattingre and colleagues 
showed that artificially induced overexpression of BCL-2 and Beclin-1 in HT-29 and 
MEF cell lines inhibited and increased autophagy activity respectively. They also 
showed by co-immunoprecipitation that endogenous BCL-2 and Beclin-1 bind to form 
an autophagy inhibiting complex in HeLa cells, and that BCL-2 is a negative regulator 
of starvation-induced autophagy in these cells (Pattingre et al., 2005). Similar 
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experiments in the cardiac muscle of BCL-transgenic mice showed that BCL-2 
overexpression inhibits autophagy under conditions of prolonged starvation in vivo 
(Pattingre et al., 2005). Inhibition of the autophagy flux due to BCL-2/Beclin-1 binding 
has also been reported by other groups in pancreatic adenocarcinoma, colorectal and 
breast cancer cell lines (Marquez and Xu, 2012; Tang et al., 2010; Wei et al., 2008). 
  
While a number of studies describe how binding between BCL-2 and Beclin-1 can 
result in autophagy inhibition, a recent study by Lindqvist et al suggests that BCL-2 and 
other pro-survival proteins do not directly affect autophagy activity, but rather indirectly 
modulate this cellular process through their anti-apoptotic function (Lindqvist et al., 
2014). Using apoptosis defective (Bax
-/-
 Bak
-/-
) MEF and factor-dependent myeloid 
(FDM) cells, Lindqvist and colleagues found that treatment with ABT-737 did not 
increase basal level or stress-induced autophagy, but that autophagy was active in 
apoptosis competent cells treated with this BH3-mimetic. These results indicate that 
BCL-2 does not directly inhibit autophagy via Beclin-1 binding, as treatment with ABT-
737, a BH3-mimetic that would disrupt this interaction, only affected autophagy when 
the mitochondria-dependent apoptosis pathway was intact. Lindqvist et al also 
evaluated the possibility that BCL-2/Beclin-1 interactions are too weak to have a 
discernible effect on autophagy by evaluating its activity in cells where BCL-2 was 
overexpressed, and found that overexpression of BCL-2 or any other anti-apoptotic 
protein did not inhibit the autophagy flux in Bax
-/-
 Bak
-/-
 cells. They therefore propose 
that BCL-2 indirectly modulates autophagy activity through its anti-apoptotic/pro-
survival function, rather than directly through binding and sequestration of Beclin-
1(Lindqvist et al., 2014).   
As interest in the role of autophagy in cancer development increases, it is important to 
understand how BCL-2 regulates this pathway in different cells. Prior to this study, it 
was unknown if BCL-2 inhibits autophagy as well as apoptosis in FL and DLBCL. 
Using techniques including IHC, Western blotting and qRT-PCR, we aimed to 
determine whether increased BCL-2 expression inhibits autophagy in FL and DLBCL. 
We evaluated the autophagy status and basal level activity in primary FL and DLBCL 
tissues and DLBCL cell lines based on their endogenous autophagy-related GEP. Our 
      Chapter VII Discussion 
 
214 
 
results show that endogenous BCL-2 is unlikely to inhibit basal level autophagy in 
primary lymphomas and BCL-2 positive DLBCL cell lines.  
7.5.2 ABT-737 induces cytoprotective autophagy in lymphoma cell lines  
BH3-mimetic compounds bind anti-apoptotic members of the BCL-2 family of proteins 
via BH3-domain interactions with varying degrees of affinity (Souers et al., 2013; 
Vogler et al., 2009). By binding these pro-survival proteins, BH3-mimetics promote the 
release of pro-death proteins such as Bax, which induce apoptosis (Davids and Letai, 
2013; Kang and Reynolds, 2009; White, 2012). Binding of these compounds to BCL-2 
has also been shown to promote autophagy activity by precluding BCL-2s autophagy-
inhibiting interactions with Beclin-1 (Levine et al., 2008; Marquez and Xu, 2012). 
Induction of autophagy following treatment with BH3-mimetics, and indeed other anti-
cancer drugs, has  been shown to both promote and hinder the pro-death role of these 
anti-neoplastic agents (Kimmelman, 2011). In their study, Pattingre et al reported that 
while binding between BCL-2 and Beclin-1 occurs at the mitochondria and the ER, only 
disruption of this interaction at the ER promotes autophagy (Kang et al., 2011; Pattingre 
et al., 2005).  
 
In this study, we confirmed that ABT-737 induces apoptosis in BCL-2
HIGH
 but not 
BCL-2
LOW
 DLBCL cell lines, irrespective of BCL-xL expression levels, as 
demonstrated by increased PARP cleavage and a change in Bax conformation to its 
active form. Our findings are in line with those of Deng et al and various other studies 
(Deng et al., 2007; Konopleva et al., 2006; Vandenberg and Cory, 2013). Sensitivity of 
BCL-2
HIGH
 DLBCL cell lines to ABT-737 is not surprising as increased expression of 
this pro-survival protein has been reported to ‘prime’ cells for death (Davids and Letai, 
2013; Deng et al., 2007). Treatment of BCL-2
HIGH 
DLBCL cell lines with ABT-737 
resulted in increased autophagy activity, as demonstrated by degradation of the 
autophagy substrates p62 and LC3. IFM experiments showed that endogenous BCL-2 
and endogenous Beclin-1 proteins co-localise in BCL-2
HIGH
 cells. Cellular fractionation 
experiments were not performed to determine the sub-cellular location at which this 
interaction occurred. However, co-immunoprecipitation experiments showed no binding 
between these proteins at the basal level. Co-localisation was not reduced following 
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treatment with ABT-737, indicating that while BCL-2 and Beclin-1 localise to the same 
cellular organelle(s) they do not bind to form an autophagy-inhibiting complex in 
lymphoma cells.  
Treatment with CQ sensitised BCL-2
HIGH
 cells to ABT-737-mediated apoptosis, 
indicating that ABT-737-induced autophagy functions as a cytoprotective mechanism 
utilised by cells to avoid death. While ABT-737 induces autophagy in BCL-2
HIGH
 
DLBCL cell lines, it appears unlikely to be due to disruption of BCL-2/Beclin-1 
binding. Instead, inhibition of BCL-2 may induce autophagy as a pro-survival, stress-
response mechanism. Indeed, induction of autophagy in DLBCL cell lines in response 
to drug treatment has previously been reported (Jia et al., 2012). Our findings indicate 
that overexpression of BCL-2 does not inhibit basal level autophagy in lymphoma cells, 
and that acquired autophagy is a survival response utilised by tumour cells to cope with 
induction of apoptosis. It is important to note that we evaluated BCL-2/Beclin-1 binding 
at the endogenous, basal level, not following modulation of protein expression levels or 
transfection, the process of which could itself induce autophagy.  
BH3-mimetcis are widely used as anti-cancer agents in the clinical setting (Davids and 
Letai, 2013; Souers et al., 2013; Wilson et al., 2010). Navitoclax (ABT-263), an orally 
available second generation ABT-737 derivative, has shown anti-tumour activity in 
various solid malignancies, CLL and FL, both as a single agent and in combination with 
standard chemotherapeutic agents (Davids and Letai, 2012; Touzeau et al., 2014; 
Wilson et al., 2010). Similarly, the third generation BH3-mimetic ABT-199 which only 
binds BCL-2, effectively promotes tumour cell death in CLL, multiple myeloma and 
other tumours, but with the distinct advantage of not inducing thrombocytopenia, a side-
effect of Navitoclax (Davids and Letai, 2013; Souers et al., 2013; Touzeau et al., 2014). 
As BH3-mimetics are increasingly being used as therapeutic agents in NHLs, our results 
indicate that inclusion of autophagy-inhibiting drugs such as CQ and HCQ in current FL 
and DLBCL treatment regimens should be considered.  
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7.5.3 Overexpression of BCL-2 does not inhibit autophagy in primary FL 
samples  
We have shown that decreased expression of p62 and LC3 at the protein level can be 
used as markers of increased autophagy flux in lymphoma cells. An increase in mRNA 
levels of the genes encoding for these proteins (SQSTM1 and MAP1LC3) and indeed 
other key autophagy-related genes, also mirrors active autophagy. Evaluation of 
endogenous p62 and LC3 levels and the autophagy-related GEP of primary FL and 
DLBCL tissues revealed that autophagy activity is increased in FL samples compared to 
RA controls and DLBCL samples. Expression of the global autophagy-related GEP was 
higher in FL samples, while p62 and LC3 protein levels were decreased, indicative of 
their degradation. We therefore propose that these data indicate that despite its 
overexpression at the gene and protein levels, BCL-2 does not inhibit basal level 
autophagy in primary lymphoma samples. Similarly, overexpression of BCL-2 in 
DLBCL cell lines did not appear to inhibit basal level or stress-induced autophagy. 
These findings are contrary to previous studies which suggest that BCL-2 inhibits 
autophagy through binding and sequestration of Beclin-1 (Pattingre et al., 2005; Tang et 
al., 2010). There are a number of possibilities which may explain our findings. 
As previously stated, autophagy activity is cell-type dependent, meaning observations 
made in one cell type do not necessarily hold true for all others (Kimmelman, 2011; 
White, 2012). Therefore, while BCL-2 overexpression has been shown to inhibit 
autophagy in other malignancies, we report here for the first time that this does not 
appear to be the case in primary purified FL B cells and un-purified tissue biopsies. 
Similarly, previous studies have reported BCL-2 to be a negative regulator of 
starvation-induced autophagy which is described as being mechanistically different to 
basal level autophagy (Kimmelman, 2011). Our study differs in that we evaluated the 
autophagy status of primary lymphoma samples at the basal level by assessing 
endogenous expression levels of autophagy-related proteins and genes, while most other 
studies use transgenic murine-models and artificially-induced BCL-2 or Beclin-1 
expression to evaluate BCL-2s role in autophagy.  
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While our findings contradict the dogma that BCL-2 overexpression inhibits autophagy, 
and disprove our initial hypothesis that increased expression of this protein negatively 
regulates autophagy in human NHLs, it is important to note that our methods of 
assessing autophagy activity have previously been shown to be suitable for evaluation 
of autophagy within lymphoma cells. In this study, and as previously described 
(Bjorkoy et al., 2005; Klionsky et al., 2012b; Mathew et al., 2009; Pankiv et al., 2007), 
increased expression of p62 at the protein level as evaluated by Western blotting and 
IHC, was taken to indicate inactive autophagy degradation, while its decreased 
expression suggested active autophagy. Similarly, in accordance with previous reports 
increased expression of autophagy-related genes such as Atg9A, Atg16L1, MAP1LC3 
and UVRAG, was taken to reflect increased autophagy flux. Our methods did differ with 
respect to the utility of LC3 as an accurate autophagy marker in lymphoma cells. While 
some studies report accumulation of LC3 to reflect LC3-II puncta and thus increased 
autophagy activity (Mizushima and Yoshimori, 2007; Sivridis et al., 2010; Tanida et al., 
2005), it is difficult to prove that increased LC3 expression is not due to impaired 
degradation without using autophagy inhibitors such as CQ (Klionsky et al., 2012b). It 
is also difficult to distinguish LC3-I from LC3-II using IHC. Following experiments 
with CQ, we took a decrease in global LC3 levels (i.e. LC3-I and LC3-II) to reflect 
conversion of LC3-I to LC3-II, degradation of LC3-II by autophagy and hence an active 
autophagy flux. Therefore while our findings differ to others, the assays employed in 
this study have been shown both here, and by others, to be valid methods with which to 
evaluate autophagy activity in lymphoma cells.  
 
Based on our findings we propose that overexpression of BCL-2 does not inhibit the 
autophagy flux in primary FL samples. Instead, basal level autophagy activity is 
increased in these lymphoma samples compared to RA-LN controls. FL cells are slow 
growing cells with a low proliferation rate; therefore, autophagy activity may be up-
regulated in these cells to facilitate the removal of old, potentially toxic aggregates and 
provide nutrients under conditions of starvation. Our finding fits with the proposed 
model of the role of autophagy in cancer development which describes how established 
tumour cells utilise autophagy as a pro-survival mechanism (Guo et al., 2011; 
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Kimmelman, 2011; Kroemer et al., 2010). It is important to distinguish this from the 
theory that autophagy inhibition promotes tumourigenesis (Kimmelman, 2011; Liang et 
al., 1998; Mathew et al., 2009). In this study, we did not evaluate the role of BCL-2 or 
autophagy in tumourigenesis or tumour cell progression, but rather their function in 
already developed tumour cells. Therefore, while BCL-2 may inhibit autophagy during 
FL development, we have demonstrated that its overexpression does not negatively 
impact autophagy activity in established FL cells. The mechanism by which FL cells 
up-regulate autophagy is unknown. One possibility is that inhibition of apoptosis by 
BCL-2 results in accumulation of aged organelles and misfolded proteins which triggers 
autophagy. Rapidly dividing, aggressive lymphomas have previously been reported to 
up-regulate autophagy in order to meet their metabolic needs (Guo et al., 2011; 
Kimmelman, 2011). In this study, we found autophagy activity is ubiquitously increased 
in FL samples but varies among DLBCL samples.  
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7.5.4 Inhibition of apoptosis by BCL-2 promotes autophagy in lymphoma 
cells  
Initially thought of as two distinct cellular processes, it is now clear that a high level of 
cross-talk occurs between the autophagy and apoptosis pathways (Eisenberg-Lerner et 
al., 2009; Mukhopadhyay et al., 2014).These processes are inter-connected as they share 
a number of common regulators including BCL-2, Beclin-1, AMBRA1 and Bim, which 
can regulate each pathway in a similar or different way. For example UVRAG is pro-
autophagic but anti-apoptotic (Mukhopadhyay et al., 2014). The inter-play between 
autophagy and apoptosis is complex and at times contradictory. Broadly speaking, these 
pathways can act in synergy to promote one another's activity or behave 
antagonistically, where activation of one blocks the other (Denton et al., 2012; 
Eisenberg-Lerner et al., 2009; Maiuri et al., 2007c; Mukhopadhyay et al., 2014).  
 
Inhibition of apoptosis has been shown to result in the induction of autophagic cell 
death. For example in Bax
-
/Bak
-
 apoptosis defective MEF cells, an initial increase in 
autophagy was followed by delayed autophagy-associated cell death (Maiuri et al., 
2007c; Shimizu et al., 2004). On the other hand, increased autophagy under conditions 
of inhibited apoptosis has been shown to promote tumour cell survival. Upon removal 
of interluekin-3 (IL3), Bax
-
/Bak
-
 defective immortalised IL3-dependent cell lines 
increased their autophagy activity which acted in a cytoprotective manner and promoted 
and maintained tumour cell survival (Lum et al., 2005a; Lum et al., 2005b). These 
reports indicate that in a similar manner to the autophagy pathway itself, cross-talk 
between autophagy and apoptosis is stimulus and cell-type dependent, as is the outcome 
of this cross-talk (Denton et al., 2012; Eisenberg-Lerner et al., 2009; Mukhopadhyay et 
al., 2014). 
 
BCL-2 is known to inhibit apoptosis in FL and DLBCL tumour cells where it is 
frequently overexpressed (Campos et al., 1993). In our study, we have shown that BCL-
2 does not simultaneously inhibit autophagy in these lymphoma cells, but rather that 
autophagy activity is increased in FL samples and a proportion of DLBCL samples. We 
therefore propose that inhibition of apoptosis by BCL-2 results in up-regulation of the 
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autophagy process, which functions as a pro-survival mechanism. Increased autophagy 
in apoptosis-defective FL and DLBCL cells is likely to facilitate and promote the 
elimination of damaged, old cellular proteins, organelles and aggregates which if 
allowed accumulate could induce necrotic cell death. Therefore FL and some DLBCL 
tumours maintain their growth survival advantage by concurrently preventing cell death 
and increasing cell survival. This further supports our previous suggestion that inclusion 
of autophagy inhibitors to current NHL treatment regimens should be considered and 
evaluated.  
 
7.6 Autophagy activity is increased in cells of the tumour 
microenvironment  
It is well established that interactions between FL and DLBCL B cells and cells of the 
tumour microenvironment are involved in the development and progression of these 
lymphomas (Alizadeh et al., 2000; Clear et al., 2010; Rosenwald et al., 2002; Yang and 
Ansell, 2012). Increased numbers of CD4
+
 T cells and CD163
+
 macrophages have been 
described in FL tissue samples (Clear et al., 2010; Lee et al., 2006), while greater 
numbers of macrophages and adipocytes have been reported in DLBCL tissues (Lenz et 
al., 2008a; Rosenwald et al., 2002) compared to normal controls. The role of the 
microenvironment in these NHLs has also been clearly demonstrated by GEP studies 
(Alizadeh et al., 2000; Dave et al., 2004; Lenz et al., 2008a; Rosenwald et al., 2002). In 
a large cohort of DLBCL patients, Lenz et al identified three distinct gene signatures as 
being predictive of outcome and modulating cells response to therapy, two of which 
were associated with CD19- stromal cells including macrophages and endothelial cells 
(Lenz et al., 2008a). Similar studies have demonstrated that survival among FL patients 
is linked with altered expression of genes associated with immune cells including T-
cells and follicular dendritic cells (Dave et al., 2004). 
In this study, we found a greater number of autophagy-related genes to be aberrantly 
expressed in un-purified FL samples compared to purified B cells, while genes 
differentially expressed in un-purified DLBCL samples were expressed by tumour-
infiltrating macrophages, not malignant B cells. These results, which demonstrate up-
regulation of  autophagy-related genes in cells of the microenvironment of primary FL 
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and DLBCL samples, suggest autophagy activity is not only increased in malignant B 
cells but also in tumour-infiltrating cells. To our knowledge, this is the first report 
which describes the autophagy pathway as being differentially regulated in the FL and 
DLBCL microenvironment.  
These results also indicate that while studying the autophagy pathway in cell lines is 
important and essential to our continued understanding of this complex process, 
examination of autophagy in primary samples is more relevant and informative as it 
reflects activity of this pathway in the whole tumour setting including the 
microenvironment, which is not possible with cell lines.   
7.7 Can expression levels of key autophagy-related proteins 
predict outcome in FL and/or DLBCL?  
7.7.1 Low levels of p62 predict a worse outcome in DLBCL  
It has previously been reported that accumulation of p62 due to defective autophagy can 
contribute to tumourigenesis by altering regulation of the NF- B pathway and its target 
genes (Mathew et al., 2009). It is therefore unsurprising that the prognostic value of this 
protein has been assessed in a variety of tumours. Some studies report increased 
expression of p62 as having no bearing on clinical outcome (Park et al., 2012), while 
others have shown that increased expression of this adaptor protein due to inactive 
autophagy predicts a worse prognosis (Choi et al., 2013b; Rolland et al., 2007). 
Luo and colleagues found p62 was overexpressed in 51 cases of triple-negative breast 
cancer (TNBC) patients (Luo et al., 2013). Comparison of survival and metastasis-free 
survival rates between patients expressing low and high levels of p62 showed patients 
with increased p62 expression as having a worse prognosis compared to p62-negative 
patients (Luo et al., 2013). In particular, high levels of p62 were identified as an 
independent marker of decreased DFS rates. Higher levels of p62 were also predictive 
of a poor outcome and chemo-radiotherapeutic resistance in a cohort of oral carcinoma 
cases (Inui et al., 2013). On the other hand, lower levels of p62, taken to be indicative of 
active autophagy, have been reported to predict shorter survival in melanoma patients 
(Ellis et al., 2014). Ellis and colleagues report that in a cohort of 121 primary cutaneous 
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melanomas, DFS was significantly shorter among the 66 patients classified as p62 low, 
while a non-significant trend towards increased melanoma-specific mortality (MSM) 
was also observed in this group (Ellis et al., 2014).  
To our knowledge, the prognostic value of p62 in NHL has not been previously 
described. In this study, we found that despite being expressed at significantly lower 
levels compared to RA controls, p62 was not associated with clinical outcome in FL. A 
possible explanation for p62 lacking of prognostic value may stem from the fact that it 
is expressed at homogeneously low levels in all FL samples; therefore, in a similar 
manner to BCL-2, while low level p62 expression may be characteristic of FL it does 
not appear to impact on survival. On the other hand, we found that p62 expression 
levels are an independent biomarker of clinical outcome in our DLBCL patient cohort. 
Among the 109 DLBCL cases evaluated, the 74 patients classified as p62
HIGH
 had 
longer OS, DSS and PFS rates compared to the 35 p62
LOW
 patients. In line with the 
studies described above, in this study low levels of p62 were taken to reflect its 
degradation and thus increased autophagy activity. However, unlike those studies who 
report that accumulation of p62 and inhibition of autophagy predicts worse survival in 
various solid cancers and is associated with tumourigenesis, but in line with the findings 
of Ellis et al (Ellis et al., 2014), we found that degradation of p62 and up-regulation of 
the autophagy pathway predicts a poor outcome in this aggressive lymphoma, but not in 
indolent FL.  
Our findings show that high p62 expression levels and inactive autophagy predicts a 
favourable clinical outcome in DLBCL. We believe this finding fits with the proposed 
theory that increased autophagy activity, as demonstrated by decreased p62 levels, 
promotes tumour cell survival, resulting in a worse clinical outcome. As mentioned 
before, the autophagy pathway and its role in tumourigenesis and cancer development is 
highly tumour specific, meaning an observation in one malignancy does not necessarily 
hold true for another. Also, the microenvironment plays an important role in the 
development and progression of DLBCL, and as we have demonstrated in this study, 
autophagy activity is altered in cells of the DLBCL, and FL, tumour microenvironment. 
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We therefore propose that p62 is a valid and important independent biomarker for 
clinical outcome in DLBCL, where its decreased expression predicts a worse prognosis.  
7.7.2 Low levels of Beclin-1 are associated with shorter survival rates in FL 
and DLBCL 
The prognostic significance of Beclin-1 in various malignancies is well reported. As it 
is classified as a haploinsufficient tumour suppressor gene (Liang et al., 1999; Marquez 
and Xu, 2012), it is unsurprising that in the majority of studies, increased expression of 
Beclin-1 is reported to be associated with a good prognosis, while decreased expression 
of this autophagy-essential protein predicts shorter survival rates (Chen et al., 2009; 
Huang et al., 2010). For example, Geng et al found that in a cohort of 271 lymph-node 
positive gastric cancers, OS was significantly higher in the 229 patients with increased 
expression of Beclin-1 (Geng et al., 2012). However, there are some reports which 
describe higher levels of Beclin-1 as being a marker of poor outcome (Wan et al., 2010). 
The prognostic significance of Beclin-1 as an independent marker of outcome in NHLs 
has previously been described (Huang et al., 2011; Nicotra et al., 2010b). In a study of 
102 NHL patients which included 21 FL cases and 32 cases of DLBCL, ~60% of 
patients, including 16 FL and 15 DLBCL, had high (≥20%) levels of Beclin-1 as 
identified by tissue immunofluorescence. Evaluation of clinical outcome identified 
Beclin-1 as an independent prognostic marker, and showed increased survival among 
Beclin-1
HIGH
 patients following chemotherapy compared to patients with decreased 
expression (Nicotra et al., 2010b). In a similar finding, Huang and colleagues (Huang et 
al., 2011) confirmed Beclin-1 to be an independent marker of prognosis in a larger (118) 
cohort of newly diagnosed DLBCL patients. They reported an association between 
decreased expression of Beclin-1 and high IPI scores, B-symptoms and an overall worse 
outcome; comparatively CR rates were higher in patients expressing high levels of 
Beclin-1 (Huang et al., 2011). In these studies, positive Beclin-1 expression was 
identified as aggregates (Nicotra et al., 2010b) and strong, cytoplasmic staining (Huang 
et al., 2011) respectively. As previously described, in this study Beclin-1-positive 
staining was identified as the most intense, dark cytoplasmic staining. Using this 
scoring method we confirmed Beclin-1 to be an independent prognostic marker in 86 
FL and 109 DLBCL patients. Increased expression of Beclin-1 was associated with 
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longer OS and DSS in the 71 Beclin-1
HIGH
 FL patients, and OS and PFS in the 84 
Beclin-1
HIGH
 cases of DLBCL. While we were unable to stratify patients as GCB or 
ABC-subtype, Huang et al have previously reported that Beclin-1 expression is similar 
among these subtypes (Huang et al., 2011). These results demonstrate that our IHC 
technique and scoring method are valid as they confirm previously reported findings.   
 
7.7.3 LC3 does not predict outcome in NHL 
The prognostic ability and significance of LC3 varies depending on tumour type (Lee et 
al., 2013). Some studies describe increased expression of LC3 as being a marker of poor 
prognosis (Han et al., 2011; Karpathiou et al., 2011), while others found low levels of 
LC3 to be associated with an unfavourable clinical outcome and tumourigenesis (He et 
al., 2013; Zhu et al., 2012). Others again report LC3 expression does not predict 
outcome (Sivridis et al., 2011).  
In a study of 163 TNBC patients, He and colleagues (He et al., 2013) identified 
decreased expression of LC3 as being an independent marker for disease-free survival 
(DFS), with shorter 10-year DFS rates observed among LC3
LOW
 patients compared to 
LC3
HIGH 
patients. They describe low levels of LC3 as being indicative of low levels of 
autophagy, and so propose that defective autophagy is associated with an aggressive 
form of TNBC, increased risk of metastasis and a worse prognosis (He et al., 2013). In a 
conflicting study, Han and colleagues (Han et al., 2011) evaluated LC3 expression and 
its prognostic ability in 70 melanoma patients. They found increased expression of LC3 
and LC3-containing vacuoles, reflective of greater numbers of autophagosomes and 
thus active autophagy, predicted a worse outcome in these patients. They therefore 
propose that high levels of autophagy may be promote metastasis of melanoma (Han et 
al., 2011). Lee et al (Lee et al., 2013) have also shown that LC3  is an independent 
prognostic marker in hepatocellular carcinoma (HCC), where its increased expression 
predicts longer OS. However they highlight that as IHC cannot clearly differentiate 
between LC3-I and LC3-II, IHC staining for this protein may not accurately reflect 
autophagic flux.  
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Nicotra et al reported that increased LC3-II expression and the presence of LC3-positive 
puncta are indicative of active autophagy and predictive of a better outcome in their 
NHL patient cohort (Nicotra et al., 2010b). They found that in the 36 cases stained for 
LC3, 7 of which were FL and 13 of which were DLBCL, there was a high concordance 
between LC3 and Beclin-1 positive staining in the majority of cases. As they also 
observed a negative correlation between Beclin-1, LC3 and BCL-2 expression, their 
data supports previous reports of increased basal levels autophagy in leukaemic cells 
following decreased BCL-2 expression (Nicotra et al., 2010b; Saeki et al., 2000). This 
study therefore indicates that in NHLs increased expression of LC3 reflects increased 
autophagy activity and in combination with high levels of Beclin-1, predicts a better 
outcome (Nicotra et al., 2010b). 
The findings in our study regarding the prognostic significance of LC3 somewhat 
conflict with those of Nicotra and colleagues. Using IHC, and consistent with the p62 
expression pattern, we found that LC3 expression is significantly decreased in our 
cohort of 86 FL patients, which was taken to reflective conversion of LC3-I to LC3-II 
and/or increased LC3-II degradation, and hence increased autophagy activity. We did 
not find LC3 expression levels to be associated with clinical outcome in either FL or 
DLBCL (109) patients; however there was a trend among DLBCL patients for longer 
OS, DSS and PFS when LC3 expression was high. While Nicotra and colleagues also 
report increased expression of LC3 to be predictive of a favourable clinical outcome, 
these findings have opposing meanings. In our study, increased LC3 expression 
indicates inactive autophagy, meaning lower autophagy activity is associated with a 
better outcome; on the other hand, Nicotra et al suggest that increased LC3 puncta 
reflects active autophagy and so an active autophagy flux is associated with a better 
outcome. Possible explanations for these opposing observations include differences in 
sample population size, the IHC scoring method employed, and potentially even the 
antibody used. These findings again highlight the lack of consistency encountered when 
using LC3 as an autophagy marker not only in lymphoma cells, but in general.     
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7.7.4 BCL-2 expression alone does not predict outcome in FL or DLBCL 
The BCL-2 protein is overexpressed in the majority of FL and a large proportion of 
DLBCL tumours, specifically the GCB sub-type (Nogai et al., 2011; Shaffer et al., 
2012). However, the impact of BCL-2 overexpression on clinical outcome varies 
between these malignancies. In FL, despite initial reports that increased expression of 
this anti-apoptotic protein predicted a worse outcome (Yunis et al., 1989), it is now 
established that overexpression of BCL-2 at the protein level, and the presence of the 
t(14;18) translocation, does not negatively impact on survival in this indolent NHL 
(Llanos et al., 2001; Pezzella et al., 1992). On the other hand, increased expression of 
BCL-2 has been reported to predict a worse outcome in DLBCL. In their study of 151 
DLBCL patients, Hermine et al found that BCL-2  is overexpressed in 44% of patients, 
and that this increased expression was associated with shorter overall and disease 
specific survival rates (Hermine et al., 1996). Gascoyne and colleagues reported similar 
findings in a cohort of 116 DLBCL patients and also showed relapse-free survival to be 
decreased in patients with high BCL-2 expression (Gascoyne et al., 1997). More 
recently, Iqbal et al have described that BCL-2 overexpression preferentially predicts a 
poor outcome in the ABC-subgroup of DLBCL patients (Iqbal et al., 2006).   
In line with previous reports, we found that BCL-2 is not a prognostic marker of clinical 
outcome in FL. However, contrary to other studies, increased expression of BCL-2 was 
not identified as an independent marker of poor survival among DLBCL patients using 
univariate analysis. After dividing DLBCL patients into four groups based on their 
combined BCL-2/p62 expression levels, we found that BCL-2
HIGH
/p62
LOW
 patients 
showed significantly shorter OS and DSS compared to all other groups, suggesting 
increased expression of BCL-2 negatively impacts survival when combined low levels 
of p62. Using a multivariate analysis, BCL-2 gained significance as a prognostic 
marker, indicating that its prognostic value is dependent on other autophagy-related 
markers.  
7.8 Conclusion 
In conclusion, we have shown that p62 is a novel, independent prognostic biomarker for 
DLBCL but not FL. Patients with decreased p62 expression had a poor prognosis, 
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indicating that increased basal level autophagy has an adverse effect on clinical outcome 
in this aggressive lymphoma. Overexpression of BCL-2 had no inhibitory effect on 
basal level autophagy in primary FL samples, but instead may increase its activity 
through inhibition of apoptosis. Other, as yet unidentified mechanisms are also likely to 
be involved in the up-regulation of this process in FL. It is unclear if increased 
autophagy is associated with disease progression as well as tumour cell maintenance. 
Autophagy activity was also increased in tumour-infiltrating cells, particularly tumour-
associated macrophages. Up-regulation of autophagy in lymphoma cells could be 
cytoprotective and conferring a survival advantage to FL cells.  We therefore propose 
that the inclusion of autophagy inhibitors in current FL, and possibly DLBCL treatment 
options should be considered.  
7.9 Future Work  
The main aims of our future work are: 
 To validate p62 is an independent prognostic marker of clinical outcome in 
DLBCL in an independent patient cohort using the same staining and analysis 
methods employed in this study. TMAs containing a further 80 patients in whom 
this analysis can be performed are available to us through our collaboration with 
the Portuguese Institute of Oncology; further patients may also be available 
through collaborations with the LLMPP consortium. While it would be 
important to confirm p62 is a prognostic marker in DLBCL independent of 
GCB/ABC-subtype classification, this would be difficult to do as this 
information is not available for historic cases present on TMAs, and there is 
poor concordance among IHC-based algorithms as to how patients should be 
categorised as GCB or ABC using IHC.  
 To determine if increased autophagy activity confers a survival advantage to 
lymphoma cells. This would be done by evaluating and comparing survival and 
proliferation rates between autophagy active and inactive lymphoma cells and 
non-malignant controls. Autophagy would be repressed genetically using siRNA 
targeted against autophagy essential genes identified as being differentially 
expressed in primary lymphoma cells and cell lines. Proliferation and viability 
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assays would be carried out to evaluate the effects of inactive autophagy on B 
cell growth and survival compared to autophagy active lymphoma cells. These 
experiments would be difficult to perform in primary FL and DLBCL samples 
meaning cell lines would have to be utilised. However, this may be difficult as 
while there are well established DLBCL cell lines available, no FL cell lines are 
available which accurately mimic the biology and growth process of this 
indolent lymphoma.  
 To evaluate if increased autophagy activity in B-cell lymphomas is associated 
with disease progression and in particular if it is involved in the progression and 
transformation of FL to DLBCL. This would be assessed in vivo so as to fully 
determine the role of autophagy in the development and pathogenesis of FL and 
DLBCL. Murine models of B-cell lymphomas in which these experiments could 
be carried out include VavP-BCL-2 and Eµ-BRD2 which mimic FL (Egle et al., 
2004) and DLBCL (Greenwald et al., 2004) respectively. The Eµ-Myc murine 
model could also be used to study the role of autophagy in progression from FL 
to DLBCL in a time dependent manner (Donnou et al., 2012). Autophagy 
activity would also be evaluated in relapsed FL patients based on p62, LC3 and 
Beclin-1 expression levels to elucidate the role of this pathway in disease 
progression. We would also aim to construct a TMA containing transformed FL 
patients to determine if increased autophagy activity is involved in the 
transformation process.  
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Appendix I  
 
1.0 Cell lines and cell culture  
Materials: 
 Fetal calf serum (FCS; Gibco Life Technologies - 10500-064) 
 Penicillin/Streptomycin (P/S; Sigma – P4333)  
 RPMI 1640 (Sigma – R8758)  
 HANKS balanced salt solution (HBSS; Gibco – 14025) 
1.1 Preparation of culture media 
55ml heat inactivated FCS (56°C for 1hr) and 5ml P/S solution (100×) were added to 
500ml RPMI 1640 containing stable glutamine and phenol red. Final concentrations are 
10% FCS, 2.0 mM L-glutamine, 100U/ml penicillin and 100µg/ml streptomycin. 
Culture medium is stored at 4 C. Cells were cultured in HBSS to induce autophagy. 
1.2 Analysis of cell viability  
Cell viability was measured using the automated Beckman Coulter Vi-Cell ™ XR Cell 
Viability Analyzer which measures cell viability and cell number. This machine 
differentiates live/dead based on trypan blue staining - live cells with intact membranes 
exclude trypan blue while dead cells take up the dye due to broken membranes. 0.5-1ml 
cell suspension was analysed per sample. 
2.0 Western blotting 
2.1 Preparation of samples for Western blotting 
Materials: 
 Protease inhibitor cocktail (PIC) (Sigma – P8340) 
 CellLytic™ M cell lysis buffer (Sigma – C2978)  
2.1.1 Preparation of cell lysates  
Cell lysis buffer  
10µl PIC was mixed with 1ml CellLytic™ M cell lysis buffer to prevent protein 
degradation.  
2.1.2 Determination of protein concentration 
Materials: 
 Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad - 500-0006) 
 Bovine serum albumin (BSA) (Sigma – A-7906)  
Bovine serum albumin (BSA) stock solution:  
A 5mg/ml stock solution of BSA was prepared by dissolving 0.013g BSA in 1ml water. 
Stock solution was stored as 1ml aliquots at -20ºC.  
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Bovine serum albumin (BSA) working solution: 
A 0.5mg/ml working solution of BSA was prepared by mixing 10µl stock solution BSA 
with 90µl second distilled water. 
Bio-Rad reagent 
A 1:5 working solution of protein assay dye reagent was prepared by mixing 20ml of 
concentrated protein assay dye reagent with 80ml second distilled water. Prior to use the 
working solution was filtered using Whatmann cellulose filter paper to remove any 
precipitates that may be present. Working solution was stored at 4ºC.  
2.2 Buffers for Western blotting 
Materials: 
 1× MOPS or MES running buffer (Invitrogen - NP0001; NP0002) 
 1× transfer buffer  
 Marvels Original dry semi-skimmed milk  
 MagicMark™ XP Western standard (Invitrogen – LC5602) 
 Nu-PAGE® LDS sample buffer 4× (Invitrogen – NP0007)  
 Pure-Cellulose extra thick 15cm×20cm (Sigma – P7796) 
 Nu-PAGE ® 4-12% Bis-Tris gel (Invitrogen – NP0336)   
 PVDF membrane (Sigma – P2813)  
 Tween-20 (Sigma – P7949) 
 ECL Plus Western blot detection system (GE Healthcare – RPN2232) 
 Restore PLUS ® Western blot stripping buffer (Thermo Scientific - 46430)  
 Polyvinylpyrrolidone (PVP; Sigma - P5288-500g) 
2.2.1 MOPS/MES running buffers 
100ml of MOPS/MES 20× running buffer was mixed with 900ml second distilled water. 
2.2.2 Transfer buffer 
10× stock solution of transfer buffer was prepared by dissolving 0.25M Tris BASE and 
1.92M Glycine in second distilled water. 1× working solution is prepared by mixing 
100ml 10× transfer buffer, 200ml methanol and 700ml second distilled water.  
2.2.3 PBS and PBST 
1% phosphate buffered saline (PBS) solution was prepared by dissolving 1 PBS tablet 
(Sigma - P4417) per 200ml of 15 Ω Millipore distilled water. 1× Dulbecco’s PBS 
without calcium and magnesium was also used. 0.1% PBST was prepared by adding 
1ml of Tween-20 to 1L of PBS.  
2.2.4 10× TBS; 1× TBS; TBST 
A 10× Tris-buffered solution (TBS) stock solution was prepared by mixing second 
distilled water with Tris-HCl and NaCl. 5M NaCl was dissolved in 300ml distilled 
water and 1M Tris-HCl prepared by dissolving Tris-Base in 500ml distilled water and 
  Appendix I 
 
261 
 
adjusted to pH7.4 using HCl. These solutions were mixed together and 200ml of 
distilled water added giving a final volume of 1L. 1× TBS was prepared by mixing 
100ml 10× TBS with 900ml distilled water. 0.1% TBST was prepared by mixing 1ml 
Tween-20 with 1L 1× TBS.  
2.2.5 5% Milk blocking solution 
A 5% blocking solution was prepared by dissolving 2.5g dried skimmed Milk was 
dissolved in 50ml PBST.  
2.2.6 PVP blocking solution  
A 5% 1L PVP blocking solution was prepared by dissolving 50g PVP in 1000ml 1× 
TBST. 
2.2.7 10% Sodium azide solution  
A 10% Sodium azide solution was prepared by dissolving 10g of sodium azide (Sigma 
– S8032) in 100ml distilled water.  
2.2.8 Primary antibody diluent  
Primary antibodies were diluted in either 10ml 5% milk blocking solution (2.5) or 7ml 
PVP blocking solution (2.6) containing 0.35ml FCS and 70µl 10% Azide solution.  
2.2.9 Secondary antibody dilutent  
Secondary antibodies were diluted in PBST if appendix 2.8 (a) was the primary 
antibody diluent or in 10ml PVP blocking buffer containing 0.35ml FCS (without 
sodium azide) if appendix 2.8 (b) was used.  
2.2.10 ECL plus 
ECL Plus was prepared according to manufacturer’s instructions. Solutions A and B 
were equilibrated to RT 15min prior to use and were mixed in a 1:1 ratio. Membranes 
were incubated with 1ml mixed solution for 5min in the dark at RT.  
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2.2.11 Western blotting antibodies  
Table A Primary antibodies for Western blotting 
Antibody Species Company Clone Cat. No. Dilution 
Atg4B Rabbit Cell Signalling  Polyclonal 5299S 1:1000 
Bak Rabbit Santa Cruz G-23 sc-832 1:3000 
Bax Mouse Santa Cruz N-20 sc-493 1:500 
BCL-2 Mouse Santa Cruz 100 sc-509 1:1000 
BCL-2 Rabbit Santa Cruz N-19 sc-492 1:1000 
BCL-xL Rabbit Santa Cruz S-10 sc-634 1:1000 
Beclin-1 Mouse Santa Cruz E-8 sc-48341 1:1000 
Bim Rabbit Santa Cruz H-191 sc-11425 1:3000 
LC3 Rabbit Abgent Polyclonal APG8 1:1000 
MCL-1 Rabbit Cell Signalling Polyclonal 4752 1:3000 
p62 Mouse Santa Cruz D-3 sc-28359 1:1000 
p62 Rabbit Abgent Polyclonal (C-term) AP2183B 1:1000 
PARP Rabbit Santa Cruz H-250 sc-7150 1:1000 
ULK1 Rabbit Abcam EPR4885(2) ab128859 1:1000 
β-Actin Rabbit Sigma AC-74 A5316 1:50,000 
GAPDH Rabbit Cell Signalling 14C10 2118L 1:2000 
 
Table B Secondary antibodies for Western blotting 
Antibody Species Company Cat. No. Dilution 
Goat Anti-Rabbit Rabbit Santa Cruz sc-2004 1:3000 
Goat Anti-Mouse Mouse Santa Cruz sc-2005 1:3000 
 
3.0 Buffers for immuno-fluorescent microscopy  
Materials: 
 Superfrost Plus chamber slides (MJ Research Inc - SLS-03111) 
 Cytofix/Cytoperm fixation/permeablisation solution (PharMingen/Becton Dickson -
554715) 
 Blocking buffer 
o Donkey serum (Sigma - D9663) 
o Goat serum (Sigma – G9023) 
o Saponin (Fluka Biochemika – 47036) 
 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI – Sigma – D9564)   
 ProLong® Gold anti-fade mounting reagent (Life Technologies – P36930) 
3.1 5% donkey/goat blocking buffer 
A 0.1% saponin, 5% donkey/goat serum buffer was prepared by dissolving 0.05g 
saponin in 2.5mls of donkey or goat serum and brought to a volume of 50mls with 1× 
TBS. Buffer is stored at -20°C in 10ml aliquots.  
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3.2 Immunofluorescent microscopy antibodies  
Table C Primary antibodies for immunofluorescent microscopy  
Antibody Species Company Clone Cat. No. Dilution 
Bax  Mouse BD Pharmingen  6A7 556467 1:100 
BCL-2 Mouse Santa Cruz  100 sc-509 1:50 
Bip Rabbit Cell Signalling  G-584 C50B12 1:25 
Beclin-1 Mouse Santa Cruz  E-8 sc-48341 1:20 
Cox IV Rabbit Abcam  Polyclonal ab16056 1:200 
 
Table D Secondary antibodies for immunofluorescent microscopy  
Antibody Species Clone Company Cat. No. Dilution 
Alexa-Flour®488 Mouse Donkey   Santa Cruz A21202 1:100 
Alexa-Flour®546 Rabbit Donkey  Santa Cruz A11035 1:100 
 
3.3 DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride)  
10µl 50mg/ml DAPI was added to 10mls PBS (1:1000 dilution) to create a 50µg/ml 
stock solution which was aliquoted and stored at -20°C in darkened eppendorf tubes. 
The final working solution of DAPI was prepared by mixing 1µl 50µg DAPI with 1ml 
PBS(T). 
4.0 Solutions and buffers for tissue microarrays 
Materials:  
 Superfrost® Plus slides (VWR– 631-0108) 
 10× Wash buffer (DAKO – S3006)  
 Xylene (VWR Chemicals – 28975.325)  
 Peroxidase (BDH – 101284N)  
 Industrial methylated spirits (IMS; Fisher Chemical – 11482874) 
 Unmasking solution (Vector Laboratories – CA94010)  
 DPX (Distrene 80, Dibutyl phthalate and Xylene) Mountant (VWR – 360294H) 
 SuperSensitive™ Polymer HRP-IHC Detection system (BioGenex – QD430-
XAKE) 
o SS Label 
o SuperEnhancer 
o Stable DAB buffer 
o Liquid DAB 
4.1 Peroxidase blocking buffer  
2% peroxidase in 100% IMS 
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4.2 Unmasking solution 
3L second distilled water was mixed with 30ml DAKO unmasking solution (1:100) and 
brought to the boil in a pressure cooker.  
4.3 Immunohistochemistry antibodies 
Table E Antibodies used for immunohistochemistry  
 
4.4 3.3’-Diaminobenzidine (DAB) 
1 drop (~38µl) of DAB chromogen was added to 1ml stable DAB buffer and mixed.  
4.5 Acid alcohol 
1% hydrochloric acid in 70% IMS 
4.6 DPX - Xylene-based permanent mounting agent  
TMA slides were mounted with the xylene-based permanent mounting agent DPX, 
purchased in a ready to use form.  
4.7 Wash buffer 
50ml DAKO 10× wash buffer was mixed with 450ml second distilled water (1:10) 
5.0 Solutions for Caspase-3 activity assay 
Materials: 
 Dithiothreitol (DTT) (Sigma – D3801) 
 Phenylmethylsulfonyl fluoride (PMSF) (Sigma – P7626) 
 7-amino-4-trifluoromethylcoumarin (AFC) (Sigma – A8401) 
 Ac-DEVD-AFC (Caspase-3 substrate) (Santa Cruz – sc-311274A) 
 3-[(3-Cholamidopropyl)dimethylammonio]-1propanesulfonate (CHAPS) (Sigma – 
C9426)  
 DMSO (D/4121/PB08) 
 
Antibody Species Company Cat. No. Antigen Retrieval Dilution 
p62 Rabbit Abgent  AP2183B Pressure Cooker 1:7000 
Beclin1 Mouse Santa Cruz  sc-48381 Pressure Cooker 1:250 
LC3B Rabbit Sigma  L7543 Pressure Cooker 1:5000 
CTSD Mouse Sigma  C0715 Pronase Enzyme 1:1000 
TGM2 Rabbit Abcam ab421 Pressure Cooker 1:750 
BCL-2 Mouse DAKO M0887 Pressure Cooker 1:200 
CD68 Mouse DAKO M0814 Pressure Cooker 1:8000 
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5.1 Caspase-3 assay lysis buffer 
10µl 100mM DTT, 10µl 100mM PMSF and 10µl PIC were added to 1ml caspase-3 
reaction buffer.  
5.1.1 100mM Dithiothreitol (DTT) 
0.015g DTT was dissolved in 1ml DMSO  
5.1.2 100mM Phenylmethylsulfonyl fluoride (PMSF) 
0.017g PMSF was dissolved in 1ml DMSO 
5.2 Caspase-3 assay reaction buffer (pH 7.4; 500ml) 
500ml caspase-3 reaction buffer was prepared by mixing the components listed in table 
H with distilled water and the final pH adjusted to pH7.4.  
Table F Caspase-3 reaction buffer components  
Reagent MW (g/L) Weight 
(g)/500ml 
Final 
Concentration 
HEPES-KOH 238.3 2.383 20mM 
KCl 74.56 0.37 10mM 
EDTA 372 0.186 1mM 
EGTA 380.4 0.192 1mM 
CHAPS* 614.9 0.5 0.1% 
 * 0.1% CHAPS is to be added freshly each time buffer is prepared  
5.3 Ac-DEVD-AFC Caspase-3 substrate 
5.3.1 10mM Ac-DEVD-AFC (stock solution) 
5mg Ac-DEVD-AFC was dissolved in 0.7ml DMSO to create a 10mM stock solution 
which was stored in 20µl aliquots at -20°C.  
5.3.2 400µM Ac-DEVD-AFC (working solution) 
6µl 10mM Ac-DEVD-AFC stock solution was mixed with 150µl caspase-3 reaction 
buffer B (1:25) to create a 400µM working solution. 5µl 400µM working solution was 
mixed with 100µl caspase-3 reaction buffer B to give a final concentration of 20µM Ac-
DEVD-AFC substrate per well.  
5.4 7-amino-4-trifluoromethylcoumarin (AFC)  
5.4.1 100mM AFC 
A 100mM AFC stock solution was prepared by dissolving 0.0229g AFC in 1ml DMSO. 
Solution was stored in the dark at -20°C.  
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5.4.2 5µM AFC 
1µl 100mM AFC was mixed with 1ml second distilled water (1:1000) to create a 
100µM solution. 50µl 100µM AFC was mixed with 1ml second distilled water (1:20) to 
give a final working solution of 5µM.  
6.0 Solutions for flow cytometry 
Materials: 
 4’, 6’-Diamidino-2-Phenylindole, Dihydrochloride (DAPI)  (Sigma – D9564) 
 Tetramethylrhodamine, Methyl Ester, Perchlorate (TMRM) (Molecular Probes – T-668) 
 DNase (Sigma – D4513) 
 Human γ-Globulin (HAG; Sigma – 4386) 
6.1 100ng/ml DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) 
(working solution) 
20µl of 50µg/ml DAPI stock solution was diluted to 10ml PBS to create a 100ng/ml 
working solution.   
6.2 Tetramethylrhodamine, Methyl Ester, Perchlorate (TMRM) 
6.2.1 2mM TMRM (stock solution) 
2mM TMRM stock solution was prepared by dissolving 2mg TMRM in 2ml DMSO. 
Solution was stored in the dark at -20°C.  
6.2.2 TMRM (working solution) 
1µl of 2mM TMRM was mixed with 1ml PBS (1:1000) to create a 2µM solution. 400µl 
2µM TMRM was mixed with 10ml PBS (1:25) to create a 80nM working solution 
6.3 Deoxyribonuclease I from bovine pancreas (DNase) 
11g DNase was mixed with 11ml PBS. Prepared DNase was kept at -20°C in 0.5ml 
aliquots.  
6.4 2% Human anti-γ-globulin antibody (HAG) 
2% HAG was prepared by dissolving 1g HAG in 50ml sterile PBS for 30min at RT. 
This solution was then filtered through a Millipore Dualex-Ultra 0.2µm filter and stored 
in 1ml aliquots at -20ºC. 50µl 2% HAG was used per 1.5×10
6
 cells. 
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6.5 Antibodies used in B cell isolation  
Table G Antibodies used to isolate B cells using flow cytometry  
Marker Clone Isotype Fluorochrome Company Cat. 
No. 
Volume/10
6 
Cells 
CD3 SK7 Mouse 
IgG1, κ 
FITC BioLegend 344804 1µl 
CD20 2H7 Mouse 
IgG2b, κ 
APC-H7 BD 
Biosciences 
641396 2.5µl
 
CD19 HIB19 Mouse 
IgG1, κ 
APC-Cy7 BioLegend  302218 2.5µl 
CD10 HI10A Mouse 
IgG1, κ 
PE BioLegend 312204 2.5µl 
Kappa  MHK-
49 
Mouse 
IgG1, κ 
APC BioLegend 316510 20µl 
Lambda  MHL-
38 
Mouse 
IgG2a, κ 
PerCp-Cy5.5 BioLegend 316618 5µl 
 
6.6 2% FACS wash  
2% FACS wash was prepared by mixing 1ml filtered FCS with 50ml sterile PBS.  
6.7 2% FACS wash containing DAPI and 1% DNase  
5ml 2% FACS wash with 2.5µl plus 2.5µl 50µg/ml DAPI and 50µl 1mg/ml DNase  
6.8 FACs Collection buffer 
Cell collection buffer was prepared by mixing 5ml filtered FCS with 50ml sterile PBS 
(10%) 
7.0 Solutions phenol-chloroform based RNA extraction (TRIzol® 
Reagent) 
Materials: 
 Trizol (Life Technologies - 15596018 ) 
 Chloroform (Sigma - 366919) 
 Isopropanol (Fisher Chemical – P/7500/17) 
7.1 75% ethanol 
10ml 75% ethanol was prepared by mixing 7.5ml of 100% pure ethanol with 2.5ml of 
distilled water.  
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8.0 Solutions for RNA extraction using QIAGEN RNeasy® Mini 
Kit 
Materials: 
 RNeasy® Mini Kit (QIAGEN - 74104) 
o Buffer RLT 
o Buffer RW1  
o Buffer RPE 
o RNase-free water 
o RNA-free 2ml collection tubes 
o RNA-free 1.5ml collection tubes 
o QIAshredder spin column 
o RNeasy spin column 
 β-mercaptoethanol ( BHD Biochemistry – 436022A) 
 RNase-free DNase set (QIAGEN - 79254) 
o DNase I, RNase-free (lyophilized) 
o Buffer RDD 
8.1 Buffer RLT 
Under a fumehood, 10µl β-mercaptoethanol was added to 1ml Buffer RLT and mixed 
by vortexing for 1min.  
8.2 70% ethanol 
10ml 70% ethanol was prepared by mixing 7ml of 100% pure ethanol with 3ml of 
distilled water.  
8.3 DNase I 
8.3.1 DNase I (stock solution)  
550µl of RNase-free water was added to lyophilized DNase and mixed. DNase was 
stored in 10µl aliquots at -20°C.   
8.3.2 DNase I Incubation Mix (working solution) 
DNase I incubation mix was prepared by mixing 10µl of DNase with 70µl of Buffer 
RDD supplied as part of the QIAGEN RNase-free DNase set.  
8.4 Buffer RPE 
44ml of 100% ethanol was added and mixed to 11ml Buffer RPE.  
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9.0 Agilent bioanalyser 
Materials: 
 Agilent 2100 Bioanalyser (Agilent Technologies)  
 Agilent RNA 6000 Nano Chips (Agilent Technologies – 5067-1521) 
 Agilent RNA 6000 Nano Reagents (Agilent Technologies – 5067-1511) 
o Agilent RNA 6000 Ladder 
o RNA Nano Dye Concentrate 
o Agilent RNA 6000 Nano Gel Matrix 
10.0 Quantitative real-time PCR  
10.1 cDNA synthesis  
Materials: 
 RT2 First strand kit (QIAGEN - 330401)  
Table H Genomic DNA elimination mix 
  
 
 
 
 
Table I Reverse-transcription (ReTr) mix 
  
 
 
 
 
Component Concentration Volume Example 
RNA 300ng Maximum 8µl 5µl 
Buffer GE NA 2µl 2µl 
RNase-free water NA Variable 3µl 
Total Volume NA 10µl 10µl 
Component Volume for 1 
Reaction 
Volume for 8 
Reactions 
5× Buffer BC3 4µl 32µl 
Control P2 1µl 8µl 
RE3 Reverse Transcriptase 
Mix 
2µl 16µl 
RNase-free Water 3µl 24µl 
Total Volume 10µl 80µl 
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10.2 qRT-PCR reaction 
Materials: 
 RT2 SYBR green ROX qPCR Mastermix (QIAGEN - 330521)  
Table J qRT-PCR Reagents Mix 
 
 
 
 
 
Table K qRT-PCR Cycling Conditions - Applied Biosystems 7900HT Cycler 
Cycles Temperature Duration 
1 95°C 10 min 
40 95°C 
60°C 
15 sec 
1 min 
1 
(Dissociation Curve) 
95°C 
60°C 
95°C 
15 sec 
15 sec 
15 sec 
 
10.3 qRT-PCR validation experiments  
Table L qRT-PCR Reagents Mix (Validation Experiments) 
 
 
 
 
 
 
 
 
 
 
Components 384 Array Format E (4 × 96 
well) 
2 × RT
2
 SYBR Green 
Mastermix 
650µl 
cDNA Synthesis Reaction 102µl 
RNase-free Water 548µl 
Total Volume per Sample 1300µl 
Components 384 Array Format E (4 × 96 
well) 
2 × RT
2
 SYBR Green Mastermix 12.5µl 
cDNA Synthesis Reaction 1µl 
RNase-free Water 10.5µl 
Total Volume per Sample 25µl 
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11.0 Solutions and buffers for Co-Immunoprecipitation 
Materials: 
 Nuclear Complex Co-IP Kit (Active Motif - 54001) 
o 5× IP Low Buffer 
o 1M DTT (Appendix 5.0) 
o PIC (Appendix 2.1) 
 Eluting Solution 
o Nu-PAGE® LDS Sample Buffer 4× (Invitrogen – NP0007) 
o Nu-PAGE® Reducing Agent 10× (Invitrogen – NP0009) 
 Dynabeads Protein A (Life Technologies – 10002D) 
 Mouse Anti-IgG (Santa Cruz – sc-2025) 
11.1 Immunoprecipitation incubation buffer 
IP incubation buffer was prepared using Active Motif Nuclear Complex Co-IP Kit and 
by following the manufacturers’ guidelines. 
Table M 5× low IP incubation buffer components  
5× low IP buffer 100µl 
PIC 2.5µl 
1M DTT 0.5µl 
dH2O 397µl 
Total Volume 500µl 
 
11.2 Immunoprecipitation wash buffer 
IP wash buffer was prepared using Active Motif Nuclear Complex Co-IP Kit and by 
following the manufacturers’ guidelines.  
Table N 5× low IP wash buffer components  
5× low IP buffer 800µl 
PIC 8µl 
1M DTT 4µl 
dH2O 3188µl 
Total Volume 4000µl 
 
11.3 Eluting solution  
Eluting solution was prepared by mixing 160µl of Nu-PAGE® 4× LDS Sample Buffer   
with 16µl of Nu-PAGE® Reducing Agent 10×.  
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12.0 Drug preparation  
12.1 ABT-737 
12.1.1 10mM ABT-737 (stock solution) 
A 10mM ABT-737 (Selleck – S1002) stock solution was prepared by dissolving 5mg 
ABT-737 in 615µl DMSO. Stock solution was stored at -80°C in 10µl aliquots. 
12.1.2 10µM ABT-737 (working solution) 
A 10µM ABT-737 stock solution was prepared by mixing 1µl 10mM ABT-737 with 
1ml culture media. Working solution was prepared fresh each time. 
12.2 50mM Chloroquine  
A 50mM Chloroquine (CQ; Sigma – C6628) stock solution was prepared by dissolving 
0.026g CQ in 1ml PBS. Stock solution was stored at -20°C. 1µl 50mM was added per 
1ml cell suspension to give a final concentration of 50µM. 
12.3 20mM Z-VAD.fmk 
A 20mM N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluromethyl ketone (Z-VAD.fmk; Sigma 
– C2105) stock solution was prepared by dissolving 0.009g Z-VAD.fmk in 1ml DMSO. 
Stock solution was stored at -20°C. 1µl 20mM Z-VAD.fmk was added per 1ml cell 
suspension to give a final concentration of 20µM. 
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Appendix II  
 
1.0 Cell line GEP data 
Table O Su-DHL4 and Su-DHL8 RIN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 1: Unsupervised clustering analysis resolves untreated Su-DHL4 
and Su-DHL8 cell lines based on expression of autophagy-related genes  
Unsupervised hierarchical clustering using triplicate Su-DHL4 and SU-DHL8 untreated RQ values. 
Samples were clustered using a Euclidean distance measure and an average agglomeration (JM) where 
each row represents a gene and each column an RQ value. Gene expression levels are represented on a 
scale of blue to red colour indicative of low to high expression.  
 
 
Sample RIN 260/280 260/230 
Su-DHL4 Untreated-1 9.9 2.14 2.2 
Su-DHL4 Untreated-2 9.9 2.12 2.22 
Su-DHL4 Untreated-3 9.9 2.14 2.18 
Su-DHL4 HANKS-1 9.7 2.13 2.16 
Su-DHL4 HANKS-2 9.8 2.13 2.14 
Su-DHL4 HANKS-3 9.7 2.2 2.19 
Su-DHL8 Untreated-1 9.9 2.16 2.21 
Su-DHL8 Untreated-2 9.9 2.18 2.11 
Su-DHL8 Untreated-3 9.9 2.18 2.23 
Su-DHL8 HANKS-1 9.9 2.28 2.21 
Su-DHL8 HANKS-2 10 2.17 1.91 
Su-DHL8 HANKS-3 10 2.35 1.92 
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Appendix Figure 2: Unsupervised clustering analysis resolves untreated and 
starved Su-DHL4 cells based on expression of autophagy-related genes  
Unsupervised hierarchical clustering using triplicate untreated and starved (HBSS; 6hrs) Su-DHL4 RQ 
values. Samples were clustered using a Euclidean distance measure and an average agglomeration (JM) 
where each row represents a gene and each column an RQ value. Gene expression levels are represented 
on a scale of blue to red colour indicative of low to high expression  
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Appendix Figure 3: Unsupervised clustering analysis resolves untreated and 
starved Su-DHL8 cells based on expression of autophagy-related genes  
Unsupervised hierarchical clustering using triplicate untreated and treated Su-DHL4 (HBSS; 6hrs) RQ 
values. Samples were clustered using a Euclidean distance measure and an average agglomeration (JM) 
where each row represents a gene and each column an RQ value. Gene expression levels are represented 
on a scale of blue to red colour indicative of low to high expression  
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2.0 Patient information  
Table P FL patient information for purified and un-purified samples 
 
 
 
 
 
 
 
 
 
¶ Staging ranges from I to IV with a higher stage indicating more widespread disease. § The Follicular Lymphoma International Prognostic Index (FLIPI) score 
ranges from 1 to 4 where 1 = low risk (0-1 prognostic factor), 2 = intermediate risk (2 prognostic factors), 3 = high risk (3-5 prognostic factors) and 4 = not 
assessable; U = unknown.  *CR= complete remission; CR(U)= undetermined complete remission; GPR= good partial remission; N/A= not applicable. † NHL= 
Non-Hodgkin lymphoma; N/A= not applicable. 
 
 
 
 
 
Pat ID Gender Age at  
Diagnosis 
Date of 
Diagnosis 
Date of 
Transformation 
Stage FLIPI 
Score 
Date of 1
st
  
Treatment 
Response Date of 
Death 
Cause of 
Death 
F9835 M 56 20/06/1997 15/04/2008 II 1 15/04/2008 Progression 03/12/2008 NHL 
F9220 M 57 01/04/2001 22/01/2008 IV 3 26/04/2001 CR(U) / GPR N/A N/A 
R8402 F 67 22/08/2005 26/04/2011 II 1 14/05/2010 CR N/A N/A 
T1979 F 74 01/12/2005 18/05/2009 IV  08/05/2009 Progression 08/07/2009 NHL 
T5728 M 29 15/07/2011 13/02/2012 IV 2 02/03/2012 CR N/A N/A 
R9130 F 25 31/05/2007 N/A II 1 04/07/2007 CR(U) / GPR N/A N/A 
T6694 M 48 24/03/2011 N/A IV 2 21/03/2012 PR N/A N/A 
R0481 F 54 12/04/2002 N/A IV 2 11/01/2005 CR(U) / GPR N/A N/A 
F5997 F 63 01/01/1998 N/A IV 3 27/08/1998 Relapse 13/01/2005 NHL 
F9713 F 89 31/08/2001 N/A IV 2 14/09/2001 N/A 28/09/2002 N/A 
T6713 M 62 07/03/2012 N/A III U N/A N/A N/A N/A 
R2856 M 76 06/10/2003 N/A III 2 N/A N/A 20/02/2006 Other 
T0167 F 74 15/04/2006 N/A IV U N/A N/A N/A N/A 
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Table Q DLBCL patient information for purified and un-purified samples 
 
 
 
 
 
 
 
 
¶ Staging ranges from I to VI with a higher stage indicating more widespread disease. § The International Prognostic Index (IPI) score ranges from 0 to 5, with 0 
indicating absence of all prognostic factors and 5 indicating all prognostic factors are present. *CR= complete remission; CR(U)= undetermined complete 
remission; GPR= good partial remission. † NHL= Non-Hodgkin lymphoma. 
 
 
Pat ID Gender Age at 
Diagnosis 
Date of 
Diagnosis 
Stage IPI 
Score 
Date of 1
st
 
Treatment 
Response Date of 
Death 
Cause of 
Death 
R1542 F 26 23/12/2002 VI 1 15/01/2003 CR N/A N/A 
R8374 M 20 29/11/2006 V 1 15/12/2006 CR N/A N/A 
T1486 M 33 08/01/2009 IV 1 27/01/2009 CR N/A N/A 
T1485 M 55 13/01/2009 II 0 20/01/2009 CR N/A N/A 
T2628 M 58 23/07/2009 I 0 20/08/2009 CR N/A N/A 
T3531 M 60 21/12/2009 III 1 03/02/2010 CR N/A N/A 
R1723 F 55 28/01/2003 IV 2 28/02/2003 CR 02/01/2006 NHL 
R8878 F 79 01/02/2007 IV 4 17/04/2007 Progression 18/03/2008 NHL 
R9083 M 33 09/05/2007 III 3 15/05/2007 CR(U) / GPR 15/11/2007 NHL 
R9515 M 80 16/08/2007 IV 4 16/08/2007 Stable disease 19/10/2007 Cardiac failure 
T0082 F 18 15/01/2008 IV 1 01/02/2008 Progression N/A N/A 
T0978 M 58 12/08/2008 IV 4 22/08/2008 Progression N/A N/A 
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Table R RIN for purified patient samples  
 
 
 
 
 
 
 
Table S RIN for un-purified patient samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disease  Pat ID  RIN  260/280  260/230  
FL  9430  8.5  1.97  1.62  
FL  7260  8.6  2.09  1.85  
FL  9093  9.8  2.12  1.61  
FL  9183  10  2.11  1.49  
FL  7823  9.8  2.11  1.05  
DLBCL  8742  7.0  2.10  0.82  
DLBCL  8555  9.7  2.78  1.23  
Reactive  1234  10  2.13  1.65  
Reactive  NML  9.7  2.07  1.65  
Reactive  1212  9.8  2.02  2.06  
Disease  Pat ID  RIN  260/280  260/230   
FL R0481 5.9  2.3  1.36  
FL F9713 6.9 1.75  1.79  
FL R9130 6.3  1.82  1.81  
FL F5997 7.6  2.01  1.24  
FL R2856 6.5  2.28  1.73  
FL F9220 6.9  1.84  1.91  
FL R8402 8.3  1.97  1.96  
FL F9835 8.6  2.34  0.73  
DLBCL  8209  7.10  2.64  1.58  
DLBCL  7851  7.00  1.89  1.58  
DLBCL  7676  7.60  2.01  1.39  
DLBCL  8105  7.60  2.28  1.19  
DLBCL  7889  6.10  2.15  1.33  
DLBCL  8365  7.30  2.05  1.57  
DLBCL  8265  6.20  2.09  1.30  
DLBCL  7535  6.70  2.10  0.55  
DLBCL  6411  5.80  2.52  1.33  
DLBCL  6488  5.60  2.42  1.54  
Reactive  6639  7.30  2.07  1.51  
Reactive  19701  6.50  2.00  0.55  
Reactive  095286  7.60  2.22  1.49  
Reactive  566960  5.90  2.48  0.85  
Reactive  2384007  7.50  2.06  1.36  
Reactive  6346677  7.00  2.06  1.07  
Reactive  961106  8.00  2.07  1.16  
Reactive  6639  7.30  2.07  1.51  
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3.0 Patient information for TMAs 
Table T Summary of clinical characteristic of FL patient samples used in IHC/TMA 
analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* indicates % of transformed; patients presented as St. Bartholomew’s hospital between 1974 and 2006; 
median age 56 (Range 26-89). 
 
 
 
 
 
 
 
 
 
 No. of patients Percentage 
 117 100 
Age, years 
  <60 
  60 
 
70 
47 
 
59.83 
40.17 
Gender 
  Male 
  Female  
 
54 
63 
 
46.15 
53.85 
Stage at diagnosis 
  I 
  II 
  III 
  IV-VI 
 
12 
14 
16 
75 
 
10.26 
11.96 
13.68 
64.10 
FLIPI score 
  1 (Low) 
  2 (Intermediate) 
  3 (High) 
  4 (not assessable) 
 
35 
29 
34 
19 
 
29.91 
24.79 
29.06 
16.24 
Proceeded to transformation 32 27.35 
Time to transformation yr 
  0-5 
  6-10 
  >11 
 
18 
8 
6 
 
56.25* 
25.00* 
18.75* 
Cause of death 
  Alive 
  Disease 
  Unrelated  
 
43 
42 
32 
 
36.75 
35.90 
27.35 
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Table U Summary of clinical characteristic of DLBCL patient samples used in 
IHC/TMA analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* LDH values <480 U/L are within the normal range; patients presented as St. Bartholomew’s hospital 
between 1983 and 2009; median age 58 (Range 21-85). 
 
 
 
 
 
 
 
 
 
 
 
 
 No. of patients Percentage 
 109 100 
Age, years 
  <60 
  60 
 
58 
51 
 
53.21 
46.79 
Gender 
  Male 
  Female  
 
72 
37 
 
66.06 
34.94 
Stage at diagnosis 
  I 
  II 
  III 
  IV-VI 
  Unknown 
 
12 
19 
33 
44 
1 
 
11.01 
17.43 
30.28 
40.37 
0.926 
B Symptoms 
  Yes 
  No 
Unknown 
 
31 
49 
29 
 
28.44 
44.95 
26.61 
Serum LDH* 
  Normal 
  Elevated 
  Unknown 
 
40 
47 
22 
 
36.70 
43.12 
20.18 
IPI score 
  0 (Low) 
  1 (Low) 
  2 (Intermediate) 
  3 (High) 
  4-5 (High) 
 
21 
30 
27 
25 
6 
 
19.27 
27.52 
24.77 
22.94 
5.5 
Cause of death 
  Alive 
  NHL-specific 
death 
  Other diseases   
 
51 
40 
18 
 
46.79 
36.70 
16.51 
  Appendix II            
281 
 
4.0 Statistical analysis of TMA data  
Table V Univariate analysis of FLIPI as a continuous variable in FL 
HR= Hazard ratio; CI= Confidence interval 
 
Table W Univariate analysis of IPI as a continuous variable in DLBCL 
HR= Hazard ratio; CI= Confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Overall survival Disease-specific 
survival 
Time to 
transformation 
HR (95% CI) p HR (95% CI) p HR (95% CI) p 
FLIPI 1.40 (1.15-1.71) 0.001 1.47 (1.12-1.92) 0.005 1.27 (0.95-1.71) 0.113 
Variable Overall survival Disease-specific 
survival 
Progression free 
survival 
HR (95% CI) p HR (95% CI) p HR (95% CI) p 
IPI 1.46 (1.17-1.81) 0.001 1.44 (1.12-1.86) 0.005 1.25 (0.98-1.59) 0.077 
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Appendix Figure 4: Higher FLIPI and IPI scores predict a worse outcome in FL and 
DLBCL respectively  
Evaluation of the prognostic significance of FLIPI and IPI scores in FL (A-C) and DLBCL (D-F) 
respectively. Based on the number of adverse prognostic factors they presented with, 116 FL and 109 
DLBCL patients were classified as FLIPI
LOW
/IPI
LOW
 (0-2) or FLIPI
HIGH
/IPI
HIGH 
(>3). The prognostic 
impact of FLIPI scores on OS (A), DSS (B) and TTT (C) in FL and of IPI scores on OS (D), DSS (E) and 
PFS (F) in DLBCL was visualised using Kaplan-Meier curves. Differences in survival between 
FLIPI
LOW
/IPI
LOW 
and FLIPI
HIGH
/IPI
HIGH
 groups were evaluated using a log-rank (Mantel-Cox) test and 
GraphPad Prism software.  OS= overall survival; DSS= disease specific survival; TTT= time to 
transformation; PFS= progression free survival; n= number; P = p value, which is classified as significant 
if <0.05 
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Table X  
(i) X-tile generated cut-points for DLBCL survival analysis 
 
Model variables Cut point p value 
OS          p62 high vs. p62 low  8.18 0.0029 
DSS        p62 high vs. p62 low  8.18 0.0144 
PFS        p62 high vs. p62 low  8.35 0.0022 
OS          BCL-2 high vs. BCL-2 low  63.74 0.0605 
DSS        BCL-2 high vs. BCL-2 low  54.97 0.1514 
PFS        BCL-2 high vs. BCL-2 low  71.49 0.6391 
OS         LC3 high vs. LC3 low  18.18 0.1429 
DSS       LC3 high vs. LC3 low  40.1 0.3457 
PFS       LC3 high vs. LC3 low  37.17 0.1126 
OS         Beclin-1 high vs. Beclin-1 low  12.91 0.0154 
DSS       Beclin-1 high vs. Beclin-1 low  15.01 0.1296 
PFS       Beclin-1 high vs. Beclin-1 low  12.88 0.0285 
OS        IPI score  0-2 vs. 3-5 0.0273 
DSS      IPI score  0-2 vs. 3-5 0.0036 
PFS      IPI score  0-2 vs. 3-5 0.0932 
 
 
 (ii) X-tile generated cut-points for DLBCL survival analysis 
 
Model variables Cut Point p value 
OS          p62 high vs. p62 low  1.54 0.527 
DSS        p62 high vs. p62 low  2.695 0.479 
TT          p62 high vs. p62 low  1.54 0.527 
OS          BCL-2 high vs. BCL-2 low  92.52 0.14 
DSS        BCL-2 high vs. BCL-2 low  92.14 0.58 
TT          BCL-2 high vs. BCL-2 low  76.52 0.3 
OS          LC3 high vs. LC3 low  40.68 0.438 
DSS        LC3 high vs. LC3 low  36.99 0.9 
TT          LC3 high vs. LC3 low  26.73 0.75 
OS          Beclin-1 high vs. Beclin-1 low  5.8 0.2 
DSS        Beclin-1 high vs. Beclin-1 low  6.12 0.3 
TT         Beclin-1 high vs. Beclin-1 low  22.84 0.43 
OS         FLIPI score  0-2 vs. 3-5 <0.001 
DSS       FLIPI score  0-2 vs. 3-5 <0.01 
TT         FLIPI score  0-2 vs. 3-5 0.014 
  Appendix II   
284 
 
 
 
 
 
Table Y 5 year survival rates for DLBCL patients based on expression levels of autophagy-related proteins  
 
 
 
 
 
 
 
 
Table Z 5 year survival rates for FL patients based on expression levels of autophagy-related proteins  
 
 
 
 
 
 
 
  
   Protein Expression Level    
% 
Survival  
p62
LOW
 p62
HIGH
 Beclin-1
LOW
 Beclin-1
HIGH
 BCL-2
LOW
 BCL-2
HIGH
 LC3
LOW
 LC3
HIGH
 
OS 40 63 34 61 61 48 55 55 
DSS 50 71 55 68 68 60 61 67 
PFS 34 67 36 62 59 49 41 66 
   Protein Expression Level    
% 
Survival  
p62
LOW
 p62
HIGH
 Beclin-1
LOW
 Beclin-1
HIGH
 BCL-2
LOW
 BCL-2
HIGH
 LC3
LOW
 LC3
HIGH
 
OS 73 69 33 73 79 68 68 77 
DSS 83 71 52 79 87 70 79 80 
TTT 10 21 17 24 14 16 17 19 
